Document 7MjJn43gezMk96VERy3oBxmwj

$6HSt - OgOO-373 A R 3 % -o a Draft Report lt\!! V;, .j 26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys & EPA-OTS 000811795V OODllTTSV PREPARED FOR: 3M COVANCE STUDY NUMBER: 6329-223 VOLUME II of II o o XD- c_ GD 1X 3 X " T -) -- m 1- CD o c=> CD rn CD I Tr* ro XT 003138 RECEIVED OPPT HCIC C O V A ' W C e T'' T H E DEVELOPMENT SERV IC ES COMPANY Sponsor: 3M St. Paul, Minnesota UNAUDITED DRAFT April 12, 2000 FINAL REPORT Study Title: 26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys Author: Peter J. Thomford, PhD Study Completion Date: To be determined Testing Facility: Covance Laboratories Inc. 3301 Kinsman Boulevard Madison, Wisconsin 53704-2595 Laboratory Study Identification: Covance 6329-223 Sponsor Study Identification: 3M Study No. T-6295.7 Volume II of II Page 502 of 821 003133 Covance 6329-223 3M T-6295.7 VOLUME H OF H CONTENTS Page APPENDIX 4 ............................................................................................................................... 504 Individual Clinical Hematology Data.................................................................................. 505 Individual Clinical Chemistry Data................................................................................. 565 Individual Clinical Urinalysis Data...................................................................................... 637 APPENDIX 5 ............................................................................................................................... 685 Individual Palmitoyl CoA Oxidase Determinations.......................................................... 686 Individual Anatomic Pathology Data.................................................................................. 690 APPENDIX 6 ............................................................................................................................... 769 Summary and Individual Blood Hormone Determination.,............................................. 770 APPENDIX 7 ............................................................................................................................... 808 Cell Proliferation Report................................................................................................... 809 00314 503 APPENDIX 4 Individual Clinical Hematology Data Individual Clinical Chemistry Data Individual Clinical Urinalysis Data Covance 6329-223 3M T-6295.7 504 0 0 3 1 4 1 ANIMAL NUMBER Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC xioV^o G/DL % FL PG % X103/jiL % Covance 6329-223 3M T-6295.7 RETIC XIOViiL Dose Level: 0 6.48 6.25 6.97 6.27 6.48 6.27 12.3 12.8 12.5 11.8 12.0 12.1 6.45 .275 6 12.2 .36 6 Dose Level: 0.03 7.28 6.22 6.67 7.79 12.5 11.8 12.5 12.9 6.99 .688 4 12.4 .46 4 Dose Level: 0.15 6.45 6.58 7.36 6.73 6.76 6.67 12.6 11.9 13.0 12.8 13.0 12,6 6.76 .315 6 12.6 .41 6 Dosage Unit: mg/kg/day 40.3 42.4 42.9 39.4 41.1 40.9 62.2 67.8 61.5 62.9 63.5 65.3 19.0 20.5 17.9 18.8 18.6 19.3 41.2 1.30 6 63.9 2.32 6 19.0 .87 6 Dosage Unit: mg/kg/day 45.5 39.8 40.9 45.3 62.5 64.0 61.3 58.1 17.2 18.9 18.7 16.6 42.9 2.95 4 61.5 2.51 4 17.8 1.13 4 Dosage Unit: mg/kg/day 42.0 39.7 44.8 43.1 44.6 43.1 65.2 60.3 60.9 64.1 66.1 64.6 19.6 18.1 17.6 19.0 19.3 18.9 42.9 1.88 6 63.5 2.38 6 18.7 .76 6 30.5 30.2 29.0 29.9 29.3 29.6 29.8 .56 6 27.5 29.6 30.6 28.5 29.0 1.34 4 30.0 29.9 29.0 29.7 29.2 29.3 29.5 .41 6 419 380 577 681 472 652 530 125.0 6 .3 .5 .5 .0 .2 .3 .3 .19 6 469 675 341 813 574 210.3 4 .5 .6 .1 .2 .4 .24 4 469 546 375 569 635 366 493 109.0 6 1.4 .5 .7 .0 .0 .3 .5 .53 6 19 31 35 0 13 19 20 12.6 6 36 37 7 16 24 14.9 4 90 33 52 0 0 20 32 34.5 6 Z&TCOO 505 ANIMAL NUMBER Appendix 4 Individual Clinical Hematology Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XlOV^L G/DL FL PG % X10V//L % Covance 6329-223 3M T-6295.7 RETIC XIOV/iL Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level: 0.75 7.63 6.94 6.89 5.90 7.20 6.73 13.4 12.0 11.9 11.4 13.1 13.1 6.88 .575 6 12.5 .82 6 Dosage Unit: mg/kg/day 45.8 41.5 42.3 40.3 44.5 44.1 60.0 59.7 61.4 68.4 61.8 65.5 17.6 17.3 17.3 19.4 18.1 19.5 43.1 2.06 6 62.8 3.44 6 18.2 1.01 6 29.3 28.9 28.1 28.4 29.3 29.7 29.0 .61 6 519 58 409 528 342 636 415 202.6 6 .6 .3 .4 1.4 .2 .1 .5 .47 6 46 21 28 83 14 7 33 27.1 6 506 ANIMAL NUMBER Group : 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group : 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N WBC XIOV^L Appendix 4 Individual Clinical Hematology Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XIOV^L XIOVm L MONO EOS IN XloV/iL x i o V m l BASO N-SEG% LYMPH% X10 /m L MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Dose Level : 0 Dosage Unit: mg/kg/day 6.6 2.1 4.0 .4 .0 0 32 61 6 0 0 9.2 3.3 4.7 1.0 .1 1 36 52 11 1 1 6.7 3.1 3.1 .4 .2 0 46 46 5 2 0 9.0 5.1 3.0 .8 .0 1 56 34 9 0 1 11.3 5.4 5.3 .5 .1 0 48 47 5 1 0 8.9 4.4 3.7 .7 .1 0 49 41 8 1 0 8.6 1.76 6 3.9 1.28 6 Dose Level : 0 .03 4.0 .6 .1 .90 .24 .08 666 Dosage Unit: mg/kg/day 0 44 47 7 1 0 05 8.9 9.2 2.4 .8 .5 666666 11.7 11.5 9.5 11.1 7.2 3.2 4.0 6.3 11.0 1.00 4 5.2 1.88 4 Dose Level : 0 .15 4.0 .4 6.2 1.5 4.4 .9 4.0 .6 .2 .5 .1 .2 4.6 .8 .2 1.05 .48 .17 444 Dosage Unit: mg/kg/day 0 62 34 3 2 0 0 28 54 13 4 0 0 42 47 10 1 0 0 56 36 6 2 0 0 47 43 8 2 0 00 15.2 9.4 4.4 1.3 .0 444444 12.5 9.4 2.4 .6 .1 .0 75 19 5 1 0 11.1 5.8 4.2 1.0 .1 .0 52 38 9 1 0 10.7 4.8 4.6 1.3 .0 .0 45 43 12 0 0 15.0 9.8 3.7 .8 .6 .0 66 25 5 4 0 9.4 4.2 4.0 1.1 .0 .1 45 42 12 0 1 12.7 5.3 5.9 .8 .7 .0 42 46 6 5 0 11.9 6.6 4.1 .9 .2 .0 54 36 8 2 0 1.95 2.42 1.14 .25 .31 .04 13.4 10.9 3.3 2.1 .4 6 66 6 666 6 66 6 003144 507 ANIMAL NUMBER Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N WBC X10 /*<L Appendix 4 Individual Clinical Hematology Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XIOVidj XIOVaL MONO EOSIN XIOV^L X103/h L BASO N-SEG% X10V*<L LYMPHS MONO EOSIN Covance 6329-223 3M T-6295.7 BASO Dose Level : 0.75 Dosage Uni t : mg/kg/day 9.3 3.0 5.0 1.1 .2 .1 32 54 12 2 1 13.7 4.9 6.3 2.1 .1 .2 36 46 15 1 2 7.5 3.3 2.8 .7 .7 .0 44 37 9 9 0 8.0 3.9 3.3 .6 .1 .0 49 41 8 1 0 7.1 1.6 4.3 1.2 .0 .0 22 60 16 0 1 11.0 5.5 4.1 1.1 .2 .1 50 37 10 2 1 9.4 3.7 4.3 1.1 .2 .1 39 46 12 2 1 2.53 1.40 1.25 .53 .25 .08 10.9 9.5 3.3 3.3 66666666666 003145 508 Appendix 4 Individual Clinical Hematology Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105508 _ _ _ _ 105517 - -- - - 105519 - -- -- 105520 - - - - - 105526 - - - - - 105527 - --- Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day 105514 - _ - 105515 - - - -- 105516 - - -- - 105521 - - - " - Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 _ _ _ 105510 - - - - - 105518 - - - - - 105523 - - - - - 105524 - - - - - 105528 - - - " - Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105506 _ _ _ _ 105507 - - - - - 105509 - - - - 105511 - - - - _ 105512 - - - - - 105522 - - - - - Covance 6329-223 3H T-6295.7 003146 509 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB ' HCT MCV MCH MCHC PLT RETIC XlOVi^L G/DL % FL PG % XIOVm D % Covance 6329-223 3M T-6295.7 RETIC X10 /m l Dose Level : 0 5.96 6.78 5.72 6.66 4.98 6.45 11.5 13.3 10.5 12.2 11.6 12.6 6.09 .681 6 12.0 .97 6 Dose Level: 0.03 6.13 5.78 6.30 7.02 10.6 12.0 10.7 12.8 6.31 .522 4 11.5 1.06 4 Dose Level : 0.15 6.95 6.16 6.23 6.72 6.76 6.39 12.7 11.3 11.7 12.3 11.8 12.0 6.54 .320 6 12.0 .49 6 Dosage Unit: mg/kg/day 37.1 45.0 34.7 40.8 36.2 41.9 62.2 66.4 60.6 61.3 72.7 65.0 19.3 19.6 18.3 18.3 23.2 19.5 39.3 3.93 6 64.7 4.51 6 19.7 1.81 6 Dosage Unit: mg/kg/day 36.7 40.0 37.4 43.9 59.9 69.1 59.3 62.5 17.3 20.8 17.0 18.2 39.5 3.26 4 62.7 4.49 4 18.3 1.73 4 Dosage Unit: mg/kg/day 43.2 38.3 39.2 40.7 38.0 41.1 62.2 62.1 62.9 60.6 56.2 64.2 18.2 18.4 18.8 18.3 17.4 18.7 40.1 1.97 6 61.4 2.79 6 18.3 .50 6 31.0 29.5 30.2 29.9 31.9 30.1 30.4 .87 6 28.8 30.2 28.6 29.1 29.2 .71 4 29.3 29.6 29.9 30.1 31.0 29.1 29.8 .68 6 631 552 584 577 471 417 539 79.5 6 .4 .3 .1 .5 1.3 1.0 .6 .46 6 529 426 558 414 482 72.4 4 .3 .9 .4 .2 .4 .31 4 433 475 477 325 615 560 481 100.9 6 .4 .3 .8 .1 .4 .7 .4 .26 6 24 20 6 33 65 64 35 24.2 6 18 52 25 14 27 17.1 4 28 18 50 7 27 45 29 16.2 6 frTCOQ 510 ANIMAL NUMBER Group : 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XIOV/^L G/DL % FL PG % X103/m L Covance 6329-223 3M T-6295.7 RETIC X I O V aL Dose Level : 0.75 6.46 6.72 6.67 6.21 6.57 6.35 12.1 13.1 12.1 11.8 12.0 11.7 6.50 .195 6 12.1 .50 6 Dosage Unit: mg/kg/day 41.2 44.2 41.7 39.6 42.4 40.0 63.8 65.8 62.6 63.8 64.5 63.0 18.7 19.5 18.2 19.0 18.2 18.5 41.5 1.68 6 63.9 1.14 6 18.7 .50 6 29.3 29.6 29.1 29.8 28.3 29.4 29.2 .52 6 337 438 606 433 492 304 435 108.9 6 .2 .4 .1 .0 .4 .4 .2 .18 6 13 27 7 0 26 25 16 11.4 6 003148 511 ANIMAL NUMBER WBC X I O V aL Appendix 4 Individual Clinical Hematology Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH X I O V m L x i o '/m l 'MONO xioV ml EOSIN xioViiL BASO N -SEG% xioyub LYMPH% MONO EOSIN Covance 6329-223 3M T-6295.7 O O OOMMOO I O O M O Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 7.4 3.4 3.3 .6 .2 .0 45 45 8 2 105530 11.7 6.0 4.9 .7 .1 .0 51 42 6 1 105531 8.4 5.0 2.6 .7 .1 .1 59 31 8 1 105535 12.6 5.0 6.0 .8 .6 .1 39 48 7 5 105544 13.0 5.3 5.8 1.2 .7 .0 40 44 9 6 105549 8.0 3.1 4.3 .5 .1 .0 38 54 6 2 MEAN S.D. N 10.2 4.6 4.5 .8 .3 .0 45 44 7 3 2.52 1.14 1.36 .24 .28 .05 8. 3 7..6 1. 2 2..1 6666666666 Group: 2 Dose Level : 0 .03 Dosage Unit: mg/kg/day 105537 105541 105547 105550 12.2 8.6 2.7 .6 .2 .0 70 22 5 8.1 3.0 4.1 .9 .1 .1 36 50 11 6.8 3.6 2.5 .6 .1 .0 53 36 9 7.6 4.6 2.4 .5 .1 .0 60 32 6 2 1 2 1 MEAN S.D. N 8.7 5.0 2.9 .6 .1 .0 55 35 8 2 2.41 2.52 .79 .17 .05 .05 14.,3 11..6 2..8 6 4444444444 Group: 3 Dose Level : 0 .15 Dosage Unit: mg/kg/day 105532 105538 105539 105545 105548 105552 7.6 2.6 3.6 1.2 .2 .0 35 48 15 12.0 7.4 3.7 .7 .2 .0 62 31 6 7.1 2.6 3.5 .9 .2 .0 36 49 12 14.4 9.4 4.2 .7 .0 .0 65 29 5 11.3 5.4 4.4 .8 .7 .0 48 39 7 8.0 3.3 3.4 .7 .6 .1 41 42 9 2 2 2 0 6 8 MEAN S.D, N 10.1 5.1 3.8 .8 .3 .0 48 40 9 3 2.94 2.81 .40 ,20 .27 .04 13. 0 8. 4 3. 8 3. 0 6666666666 -OOOOO 003149 512 ANIMAL NUMBER Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N WBC XlOV^iL Appendix 4 Individual Clinical Hematology Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH `MONO EOS IN X103/m L xioV/zL X103/aL XIOV^L BASQ N-SEG% XIOV^L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Dose Level : 0.75 Dosage Unit: mg/kg/day 10.0 4.1 5.1 .7 .0 .0 41 51 7 0 0 13.3 6.9 5.2 .7 .4 .0 52 39 6 3 0 9.6 4.4 3.5 1.3 .3 .1 46 36 14 3 1 8.9 5.4 2.4 .9 .1 .0 61 27 10 1 0 8.3 5.9 2.0 .4 .0 .0 71 24 4 0 0 3.8 2.0 1.2 .5 .0 .0 53 32 14 1 0 9.0 4.8 3.2 .8 .1 .0 54 35 9 1 0 3.08 1.70 1.66 .32 .18 .04 10.7 9.7 4.2 1.4 6666 666666 6 OSTCOO 513 Appendix 4 Individual Clinical Hematology Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105529 105530 105531 105535 105544 105549 Group: 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0 Dose Level: 0.03 Dose Level: 0.15 Dose Level: 0.75 Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Covance 6329-223 3M T-6295.7 003151 514 ANIMAL NUMBER Group: 1 I0550B 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XlOV/iL G/DL t FL PG % x i o 3/a<l Covance 6329-223 3M T-6295.7 RETIC XlOVAiL Dose Level: 0 6.53 6.32 6.83 6.50 6.20 6.34 13.0 13.0 12.2 12.1 11.6 12.2 6.45 .221 6 12.4 .55 6 Dose Level : 0.03 7.32 6.51 6.35 7.26 13.0 12.5 12.2 12.2 6.86 .501 4 12.5 .38 4 Dose Level : 0.15 6.34 6.99 7.20 6.78 6.31 6.34 12.8 12.3 12.7 12.6 12.3 12.1 6.66 .385 6 12.5 .27 6 Dosage Unit: mg/kg/day 41.4 42.7 40.9 39.5 38.6 40.6 63.4 67.5 59.8 60.7 62.3 64.0 19.9 20.5 17.8 18.6 18.7 19.3 40.6 1.44 6 63.0 2.74 6 19.1 .97 6 Dosage Unit: mg/kg/day 47.9 42.5 39.0 40.3 65.5 65.2 61.4 55.6 17.8 19.2 19.2 16.8 42.4 3.93 4 61.9 4.61 4 18.2 1.17 4 Dosage Unit: mg/kg/day 41.3 41.5 42.1 41.3 41.4 39.8 65.1 59.3 58.5 60.9 65.6 62.7 20.3 17.6 17.7 18.5 19.5 19.1 41.2 .76 6 62.0 2.96 6 18.8 1.06 6 31.4 30.4 29.8 30.7 30.0 30.1 30.4 .58 6 27.2 29.4 31.2 30.1 29.5 1.69 4 31.1 29.7 30.2 30.5 29.7 30.4 30.3 .53 6 369 443 474 644 375 614 486 117.8 6 492 629 344 665 532 146.1 4 421 483 498 544 519 388 476 59.6 6 .1 .2 .3 .1 .1 .5 .2 .16 6 .6 .8 .3 .0 .4 .35 4 .3 .4 .6 .4 .2 .3 .4 .14 6 7 13 20 6 6 32 14 10.4 6 44 52 19 0 29 23.8 4 19 28 43 27 13 19 25 10.5 6 003152 515 ANIMAL NUMBER Appendix 4 Individual Clinical Hematology Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC X106/m L G/DL % FL PG % XIOV^L % Covance 6329-223 3M T-6295.7 RETIC XIOV^L Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 7.03 6.57 6.84 5.80 6.60 6.32 12.3 11.4 12.1 10.9 12.1 12.3 6.53 .431 6 11.8 .57 6 Dosage Unit: mg/kg/day 41.0 39.6 41.9 37.1 40.3 41.5 58.3 60.2 61.3 63.9 61.0 65.6 17.4 17.3 17.6 18.8 18.3 19.4 40.2 1.74 6 61.7 2.63 6 18.1 .85 6 29.9 28.7 28.8 29.5 30.1 29.6 29.4 .57 6 459 69 PA 399 490 362 519 383 164.3 6 .3 .3 .3 .4 .5 .5 .4 .10 6 21 20 21 23 33 32 25 5.! 6 stc o o 516 ANIMAL NUMBER Group : 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N WBC XIOVm L Appendix 4 Individual Clinical Hematology Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XIO V m L X10 /m l MONO xioV ml EOSIN xioV ml BASO N -SEG% XIOVm L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Dose Level : 0 Dosage Unit: mg/kg/day 5.2 1.8 2.9 .4 .0 .0 34 57 9 1 0 7.8 2.5 4.2 .9 .0 .2 32 53 12 0 2 7.1 3.5 3.4 .2 .1 .0 49 48 3 1 0 6.8 3.5 2.9 .4 .0 .0 52 43 5 0 0 7.5 4.7 2.2 .3 .2 .0 63 30 4 3 0 11.2 7.5 2.8 .9 .0 .0 67 25 8 0 0 7.6 3.9 3.1 .5 .0 .0 50 43 7 1 0 1.98 2.01 .67 .31 .08 .08 14. 4 12. 8 3..4 1. 2 8 66666666666 Dose Level : 0 .03 Dosage Unit: mg/kg/day 11.9 5.9 5.3 .5 .2 .0 50 44 4 2 0 8.0 3.1 4.1 .6 .2 .0 39 51 7 2 0 12.1 8.2 3.1 .7 .2 .0 67 25 5 2 0 11.0 8.1 2.4 .3 .1 .0 74 22 3 1 0 10.8 6.3 3.7 .5 .2 .0 58 36 5 2 0 1.89 2.40 1.26 .17 .05 .00 15. 9 14. 2 1,.7 .5 .0 44444444444 Dose Level : 0 .15 Dosage Unit: mg/kg/day 11.7 9.3 2.0 .2 .3 .0 79 17 2 2 0 8.8 5.1 2.9 .7 .0 .0 58 32 8 1 0 9.4 3.9 4.6 .8 .0 .0 42 49 8 0 0 11.1 7.0 3.6 .4 .1 .0 63 32 4 1 0 6.9 3.5 2.6 .8 .0 .1 50 37 12 0 1 12.4 7.2 3.6 .7 .8 .1 58 30 5 6 0 10.0 6.0 3.2 .6 .2 .0 58 33 6 2 0 2.06 2.23 .91 .24 .32 .05 12. 5 10. 4 3. 6 2. 3 4 66666666666 003154 517 ANIMAL NUMBER Group : 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N WBC X103/m L Appendix 4 Individual Clinical Hematology Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH X103/*tL X103/#iL MONO EOS IN X103/m L XIOVwL BASO N-SEG% X103/^L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Dose Level : 0.75 Dosage Unit: mg/kg/day 7.1 3.4 2.9 .7 .1 .0 48 41 9 1 1 17.9 13.3 3.8 .7 .1 .1 74 21 4 0 1 11.6 8.0 2.8 .4 .3 .0 69 24 4 3 0 8.5 5.5 2.4 .5 .1 .1 65 28 6 1 1 6.6 3.5 2.4 .7 .0 .0 53 36 10 0 1 10.2 6.2 3.0 .9 .0 .1 61 30 9 0 1 10.3 6.6 2.9 .6 .1 .0 62 30 7 1 1 4.16 3.69 .52 .18 .11 .05 9.8 7.5 2.7 1.2 66666666666 SSTOO 518 Appendix 4 Individual Clinical Hematology Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105508 105517 105519 105520 105526 105527 Group: 2 105514 105515 105516 105521 Group: 3 105505 105510 105518 105523 105524 105528 Group: 4 105506 105507 105509 105511 105512 105522 Dose Level: 0 _ -- -- --- -- Dose Level: 0.0: __ -- -- -- Dose Level: 0.1! __ -- ---- - Dose Level: 0.7! __ -- ---- -- Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Covance 6329-223 3M T-6295.7 003156 519 ANIMAL NUMBER Appendix 4 Individual Clinical Hematology Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC X106//<L G/DL % FL PG % xioV ml % Covance 6329-223 3M T-6295.7 RETIC XIOV^L Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level: 0 6.43 6.51 6.37 6.52 5.78 6.85 12.3 12.7 11.6 11.8 11.6 13.3 6.41 .351 6 12.2 .69 6 Dose Level : 0.03 6.60 5.70 6.79 7.29 10.9 11.7 11.6 13.2 6.60 .664 4 11.8 .97 4 Dose Level : 0.15 6.43 6.40 6.35 6.85 7.09 6.19 11.9 11.3 12.0 12.4 11.9 11.4 6.55 .343 6 11.8 .41 6 Dosage Unit: mg/kg/day 40.4 42.1 38.8 39.1 37.9 44.4 62.8 64.7 60.8 60.0 65.6 64.8 19.1 19.6 18.1 18.0 20.0 19.5 40.5 2.42 6 63.1 2.31 6 19.0 .83 6 Dosage Unit: mg/kg/day 38.1 40.5 39.0 44.7 57.8 70.9 57.4 61.3 16.6 20.6 17.0 18.1 40.6 2.92 4 61.8 6.28 4 18.1 1.80 4 Dosage Unit: mg/kg/day 39.5 38.4 40.6 41.2 39.8 38.8 61.3 60.1 63.8 60.1 56.1 62.7 18.5 17.7 18.9 18.1 16.8 18.5 39.7 1.06 6 60.7 2.68 6 18.1 .75 6 30.5 30.2 29.8 30.0 30.5 30.0 30.2 .29 6 28.7 29.0 29.7 29.6 29.2 .48 4 30.1 29.5 29.5 30.1 29.8 29.5 29.7 .29 6 647 629 439 538 499 475 538 84.2 6 448 391 417 411 417 23.6 4 451 398 406 300 553 478 431 85.3 6 .3 .5 .2 .1 .4 .5 .3 .16 6 .3 .7 .1 .1 .3 .28 4 .4 .4 .1 .3 .3 .2 .3 .12 6 19 33 13 7 23 34 22 10.8 6 20 40 7 7 18 15.6 4 26 26 6 21 21 12 19 8.0 6 003157 520 ANIMAL NUMBER Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC X106/m L G/DL FL PG XlOV^iL Covance 6329-223 3M T-6295.7 RETIC xioV m Dose Level: 0.75 6.04 5.91 6.43 6.09 6.66 6.12 11.6 11.3 11.7 11.4 12.2 11.1 6.21 .280 6 11.6 .38 6 Dosage Unit : mg/kg/day 38.0 38.4 41.3 37.1 41.8 37.9 62.8 65.0 64.2 60.9 62.8 62.0 19.1 19.2 18.3 18.7 18.3 18.2 39.1 1.96 6 63.0 1.48 6 18.6 .44 6 30.5 29.5 28.4 30.8 29.2 29.3 29.6 .89 6 345 532 531 501 555 351 469 95.4 6 .3 .7 .2 .1 .2 .5 .3 .23 6 18 41 13 6 13 31 20 13.1 6 003158 521 animal NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group : 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N WBC XIOVm L Appendix 4 Individual Clinical Hematology Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XIOV^L x i o 3/m l MONO EOSIN XIOV/ZL XIOViiL BASO N -SEG% XlOV/aL LYMPH% MONO* EOSIN% Covance 6329-223 3M T-6295.7 BASO% Dose Level: 0 Dosage Unit: mg/kg/day 9.6 6.2 2.8 .5 .1 .0 65 30 5 1 0 12.1 8.3 2.8 1.0 .0 .0 68 23 8 0 0 14.6 11.7 1.9 .9 .1 .1 80 13 6 1 0 21.4 12.2 5.9 2.4 .7 .2 57 28 11 3 1 8.6 2.3 5.2 .7 .3 .0 26 61 8 4 1 10.1 5.9 2.8 1.0 .4 .0 58 28 10 4 0 12.7 4.75 6 7.8 3.77 6 Dose Level : 0.03 3.6 1.59 6 1.1 .67 6 .3 .26 6 Dosage Unit: mg/kg/day .0 59 30 8 2 0 .08 18.2 16. 2 2.,3 1..7 .5 666666 7.7 3.5 2.8 .8 .5 .1 46 36 10 6 2 11.5 6.5 3.7 1.1 .2 .0 56 32 10 2 0 7.3 5.0 1.7 .5 .1 .0 68 24 7 1 0 11.7 7.9 2.8 .8 .2 .0 68 24 6 2 0 9.6 5.7 2.8 .8 .2 .0 60 29 8 3 0 2.37 1.90 .82 .24 .17 .05 10.6 6.,0 2. 1 2. 2 1, 0 44444444444 Dose Level : 0.15 Dosage Unit: mg/kg/day 8.0 5.4 2.0 .4 .1 .0 68 25 5 2 0 9.4 5.1 3.4 .6 .3 .0 54 36 6 3 0 4.4 1.2 2.8 .4 .1 .0 26 63 8 2 0 10.0 5.2 3.9 .7 .1 .0 52 39 7 1 0 11.7 7.7 3.0 .5 .4 .0 66 26 4 4 0 11.2 8.2 2.2 .4 .5 .0 73 19 4 4 0 9.1 5.5 2.9 .5 .2 .0 56 35 6 3 0 2.66 2.48 .72 .13 .18 .00 17.0 15. 7 1. 6 1. 2 0 66666666666 6STD00 522 ANIMAL NUMBER Group : 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N WBC XloVrtL Appendix 4 Individual Clinical Hematology Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XIOVm L XIOVaL MONO EOSIN XlOVnL XIOVm L BASO N-SEG% X10///L LYMPH% MONO EOSIN Covance 6329-223 3M T-6295.7 BASO Dose Level : 0.75 Dosage Unit: mg/kg/day 8.8 3.9 4.4 .4 .0 .0 45 50 5 0 0 8.8 4.6 3.0 .9 .2 .0 52 34 11 3 1 7.6 4.8 2.0 .6 .1 .0 63 27 8 2 0 9.7 5.0 3.9 .6 .1 .0 51 40 7 1 0 13.7 11.5 1.8 .4 .0 .0 84 13 3 0 0 5.0 2.2 2.3 .4 .1 .0 44 47 7 2 0 8.9 5.3 2.9 .6 .1 .0 56 35 7 1 0 2.85 3.19 1.06 .20 .08 .00 15.1 13.7 2.7 1.2 66666666666 003160 523 Appendix 4 Individual Clinical Hematology Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105529 105530 105531 105535 105544 105549 Dose Level: 0 ___ ___ ___ ___ ___ Group: 2 105537 105541 105547 105550 Dose Level: 0.03 ___ ___ ___ ___ Group: 3 105532 105538 105539 105545 105548 105552 Dose Level: 0.15 ___ ___ ___ ___ ___ Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0.75 --___ ___ - Dosage Unit: mg/kg/day __ __ __ __ __ Dosage Unit: mg/kg/day __ __ __ __ Dosage Unit: mg/kg/day __ __ __ __ __ Dosage Unit: mg/kg/day -__ __ Covance 6329-223 3M T-6295.7 T9TC00 524 ANIMAL NUMBER Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XIOVliL G/DL % FL PG % X103/#/L % Covance 6329-223 3M T-6295.7 RETIC XlOV/iL Dose Level : 0 6.68 6.29 6.93 6.53 6.10 6.43 13.2 12.9 12.2 12.4 11.7 12.5 6.49 .292 6 12.5 .53 6 Dose Level: 0.03 6.86 6.61 6.44 7.44 12.2 12.6 12.0 12.7 6.84 .437 4 12.4 .33 4 Dose Level : 0.15 6.47 6.82 7.10 6.51 6.54 6.19 13.0 12.4 12.7 12.7 12.6 11.5 6.60 .315 6 12.5 .52 6 Dosage Unit: mg/kg/day 42.0 42.8 41.6 39.9 38.1 42.3 62.8 68.0 59.9 61.1 62.4 65.8 19.8 20.4 17.6 18.9 19.1 19.4 41.1 1.78 6 63.3 3.03 6 19.2 .95 6 Dosage Unit : mg/kg/day 41.7 42.3 39.4 42.2 60.9 63.9 61.1 56.8 17.7 19.1 18.7 17.1 41.4 1.36 4 60.7 2.92 4 18.2 .91 4 Dosage Unit: mg/kg/day 41.6 40.1 41.5 40.9 42.1 38.2 64.2 58.8 58.5 62.8 64.3 61.8 20.1 18.2 17.8 19.5 19.3 18.6 40.7 1.42 6 61.7 2.56 6 18.9 .87 6 31.5 30.1 29.4 31.0 30.7 29.5 30.4 .84 6 29.1 29.9 30.6 30.0 29.9 .62 4 31.3 30.9 30.5 31.0 30.0 30.2 30.6 .50 6 463 423 524 699 377 644 522 126.9 6 .1 .5 .3 .0 .1 .7 .3 .27 6 438 647 376 684 536 152.1 4 .1 1.0 .4 .0 .4 .45 4 450 499 578 625 520 349 504 97.3 6 .5 .5 .6 .1 .0 .2 .3 .25 6 7 31 21 0 6 45 18 17.3 6 7 66 26 0 25 29.6 4 32 34 43 7 0 12 21 17.3 6 Z9TC00 525 ANIMAL NUMBER Appendix 4 Individual Clinical Hematology Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XIOViiL G/DL % FL PG % xioVnL % Covance 6329-223 3M T-6295.7 RETIC XIOV/iL Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 7.46 6.81 6.69 5.86 6.90 6.65 13.1 12.1 11.9 11.1 12.8 12.8 6.73 .516 6 12.3 .75 6 Dosage Unit: mg/kg/day 43.4 40.5 40.0 37.6 41.6 43.8 58.2 59.4 59.8 64.1 60.3 65.9 17.6 17.7 17.7 18.9 18.5 19.3 41.2 2.31 6 61.3 3.02 6 18.3 .72 6 30.2 29.8 29.6 29.5 30.7 29.3 29.8 .52 6 534 36 480 629 359 586 437 217.8 6 .3 .1 .5 .4 .0 .4 .3 .19 6 22 7 33 23 0 27 19 12.6 6 C9TOO 526 ANIMAL NUMBER Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N WBC XlOV^L Appendix 4 Individual Clinical Hematology Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH x i o V m l X103/m L MONO EOS IN X10 /m l XIOV/iL BASO N-SEG% xioV ml LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Dose Level : 0 7.4 3.7 8.0 2.1 6.7 3.1 8.0 3.8 6.0 3.2 7.8 2.4 7.3 .81 6 3.0 .68 6 Dose Level : 0 .03 8.1 10.3 12.1 11.6 5.0 4.6 7.3 7.5 10.5 1.79 4 6.1 1.51 4 Dose Level : 0 .15 10.8 13.3 9.9 12.7 7.7 16.4 8.0 8.7 3.2 7.7 3.2 11.1 11.8 3.02 6 7.0 3.16 6 Dosage Unit: mg/kg/day 3.3 .4 4.7 1.0 3.2 .4 3.4 .6 2.2 .5 4.2 .9 .0 .1 .0 .1 .1 .2 3.5 .6 .1 .87 .26 .08 666 Dosage Unit: mg/kg/day 2.3 .5 4.3 1.2 3.5 1.1 3.4 .5 .2 .2 .1 .2 3.4 .8 .2 .82 .38 .05 444 Dosage Unit: mg/kg/day 2.3 .2 3.7 .7 5.8 .8 4.5 .4 3.4 1.0 3.6 1.3 .3 .1 .1 .1 .1 .4 3.9 .7 .2 1.18 .40 .13 666 .0 49 45 5 1 0 .1 27 59 12 1 2 .0 46 48 5 1 0 .1 48 43 7 1 1 .0 52 36 9 2 0 .0 31 54 12 3 0 .0 42 48 8 2 0 .05 10. 5 8. 2 3..2 .8 .8 66 666 6 .0 62 29 6 2 0 .0 44 42 12 2 0 .0 61 29 9 1 0 .0 65 29 4 2 0 .0 58 32 8 2 0 .00 9. 5 6.,5 3.,5 .5 .0 444444 .0 73 21 2 3 0 .0 65 28 6 1 0 .0 32 59 8 1 0 .0 60 36 3 1 0 .1 41 44 13 1 1 .1 68 22 8 2 0 .0 56 35 7 2 0 .05 16. 3 14. 6 4. 0 8 .4 66 666 6 003164 527 ANIMAL NUMBER Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N WBC XloVnL Appendix 4 Individual Clinical Hematology Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH xioVnt XIOV^L MONO EOS IN XIOVm L XIOVnL BASO N-SEG% X10V//L LYMPH% MONO% EOSIN% Covance 6329-223 3H T-6295.7 BASO% Dose Level : 0.75 Dosage Unit: mg/kg/day 6.5 2.5 3.5 .4 .1 .0 38 54 6 1 0 14.6 9.6 3.6 1.0 .2 .2 66 24 7 2 1 10.6 6.4 2.8 .7 .6 .1 60 27 7 6 1 7.7 4.2 3.0 .4 .1 .0 54 39 5 1 0 7.7 3.6 3.5 .6 .0 .0 46 45 8 0 0 10.7 5.5 4.3 .7 .2 .0 51 40 6 2 0 9.6 5.3 3.4 .6 .2 .0 52 38 6 2 0 2.97 2.52 .52 .23 .21 .08 10.0 11.2 1.0 2.1 666 6666 6 6 6 6 9T00 528 Appendix 4 Individual Clinical Hematology Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105508 _ _ _ 105517 - - - 105519 - - - 105520 - - - 105526 - - - 105527 - _- --- -- -- "- Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day 105514 105515 105516 105521 _ - - _ - ___ --- - -*-- Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 - - _ _ _ 105510 - -- - - 105518 - - - - - 105523 - - - - - 105524 - - - - - 105528 - -*- Group: 4 105506 105507 105509 105511 105512 105522 Dose Level: 0.75 __ ------ - Dosage Unit: mg/kg/day _ -_ ----- Covance 6329-223 3M T-6295.7 0031G 6 529 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group : 2 105537 105541 105547 105550 MEAN S.D. N Group : 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC xioV ml G/DL % FL PG % X103//iL Covance 6329-223 3M T-6295.7 RETIC X103///L Dose Level: 0 6.15 5.93 6.56 7.02 4.91 6.83 12.0 12.1 12.1 12.7 11.5 13.4 6.23 .766 6 12.3 .66 6 Dose Level : 0.03 6.44 5.67 6.82 7.01 10.9 12.2 11.9 12.9 6.48 .593 4 12.0 .83 4 Dose Level : 0.15 9.13 6.64 6.45 6.74 6.80 6.21 17.2 11.8 12.5 12.2 11.7 11.6 7.00 1.068 6 12.8 2.17 6 Dosage Unit: mg/kg/day 38.4 39.7 40.5 42.4 35.4 44.9 62.4 66.8 61.6 60.4 72.1 65.8 19.5 20.3 18.5 18.2 23.4 19.6 40.2 3.27 6 64.9 4.33 6 19.9 1.87 6 Dosage Unit: mg/kg/day 37.8 40.5 39.2 43.4 58.8 71.3 57.4 62.0 16.9 21.4 17.4 18.4 40.2 2.39 4 62.4 6.25 4 18.5 2.02 4 Dosage Unit: mg/kg/day 55.9 40.0 40.4 40.3 38.4 38.9 61.2 60.3 62.6 59.8 56.4 62.6 18.8 17.8 19.3 18.0 17.2 18.6 42.3 6.70 6 60.5 2.31 6 18.3 .76 6 31.3 30.4 30.0 30.0 32.4 29.8 30.6 1.01 6 28.8 30.1 30.3 29.7 29.7 .67 4 30.8 29.5 30.9 30.2 30.4 29.7 30.3 .57 6 668 515 644 600 506 501 572 74.6 6 357 507 548 437 462 83.8 4 306 456 374 326 667 486 436 133.5 6 .5 .6 .1 .3 .7 .5 .4 .22 6 .3 .7 .8 .0 .4 .37 4 .1 .6 .0 .7 .3 .5 .4 .28 6 31 36 7 21 34 34 27 11.2 6 19 40 55 0 28 24.1 4 9 40 0 47 20 31 24 18.2 6 003167 530 ANIMAL NUMBER Appendix 4 Individual Clinical Hematology Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC X106/m L G/DL % FL PG % X10V//L % Covance 6329-223 3M T-6295.7 RETIC XlOViiL Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 6.04 5.74 6.72 6.13 6.75 6.32 11.7 11.4 12.2 11.9 12.1 11.7 6.28 .397 6 11.8 .29 6 Dosage Unit : mg/kg/day 39.0 37.9 42.6 39.5 42.6 39.5 64.6 66.0 63.5 64.5 63.0 62.5 19.3 19.8 18.2 19.4 18.0 18.6 40.2 1.96 6 64.0 1.27 6 18.9 .72 6 29.9 30.0 28.7 30.1 28.5 29.7 29.5 .70 6 355 620 622 432 665 333 504 148.3 6 .4 .5 .1 .6 .0 .1 .3 .25 6 24 29 7 37 0 6 17 14.' 6 003168 531 ANIMAL NUMBER WBC X103//iL Appendix 4 Individual Clinical Hematology Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH 'MONO EOSIN BASO N-SEG% XI03/A X103/aL X10 /m l X103/*iL X10V/iL LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 5.8 2.9 2.2 .5 .1 .0 50 38 9 1 1 105530 13.0 7.8 4.5 .5 .1 .0 60 35 4 1 0 105531 14.1 9.9 3.0 .9 .2 .1 70 22 6 1 1 105535 10.9 3.5 5.4 1.4 .5 .2 32 49 13 5 1 105544 10.5 2.9 7.0 .0 .5 .0 27 67 0 5 0 105549 12.4 7.9 3.7 .4 .3 .0 64 30 3 2 0 MEAN S.D. N 11.1 5.8 4.3 .6 .3 .0 50 40 6 2 0 2.93 3.08 1.73 .48 .18 .08 17. 6 15,,9 4..6 2..0 .5 66666666666 Group: 2 Dose Level : 0 .03 Dosage Unit: mg/kg/day 105537 10.6 5.7 3.4 .8 .5 .1 54 33 8 5 1 105541 8.3 2.4 5.0 .6 .2 .1 29 61 8 2 1 105547 7.2 3.7 2.7 .5 .2 .0 52 38 7 2 0 105550 8.8 5.6 2.4 .7 .1 .0 63 27 8 1 0 MEAN S.D. N 8.7 4.4 3.4 .6 .2 .0 50 40 8 2 0 1.42 1.59 1.16 .13 .17 .06 14..5 14. 9 ,5 1. 7 6 44444444444 Group: 3 Dose Level : 0 .15 Dosage Unit: mg/kg/day 105532 8.9 5.7 2.3 .7 .1 .0 64 26 8 1 0 105538 10.6 5.7 4.1 .4 .4 .0 54 39 4 4 0 105539 6.1 2.2 3.1 .5 .2 .1 37 51 9 3 1 105545 9.7 4.0 5.0 .5 .2 .0 41 51 5 2 0 105548 7.1 2.3 3.7 .7 .3 .1 32 52 10 5 1 105552 10.1 6.0 3.2 .3 .5 .0 60 32 3 5 0 MEAN S.D. N 8.8 4.3 3.6 .5 .3 .0 48 42 6 3 0 1.78 1.75 .93 .16 .15 .05 13. 1 11. 2 2. 9 1. 6 5 6 66 6 6 66 6 6 6 6 G9TC00 532 ANIMAL NUMBER WBC x i o '/m l Appendix 4 Individual Clinical Hematology Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XIOV^L XlOVliL MONO EOSIN X103/m L XIOV/^L BASO N-SEG% XlOV^L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day O O iH O O O 105533 8.4 3.2 4.8 .4 .0 .0 38 57 4 0 105534 18.0 12.8 3.6 1.4 .2 .1 71 20 8 1 105536 6.7 3.9 1.8 .7 .2 .1 58 27 11 3 105540 8.1 4.5 2.9 .6 .1 .0 55 36 7 1 i 105542 10.0 6.9 2.6 .4 .1 .0 69 27 4 1 l 105551 4.8 2.1 2.3 .3 .1 .0 44 48 6 1 i MEAN S.D, N 9.3 5.6 3.0 .6 .1 .0 56 36 7 1 l 4.59 3.89 1.07 .40 .08 .05 13.2 14.2 2.7 1.0 6 666 6 66 6 66 i (V.TP0O 533 Appendix 4 Individual Clinical Hematology Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105529 105530 105531 105535 105544 105549 Dose Level: 0 --------- Group: 2 105537 105541 105547 105550 Dose Level: 0.03 ------- Group: 3 105532 105538 105539 105545 105548 105552 Dose Level: 0.15 ------------- Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0.75 ------------- Dosage Unit: mg/kg/day -- -- --- Dosage Unit: mg/kg/day -- --- Dosage Unit: mg/kg/day ------- Dosage Unit: mg/kg/day ------- Covance 6329-223 3M T-6295.7 003171 534 ANIMAL NUMBER Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XIOVm L G/DL % FL PG % XIOV/iL t Covance 6329-223 3M T-6295.7 RETIC X103/*iL Dose Level: 0 6.39 6.21 6.92 6.45 6.01 6.59 12.8 12.8 12.2 12.1 11.5 12.8 6.43 .314 6 12.4 .53 6 Dose Level: 0.03 6.96 6.71 6.43 7.88 12.3 12.8 12.2 13.4 7.00 .628 4 12.7 .55 4 Dose Level : 0.15 6.07 6.64 6.95 6.33 6.48 6.51 12.1 12.2 12.5 12.5 12.4 12.3 6.50 .295 6 12.3 .16 6 Dosage Unit: mg/kg/day 39.6 41.3 40.7 39.2 37.4 43.8 62.0 66.6 58.8 60.8 62.3 66.4 20.0 20.7 17.6 18.8 19.2 19.4 40.3 2.17 6 62.8 3.11 6 19.3 1.06 6 Dosage Unit: mg/kg/day 42.2 42.9 40.4 44.7 60.6 63.9 62.8 56.8 17.7 19.1 19.0 17.0 42.5 1.78 4 61.0 3.13 4 18.2 1.02 4 Dosage Unit: mg/kg/day 39.4 39.6 40.9 40.0 41.9 40.3 64.8 59.6 58.8 63.2 64.6 61.8 19.9 18.3 18.0 19.7 19.2 18.8 40.4 .93 6 62.1 2.53 6 19.0 .76 6 32.2 31.1 29.9 30.8 30.8 29.3 30.7 1.00 6 29.2 29.8 30.2 30.0 29.8 .43 4 30.7 30.7 30.5 31.2 29.7 30.5 30.6 .49 6 387 406 475 671 384 614 490 124.3 6 .3 .7 .1 .1 .2 .6 .3 .26 6 389 630 290 741 512 208.8 4 .3 1.0 1.3 .2 .7 .54 4 505 487 501 585 555 346 496 82.6 6 1.6 .4 .2 .4 .2 .3 .5 .54 6 19 43 7 6 12 40 21 16.4 6 21 67 84 16 47 33.7 4 97 27 14 25 13 20 33 32.0 6 000172 535 ANIMAL NUMBER Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC X106/*<L G/DL FL PG % Xl03/iiL % Covance 6329-223 3M T-6295.7 RETIC X10V//L Dose Level: 0.75 7.22 6.81 6.37 5.94 7.13 6.48 13.0 11.9 11.3 11.2 12.9 12.7 6.66 .488 6 12.2 .81 6 Dosage Unit: mg/kg/day 42.6 41.5 38.3 38.0 43.0 42.3 59.0 61.0 60.2 64.0 60.2 65.3 18.0 17.4 17.7 18.8 18.1 19.5 41.0 2.23 6 61.6 2.47 6 18.2 .77 6 30.5 28.6 29.4 29.4 30.0 29.9 29.6 .65 6 522 50 475 552 396 592 431 198.6 6 .3 .4 .6 .4 .1 .6 .4 .19 6 22 27 38 24 7 39 26 11.8 6 003173 536 ANIMAL NUMBER WBC X10 /iL Appendix 4 Individual Clinical Hematology Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH x i o V m l XIO V aL MONO EOS IN X10V*<L XlOV^iL BASO N -SEG% XIOV^L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105508 6.1 2.3 3.2 .3 .2 .0 38 52 5 4 1 105517 7.8 2.9 4.2 .6 .1 .1 37 54 8 1 1 105519 5.8 2.5 3.0 .2 .0 .0 44 52 3 1 0 105520 5.1 1.7 2.9 .4 .1 .0 34 57 8 1 1 105526 5.1 1.7 2.8 .4 .1 .0 34 56 8 3 0 105527 10.2 3.3 6.0 .6 .2 .0 33 59 6 2 0 MEAN S.D. N 6.7 2.4 3.7 .4 .1 .0 37 55 6 2 0 1.99 .64 1.24 .16 .08 .04 4..1 2..8 2..1 1.3 .5 66666666666 Group: 2 Dose Level : 0 .03 Dosage Unit: mg/kg/day 105514 6.9 3.5 2.6 .6 .3 .0 50 38 8 4 0 105515 7.7 2.4 4.5 .6 .2 .0 31 58 8 2 0 105516 10.6 6.4 3.4 .6 .1 .0 60 32 6 1 0 105521 8.7 5.3 2.7 .6 .1 .0 61 31 7 1 0 MEAN S.D. N 8.5 4.4 3.3 .6 .2 .0 50 40 7 2 0 1.60 1.79 .88 .00 .10 .00 13.,9 12,.6 1.,0 1.4 .0 44444444444 Group: 3 Dose Level : 0 .15 Dosage Unit: mg/kg/day 105505 8.9 6.2 2.2 .3 .1 .0 70 25 4 1 0 105510 10.7 6.4 3.2 .9 .1 .1 60 30 9 1 1 105518 15.8 7.9 6.8 1.0 .1 .1 50 43 6 1 1 105523 8.6 4.3 3.7 .4 .1 .0 50 43 5 1 0 105524 6.4 2.8 2.8 .7 .0 .1 44 44 11 0 1 105528 11.4 6.8 3.4 .6 .5 .0 59 30 6 5 0 MEAN S.D. N 10.3 5.7 3.7 .6 .2 .0 56 36 7 2 0 3.21 1.85 1.61 .27 .18 .05 9. 3 8. 4 2. 6 1.8 .5 66666666666 003174 537 ANIMAL NUMBER Group : 4 I055Q6 105507 105509 105511 105512 105522 MEAN S.D. N WBC xioV ml Appendix 4 Individual Clinical Hematology Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH x i o V m l X10V/^L MONO EOSIN x i o V m l X103/*iL BASO N-SEG% X103/*L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO Dose Level : 0.75 Dosage Unit: mg/kg/day 7.9 3.6 3.5 .6 .1 .0 46 45 7 1 1 10.3 5.0 3.9 1.1 .2 .1 48 38 10 2 1 9.1 5.3 2.8 .5 .4 .0 58 31 6 5 0 11.5 7.5 3.4 .4 .2 .0 65 30 4 1 0 5.3 2.0 2.7 .5 .0 .1 38 50 10 1 1 12.3 7.0 4.6 .3 .4 .0 57 37 2 3 0 9.4 5.1 3.5 .6 .2 .0 52 38 6 2 0 2.56 2.06 .71 .28 .16 .05 9.8 7.8 3.2 1.6 6666 6 666 66 6 003175 538 Appendix 4 Individual Clinical Hematology Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105508 _ _ _ _ _ 105517 - - --- 105519 - --- - 105520 - ---- 105526 - - -- - 105527 - --- Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day 105514 105515 105516 105521 .. - - _ - ___ -- - --- -- Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 _ __ 105510 - - -- - 105518 - - - - 105523 - --- - 105524 - - - - - 105528 - * - - - Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105506 _ _ _ 105507 - - - _ - 105509 - - - - - 105511 - - - - _ 105512 - - - - - 105522 - - - - - Covance 6329-223 3M T-6295.7 9TC00 539 ANIMAL NUMBER Group : 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group : 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC X10 /tL G/DL % FL PG % X103//iL % Covance 6329-223 3M T-6295.7 RETIC XIOVm L Dose Level: 0 6.13 6.50 6.44 6.71 5.26 6.81 11.9 13.0 12.0 12.1 11.3 13.4 6.31 .565 6 12.3 .77 6 Dose Level : 0.03 6.22 5.52 6.49 6.55 10.6 12.8 11.3 12.2 6.20 .472 4 11.7 .97 4 Dose Level : 0.15 6.49 6.70 6.16 6.89 6.59 6.14 12.2 12.0 12.1 12.7 11.5 11.7 6.50 .298 6 12.0 .42 6 Dosage Unit: mg/kg/day 38.3 43.2 39.2 40.1 37.0 44.1 62.5 66.5 60.9 59.9 70.4 64.7 19.4 20.0 18.6 18.0 21.5 19.7 40.3 2.79 6 64.1 3.90 6 19.5 1.21 6 Dosage Unit: mg/kg/day 37.1 40.8 37.5 41.3 59.7 73.9 57.8 63.0 17.0 23.1 17.5 18.6 39.2 2.18 4 63.6 7.19 4 19.0 2.78 4 Dosage Unit : mg/kg/day 40.0 40.8 39.3 40.9 37.6 37.8 61.6 61.0 63.8 59.3 56.9 61.6 18.8 18.0 19.7 18.4 17.5 19.0 39.4 1.44 6 60.7 2.35 6 18.6 .78 6 31.0 30.1 30.5 30.1 30.5 30.4 30.4 .33 6 28.4 31.3 30.2 29.6 29.9 1.21 4 30.6 29.5 30.8 31.1 30.7 30.9 30.6 .57 6 682 556 629 515 446 544 562 83.6 6 492 462 493 422 467 33.4 4 423 432 394 355 585 461 442 78.9 6 .2 .3 .4 .4 .3 .3 .3 .08 6 .5 .5 .6 .3 .5 .13 4 .2 .1 .3 .3 .3 .1 .2 .10 6 12 20 26 27 16 20 20 5.' 6 31 28 39 20 30 7.! 4 13 7 18 21 20 6 14 6. ( 6 TCOO 540 ANIMAL NUMBER Appendix 4 Individual Clinical Hematology Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC X106/^L G/DL % FL PG % XlOVAdi Covance 6329-223 3M T-6295.7 RETIC X10V//L Group : 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level : 0.75 6.39 6.06 6.35 6.47 6.57 6.07 11.9 11.8 11.7 12.5 11.9 11.4 6.32 .210 6 11.9 .36 6 Dosage Unit: mg/kg/day 40.1 39.8 40.4 42.2 41.6 37.8 62.7 65.7 63.6 65.2 63.3 62.3 18.7 19.5 18.4 19.3 18.2 18.7 40.3 1.54 6 63.8 1.37 6 18.8 .51 6 29.8 29.7 28.9 29.5 28.7 30.1 29.4 .54 6 328 520 568 597 635 378 504 124.1 6 .1 .4 .1 .3 .0 .3 .2 .15 6 6 24 6 19 0 18 12 9.. 6 003178 541 ANIMAL NUMBER WBC xioV^l Appendix 4 Individual Clinical Hematology Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XlOV/iL XIOVpL MONO EOSIN Xl0V/tL XlOVnL BASO N-SEG% XlOVpL LYMPH % MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 6.4 3.2 2.6 .5 .1 .0 50 41 8 1 1 105530 11.1 6.2 4.1 .6 .2 .0 56 37 5 2 0 105531 9.1 4.7 3.5 .6 .3 .0 51 38 7 3 0 105535 11.7 3.0 7.1 .8 .7 .1 26 61 7 6 1 105544 9.1 2.8 5.1 .6 .7 .0 30 56 6 7 0 105549 8.7 4.4 3.5 .6 .2 .0 50 40 7 2 0 MEAN S.D. N 9.4 4.0 4.3 .6 .4 .0 44 46 7 4 0 1.89 1.31 1.59 .10 .27 .04 12,.5 10,.3 1..0 2..4 6 66 6666 6 66 6 Group: 2 Dose Level : 0 .03 Dosage Unit: mg/kg/day 105537 8.3 3.5 3.0 1.3 .3 .2 42 37 15 3 2 105541 10.4 4.4 4.9 .8 .2 .0 42 47 8 2 0 105547 4.1 1.7 2.0 .3 .1 .0 41 48 8 3 0 105550 12.0 8.2 2.9 .8 .1 .0 68 24 6 1 0 MEAN S.D. N 8.7 4.4 3.2 .8 .2 .0 48 39 9 2 0 3.42 2.74 1.22 .41 .10 .10 13..2 11..2 3. 9 1, 0 1 44444444444 Group: 3 Dose Level : 0 .15 Dosage Unit: mg/kg/day 105532 105538 105539 105545 105548 105552 MEAN S.D. N 6.5 3.6 2.4 .3 .1 .0 56 37 5 2 o 9.5 5.2 3.2 .8 .2 .0 55 34 9 2 0 8.5 3.3 4.4 .5 .2 .0 39 52 6 2 1 8.8 4.4 3.5 .7 .1 .0 50 40 8 1 o 10.2 5.2 3.9 .7 .3 .0 51 38 7 3 o 8.9 4.9 3.1 .5 .4 .0 55 35 6 4 0 8.7 4.4 3.4 .6 .2 .0 51 39 7 2 o 1.25 .82 .69 .18 .12 .00 6. 4 6. 6 1. 5 1. 0 66666666666 o Vi 542 ANIMAL NUMBER WBC X10 /(L Appendix 4 Individual Clinical Hematology Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH Xl0V/iL XIOVm L MONO EOS IN x i o V m l XIO'/^L BASO N-SEG% XIOVm L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 8.2 3.1 4.3 .7 .1 .1 38 53 8 1 1 105534 8.5 4.1 3.1 1.0 .2 .1 48 37 12 3 1 105536 5.7 2.8 2.2 .6 .2 .0 50 38 10 3 0 105540 10.7 6.5 3.8 .4 .1 .0 60 35 4 1 0 105542 9.5 7.0 2.2 .3 .0 .0 74 23 3 0 0 105551 6.2 4.1 1.7 .4 .1 .0 66 27 6 1 0 MEAN S.D. N 8.1 4.6 2.9 .6 .1 .0 56 36 7 2 0 1.91 1.75 1.02 .26 .08 .05 13.1 10.4 3.5 1.2 666 6 666 66 6 6 003180 543 Appendix 4 Individual Clinical Hematology Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105529 105530 105531 105535 105544 105549 Dose Level: 0 __ ----- - Dosage Unit: mg/kg/day _ __ - -- -- - -- - - -- --- Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day 105537 _ _ ___ 105541 - - _ - _ 105547 - - - - _ 105550 - --- Group: 3 105532 105538 105539 105545 105548 105552 Dose Level: 0.15 __ -- ---- - Dosage Unit: mg/kg/day __ --_ ----_ - ---- Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105533 _ - __ 105534 - - _ - _ 105536 - - - _ _ 105540 - - - - _ 105542 - - _ - - 105551 - - - - _ Covance 6329-223 3M T-6295.7 003181 544 ANIMAL NUMBER Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XIOV^iL G/DL FL PG % XIOVi/L % Covance 6329-223 3M T-6295.7 RETIC XIOVm L Dose Level : 0 6.44 6.54 7.40 6.44 6.28 6.95 12.3 13.1 12.8 12.1 11.7 12.9 6.68 .421 6 12.5 .54 6 Dose Level : 0.03 6.80 7.26 6.55 7.71 12.0 13.0 12.4 12.9 7.08 .513 4 12.6 .46 4 Dose Level : 0.15 6.35 7.19 7.53 6.39 6.74 6.50 12.6 12.6 13.2 12.2 12.8 12.2 6.78 .479 6 12.6 .38 6 Dosage Unit: mg/kg/day 39.3 43.3 42.9 38.7 38.6 42.8 61.0 66.3 58.0 60.1 61.3 61.6 19.1 20.0 17.3 18.8 18.7 18.5 40.9 2.28 6 61.4 2.74 6 18.7 .88 6 Dosage Unit: mg/kg/day 40.8 44.0 39.6 42.4 59.9 60.7 60.5 55.0 17.7 17.9 18.9 16.7 41.7 1.91 4 59.0 2.70 4 17.8 .90 4 Dosage Unit: mg/kg/day 40.5 41.3 43.4 39.8 42.8 40.2 63.7 57.5 57.6 62.3 63.5 61.9 19.9 17.5 17.6 19.2 19.1 18.8 41.3 1.47 6 61.1 2.82 6 18.7 .95 6 31.4 30.2 29.9 31.2 30.5 30.1 30.6 .62 6 29.5 29.5 31.2 30.4 30.2 .82 4 31.2 30.5 30.5 30.8 30.0 30.4 30.6 .40 6 351 379 447 643 354 613 464 131.6 6 389 618 296 630 483 167.0 4 406 496 546 783 515 366 519 146.4 6 .1 .2 .4 .0 .1 .7 .2 .26 6 .2 .2 .4 .0 .2 .16 4 .5 .2 .4 .4 .6 .6 .4 .15 6 6 13 30 0 6 49 17 18.7 6 14 15 26 0 14 10.7 4 32 14 30 26 40 39 30 9.6 6 003182 545 ANIMAL NUMBER Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Appendix 4 individual Clinical Hematology Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC XIOVmL HGB G/DL HCT MCV % ' FL MCH MCHC PLT RETIC PG % x i o 3/m l % Covance 6329-223 3M T-6295.7 RETIC x i o '/m l Dose Level : 0.75 7.78 6.93 6.08 6.10 6.61 6.38 13.4 11.7 10.3 11.1 12.0 12.1 6.65 .641 6 11.8 1.04 6 Dosage Unit : mg/kg/day 45.8 39.3 36.1 37.7 40.4 40.5 59.0 56.7 59.4 61.8 61.2 63.6 17.3 16.8 16.9 18.2 18.2 19.0 40.0 3.32 6 60.3 2.43 6 17.7 .87 6 29.3 29.7 28.5 29.5 29.7 29.9 29.4 .50 6 486 21 373 553 405 552 398 199.1 6 .4 .1 .7 1.1 1.2 .1 .6 .48 6 31 7 43 67 79 6 39 30.: 6 003183 546 ANIMAL NUMBER WBC X103/m L Appendix 4 Individual Clinical Hematology Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XIOV/^L XIOV^L MONO EOSIN XIOV/iL X103/h L BASO N-SEG XIOVkL LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO Group; 1 Dose Level : 0 Dosage Unit: mg/kg/day 105508 5.3 1.8 2.9 .3 .4 .0 34 54 5 7 0 105517 6.7 1.7 4.5 .4 .0 .0 25 68 6 0 0 105519 6.7 2.9 3.5 .2 .1 .0 43 52 3 1 0 105520 7.8 2.3 4.3 .7 .3 .2 30 55 9 4 2 105526 5.2 1.6 2.9 .6 .1 .0 32 56 11 1 0 105527 12.3 5.9 5.1 1.0 .1 .0 48 42 8 1 0 MEAN S.D. N 7.3 2.7 3.9 .5 .2 .0 35 54 7 2 0 2.62 1.64 .91 .29 .15 .08 8. 6 8..3 2.,9 2.7 6 66 6 6 66 6 6 6 6 Group: 2 Dose Level : 0 .03 Dosage Unit: mg/kg/day 105514 10.0 6.2 3.0 .4 .3 .0 62 30 4 3 0 105515 8.8 3.1 4.8 .6 .2 .0 35 55 7 3 0 105516 11.3 6.4 3.8 .9 .2 .0 56 34 8 2 0 105521 9.6 6.8 2.3 .5 .1 .0 70 24 5 1 0 MEAN S.D. N 9.9 5.6 3.5 .6 .2 .0 56 36 6 2 0 1.04 1.70 1.08 .22 .08 .00 15..0 13..5 1, 8 1.0 44444444444 Group: 3 Dose Level : 0 .15 Dosage Unit: mg/kg/day 105505 105510 105518 105523 105524 105528 MEAN S.D. N 11.8 8.6 2.5 .5 .3 .0 73 21 4 2 0 9.3 5.5 3.1 .6 .1 .0 59 33 7 1 0 9.7 2.9 5.9 .8 .1 .1 30 61 9 1 1 13.8 8.3 4.4 .6 .4 .0 60 32 4 3 0 6.7 1.9 4.1 .7 .1 .1 28 61 10 1 1 9.2 3.8 3.9 .8 .6 1 42 43 8 6 1 10.1 5.2 4.0 .7 .3 .0 49 42 7 2 0 2.44 2.81 1.17 .12 .21 .05 18. 2 16. 4 2..5 2.0 66666666666 003184 547 ANIMAL NUMBER WBC X103/ML Appendix 4 Individual Clinical Hematology Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH X103/*iL X103//4L MONO EOSIN x i o V m l X IOVajL BASO N-SEG% X10V*<L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105506 6.7 2.5 3.6 .5 .1 .0 38 54 7 1 0 105507 8.9 3.9 4.4 .5 .1 .0 44 50 5 1 0 105509 13.2 10.0 1.8 1.4 .0 .0 76 13 11 0 0 105511 5.9 2.2 3.2 .3 .2 .0 37 55 6 3 0 105512 7.6 2.2 4.0 1.2 .1 .0 29 53 15 2 0 105522 11.6 5.2 4.9 .9 .5 .1 45 42 8 4 1 MEAN S.D. N 9.0 4.3 3.6 .8 .2 .0 45 44 9 2 0 2.87 3.02 1.08 .44 .18 .04 16.3 16.1 3.7 1.5 66666666666 003185 548 Appendix 4 Individual Clinical Hematology Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105508 105517 105519 105520 105526 105527 Group: 2 105514 105515 105516 105521 Group: 3 105505 105510 105518 105523 105524 105528 Group: 4 105506 105507 105509 105511 105512 105522 Dose Level : 0 Dose Level: 0.03 Dose Level: 0.15 Dose Level: 0.75 Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Covance 6329-223 3M T-6295.7 003186 549 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC x i o V a<l G/DL % FL PG % XlO'/nL % Covance 6329-223 3M T-6295.7 RETIC XIOViiL Dose Level: 0 5.82 6.31 6.88 7.30 6.25 7.02 11.3 12.5 12.6 12.9 11.6 13.6 6.60 .559 6 12.4 .85 6 Dose Level: 0.03 6.74 5.74 6.96 7.20 10.9 12.2 11.7 13.1 6.66 .641 4 12.0 .92 4 Dose Level: 0.15 6.80 6.37 6.59 7.00 6.84 6.39 12.5 11.7 12.3 12.7 11.6 11.9 6.66 .257 6 12.1 .45 6 Dosage Unit: mg/kg/day 36.1 41.0 40.7 42.9 38.7 44.4 61.9 65.1 59.1 58.7 62.0 63.3 19.3 19.8 18.3 17.7 18.6 19.3 40.6 2.96 6 61.7 2.45 6 18.8 .77 6 Dosage Unit: mg/kg/day 38.5 40.3 39.0 43.9 57.0 70.3 56.0 61.0 16.2 21.2 16.8 18.2 40.4 2.44 4 61.1 6.52 4 18.1 2.23 4 Dosage Unit: mg/kg/day 40.8 38.5 40.6 41.5 38.3 39.4 60.0 60.5 61.6 59.3 55.9 61.6 18.4 18.4 18.7 18.1 17.0 18.7 39.9 1.31 6 59.8 2.12 6 18.2 .64 6 31.2 30.4 31.0 30.2 30.0 30.5 30.6 .46 6 28.4 30.2 30.0 29.8 29.6 .82 4 30.7 30.4 30.3 30.6 30.3 30.3 30.4 .18 6 609 544 586 469 498 416 520 73.1 6 .2 .5 .1 .0 .7 .7 .4 .31 6 322 385 450 391 387 52.3 4 .4 1.5 .1 .5 .6 .61 4 424 425 506 326 545 532 460 83.7 6 .7 .4 .3 .0 .2 .2 .3 .24 6 12 32 7 0 44 49 24 20.5 6 27 86 7 36 39 33.6 4 48 25 20 0 14 13 20 16.1 6 003187 550 ANIMAL NUMBER Appendix 4 Individual Clinical Hematology Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC x i o 6/*<l G/DL % FL PG % XIOV^L % Covance 6329-223 3M T-6295.7 RETIC XlOV^L Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 6.67 6.20 6.07 5.97 6.56 6.51 12.2 12.1 11.0 11.5 11.6 11.9 6.33 .288 6 11.7 .44 6 Dosage Unit : mg/kg/day 41.2 41.4 36.8 37.3 40.0 40.3 61.7 66.7 60.7 62.4 60.9 61.9 18.4 19.5 18.2 19.2 17.6 18.3 39.5 1.98 6 62.4 2.21 6 18.5 .70 6 29.8 29.3 30.0 30.8 28.9 29.6 29.7 .65 6 320 582 563 491 671 322 492 144.0 6 .3 .3 .1 .0 .1 .2 .2 .12 6 20 19 6 0 7 13 11 7.! 6 000188 551 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group : 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N WBC XIOVk L Appendix 4 Individual Clinical Hematology Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH x i o V m l X103/k L MONO EOS IN XIOV/L XIO V m L BASO N -SEG% XI O V aiL LYMPH% MONO* EOSIN* Covance 6329-223 3M T-6295.7 BASO* Dose Level: 0 Dosage Unit: mg/kg/day 8.4 5.1 2.6 .6 .1 .0 60 31 7 1 0 8.3 1.8 5.9 .5 .1 .0 22 70 6 2 0 14.5 9.9 3.8 .7 .1 .0 68 26 5 1 0 8.3 2.4 4.4 1.0 .5 .1 28 52 12 6 1 8.7 2.9 3.9 1.3 .4 .1 34 45 15 5 1 10.0 5.3 3.8 .7 .1 .1 53 38 7 1 1 9.7 4.6 4.1 .8 .2 .0 44 44 9 3 0 2.44 2.98 1.08 .30 .18 .05 18..7 15. 9 3. 9 2..3 .5 66666666666 Dose Level : 0.03 Dosage Unit: mg/kg/day 8.5 4.2 3.0 .9 .4 .2 49 35 10 4 2 6.5 2.2 3.6 .5 .1 .1 34 56 8 1 1 15.9 10.2 2.8 2.6 .1 .1 64 18 16 1 0 6.4 3.5 2.1 .5 .2 .0 55 34 9 2 0 9.3 5.0 2.9 1.1 .2 .1 50 36 11 2 1 4.49 3.55 .62 1.00 .14 .08 12.,6 15..6 3. 6 1. 4 1. 0 44444444444 Dose Level: 0.15 Dosage Unit: mg/kg/day 5.6 2.5 2.4 .6 .1 .0 45 43 10 1 1 10.6 6.6 2.9 .8 .3 .0 63 27 7 3 0 6.3 1.1 4.5 .5 .2 .0 18 71 8 3 0 11.0 5.3 4.8 .6 .2 .0 48 44 5 2 0 7.6 3.2 3.1 .8 .4 .0 42 41 11 5 0 7.5 3.4 3.0 .5 .5 .0 45 40 7 6 1 8.1 3.7 3.4 .6 .3 .0 44 44 8 3 0 2.23 1.98 .96 .14 .15 .00 14. 5 14. 4 2. 2 1. 9 5 6666 666 6 66 6 003189 552 ANIMAL NUMBER WBC X103/**L Appendix 4 Individual Clinical Hematology Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH x i o 3/m l XIOVaL MONO EOS IN x i o V m l X103/*iL BASO N-SEG% XIOV^L LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 8.2 2.1 4.9 .9 .2 .1 26 60 11 3 1 105534 13.2 3.8 7.9 1.0 .4 .1 29 60 7 3 1 105536 10.1 6.6 1.9 1.3 .2 .1 65 19 13 2 1 105540 11.7 7.4 3.5 .6 .1 .0 64 30 5 1 0 105542 9.0 5.0 3.6 .3 .2 .0 55 39 3 2 0 105551 4.6 1.7 2.2 .6 .0 .0 38 48 13 1 1 MEAN S.D. N 9.5 4.4 4.0 .8 .2 .0 46 43 9 2 1 2.99 2.33 2.19 .35 .13 .05 17.4 16.5 4.3 .9 66666666666 003190 553 Appendix 4 Individual Clinical Hematology Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 Dose Level: 0 105529 105530 105531 105535 105544 105549 _ _ _ - _ _ _ _ _ _ Group: 2 Dose Level: 0.03 105537 - 105541 - 105547 _ _ _ 105550 _ _ _ Group: 3 105532 105538 105539 105545 105548 105552 Dose Level: 0.15 ___ ___ ___ ___ Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0.75 ___ ___ ___ ___ ___ Dosage Unit: mg/kg/day __ __ __ Dosage Unit: mg/kg/day __ __ Dosage Unit: mg/kg/day __ __ __ __ Dosage Unit: mg/kg/day __ __ __ __ __ Covance 6329-223 3M T-6295.7 T6T?00 554 ANIMAL NUMBER Group : 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XlOV^L G/DL % FL PG t XIO'/HL % Covance 6329-223 3M T-6295.7 RETIC XI03/uh Dose Level : 0 6.43 6.72 7.22 6.17 6.48 6.57 12.8 13.1 12.7 11.7 12.2 12.3 6.60 .354 6 12.5 .50 6 Dose Level : 0.03 6.88 6.47 6.61 7.86 12.1 12.2 12.5 13.1 6.96 .627 4 12.5 .45 4 Dose Level : 0.15 6.43 6.98 7.21 6.50 6.57 6.21 12.5 12.4 12.8 12.6 12.6 11.9 6.65 .372 6 12.5 .31 6 Dosage Unit: mg/kg/day 40.3 44.2 42.0 38.0 40.4 41.7 62.7 65.8 58.1 61.6 62.3 63.5 19.9 19.5 17.6 18.9 18.8 18.8 41.1 2.07 6 62.3 2.53 6 18.9 .78 6 Dosage Unit : mg/kg/day 42.5 40.7 40.8 44.5 61.7 62.9 61.7 56.6 17.6 18.8 18.9 16.7 42.1 1.79 4 60.7 2.81 4 18.0 1.05 4 Dosage Unit : mg/kg/day 41.8 40.8 42.1 40.7 41.8 39.0 65.0 58.4 58.4 62.6 63.5 62.9 19.5 17.8 17.7 19.3 19.2 19.1 41.0 1.15 6 61.8 2.76 6 18.8 .80 6 31.7 29.6 30.2 30.7 30.2 29.6 30.3 .79 6 404 399 445 591 392 - 571 467 90.4 6 28.5 29.9 30.6 29.5 29.6 .88 4 398 559 246 663 466 183.0 4 30.0 30.4 30.4 30.9 30.2 30.4 30.4 .30 6 411 464 514 526 527 380 470 63.1 6 .1 .2 .2 .1 .1 .3 .2 .08 6 .4 .2 .0 .1 .2 .17 4 .3 .3 .3 .3 .2 .3 .3 .04 6 6 13 14 6 6 20 11 5.8 6 28 13 0 8 12 11.8 4 19 21 22 20 13 19 19 3.2 6 003192 555 ANIMAL NUMBER Appendix 4 individual Clinical Hematology Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XlOV/zL G/DL % FL PG % x i o 3/al % Covance 6329-223 3M T-6295.7 RETIC XlOV^L Group: 4 105506 a 105507 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 7.69 6.64 5.76 6.46 6.44 13.3 11.0 10.4 11.7 12.3 6.32 .387 4 11.4 .83 4 Dosage Unit: mg/kg/day 44.3 38.4 35.7 39.8 41.5 57.7 57.9 62.0 61.6 64.5 17.2 16.5 18.1 18.1 19.1 38.8 2.45 4 61.5 2.72 4 17.9 1.08 4 29.9 28.5 29.2 29.4 29.6 29.2 .48 4 560 78 PA 486 429 610 401 228.0 4 .2 .3 .5 .0 .0 .2 .24 4 15 20 29 0 0 12 14.6 4 a unscheduled sacrifice on Day 179. 003193 556 ANIMAL NUMBER WBC XIOV^L Appendix 4 Individual Clinical Hematology Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH XIOV/iL X10V//L MONO EOSIN x i o V m l X103/WL BASO N-SEG% XlOVjiL LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105508 9.5 3.6 4.8 .6 .5 .0 38 50 6 6 0 105517 9.0 2.6 5.6 .6 .1 .1 30 62 7 1 1 105519 6.8 4.0 2.5 .3 .1 .0 58 37 4 1 0 105520 12.0 5.8 5.0 .7 .4 .1 49 42 6 3 1 105526 10.0 6.7 2.8 .4 .1 .0 67 28 4 1 0 105527 10.8 2.8 6.0 1.6 .3 .1 26 55 15 3 1 MEAN S.D. N 9.7 4.2 4.4 .7 .2 .0 45 46 7 2 0 1.76 1.66 1.46 .46 .18 .05 16.,1 12. 4 4..1 2.0 66666666666 Group: 2 Dose Level : 0 .03 Dosage Unit: mg/kg/day 105514 105515 105516 105521 8.9 5.7 2.6 .4 .2 .0 64 30 4 2 0 7.5 2.7 3.6 .9 .2 .0 36 48 12 3 1 8.1 5.8 1.9 .3 .1 .0 71 23 4 1 0 9.1 5.2 3.2 .6 .1 .0 58 35 6 1 0 MEAN S.D. N 8.4 4.8 2.8 .6 .2 .0 57 34 6 2 0 .74 1.46 .74 .26 .06 .00 15..1 10. 6 3. 8 1.0 44444444444 Group : 3 Dose Level : 0 .15 Dosage Unit: mg/kg/day 105505 105510 105518 105523 105524 105528 MEAN S.D. N 10.3 7.5 2.3 .4 .2 .0 72 22 4 2 0 9.1 4.6 3.9 .4 .1 .0 51 43 5 1 0 13.6 6.6 6.6 .3 .1 .0 48 48 2 0 0 10.8 6.3 3.8 .5 .1 .0 59 35 5 1 0 6.1 1.6 3.8 .5 .1 .0 26 63 9 1 0 10.0 4.6 4.1 .7 .6 .0 46 41 7 6 0 10.0 5.2 4.1 .5 .2 .0 50 42 5 2 0 2.44 2.10 1.39 .14 .20 .00 15. 2 13. 6 2. 4 2.1 66666666666 003194 557 ANIMAL NUMBER Group: 4 105506 a 105507 105511 105512 105522 MEAN S.D. N WBC X103// Appendix 4 Individual Clinical Hematology Data Males Day 182 26-WEEK c a p s u l e t o x i c i t y s t u d y w i t h p e r f l u o r o o c t a n e s u l f o n i c a c i d POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH X103/aiL XIOV^L MONO xiovml EOSIN XIOVm L BASO N-SEG% X10 /vL LYMPH% MONO EOSIN Covance 6329-223 3M T-6295.7 BASO Dose Level : 0.75 Dosage Unit: mg/kg/day 19.7 14.7 4.0 1.0 .0 .0 74 20 5 0 0 9.4 3.9 4.9 .4 .1 .0 42 52 5 1 0 5.1 2.0 2.3 .6 .2 .1 39 45 11 4 1 6.6 1.9 4.3 .4 .0 .0 28 66 5 0 0 9.2 3.9 4.5 .6 .2 .1 43 49 6 2 1 7.6 2.9 4.0 .5 .1 .0 38 53 7 2 0 2.09 1.13 1.16 .12 .10 .06 6.9 9.1 2.9 1.7 4 44 44 44 4 4 4 4 a Unscheduled sacrifice on Day 179. 003195 558 003196 Appendix 4 Individual Clinical Hematology Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105508 105517 105519 105520 105526 105527 Dose Level : 0 __ - '----- Dosage Unit: mg/kg/day _-_ - ------ -- --- Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day 105514 _ _ _ _ _ 105515 - - - - - 105516 b - - - - - 105521 - * - - - Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 _ _ _ _ _ 105510 - - - - - 105518 - - - - _ 105523 - - - - - 105524 - - - - - 105528 - - - - - Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105506 a _ ___ 105507 - - - - - 105511 - - - - - 105512 - - - - - 105522 - - - - - a Unscheduled sacrifice on Day 179. b Plasmodium was observed. 559 Covance 6329-223 3M T-6295.7 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Appendix 4 Individual Clinical Hematology Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC X106/m L G/DL % FL PG % xi<r/*<L % Covance 6329-223 3M T-6295.7 RETIC X10 /<L Dose Level: 0 5.66 6.38 6.63 7.04 6.20 6.52 11.0 12.6 12.0 12.7 11.9 12.5 6.40 .461 6 12.1 .64 6 Dose Level: 0.03 6.69 5.80 5.20 6.92 10.8 12.2 9.0 12.7 6.15 .798 4 11.2 1.66 4 Dose Level: 0.15 6.65 6.14 6.67 6.81 6.75 6.38 12.3 11.0 12.5 12.4 11.3 11.9 6.57 .256 6 11.9 .62 6 Dosage Unit: mg/kg/day 35.7 42.6 40.5 42.8 40.9 42.3 63.0 66.8 61.2 60.8 65.9 64.9 19.5 19.7 18.1 18.1 19.2 19.2 40.8 2.67 6 63.8 2.49 6 19.0 .70 6 Dosage Unit : mg/kg/day 38.9 41.4 30.1 42.7 58.2 71.3 58.0 61.8 16.2 21.1 17.4 18.3 38.3 5.67 4 62.3 6.23 4 18.2 2.09 4 Dosage Unit: mg/kg/day 40.8 37.6 41.9 41.0 37.8 40.2 61.3 61.2 62.7 60.3 56.1 63.0 18.4 17.9 18.8 18.3 16.8 18.7 39.9 1.78 6 60.8 2.50 6 18.2 .73 6 31.0 29.6 29.5 29.7 29.1 29.6 29.7 .65 6 27.9 29.5 30.0 29.7 29.3 .94 4 30.1 29.3 29.9 30.3 30.0 29.7 29.9 .35 6 595 583 534 369 439 383 484 100.1 6 442 380 501 394 429 54.7 4 373 381 400 318 484 517 412 74.4 6 .2 .4 .3 .2 .8 .6 .4 .24 6 .2 .2 .4 .1 .2 .13 4 .3 .3 .2 .0 .2 .1 .2 .12 6 11 26 20 14 50 39 27 15.1 6 13 12 21 7 13 5.8 4 20 18 13 0 14 6 12 7.5 6 003197 560 ANIMAL NUMBER Appendix 4 Individual Clinical Hematology Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC HGB HCT MCV MCH MCHC PLT RETIC XlOV^L G/DL % FL PG % XIOVm L Covance 6329-223 3M T-6295.7 RETIC XIOVk L Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level : 0.75 6.00 5.65 6.08 5.99 6.75 6.09 11.3 11.0 10.9 11.6 11.9 11.3 6.09 .360 6 11.3 .37 6 Dosage Unit: mg/kg/day 37.6 37.7 39.3 38.6 43.4 38.4 62.6 66.8 64.6 64.5 64.3 63.1 18.9 19.4 17.9 19.3 17.7 18.6 39.2 2.17 6 64.3 1.46 6 18.6 .71 6 30.1 29.1 27.8 29.9 27.5 29.5 29.0 1.09 6 288 587 559 454 725 328 490 166.0 6 .2 .5 .0 .0 .4 .1 .2 .21 6 12 28 0 0 27 6 12 12. 6 003198 561 ANIMAL NUMBER WBC xioV ml Appendix 4 Individual Clinical Hematology Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH x i o V m l XlOV/tL MONO EOSIN xioV/a, XloV/tL BASO N-SEG% X10 V/iL LYMPH% MONO% EOSIN% Covance 6329-223 3M T-6295.7 BASO% Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 14.6 11.4 2.5 .6 .1 .1 78 17 4 1 1 105530 7.3 2.6 3.9 .6 .2 .0 35 54 8 3 0 105531 10.5 5.2 4.3 .7 .2 .1 50 41 7 2 1 105535 13.9 5.5 7.0 1.0 .3 .1 39 50 7 2 1 105544 10.4 2.9 6.2 .6 .6 .0 28 60 6 6 0 105549 5.4 2.4 2.1 .7 .1 .0 44 40 14 2 0 MEAN S.D. N 10.4 5.0 4.3 .7 .2 .0 46 44 8 3 0 3.59 3.41 1.96 .15 .19 .05 17. 5 15.,1 3. 4 1. 8 .5 66666666666 Group : 2 Dose Level : 0.03 Dosage Unit: mg/kg/day 105537 10.1 5.4 3.1 1.1 .4 .2 54 30 11 4 2 105541 6.6 2.4 3.5 .5 .2 .0 37 53 7 3 0 105547 6.8 4.0 2.4 - .4 .1 .0 58 35 6 1 0 105550 10.4 5.5 3.7 .8 .4 .0 53 35 7 4 0 MEAN S.D. N 8.5 4.3 3.2 .7 .3 .0 50 38 8 3 0 2.05 1.45 .57 .32 .15 .10 9. 3 10. 1 2. 2 1. 4 1.,0 44444444444 Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105532 8.2 3.9 3.8 .4 .1 .0 48 46 5 1 0 105538 9.2 4.5 3.8 .6 .3 .0 49 41 6 4 0 105539 7.5 1.6 4.9 .8 .1 .1 22 65 10 2 2 105545 11.0 6.3 3.9 .6 .1 .0 57 36 6 1 0 105548 11.3 6.2 3.7 .6 .7 .0 55 33 5 6 0 105552 8.0 4.3 3.0 .3 .4 .0 54 37 4 4 0 MEAN S.D. N 9.2 4.5 3.8 .6 .3 .0 48 43 6 3 0 1.61 1.73 .61 .18 .24 .04 13. 0 11. 7 2. 1 2. 0 8 66666666666 003199 562 ANIMAL NUMBER Group : 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N WBC X10 /L Appendix 4 Individual Clinical Hematology Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS N-SEG LYMPH x i o V ail XlOV^L MONO EOS IN X103/AL XIOVm L BASO N-SEG% X I O V aiL LYMPH% MONO EOSIN Covance 6329-223 3M T-6295.7 BASO Dose Level s 0.75 Dosage Unit: mg/kg/day 7.5 3.2 3.8 .4 .1 .1 42 51 5 1 1 12.1 5.0 6.0 1.0 .2 .1 41 49 8 1 1 8.4 4.1 2.8 1.2 .2 .1 49 34 14 2 1 10.3 5.9 3.8 .5 .1 .0 58 37 5 1 0 13.4 3.0 9.3 .8 .3 .1 22 69 6 3 0 6.4 4.0 1.8 .5 .1 .0 63 28 8 1 0 9.7 4.2 4.6 .7 .2 .1 46 45 8 2 0 2.73 1.10 2.70 .32 .08 .05 14.6 14.8 3.4 .8 66666666666 003200 563 Appendix 4 Individual Clinical Hematology Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105529 105530 105531 105535 105544 105549 Group: 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0 Dose Level: 0.03 Dose Level: 0.15 Dose Level: 0.75 Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Covance 6329-223 3M T-6295.7 003201 564 ANIMAL NUMBER APPENDIX 4 Individual Clinical Hematology Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOF.OOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC HGB HCT MCV MCH MCHC PLT RETIC X107//L G/DL .% FL PG % XIO'/uL % Covance 6329-223 3M Study No. T-6295.7 RETIC XIOVmL Group : 1 105520 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level: 0 6.27 6.26 12.1 11.8 6.26 .007 2 12.0 .21 2 Dose Level: 0.15 6.53 6.45 13.0 12.4 6.49 .057 2 12.7 .42 2 Dose Level: 0.75 5.93 5.87 11.6 11.5 5.90 .042 2 11.6 .07 2 Dosage Unit: mg/kg/day 38.3 37.9 61.0 60.5 19.3 18.9 38.1 .28 2 60.8 .35 2 19.1 .28 2 Dosage Unit: mg/kg/day 41.6 39.8 63.7 61.8 19.9 19.3 40.7 1.27 2 62.8 1.34 2 19.6 .42 2 Dosage Unit: mg/kg/day 38.2 37.3 64.5 63.5 19.5 19.6 37.8 .64 2 64.0 .71 2 19.5 .07 2 31.7 31.2 31.5 .35 2 31.3 31.2 31.2 .07 2 30.3 30.9 30.6 .42 2 620 346 483 193.7 2 404 572 488 118.8 2 485 453 469 22.6 2 .3 .4 .4 .07 2 .4 .2 .3 .14 2 .3 .6 .4 .21 2 19 25 22 4.2 2 26 13 20 9.2 2 18 35 26 12.0 2 003202 ANIMAL NUMBER WBC X103/^L APPENDIX 4 Individual clinical Hematology Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH X107//L X107/JL MONO EOSIN 3U07/'L XIOVwL BASO N -SEG% X10r/uh LYMPH% MONO! Covance 6329-223 3M Study No. T-6295.7 EOSIH% BASO% Group: i Dose Level : 0 Dosage Unit: mg/kg/day IO5520 105526 MEAN 3.D. N 8.5 2.5 5.2 .5 .3 .0 30 61 6 3 1 6.1 2.3 2.9 .7 .2 .0 37 47 12 3 1 7.3 2.4 4.0 .6 .2 .0 34 54 9 3 1 1.70 .14 1.63 .14 .07 .00 4.9 9.9 4.2 .0 .0 22222222222 Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day IU5505 8.8 4.7 3.0 .7 .4 .0 53 34 8 5 0 105523 14.2 7.6 6.0 .4 .2 .0 53 42 31 0 MEAN S.D. N 11.5 6.2 4.5 .6 .3 .0 53 38 6 3 0 3.82 2.05 2.12 .21 .14 .00 .0 5.7 3.5 2.8 .0 22222222222 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 8.9 4.1 3.9 .5 .4 .0 46 44 5 4 0 105522 14.7 7.9 5.0 1.3 .5 .0 54 34 9 4 0 MEAN S.D. N 11.8 6.0 4.4 .9 .4 .0 50 39 7 4 0 4.10 2.69 .78 .57 .07 .00 5.7 7.1 2.8 .0 0 2 22 22 2 22 2 22 o CO fO 003204 APPENDIX 4 Individual Clinical Hematology Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOF.OOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 Dose Level: 0 105520 105526 - -- Group: 3 I055U5 105523 Dose Level: 0.15 ----- Group: 4 105511 105522 Dose Level: 0.75 ----- Dosage Unit: mg/kg/day -- Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Hematology Data Females Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-629S) IN CYNOMOLGUS RBC HGB HCT MCV MCH MCHC PLT RETIC XIOV/'L G/DL % FL PG % XIO'/oL % Covance 6329-223 3M Study No. T-6295.7 RETIC X10 /k L Group : i 105529 11)5549 MEAN S.D. N Group: 3 IU5539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level : 0 5.44 6.45 10.9 12.6 5.94 .714 2 11.8 1.20 2 Dose Level : 0.15 6.07 6.20 11.8 12.0 6.14 .092 2 11.9 .14 2 Dose Level : 0.75 6.13 6.72 11.8 12.2 6.42 .417 2 12.0 .28 2 Dosage Unit: mg/kg/day 33.5 40.3 61.5 62.4 20.1 19.6 36.9 4.81 2 62.0 .64 2 19.8 .35 2 Dosage Unit: mg/kg/day 37.2 38.0 61.4 61.3 19.5 19.4 37.6 .57 2 61.4 .07 2 19.5 .07 2 Dosage Unit: mg/kg/day 38.2 42.3 62.2 63.0 19.2 18.2 40.2 2.90 2 62.6 .57 2 18.7 .71 2 32.7 31.3 32.0 .99 2 31.8 31.6 31.7 .14 2 30.8 28.9 29.8 1.34 2 547 390 468 111.0 2 382 435 408 37.5 2 330 557 444 160.5 2 .1 .5 .3 .28 2 .2 .5 .4 .21 2 .3 .7 .5 .28 2 5 32 18 19.1 2 12 31 22 13.4 2 18 47 32 20.5 2 003205 ANIMAL NUMBER WBC X10 7//L APPENDIX 4 Individual Clinical Hematology Data Females Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH X10//<L X107//L MONO EOSIN X10 7 i/L XIO/uL BASO N-SEG% xio7l LYMPH% MONO% Covance 6329-223 3M Study No. T-6295.7 EOSIN% BASO% Group: 1 Dose Level : 0 Dosage Unit : mg/kg/day 105529 10.1 6.1 3.0 .8 .1 .0 60 30 8 1 1115549 6.2 3.1 2.5 .4 .1 .0 50 41 7 2 0 MEAN S.D. N 8.2 4.6 2.8 .6 .1 .0 55 36 8 2 0 2.76 2.12 .35 .28 .00 .00 222222 7.1 7.8 .7 .7 2 22 2 2 Group: 3 Dose Level : 0.15 Dosage Unit : mg/Kg/day IU5539 IU5552 6.9 1.8 4.3 .7 .2 .1 26 61 10 3 i 8.4 3.5 3.8 .5 .5 .0 41 45 6 6 i MEAN S.D. H 7.6 2.6 4.0 .6 .4 .0 34 53 8 4 i 1.06 1.20 .35 .14 .21 .07 10.6 11.3 2.8 2.1 22222222222 Group : 4 Dose Level : 0.75 Dosage Unit; mg/kg/day 105533 7.7 2.1 5.0 .3 .3 .0 27 65 4 4 0 105542 10.9 3.0 6.7 .8 .2 .1 28 62 8 2 1 MEAN S.D. N 9.3 2.6 5.8 .6 .2 .0 28 64 6 3 0 2.26 .64 1.20 .35 .07 .07 .7 2.1 2.8 1.4 22222222222 902C00 003207 APPENDIX 4 Individual Clinical Hematology Data Females Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105529 105549 Dose Level: 0 ----- Group: 3 105539 105552 Dose Level: 0.15 ----- Group: 4 Dose Level: 0.75 105533 - - - 105542 - - - Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual clinical Hematology Data Males Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC HGB HCT MCV MCH MCHC PLT RETIC XlOVliL G/DL % FL PG % X10V//L Covance 6329-223 3M Study No. T-6295.7 RETIC XIOV^L Group: 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level: 0 6.75 6.28 13.0 12.2 6.52 .332 2 12.6 .57 2 Dose Level: 0.15 6.75 6.82 13.3 13.3 6.78 .049 2 13.3 .00 2 Dose Level: 0.75 6.06 6.33 11.4 12.4 6.20 .191 2 11.9 .71 2 Dosage Unit: mg/kg/day 40.6 37.9 60.2 60.3 19.3 19.4 39.2 1.91 2 60.2 .07 2 19.4 .07 2 Dosage Unit: mg/kg/day 42.5 41.8 62.9 61.3 19.8 19.4 42.2 .49 2 62.1 1.13 2 19.6 .28 2 Dosage unit: mg/kg/day 39.0 39.9 64.4 63.0 18.8 19.5 39.5 .64 2 63.7 .99 2 19.2 .49 2 32.1 32.1 32.1 .00 2 31.4 31.7 31.6 .21 2 29.2 31.0 30.1 1.27 2 685 428 556 181.7 2 467 519 493 36.8 2 501 562 532 43.1 2 .1 .3 .2 .14 2 .1 .2 .2 .07 2 .8 .4 .6 .28 2 7 19 13 8.5 2 7 14 10 4.9 2 48 25 36 16.3 2 SQZVOO ANIMAL NUMBER WBC X10//<L APPENDIX 4 Individual Clinical Hematology Data Males Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH X10V//L x i o V hl MONO EOSIN XlQ /uL XIO'AuL BASO N -SEG% X I O V a/L LYMPH% MONO% Covance 6329-223 3M Study No. T-6295.7 EOSIN% BASO% Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 12.1 3.8 7.6 .5 .3 .0 31 63 4 2 0 105526 8.0 2.7 4.6 .4 .3 .0 33 58 5 4 0 MEAN S.D. H 10.0 3.2 6.1 .4 .3 .0 32 60 4 3 0 2.90 .78 2.12 .07 .00 .00 1.4 3.5 .7 1.4 22222222222 Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 105523 10.6 5.2 4.1 .8 .4 .0 49 39 12.2 5.8 5.6 .4 .3 .0 48 46 a4 32 0 0 MEAN S.D. N 11.4 5.5 4.8 .6 .4 .0 48 42 6 3 0 1.13 .42 1.06 .28 .07 .00 .7 4.9 3.5 1.4 22222222222 Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 105522 9.5 3.6 4.9 .6 .4 .1 38 51 17.3 7.6 7.4 1.5 .6 .1 44 43 64 94 1 1 MEAN S.D. N 13.4 5.6 6.2 1.0 .5 .1 41 47 84 1 5.52 2.83 1.77 .64 .14 .00 4.2 5.7 2.1 .0 22222222222 60ZD00 APPENDIX 4 Individual Clinical Hematology Data Males Day 24S 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Covance 6329-223 3M Study No. T-6295.7 Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105520 105526 - - - - - 'J Group : 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 105523 Group : 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105511 105522 TZVQQ ANIMAL NUMBER APPENDIX 4 Individual clinical Hematology Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC HGB HCT MCV MCH MCHC PLT RETIC X10 IwL G/DL % FL PG % X10 /nL % Covance 6329-223 3M Study No. T-6295.7 RETIC X10 InL Group: 1 105529 105549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 5.70 6.74 11.3 13.3 6.22 .735 2 12.3 1.41 2 Dose Level : 0.15 6.88 6.61 12.9 12.5 6.74 .191 2 12.7 .28 2 Dose Level: 0.75 6.38 7.02 12.2 12.8 6.70 .453 2 12.5 .42 2 Dosage Unit: mg/kg/day 34.9 41.9 61.1 62.1 19.8 19.7 38.4 4.95 -t 61.6 .71 2 19.8 .07 2 Dosage Unit: mg/kg/day 40.9 40.4 59.4 61.2 18.7 18.9 40.7 .35 2 60.3 1.27 2 18.8 .14 2 Dosage Unit: mg/kg/day 39.9 44.1 62.5 62.8 19.2 18.2 42.0 2.97 2 62.7 .21 2 18.7 .71 2 32.4 31.7 32.1 .49 2 31.4 31.0 31.2 .28 2 30.7 29.0 29.8 1.20 2 577 461 519 82.0 2 391 459 425 48.1 2 335 546 440 149.2 2 .2 .3 .2 .07 2 .1 .2 .2 .07 2 .1 .4 .2 .21 2 11 20 16 6.4 2 7 13 10 4.2 2 6 28 17 15.6 2 TTZOO ANIMAL NUMBER WBC XI0 //tL APPENDIX 4 Individual Clinical Hematology Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT <PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH X10/nL X107pL MONO EOSIN X10 /nL X105/L BASO N-SEG% X10/ivL LYMPH% MONO% Covane 6329-223 3M Study No. T-6295.7 EOSIN% BASO% Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 12.5 9.1 2.8 .5 .1 .n 73 22 4 1 0 105549 10.3 5.1 4.0 .9 .3 .0 50 39 8 3 0 MEAN S.D. N 11.4 7.1 3.4 .7 .2 .0 62 30 6 2 0 1.56 2.83 .85 .28 .14 .00 16.3 12.0 2.8 1.4 .0 2 2 2 2 2 it 2222 Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105539 7.5 .9 5.3 1.0 .2 .1 12 71 13 3 1 105552 11.4 5.1 4.6 1.0 .6 .0 45 40 9 5 0 MEAN S.D. N 9.4 3.0 5.0 1.0 .4 .0 28 56 11 4 0 2.76 2.97 .49 .00 .28 .07 23.3 21.9 2.8 1.4 .7 22222222222 Group: 4 Dose Level;: 0.75 Dosage Unit: mg/kg/day 105533 10.8 4.5 5.0 1.1 .2 .1 41 46 10 11 105542 11.1 2.6 7.5 .7 .3 .1 23 67 6 3 1 MEAN S.D. N 11.0 3.6 6.2 .9 .2 .1 32 56 8 2 1 .21 1.34 1.77 .28 .07 .00 12.7 14.8 2.8 1.4 0 22 2 22 2 22 2 22 C.J N APPENDIX 4 Individual Clinical Hematology Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-62951 IN CYNOMOLGUS ANIMAL NUMBER AIJISO POLY POIK HYPO TOXNEUT Group: 1 105529 105549 Group: 3 105539 105552 Group : 4 105533 105542 Dose Level: 0 - Dose Level: 0.15 - Dose Level: 0.75 - Dosage Unit : mg/kg/day - - Dosage Unit : mg/kg/day - - Dosage Unit: mg/kg/day -- a Plasmodium was observed. Covance 6329-223 3M Study No. T-6295.7 oo C*5 N ANIMAL NUMBER APPENDIX 4 Individual Clinical Hematology Data Males Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC HGB -HCT MCV MCH MCHC PLT RETIC X10(/L G/DL % FL PG % XlOVfiL % Covance 6329-223 3M Study No. T-6295.7 RETIC XIO'VjiL Group : 1 105520 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level : 0 6.78 6.67 12.9 12.4 6.72 .078 2 12.6 .35 2 Dose Level: 0.15 6.89 6.71 13.6 12.8 6.80 .127 2 13.2 .57 2 Dose Level: 0.75 6.08 6.36 11.5 12.1 6.22 .198 2 11.8 .42 2 Dosage Uni t: mg /kg/day 40.6 39.8 59.8 59.7 19.0 18.6 40.2 .57 2 59.8 .07 2 18.8 .28 2 Dosage Unit: mg/kg/day 43.2 40.6 62.6 60.5 19.8 19.1 41.9 1.84 2 61.5 1.48 2 19.4 .49 2 Dosage Unit: mg/kg/day 37.8 38.3 62.1 60.2 18.9 19.0 38.1 .35 2 61.1 1.34 2 19.0 .07 2 31.8 31.2 31.5 .42 2 31.6 31.5 31.5 .07 2 30.5 31.5 31.0 .71 2 692 396 544 209.3 2 434 548 491 80.6 2 542 603 572 43.1 2 .5 .1 .3 .28 2 .2 .1 .2 .07 2 .8 .3 .6 .35 2 34 7 20 19.1 2 14 7 10 4.9 2 49 19 34 21.2 2 003214 ANIMAL NUMBER WBC X10/gL APPENDIX 4 Individual Clinical Hematology Data Males Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH X10`7/iL X10 7//L MONO EOSIN XIO'/n L X10 7/jL BASO N -SEG% XIO '/iiL LYMPH% MONO% Covance 6329-223 3M Study No. T-6295.7 Eosun BASO% Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 105526 9.5 4.3 4.5 .6 .1 .0 45 47 7 l 0 7.8 4.0 3.0 .7 .1 .0 52 38 9 l 0 MEAN S.D. N 8.6 4.2 3.8 .6 .1 .0 48 42 8 1 0 1.20 .21 1.06 .07 .00 .00 4.9 6.4 1.4 .0 222222222 22 Group: 3 Dose Level : 0 .15 Dosage Unit: mg/kg/day 105505 13.7 9.6 3.0 .9 .2 .0 70 22 7 1 0 105523 11.8 6.7 4.4 .6 .1 .0 57 37 5 1 0 MEAN S.D. N 12.8 8.2 3.7 .8 .2 .0 64 30 6 1 0 1.34 2.05 .99 .21 .07 .00 9.2 10.6 1.4 .0 222222222 22 Group : 4 Dose Level: 0 .75 Dosage Unit: mg/kg/day 105511 6.3 2.2 3.1 .8 .2 .1 36 49 12 3 1 105522 11.6 5.8 4.7 .9 .1 .0 50 40 8 1 0 MEAN S.D. N 9.0 4.0 3.9 .8 .2 .0 43 44 10 2 0 3.75 2.55 1.13 .07 .07 .07 9.9 6.4 2.8 1.4 2 2 2 2 2 2 2 2 2- 2 2 ooazis 9T2C00 APPENDIX 4 Individual clinical Hematology Data Males Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTAHE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 Dose Level: 0 105520 105526 - Group: 3 Dose Level: 0.15 105505 105523 - Group: 4 105511 105522 Dose Level: 0.75 ----- Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day --- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Hematology Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC HGB . HCT MCV MCH MCHC PLT RETIC X10* /ivL G/DL % FL PG % X10 /L % Covance 6329-223 3M Study No. T-6295.7 RETIC XIO'/h L Group : 1 105529 105549 MEAN S .D. N Group : 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level: 0 6.04 6.61 11.9 12.8 6.32 .403 2 12.3 .64 2 Dose Level: 0.15 6.81 6.71 12.5 12.5 6.76 .071 2 12.5 .00 2 Dose Level: 0.75 6.20 6.81 11.6 12.2 6.50 .431 2 11.9 .42 2 Dosage Unit: mg/kg/day 36.9 39.9 61.1 60.4 19.7 19.4 38.4 2.12 2 60.8 .49 2 19.6 .21 2 Dosage Unit: mg/kg/day 39.6 40.7 58.2 60.7 18.3 18.6 40.1 .78 2 59.4 1.77 2 18.4 .21 2 Dosage Unit: mg/kg/day 37.9 41.0 61.2 60.3 18.8 17.9 39.5 2.19 2 60.8 .64 2 18.4 .64 2 32.2 32.1 32.1 .07 2 31.5 30.6 31.0 .64 2 30.7 29.7 30.2 .71 2 645 447 546 140.0 2 399 546 472 103.9 2 314 534 424 155.6 2 .1 .3 .2 .14 2 .4 .3 .4 .07 2 .1 .5 .3 .28 2 6 20 13 9.9 2 27 20 24 4.9 2 6 34 20 19.8 2 003217 ANIMAL NUMBER WBC XX07/-L APPENDIX 4 Individual Clinical Hematology Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH X10 />vL Xl0'/nL MONO EOSIN XIO'/iiL XlO'AuL BASO N -SEG% X10/L LYMPH% MONO% Covance 6329-223 3M Study No. T-6295.7 EOSINl BASO% Group : i Dose Level: 0 Dosage Unit: mg/kg/day 105529 105549 14.9 10.0 3.2 1.4 .2 .0 67 22 10 8.7 4.4 3.3 .6 .3 .0 51 38 7 10 30 MEAN S.D. N 11.8 7.2 3.2 1.0 .2 .0 59 30 8 0 4.38 3.96 .07 .57 .07 .00 11.3 11.3 2.1 1.4 222222 222 22 Group : 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105539 7.4 2.0 4.5 .7 .2 .0 27 61 10 3 0 105552 11.4 6.5 3.9 .4 .6 .0 57 34 4 5 0 MEAN S.D. N 9.4 4.2 4.2 .6 .4 .0 42 48 7 4 0 2.83 3.18 .42 .21 .28 .00 21.2 19.1 4.2 1.4 222 222 222 22 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 7.8 2.3 5.0 .5 .1 .0 29 63 7 i0 105542 10.0 3.1 6.1 .6 .2 .0 31 61 6 2 0 MEAN S.D. N 8.9 2.7 5.6 .6 .2 .0 30 62 6 2 0 1.56 .57 .78 .07 .07 .00 1.4 1.4 .7 .7 222 222 222 22 003218 003219 APPENDIX 4 Individual Clinical Hematology Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-629SI IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 105529 105549 1 Dose - Level: 0 --- Group: 3 Dose Level: 0.15 105539 - - - 105552 - - - Group: 105533 105542 4 Dose - Level: 0.75 --- Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Hematology Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC HGB HCT MCV MCH MCHC PLT RETIC X10///L G/DL % FL PG % x i o 7/vl % Covance 6329-223 3M Study No. T-6295.7 RETIC X107i/L Group: 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level: 0 6.82 6.44 13.3 12.5 6.63 .269 2 12.9 .57 2 Dose Level: 0.15 7.19 7.12 14.1 13.8 7.16 .049 2 14.0 .21 2 Dose Level: 0.75 5.93 6.68 11.9 13.2 6.30 .530 2 12.6 .92 2 Dosage Unit: mg/kg/day 41.2 39.3 60.4 61.0 19.4 19.4 40.2 1.34 2 60.7 .42 2 19.4 .00 2 Dosage Unit: mg/kg/day 46.3 44.9 64.3 63.0 19.6 19.4 45.6 .99 2 63.7 .92 2 19.5 .14 2 Dosage Unit: mg/kg/day 38.7 42.5 65.3 63.7 20.1 19.8 40.6 2.69 2 64.5 1.13 2 19.9 .21 2 32.2 31.8 32.0 .28 2 30.5 30.8 30.6 .21 2 30.9 31.1 31.0 .14 2 584 337 460 174.7 2 .4 .2 .3 .14 2 415 566 490 106.8 2 .5 .1 .3 .28 2 445 576 510 92.6 2 1.4 .0 .7 .99 2 27 13 20 9. 2 36 7 22 20. 2 83 0 42 58. 2 003220 ANIMAL NUMBER WBC XIOV//L APPENDIX 4 Individual Clinical Hematology Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH XIOVo L Xl0'/(/L MONO EOSIN XIO'/itL XlOVivL BASO N-SEG% XIO'/^L LYMPH% MONO% Covance 6329-223 3M Study No. T-6295.7 EOSIN% BASO% Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 11.2 5.4 4.9 .7 .1 .1 48 44 6 1 1 105526 12.0 7.5 3.8 .6 .1 .0 62 32 5 1 0 MEAN S.D. N 11.6 6.4 4.4 .6 .1 .0 55 38 6 1 0 .57 1.48 .78 .07 .00 .07 9.9 8.5 .7 .0 .7 22222222222 Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 10.7 4.1 5.6 .8 .2 .0 38 52 7 2 0 105523 12.5 5.7 6.2 .5 .2 .0 45 49 4 1 0 MEAN S.D. N 11.6 4.9 5.9 .6 .2 .0 42 50 6 2 0 1.27 1.13 .42 .21 .00 .00 4.9 2.1 2.1 .7 0 22222222222 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 12.0 7.5 3.5 .7 .2 .1 63 29 6 1 1 105522 21.2 13.1 6.0 1.6 .5 .1 62 28 7 3 0 MEAN S.D. N 16.6 10.3 4.8 1.2 .4 .1 62 28 6 2 0 6.51 3.96 1.77 .64 .21 .00 .7 .7 .7 1.4 22222222222 TZZOO APPENDIX 4 Individual Clinical Hematology Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Covance 6329-223 3M Study No. T-6295.7 Group: 1 105520 105526 Dose Level: 0 ----- Dosage Unit: mg/kg/day --- | Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 105523 - -- ---- - Group: 4 105511 I5522 Dose Level: 0.75 ----- Dosage Unit: mg/kg/day --- zzzcoo ANIMAL NUMBER APPENDIX 4 Individual Clinical Hematology Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC HGB HCT MCV MCH MCHC PLT RET1C XlO'/xL G/DL *% FL PG % XIOVoL % Covance 6329-223 3M Study No. T-6295.7 RETIC X10 7//L Group: i 105529 105549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level : 0 5.63 6.88 11.3 13.5 6.26 .884 2 12.4 1.56 2 Dos Level: 0.15 6.61 6.70 12.7 12.7 6.66 .064 2 12.7 .00 2 Dose Level : 0.75 6.62 7.51 12.7 13.5 7.06 .629 2 13.1 .57 2 Dosage Unit: mg/kg/day 34.8 42.2 61.8 61.3 20.1 19.6 38.5 5.23 2 61.6 .35 2 19.8 .35 2 Dor-age Unit: mg/kg/day 40.2 41.4 60.9 61.9 19.3 19.0 40.8 .85 2 61.4 .71 2 19.2 .21 2 Dosage Unit: mg/kg/day 40.7 45.2 61.4 60.1 19.1 18.0 42.9 3.18 2 60.8 .92 2 18.5 .78 2 32.6 31.9 32.2 .49 2 31.7 30.6 31.2 .78 2 31.2 29.9 30.6 .92 2 580 407 494 122.3 2 441 461 451 14.1 2 293 598 446 215.7 2 .6 .4 .5 .14 .4 .2 .3 .14 2 .0 .3 .2 .21 2 34 28 31 4.2 2 26 13 20 9.2 2 0 23 12 16.3 2 003223 ANIMAL NUMBER WBC X107//L APPENDIX 4 Individual Clinical Hematology Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH XlO/fjL X107//L MONO EOSIN XlO'/i'L X10V//L BASO N-SEG% XIO'A/L LYMPH% MOHO% Covance 6329-223 3M Study No. T-6295.7 EOSINt BAS0% Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 105549 8.2 4.5 2.9 .6 .2 .0 55 36 7 2 0 9.3 4.3 3.8 .8 .4 .0 46 41 84 0 MEAN S.D. N 8.8 4.4 3.4 .7 .3 .0 50 38 8 3 0 .78 .14 .64 .14 .14 .00 2 2 22 2 2 6.4 3.5 .7 1.4 2 2 -3 2 2 Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105539 11.1 5.0 4.7 1.0 .4 .0 45 43 93 0 105552 8.7 2.6 4.6 .8 .8 .0 29 52 9 9 0 MEAN S.D. N 9.9 3.8 4.6 .9 .6 .0 37 48 9 6 0 1.70 1.70 .07 .14 .28 .00 11.3 6.4 .0 4.2 22222222222 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 9.9 3.5 5.1 1.0 .2 .1 36 51 10 2 1 105542 11.2 2.5 7.3 .9 .4 .2 22 65 84 2 MEAN S.D. N 10.6 3.0 6.2 1.0 .3 .2 29 58 9 3 2 .92 .71 1.56 .07 .14 .07 9.9 9.9 1.4 1.4 22 22 2 22 22 22 003224 S2ZC00 APPENDIX 4 Individual Clinical Hematology Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXHEUT Group: 1 Dose Level: 0 105529 - - - 105549 - - - Group: 3 Dose Level: 0.15 105539 - - - 105552 - - - Group: 4 105533 105542 Dose Level: 0.75 ----- Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Hematology Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS: T-6295) IN CYNOMOLGUS RBC HGB HCT MCV MCH MCHC PLT RETIC X10 7/:L G/DL % FL PG % XlO'/iiL % Covance 6329-223 3M Study No. T-6295.7 RETIC X107//L Group : i 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 6.54 6.59 12.6 12.6 6.56 .035 2 12.6 .00 2 Dose Level : 0.15 6.80 7.00 13.5 13.8 6.90 .141 2 13.6 .21 2 Dose Level: 0.75 6.42 6.42 12.7 12.5 6.42 .000 2 12.6 .14 2 Dosage Unit: mg/kg/day 39.9 41.4 61.0 62.8 19.2 19.1 40.7 1.06 2 61.9 1.27 2 19.2 .07 2 Dosage Unit: mg/kg/day 43.6 44.2 64.1 63.1 19.8 19.8 43.9 .42 2 63.6 .71 2 19.8 .00 2 Dosage Unit: mg/kg/day 43.5 41.3 67.6 64.3 19.7 19.5 42.4 1.56 2 66.0 2.33 2 19.6 .14 2 31.5 30.5 31.0 .71 2 30.9 31.3 31.1 .28 2 29.2 30.3 29.8 .78 2 503 366 434 96.9 2 377 369 373 5.7 2 478 562 520 59.4 2 .7 .3 .5 .28 2 .7 .7 .7 .00 2 .9 .3 .6 .42 2 46 20 33 18.4 2 48 49 48 .7 2 58 19 38 27.6 2 003226 ANIMAL NUMBER WBC XIOVpL APPENDIX 4 Individual Clinical Hematology Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH X10'/i/L X10 /L MONO EOSIN XIO'A/L XIOVuL BASO N -SEG% X107.//L LYHPH% MONO% Covance 6329-223 3M Study No. T-6295.7 EOSIH% BASOt Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 105526 7.1 2.0 4.3 .5 .1 .3 28 60 7 1 4 9.6 4.2 4.1 1.1 .1 .0 44 43 11 1 1 MEAN S.D. N 8.4 3.1 4.2 .8 .1 .2 36 52 9 1 2 1.77 1.56 .14 .42 .00 .21 11.3 12.0 2.8 .0 2.1 22222222222 Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 8.1 3.8 3.2 .9 .2 .1 47 39 11 2 1 105523 13.7 6.2 6.2 .7 .5 .1 45 45 53 1 MEAN S.D. N 10.9 5.0 4.7 .8 .4 .1 46 42 8 2 1 3.96 1.70 2.12 .14 .21 .00 1.4 4.2 4.2 .7 .0 222 2 22 222 22 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 15.7 10.9 3.4 1.2 .1 .1 70 22 7 1 1 105522 16.2 8.8 5.4 1.3 .4 .3 54 33 8 2 2 MEAN S.D. N 16.0 9.8 4.4 1.2 .2 .2 62 28 8 2 2 .35 1.48 1.41 .07 .21 .14 11.3 7.8 .7 ,7 .7 22222222222 003227 003228 APPENDIX 4 Individual clinical Hematology Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 105520 105526 Dose Level: 0 ----- Group: 3 105505 105523 Dose Level: 0.15 ----- Group: 4 105511 105522 Dose Level: 0.75 ----- Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Dosage Unit: mg/kg/day --- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Hematology Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTAHE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC HGB . HCT MCV MCH MCHC PLT RETIC XlO'/i/L G/DL % FL PG % X107//L % Covance 6329-223 3M Study No. T-6295.7 RETIC XIO'/m D Group : 1 105529 105549 MEAN S.D. N Group : 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level: 0 5.52 6.51 11.1 12.6 6.02 .700 2 11.8 1.06 2 Dose Level: 0.15 6.60 6.33 12.6 12.0 6.46 .191 2 12.3 .42 2 Dose Level: 0.75 6.62 6.81 12.5 12.3 6.72 .134 2 12.4 .14 2 Dosage Unit: mg/kg/day 34.6 40.5 62.6 62.3 20.1 19.4 37.5 4.17 2 62.5 .21 2 19.8 .49 2 Dosage Unit: mg/kg/day 41.2 39.3 62.4 62.1 19.1 18.9 40.2 1.34 2 62.2 .21 2 19.0 .14 2 Dosage Unit: mg/kg/day 41.0 40.6 61.9 59.7 18.9 18.1 40.8 .28 2 60.8 1.56 2 18.5 .57 2 32.1 31.1 31.6 .71 2 30.7 .30.5 30.6 .14 2 30.5 30.3 30.4 .14 2 533 483 508 35.4 2 405 408 406 2.1 2 293 500 396 146.4 2 .6 33 .3 20 .4 26 .21 9.2 22 .3 20 .6 38 .4 29 .21 12.7 22 .2 13 .4 27 .3 20 .14 9.9 2 2 00322 ANIMAL NUMBER WBC XIOV/jL APPENDIX 4 Individual Clinical Hematology Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS N-SEG LYMPH XlO'/pL X10 7L MONO EOSII1 XlOVciL XlO/wL BASO N -SEG% XlO/jiL LYMPH% MONO% Covance 6329-223 3M Study No. T-6295.7 EOSIN% BASOI Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 6.9 3.5 2.5 .7 .2 .1 50 36 10 2 1 105549 15.6 10.5 3.2 1.3 .4 .2 67 20 9 3 1 MEAN S.D. M 11.2 7.0 2.8 1.0 .3 .2 58 28 10 2 1 6.15 4.95 .49 .42 .14 .07 12.0 11.3 .7 .7 22222222222 Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105539 13.8 7.1 5.1 1.0 .4 .2 51 37 8 3 2 105552 9.2 3.8 3.4 1.1 .7 .2 41 37 12 7 2 MEAN S.D. N 11.5 5.4 4.2 1.0 .6 .2 46 37 10 5 2 3.25 2.33 1.20 .07 .21 .00 7.1 .0 2.8 2.8 22222222222 Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 9.8 3.2 5.7 .5 .1 .2 33 58 5 1 2 105542 11.0 3.0 7.0 .5 .3 .1 28 64 5 2 i MEAN S.D. N 10.4 3.1 6.4 .5 .2 .2 30 61 5 2 2 .85 .14 .92 .00 .14 .07 3.5 4.2 .0 .7 22222222222 OEZCOO 003231 APPENDIX 4 Individual Clinical Hematology Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER ANISO POLY POIK HYPO TOXNEUT Group: 1 Dose Level: 0 105529 105549 Group: 3 Dose Level: 0.15 105539 - - - 105552 - - - Group: 4 Dose Level: 0.75 105533 - - - 105542 - - - Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day --Dosage Unit: mg/kg/day --- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Hales Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT T PRO MG/DL ' G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covature 6329-223 3M T-6295.7 TRIG MG/DL Group : 1 I0S508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level: 0 62 22 76 21 74 27 69 17 75 19 99 17 76 12.5 6 20 3. 8 6 Dose Level: 0. 03 76 17 69 17 58 29 75 16 70 8.3 4 20 6. 2 4 Dose Level: 0. 15 59 20 138 16 95 22 76 20 69 25 58 24 82 30.4 6 21 3. 3 6 Dosage Unit: mg/kg/day 1.0 8.7 4.6 1.3 9.2 4.7 1.2 9.3 5.0 1.1 8.7 4.9 1.1 9.4 5.2 1.2 8.8 4.9 1.2 .10 6 9.0 .32 6 4.9 .21 6 Dosage Unit: mg/kg/day 1.2 9.7 1.0 9.5 1.1 8.8 1.4 10.2 5.5 4.6 5.0 5.6 1.2 .17 4 9.6 .58 4 5.2 .46 4 Dosage Unit: mg/kg/day 1.2 9.3 .9 8.8 1.5 10.1 1.1 9.3 1.4 9.6 1.3 9.7 5.2 4.4 5.3 5.2 5.2 5.2 1.2 .22 6 9.5 .44 6 5.1 .34 6 4.1 4.5 4.3 3.8 4.2 3.9 4.1 .26 6 4.2 4.9 3.8 4.6 4.4 .48 4 4.1 4.4 4.8 4.1 4.4 4.5 4.4 .26 6 1.3 1.0 .3 .7 .3 .2 .6 .45 6 .5 .2 .6 .3 .4 .18 4 1.3 .3 .5 .3 .7 .7 .6 .37 6 5 11 10 9 9 9 9 2,,0 6 88 137 174 111 150 170 138 33..7 6 71 92 58 78 63 58 70 13,.3 6 9 8 11 8 9 1..4 4 138 111 98 93 110 20..1 4 41 48 113 41 61 35,,0 4 14 10 9 8 10 8 10 2. 2 6 186 157 124 124 141 175 151 26. 1 6 48 59 55 53 62 57 56 4. 9 6 003232 565 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day -27 26-w e e k c a p s u l e t o x i c i t y s t u d y w i t h p e r f l u o r o o c t a n e s u l f o n i c a c i d POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Group : 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 67 18 102 22 71 22 58 21 75 22 64 18 73 15.4 6 20 2..0 6 Dosage Unit: mg/kg/day 1.3 9.6 5.1 1.4 9.9 5.0 1.4 9.5 5.3 1.1 8.8 4.7 1.3 9.2 5.3 1.3 9.5 5.5 1.3 .11 6 9.4 .38 6 5.2 .28 6 4.5 4.9 4.2 4.1 3.9 4.0 4.3 .37 6 .4 .4 .8 1.0 .3 .3 .5 .29 6 10 7 10 8 10 9 9 1.3 6 129 121 117 115 188 159 138 29.3 6 68 58 62 55 77 83 67 11.0 6 003233 566 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level: 0 58 24 84 51 58 33 36 26 58 31 43 29 56 16. 5 6 32 9. 7 6 Dose Level: 0.03 53 27 38 43 43 48 43 26 44 6.3 4 36 11.2 4 Dose Level : 0.15 66 99 39 29 54 34 99 78 84 118 93 56 72 23.5 6 69 35.7 6 Dosage Unit: mg/kg/day 546 628 514 866 1156 556 152 125 117 88 211 113 8 9 9 4 7 6 711 252.6 6 134 42.8 6 7 1.9 6 Dosage Unit: mg/kg/day 642 787 1002 369 155 125 182 103 4 4 2 3 700 265.6 4 141 34.5 4 3 1.0 4 Dosage Unit: mg/kg/day 720 814 579 716 1165 624 194 130 124 82 154 . 278 12 4 2 16 10 5 770 210.3 6 160 68.4 6 8 5.4 6 1086 1908 783 660 1671 692 1133 535.3 6 1955 348 848 595 936 709.0 4 670 1109 1047 1549 820 1329 1087 322.3 6 451 508 448 336 250 376 395 93.4 6 413 715 435 340 476 164. 6 4 367 450 326 471 469 236 386 94. 5 6 12 226 12 17 25 37 55 84.4 6 19 43 60 17 35 20.6 4 133 15 33 29 56 39 51 42.4 6 284 325 249 220 168 235 247 54 6 243 441 326 196 302 107..4 4 190 301 218 291 296 156 242 62. 4 6 003234 567 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level: 0.75 54 49 54 94 80 181 71 32 69 48 80 78 68 11. 7 6 80 54. 2 6 Dosage Unit: rag/kg/day 1443 447 585 927 646 992 167 138 156 199 105 259 6 9 6 6 5 5 840 360.9 6 171 53.3 6 6 1.5 6 1602 575 1265 540 907 1676 1094 497.4 6 653 515 704 543 396 362 529 135.6 6 52 19 39 99 15 21 41 31.8 6 359 326 435 325 274 224 324 72.2 6 003235 568 003236 Appendix 4 Individual Clinical- Chemistry Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D, N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level : 0 10.2 10.3 11.1 10.5 11.8 10.7 6.5 5.8 6.6 6.1 7.5 5.0 10.8 .60 6 6.2 .84 6 Dose Level: 0 ..03 12.2 11.3 11.1 12.0 6.5 6.9 7.1 6.1 11.6 .53 4 6.6 .44 4 Dose Level: 0 ,.15 11.9 10.7 12.2 11.2 11.9 10.9 5.9 7.5 6.9 6.6 8.8 6.7 11.5 .62 6 7.1 .99 6 Dosage Unit: mg/kg/day 154 4.9 106 154 4.8 106 161 5.9 113 158 5.7 111 166 6.1 111 160 4.9 109 159 4.6 6 5.4 .58 6 109 2 6 Dosage Unit: mg/kg/day 171 6.2 114 159 5.8 110 159 5.5 109 167 6.1 112 164 6.0 4 5.9 .32 4 111 2 4 Dosage Unit: mg/kg/day 161 5.8 112 156 5.8 111 169 7.2 113 164 6.1 116 168 7.0 110 158 6.3 108 163 5.3 6 6.4 .60 6 112 2 6 569 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 11.8 11.3 10.9 10.5 11.8 11.7 8.0 6.0 5.9 6.1 7.0 8.3 11.3 .54 6 6.9 1.06 6 Dosage Unit: mg/kg/day 165 6.1 112 157 6.5 108 158 5.5 104 156 4.8 106 162 5.8 109 168 6.3 110 161 4.8 6 5.8 .62 6 108 2 6 Covance 6329-223 3M T-6295.7 cznoo 570 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level: 0 54 23 108 23 70 23 51 19 82 22 92 21 76 22.2 6 22 1.6 6 Dose Level : 0.03 71 21 66 23 89 22 67 24 73 10.7 4 22 1.3 4 Dose Level: 0.15 86 20 87 21 82 29 72 20 55 21 74 27 76 12.0 6 23 3.9 6 Dosage Unit: mg/kg/day 1.2 9.4 1.3 9.9 1.3 8.6 1.3 9.9 1.2 10.8 1.1 9.0 5.1 5.5 4.6 4.6 4.7 4.9 1.2 .08 6 9.6 .78 6 4.9 .35 6 Dosage Unit: mg/kg/day 1.3 10.0 1.2 9.2 1.2 8.9 1.1 9.0 4.9 4.5 4.6 4.8 1.2 .08 4 9.3 .50 4 4.7 .18 4 Dosage Unit: mg/kg/day 1.2 10.7 1.1 9.8 1.3 9.2 1.1 9.1 1.0 9.1 1.1 9.8 5.5 5.2 3.9 4.7 4.4 4.6 1.1 .10 6 9.6 .62 6 4.7 .57 6 4.3 4.4 4.0 5.3 6.1 4.1 4.7 .83 6 5.1 4.7 4.3 4.2 4.6 .41 4 5.2 4.6 5.3 4.4 4.7 5.2 4.9 .38 6 1.2 .3 .5 .5 .4 .3 .5 .34 6 .5 .7 .3 .6 .5 .17 4 .8 .3 .6 .9 .5 .6 .6 .21 6 7 10 7 4 7 7 7 1.9 6 93 168 137 203 133 159 149 37.2 6 56 91 54 131 56 48 73 32.4 6 5 120 6 133 9 146 6 120 6 130 1.7 12.4 44 68 69 55 56 62 7.5 4 7 7 7 37 11 6 12 12.1 6 162 142 141 156 122 140 144 14.0 6 50 42 66 74 63 53 58 11.7 6 8CZH00 571 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 106 27 71 21 88 17 74 26 71 25 60 26 78 16.3 6 24 3.9 6 Dosage Unit: mg/kg/day 1.3 9.4 1.4 10.1 1.2 10.5 1.1 8.6 1.3 8.8 .9 8.8 4.9 5.5 4.6 4.4 4.6 4.5 1.2 .18 6 9.4 .78 6 4.8 .40 6 4.5 4.6 5.9 4.2 4.2 4.3 4.6 .65 6 .4 .4 .3 .4 .5 1.3 .6 .37 6 11 8 9 8 9 7 9 1.4 6 163 149 137 164 152 158 154 10.1 6 69 65 53 37 86 56 61 16.6 6 003239 572 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day -27 2G-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance G329-223 3H T-6295.7 Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level:: 0 66 202 65 211 75 215 61 48 61 82 55 83 64 6.7 6 140 76.,9 6 Dose Level :: 0 .03 68 89 54 146 44 80 50 98 54 10.2 4 103 29. 4 4 Dose Level:: 0 .15 77 76 68 135 39 65 140 160 74 143 48 78 74 35.5 6 110 41. 0 6 Dosage Unit: mg/kg/day 195 101 274 121 217 98 550 163 256 204 254 50 3 5 7 5 3 3 291 130.1 6 123 54.0 6 4 1. 6 6 Dosage Unit: mg/kg/day 200 166 184 72 210 62 211 75 2 3 3 4 201 12.5 4 94 48.5 4 3 8 4 Dosage Unit: mg/kg/day 201 454 122 198 334 232 257 118.5 6 127 120 64 41 80 91 87 32.9 6 2 4 2 8 6 3 4 2. 4 6 484 1588 792 872 896 1242 979 384,,3 6 706 395 477 356 484 156..7 4 1192 1003 362 663 1073 769 844 306. 4 6 425 281 360 314 595 272 374 121..9 6 219 293 433 566 378 153. 7 4 366 411 269 484 352 617 416 121. 0 6 27 39 46 12 27 19 28 12..5 6 265 135 211 184 342 185 220 73 6 25 12 17 48 26 15. 9 4 152 189 286 322 237 79 4 35 46 44 25 0 62 35 21. 2 6 177 230 179 272 210 393 244 81 6 003240 573 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 101 216 63 88 68 148 57 126 74 99 67 63 72 15. 4 6 123 54..2 6 Dosage Unit: mg/kg/day 301 121 329 64 575 63 182 52 204 79 269 70 5 3 7 4 3 1 310 141.4 6 75 24.3 6 4 2.0 6 3858 902 2229 417 1377 964 1624 1251. 5 6 411 545 336 380 294 337 384 88.6 6 25 0 15 39 31 4 19 15.4 6 269 343 205 223 196 246 247 54 6 003241 574 ZZVOO Appendix 4 Individual Clinical Chemistry Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group : 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level : 0 10.9 13.0 10.4 12.4 11.5 10.3 5.8 6.5 5.6 7.1 6.8 5.7 11.4 1.10 6 6.2 .63 6 Dose Level: 0,.03 10.9 11.7 10.3 10.8 4.4 3.8 4.4 6.1 10.9 .58 4 4.7 .99 4 Dose Level: 0,.15 11.5 11.5 10.5 10.3 10.6 11.6 6.2 5.6 6.1 4.9 5.3 7.1 11.0 .59 6 5.9 .78 6 Dosage Unit: mg/kg/day 155 5.6 106 173 8.0 119 159 5.4 110 166 6.4 116 167 6.0 118 156 5.7 112 163 7.1 6 6.2 .96 6 114 5 6 Dosage Unit: mg/kg/day 165 5.2 113 164 6.5 117 158 5.4 112 165 6.5 119 163 3.4 4 5.9 .70 4 115 3 4 Dosage Unit: mg/kg/day 167 6.4 113 164 6.3 116 164 6.3 118 156 5.3 111 152 5.5 112 166 7.0 118 162 6.1 6 6.1 .63 6 115 3 6 575 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level : 0.75 10.9 11.6 12.1 10.7 11.7 10.7 5.1 5.7 5.7 6.1 4.7 5.6 11.3 .59 6 5.5 .50 6 Dosage Unit: mg/kg/day 163 5.1 114 164 6.3 112 168 6.0 115 159 6.8 116 167 7.1 115 155 5.3 113 163 4.9 6 6.1 .80 6 114 1 6 Covance 6329-223 3M T-6295.7 003243 576 ANIMAL NUMBER Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; 1'-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Dose Level: 0 54 20 68 19 57 26 62 19 54 19 65 16 60 5.9 6 20 3. 3 6 Dose Level: 0. 03 65 22 72 14 58 21 53 16 62 8.3 4 18 3.,9 4 Dose Level: 0. 15 52 17 62 17 71 19 68 18 68 26 47 28 61 9.8 6 21 4.,9 6 Dosage Unit: mg/kg/day 1.1 9.2 4.8 1.2 9.9 4.8 1.1 8.5 4.5 1.0 8.7 4.8 .9 8.4 4.6 1.2 8.8 4.8 1.1 .12 6 8.9 .56 6 4.7 .13 6 Dosage Unit: mg/kg/day 1.4 10.0 1.1 9.9 1.0 7.8 1.3 9.5 5.7 4.8 4.7 4.9 1.2 .18 4 9.3 1.02 4 5.0 .46 4 Dosage Unit: mg/kg/day 1.1 9.0 5.0 .8 9.0 4.7 1.4 9.7 4.9 1.1 9.3 5.2 1.4 8.8 4.5 1.1 9.4 4.7 1.2 .23 6 9.2 .33 6 4.8 .25 6 4.4 5.1 4.0 3.9 3.8 4.0 4.2 .49 6 4.3 5.1 3.1 4.6 4.3 .85 4 4.0 4.3 4.8 4.1 4.3 4.7 4.4 .32 6 1.4 1.1 .4 .9 .4 .4 .8 .43 6 .6 .2 .4 .4 .4 .16 4 1.0 .3 .4 .3 .6 .7 .6 .27 6 8 11 9 7 10 8 9 1.,5 6 118 171 161 117 134 139 140 22.,1 6 9 148 7 132 8 108 6 83 8 118 1. 3 28. 4 44 7 176 7 159 8 135 8 116 7 134 9 155 8 146 8 21. 5 66 70 85 45 90 48 74 69 18.,7 6 51 45 50 41 47 4. 6 4 50 54 61 65 59 56 58 5. 3 6 003244 577 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Group : 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 58 20 75 24 66 19 54 21 64 23 71 18 65 7.8 6 21 2.3 6 Dosage Unit: mg/kg/day 1.4 9.1 4.9 1.4 9.4 5.0 1.3 9.9 5.4 1.1 9.3 4.5 1.2 8.8 5.1 1.3 9.4 5.5 1.3 .12 6 9.3 .37 6 5.1 .36 6 4.2 4.4 4.5 4.8 3.7 3.9 4.2 .40 6 .5 .3 .4 .7 .2 .4 .4 .17 6 8 112 109 6 109 72 6 127 68 5 130 62 8 156 108 9 143 128 7 130 1.5 18.0 66 91 27 6 003245 578 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level: 0 37 30 53 59 46 28 26 23 35 27 71 69 45 15.9 6 39 19.5 6 Dose Level: 0.03 30 23 38 53 35 36 45 46 37 6.3 4 40 13.0 4 Dose Level : 0.15 55 58 25 20 46 38 35 45 54 91 70 45 48 15.9 6 50 23.8 6 Dosage Unit: mg/kg/day 776 605 690 876 1552 830 159 130 112 77 203 126 4 7 11 5 9 7 888 339.5 6 134 42.9 6 7 2.6 6 Dosage Unit : mg/kg/day 855 999 1284 365 144 104 153 77 2 4 2 5 876 384.3 4 120 35.4 4 3 1.5 4 Dosage Unit: mg/kg/day 721 1042 733 878 1359 643 154 127 117 73 103 239 10 1 3 6 6 3 896 267.3 6 136 57.3 6 5 3.2 6 173 170 231 99 160 1291 354 461.0 6 169 137 186 273 191 58.2 4 176 138 140 143 222 287 184 59.7 6 482 268 451 349 235 462 374 106.3 6 440 666 421 310 459 149.3 4 339 451 339 436 407 240 369 78.9 6 21 23 12 11 17 45 22 12.5 6 288 155 235 223 152 278 222 58 6 14 44 18 20 24 13.6 4 252 391 314 171 282 93 4 29 6 61 39 42 65 40 21.7 6 163 295 212 264 238 155 221 55 6 03246 579 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Hales Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 29 20 33 35 54 87 46 36 50 43 48 54 43 10.0 6 46 23.0 6 Dosage Unit: mg/kg/day 1772 564 967 798 808 1069 149 112 169 138 85 197 3 2 2 2 2 2 996 417.0 6 142 39.9 6 2 .4 6 154 164 436 143 329 473 283 149.7 6 675 536 626 539 348 409 522 124.7 6 38 9 21 35 20 30 26 10.9 6 341 329 380 311 236 247 307 55.9 6 003247 580 003248 Appendix 4 Individual Clinical Chemistry Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOSi T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level : 0 10.3 11.0 10.6 10.5 10.4 10.7 7.0 6.7 7.0 6.8 7.4 5.1 10.6 .25 6 6.7 .80 6 Dose Level: 0 ,03 12.9 10.8 10.5 10.7 9.0 6.8 6.5 5.2 11.2 1.12 4 6.9 1.58 4 Dose Level : 0..15 11.2 11.2 11.4 10.9 10.4 10.6 5.4 7.4 6.4 6.9 8.3 6.3 11.0 .39 6 6.8 1.00 6 Dosage Unit: mg/kg/day 161 5.4 114 163 5.8 115 155 5.3 112 158 5.2 115 159 5.2 114 165 5.8 122 160 3.6 6 5.4 .28 6 115 3 6 Dosage Unit: mg/kg/day 180 6.6 121 162 6.2 114 160 5.1 116 158 5.2 111 165 10.1 4 5.8 .74 4 116 4 4 Dosage Unit: mg/kg/day 159 5.1 114 161 5.3 116 162 5.6 114 163 6.1 116 163 5.8 115 155 5.9 115 160 3.1 6 5.6 .38 6 115 6 581 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 10.6 10.6 10.9 10.6 11.3 11.6 7.8 5.1 6.1 5.2 7.8 7.6 10.9 .43 6 6.6 1.29 6 Dosage Unit: mg/kg/day 164 5.1 119 158 5.1 111 162 5.4 115 157 5.8 114 162 5.5 114 166 5.7 113 162 3.4 6 5.4 .29 6 114 2 6 Covance 6329-223 3M .T-6295.7 003249 582 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group : 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Dose Level : 0 50 21 86 25 57 25 43 16 59 27 55 18 58 14.7 6 22 4..4 6 Dose Level: 0. 03 87 20 65 22 65 18 50 25 67 15.2 4 21 3..0 4 Dose Level: 0. 15 53 22 60 21 72 15 64 17 48 20 60 25 60 8.4 6 20 3. 6 6 Dosage Unit: mg/kg/day .9 9.2 1.3 9.0 1.2 8.5 1.1 9.6 1.1 10.6 .9 9.1 4.5 4.8 4.4 4.0 4.5 4.5 1.1 .16 6 9.3 .71 6 4.4 .26 6 Dosage Unit: mg/kg/day 1.1 9.1 4.4 1.1 9.3 4.4 1.0 8.4 4.4 1.1 9.2 4.7 1.1 .05 4 9.0 .41 4 4.5 .15 4 Dosage Unit: mg/kg/day 1.0 9.4 4.4 1.0 9.0 4.7 1.1 9.0 3.9 1.0 9.4 4.7 1.0 8.9 4.0 1.0 9.5 4.0 1.0 .04 6 9.2 .26 6 4.3 .37 6 4.7 4.2 4.1 5.6 6.1 4.6 4.9 .80 6 4.7 4.9 4.0 4.5 4.5 .39 4 5.0 4.3 5.1 4.7 4.9 5.5 4.9 .40 6 1.1 .4 .8 .3 .6 .2 .6 .34 6 .4 .8 .2 .5 .5 .25 4 .7 .4 .7 .6 .4 .5 .6 .14 6 8 106 64 8 154 56 7 160 65 7 183 123 8 127 63 8 151 56 8 147 .5 26..9 66 71 25..7 6 5 10 10 10 9 2..5 4 114 130 137 116 124 11. 1 4 60 78 50 69 64 12. 0 4 8 7 7 15 7 7 8 3. 2 6 146 105 149 162 114 123 133 22. 4 6 60 36 65 66 54 63 57 11. 3 6 003250 583 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level : 0.75 86 27 70 19 77 15 58 21 74 30 56 22 70 11.5 6 22 5.4 6 Dosage Unit: mg/kg/day 1.1 9.2 4.3 1.3 9.1 4.3 1.1 9.6 4.3 1.0 9.0 4.5 1.2 8.7 4.5 .9 8.9 4.4 1.1 .14 6 9.1 .31 6 4.4 .10 6 4.9 4.8 5.3 4.5 4.2 4.5 4.7 .38 6 .3 .3 .3 .4 .4 .7 .4 .15 6 9 136 68 6 130 59 7 102 51 6 121 61 7 138 110 6 113 46 7 123 1.2 14.1 66 66 23.0 6 003251 584 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3m T-6295.7 1H ' GO e- Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level: 0 28 36 54 108 33 51 44 38 44 38 60 85 44 12.1 6 59 30.2 6 Dose Level :: 0..03 49 73 68 81 29 51 49 76 49 15.9 4 70 13.3 4 Dose Level :: 0..15 33 35 41 69 26 49 45 125 35 70 38 60 36 6.6 6 68 30.9 6 Dosage Unit: mg/kg/day 209 88 400 98 330 80 583 138 351 164 298 44 3 9 4 7 3 5 362 125.6 6 102 42.9 6 5 2.4 6 Dosage Unit: mg/kg/day 210 170 257 65 193 54 301 64 3 2 3 5 240 48.7 4 88 54.7 4 3 1.3 4 Dosage Unit: mg/kg/day 286 103 459 90 130 73 219 43 423 70 396 76 1 4 2 2 5 4 319 129.0 6 76 20.3 6 3 1.5 6 109 205 156 180 274 518 240 146..6 6 287 761 165 301 378 262. 2 4 206 121 110 267 123 363 198 101.3 6 376 244 326 332 494 263 339 89..9 6 254 344 423 514 384 110. 9 4 364 387 305 533 317 580 414 115.1 6 14 27 38 11 18 0 18 13..2 6 232 107 188 186 279 169 194 58..2 6 24 15 23 50 28 15. 2 4 168 218 273 290 237 55. 5 4 41 50 36 41 0 36 34 17.4 6 172 200 198 282 179 350 230 70 6 003252 585 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L 1? AMYL U/L Covance 6329-223 3M T-6295.7 Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level): 0.75 34 56 37 35 42 49 37 50 22 40 45 46 36 8.0 6 46 7.5 6 Dosage Unit : mg/kg/day 305 95 543 37 743 52 269 46 296 61 332 60 1 2 2 3 3 1 415 188.9 6 58 20.0 6 2 .9 6 153 766 352 413 130 174 331 242.1 6 404 485 341 394 233 383 373 83.3 6 32 15 20 27 24 21 23 5.9 6 261 298 203 215 119 284 230 66.0 6 003253 586 ANIMAL NUMBER Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Dose Level : 0 51 21 71 17 54 26 56 16 52 22 70 17 59 9.1 6 20 3..9 6 Dose Level : 0. 03 56 18 62 17 61 25 57 18 59 2.9 4 20 3.,7 4 Dose Level : 0. 15 58 16 59 14 83 16 84 19 62 22 54 24 67 13.3 6 18 3. 9 6 Dosage Unit: mg/kg/day 1.1 9.1 4.7 1.2 9.3 4.8 1.1 8.4 4.7 1.0 8.3 4.4 1.0 8.1 4.7 1.1 8.2 4.4 1.1 .08 6 8.6 .50 6 4.6 .17 6 Dosage Unit: mg/kg/day 1.2 8.6 4.9 1.3 9.9 4.8 1.0 8.4 4.2 1.3 9.3 5.0 1.2 .14 4 9.0 .69 4 4.7 .36 4 Dosage Unit: mg/kg/day 1.1 8.8 4.9 .8 8.1 4.1 1.3 9.0 4.8 1.2 9.0 5.4 1.3 8.4 4.4 1.2 9.2 4.3 1.2 .19 6 8.8 .42 6 4.6 .48 6 4.4 4.5 3.7 3.9 3.4 3.8 4.0 .42 6 3.7 5.1 4.2 4.3 4.3 .58 4 3.9 4.0 4.2 3.6 4.0 4.9 4.1 .44 6 1.3 1.0 .4 .8 .3 .3 .7 .42 6 .5 .4 .3 .3 .4 .10 4 .9 .3 .3 .3 .5 .5 .5 .23 6 8 11 11 8 8 10 9 1..5 6 132 179 178 124 147 158 153 23..0 6 13 8 10 9 10 2. 2 4 142 129 98 89 114 25.,1 4 9 8 10 13 10 9 10 1. 7 6 183 145 142 130 135 132 144 19. 7 6 67 97 44 63 48 56 62 19..0 6 57 73 71 41 60 14. 8 4 53 57 48 55 46 83 57 13. 4 6 003254 589 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105506 105507 105509 105511 105512 105522 68 18 1.3 8.2 4.4 3.8 .3 10 106 70 95 23 1.4 9.1 4.5 4.6 .3 8 104 81 71 18 1.2 9.3 5.1 4.2 .3 14 117 62 67 17 1.1 8.8 4.3 4.5 .4 6 125 56 71 22 1.4 8.4 4.9 3.5 .2 11 144 96 70 17 1.2 8.8 5.7 3.1 .3 9 155 94 MEAN S.D. N 74 19 1.3 8.8 4.8 4.0 .3 10 125 76 10.6 2.6 .12 .41 .53 .59 .06 2.7 20.6 16.6 6666666666 003255 590 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level :: 0 34 24 44 47 45 27 24 21 33 27 33 59 36 7.9 6 34 15..2 6 Dose Level:: 0..03 26 16 43 57 38 40 34 28 35 7.2 4 35 17. 5 4 Dose Level : 0..15 44 41 23 20 38 31 41 40 49 55 47 33 40 9.4 6 37 11. 7 6 Dosage Unit: mg/kg/day 709 512 742 848 1455 767 154 102 125 77 209 114 4 8 9 5 9 5 839 321.9 6 130 46.2 6 7 2..3 6 Dosage Unit: mg/kg/day 634 955 1125 287 121 109 147 87 5 5 2 5 750 369.9 4 116 25.0 4 4 1.,5 4 Dosage Unit: mg/kg/day 643 980 698 798 1181 535 143 134 109 80 106 194 10 1 3 6 9 2 806 237.8 6 128 39.4 6 5 3. 8 6 116 144 148 82 143 156 132 27..8 6 93 173 201 129 149 47.,7 4 127 157 133 175 152 173 153 19. 9 6 510 280 448 365 197 428 371 115..8 6 359 641 383 331 428 143. 3 4 305 442 327 436 354 203 344 89. 3 6 18 47 9 11 20 27 22 13..9 6 312 168 235 241 133 256 224 64.2 6 11 38 9 27 21 13. 8 4 214 390 295 182 270 92.9 4 14 0 32 24 23 26 20 11. 3 6 155 294 216 268 212 135 213 61.7 6 003256 591 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group : 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level:: 0.75 26 28 27 31 36 64 43 38 34 34 35 63 34 6.3 6 43 16.2 6 Dosage Unit: mg/kg/day 1502 462 626 683 725 941 139 96 127 127 89 171 4 2 2 2 3 3 823 367.0 6 125 29.9 6 3 .8 6 155 163 300 169 189 244 203 57.2 6 657 496 593 516 340 390 499 119.4 6 38 14 15 20 8 40 22 13.4 6 349 312 367 299 237 243 301 53.4 6 003257 592 8SZC00 Appendix 4 Individual Clinical Chemistry Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level: 0 10.0 10.8 10.6 10.0 10.9 10.3 6.8 6.9 7.6 6.4 8.2 6.8 10.4 .39 6 7.1 .66 6 Dose Level : 0,.03 10.0 11.0 10.3 10.7 6.8 7.2 7.5 5.5 10.5 .44 4 6.8 .88 4 Dose Level : 0 .15 10.6 10.1 10.7 10.4 10.2 10.1 5.3 7.4 6.6 7.2 7.8 5.3 10.4 .26 6 6.6 1.08 6 Dosage Unit: mg/kg/day 159 4.7 116 161 5.7 118 157 5.7 121 158 5.4 120 159 5.0 121 165 5.8 123 160 2. 9 6 5.4 .44 6 120 2 6 Dosage Unit: mg/kg/day 160 5.1 117 185 7.0 136 159 5.2 116 161 5.2 120 166 12.,5 4 5.6 .92 4 122 9 4 Dosage Unit: mg/kg/day 158 4.9 121 154 4.9 115 161 6.1 120 162 5.1 121 161 5.8 120 164 5.3 126 160 3.,5 6 5.4 .50 6 120 3 6 593 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 10.0 10.3 10.1 10.1 11.1 11.4 7.6 6.2 5.9 5.1 8.7 7.3 10.5 .60 6 6.8 1.31 6 Dosage Unit: mg/kg/day 159 5.3 121 153 5.6 118 158 5.3 121 152 4.7 115 163 6.5 123 169 6.0 120 159 6.4 6 5.6 .63 6 120 2.8 6 Covance 6329-223 3M T-6295.7 003259 594 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN 1MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Dose Level : 0 Dosage Unit: mg/kg/day 51 18 .9 8.5 4.4 4.1 69 22 1.2 8.6 4.5 4.1 61 25 1.2 8.5 4.5 4.0 47 16 1.2 9.5 4.2 5.3 67 24 1.2 9.8 4.0 5.8 46 22 1.0 9.3 4.5 4.8 .9 8 93 59 .3 9 152 59 .7 8 176 61 .4 9 227 185 .6 9 126 79 .3 10 156 70 57 10.2 6 21 3..5 6 1.1 .13 6 9.0 .57 6 4.4 .21 6 4.7 .75 6 .5 .24 6 9 155 .8 45..4 66 86 49..4 6 Dose Level : 0. 03 Dosage Unit: mg/kg/day 92 19 1.1 9.2 4.4 4.8 62 23 1.1 9.2 4.2 5.0 58 19 1.0 8.3 4.3 4.0 54 26 1.1 8.7 4.4 4.3 .4 7 126 .8 8 130 .3 15 140 .8 12 113 87 99 50 68 66 22 1.1 8.8 4.3 4.5 .6 10 127 76 17.3 3. 4 .05 .44 .10 .46 .26 3.7 11. 2 21. 5 444 44 4 44 4 4 Dose Level : 0. 15 Dosage Unit: mg/kg/day 53 20 1.2 9.2 4.7 4.5 .8 10 148 58 60 20 1.0 9.1 4.6 4.5 .4 9 113 33 76 18 1.1 8.9 4.0 4.9 .8 6 153 86 79 16 .9 9.0 4.4 4.6 .4 15 153 62 48 20 1.0 8.8 4.0 4.8 .5 13 112 75 57 24 1.0 9.1 4.0 5.1 .6 9 145 68 62 20 1.0 9.0 4.3 4.7 .6 10 137 64 12.6 2. 7 .10 .15 .33 .24 .18 3.2 19. 5 18. 0 6666666666 00S260 595 ANIMAL NUMBER Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Dose Level 0.75 Dosage Unit: mg/kg/day 88 19 1.2 8.8 4.4 4.4 .3 9 139 53 73 20 1.4 9.5 4.7 4.8 .5 9 142 63 75 14 1.2 9.6 4.3 5.3 .2 9 101 56 68 18 1.1 9.0 4.5 4.5 .4 12 148 78 74 19 1.2 8.5 4.2 4.3 .3 6 120 68 69 29 1.0 8.7 4.4 4.3 .4 8 111 50 74 7.2 6 20 5.0 6 1.2 .13 6 9.0 .44 6 4.4 .17 6 4.6 .39 6 .4 .10 6 9 127 1.9 18.9 66 61 10.5 6 003261 596 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance G329-223 3M T-6295.7 Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level:: 0 35 49 38 49 32 45 39 39 41 49 40 86 38 3.4 6 53 16. 7 6 Dose Level:: 0.03 55 77 41 98 33 60 51 73 45 9.9 4 77 15. 8 4 Dose Level :: 0 .15 35 31 46 87 29 43 48 105 33 41 33 54 37 7.8 6 60 29. 3 6 Dosage Unit: mg/kg/day 245 86 331 92 321 83 665 170 290 159 308 48 2 6 5 6 2 4 360 152.5 6 106 47.7 6 4 1..8 6 Dosage Unit: mg/kg/day 241 150 239 67 186 53 297 66 3 2 4 7 241 45.3 4 84 44.5 4 4 2..2 4 Dosage Unit: mg/kg/day 233 99 451 89 129 72 202 39 428 68 386 81 2 5 3 4 4 4 305 134.0 6 75 20.8 6 4 1. 0 6 182 226 490 294 245 138 262 123. 6 6 316 334 182 270 276 67. 9 4 302 124 121 253 142 224 194 76. 1 6 352 272 346 330 498 251 342 86..9 6 244 296 410 483 358 108..3 4 365 381 271 528 310 605 410 129.,7 6 11 5 38 5 26 0 14 14.7 6 219 118 201 191 286 170 198 55 6 27 0 12 38 19 16.7 4 166 196 270 280 228 55 4 41 35 30 11 0 53 28 19.6 6 172 208 180 283 182 380 234 82 6 003262 597 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group : 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 29 39 35 41 31 44 31 52 19 33 43 42 31 7. 8 6 42 6..2 6 Dosage Unit : mg/kg/day 285 96 506 39 755 52 240 48 250 52 351 62 2 2 1 2 2 2 398 200.5 6 58 20.0 6 2 .4 6 172 285 204 483 113 200 243 130,.1 6 414 503 340 434 241 377 385 89.4 6 30 41 23 34 18 15 27 9.9 6 271 317 204 240 161 283 246 56 6 003263 598 003264 Appendix 4 Individual Clinical Chemistry Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level : 0 9.7 9.6 10.4 10.3 9.9 10.3 5.9 6.2 5.9 6.5 5.7 5.5 10.0 .34 6 6.0 .36 6 Dose Level : 0..03 9.7 10.2 10.0 9.8 4.8 4.2 4.4 4.8 9.9 .22 4 4.6 .30 4 Dose Level: 0 .15 9.7 10.0 8.8 10.1 9.9 9.4 5.2 4.8 5.3 4.3 5.2 5.8 9.6 .48 6 5.1 .51 6 Dosage Unit: mg/kg/day 151 4.7 114 159 6.3 114 166 6.0 123 167 6.1 125 160 5.5 119 168 6.0 125 162 6. 5 6 5.8 .59 6 120 5 6 Dosage Unit: mg/kg/day 159 4.9 120 163 5.6 119 156 4.8 118 160 5.6 123 160 2. 9 4 5.2 .43 4 120 2 4 Dosage Unit: mg/kg/day 166 6.5 127 156 5.4 121 160 5.6 127 158 5.5 121 158 4.7 122 162 5.1 121 160 3. 6 6 5.5 .60 6 123 3 6 599 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level : 0.75 9.9 10.8 11.0 9.4 10.4 10.0 5.0 4.6 5.1 5.2 4.7 5.4 10.2 .60 6 5.0 .30 6 Dosage Unit: mg/kg/day 157 5.4 118 163 6.9 121 160 6.2 119 157 5.8 121 164 5.1 119 165 5.3 123 161 3.5 6 5.8 .67 6 120 1 6 Covance 6329-223 3M T-6295.7 003265 600 ANIMAL NUMBER Group : 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group : 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN 1MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3m T-6295.7 TRIG MG/DL Dose Level : 0 53 19 64 19 57 29 54 19 56 17 74 20 60 8.0 6 20 4. 3 6 Dose Level : 0. 03 57 19 74 14 64 26 59 19 64 7.6 4 20 4. 9 4 Dose Level : 0. 15 65 15 70 14 108 19 78 16 75 26 53 22 75 18.5 6 19 4. 6 6 Dosage Unit: mg/kg/day 1.0 8.7 4.7 1.3 9.1 4.8 1.1 8.3 4.7 1.0 8.4 4.7 1.1 8.3 4.8 1.3 9.2 5.0 1.1 .14 6 8.7 .40 6 4.8 .12 6 Dosage Unit: mg/kg/day 1.2 9.0 1.2 10.3 1.1 8.5 1.6 10.5 5.1 5.2 5.1 5.9 1.3 .22 4 9.6 .98 4 5.3 .39 4 Dosage Unit: mg/kg/day 1.2 8.7 5.1 1.0 9.0 4.9 1.3 9.0 5.0 1.0 9.1 5.2 1.4 8.8 4.8 1.2 9.2 5.0 1.2 .16 6 9.0 .19 6 5.0 .14 6 4.0 4.3 3.6 3.7 3.5 4.2 3.9 .33 6 3.9 5.1 3.4 4.6 4.2 .75 4 3.6 4.1 4.0 3.9 4.0 4.2 4.0 .21 6 1.2 1.1 .5 .8 .3 .4 .7 .38 6 .6 .3 .4 .4 .4 .13 4 .8 .3 .2 .3 .5 .5 .4 .22 6 6 119 61 8 177 101 9 170 56 8 132 81 7 151 43 9 177 66 8 154 1..2 24..6 66 68 20..4 6 7 143 8 132 7 109 8 119 8 126 6 14.,9 44 51 60 64 42 54 9. 8 4 8 6 8 9 14 8 9 2. 7 6 173 163 125 139 136 161 150 18. 8 6 49 56 38 48 68 44 50 10. 4 6 003266 601 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105506 105507 105509 105511 105512 105522 63 20 1.6 9.5 5.5 4.0 111 21 1.6 9.8 5.1 4.7 75 18 1.3 9.8 5.4 4.4 62 18 1.1 9.0 4.7 4.3 63 20 1.4 9.0 5.3 3.7 65 18 1.3 9.5 5.5 4.0 .3 9 107 88 .2 8 80 57 .3 17 90 59 .3 9 105 56 .2 10 147 68 .3 7 141 108 MEAN S.D. N 73 19 1.4 9.4 5.2 4.2 .3 10 112 73 19.1 1.3 .19 .36 .31 .35 .05 3.6 27.0 21.0 6666666666 003267 602 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level:: 0 41 25 48 45 46 31 27 24 36 24 36 63 39 7.7 6 35 15. 8 6 Dose Level:: 0..03 26 16 35 38 37 46 43 142 35 7.0 4 60 55..8 4 Dose Level:: 0..15 46 39 25 21 41 37 34 38 45 87 61 49 42 12.2 6 45 22. 4 6 Dosage Unit : mg/kg/day 706 533 782 901 1408 863 152 102 130 82 226 126 4 6 11 7 9 5 866 296.2 6 136 50.1 6 7 2,.6 6 Dosage Unit: mg/kg/day 692 824 1306 335 127 113 181 104 5 4 2 5 789 401.7 4 131 34.5 4 4 1..4 4 Dosage Unit: mg/kg/day 710 1097 645 724 1271 660 143 160 111 76 108 244 11 1 4 11 4 3 851 265.3 6 140 58.6 6 6 4. 3 6 222 164 166 120 167 168 168 32..4 6 130 153 189 227 175 42.,5 4 164 137 140 129 194 220 164 36. 2 6 525 275 437 377 251 487 392 111..8 6 386 741 396 338 465 185..6 4 356 501 324 454 394 235 377 94. 9 6 18 23 0 20 53 84 33 30..3 6 10 134 30 18 48 57..9 4 38 5 25 25 12 56 27 18. 3 6 359 184 261 275 186 325 265 71.2 6 254 492 322 205 318 125.4 4 200 365 240 306 266 174 258 70.1 6 S92TC00 603 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT {PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L 1? AMYL U/L Covance 6329-223 3M T-6295.7 Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level: 0.75 29 21 30 34 40 75 43 35 31 34 41 65 36 6..3 6 44 21.0 6 Dosage Unit: mg/kg/day 1624 463 563 566 726 900 154 108 122 118 95 166 3 2 2 1 2 2 807 428.6 6 127 27.4 6 2 .6 6 133 174 305 204 157 308 214 75.7 6 730 556 409 345 353 414 468 149.1 6 63 18 26 35 15 38 32 17.5 6 433 381 417 320 263 287 350 70.4 6 003269 604 Appendix 4 Individual Clinical Chemistry Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level : 0 9.7 11.0 9.8 10.2 9.5 11.4 6.9 6.3 6.6 6.7 6.9 7.4 10.3 .77 6 6.8 .37 6 Dose Level : 0..03 9.8 10.1 10.6 11.6 6.9 6.7 7.5 5.8 10.5 .79 4 6.7 .70 4 Dose Level : 0..15 11.0 11.4 10.0 10.7 10.4 10.3 5.8 8.2 6.6 6.5 8.0 5.8 10.6 .51 6 6.8 1.05 6 Dosage Unit: mg/kg/day 158 4.7 115 160 5.1 117 154 4.7 112 156 5.2 114 159 4.9 119 174 6.2 127 160 7.1 6 5.1 .56 6 117 5 6 Dosage Unit: mg/kg/day 163 4.6 117 173 6.8 125 163 5.1 117 169 6.4 123 167 4.9 4 5.7 1.04 4 120 4 4 Dosage Unit: mg/kg/day 160 4.8 117 169 5.6 129 159 5.3 115 160 5.7 122 162 5.7 110 155 5.3 112 161 4.6 6 5.4 .35 6 118 7 6 Covance 6329-223 3M T-6295.7 0032 O 605 Appendix 4 Individual Clinical Chemistry Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 10.7 11.2 10.4 10.3 11.2 11.1 7.1 6.7 5.6 5.0 6.6 7.5 10.8 .41 6 6.4 .94 6 Dosage Unit: mg/kg/day 170 5.1 125 160 5.8 114 158 5.1 117 158 5.0 116 163 5.2 115 167 6.1 114 163 5.0 6 5.4 .45 6 117 4 6 Covance 6329-223 3M T-6295.7 003271 606 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Dose Level : 0 Dosage Uni t : mg/kg/day 48 20 1.0 8.8 4.7 4.1 .7 8 99 65 78 22 1.3 9.8 5.4 4.4 .3 6 189 65 95 21 1.2 8.5 4.5 4.0 .4 10 182 61 58 15 1.2 9.4 4.4 5.0 .3 7 217 88 78 22 1.1 9.7 4.4 5.3 .5 9 136 57 42 18 1.1 9.3 4.7 4.6 .3 9 171 65 66 20.5 6 20 2..7 6 Dose Level : 0,.03 1.2 .10 6 9.2 .51 6 4.7 .38 6 Dosage Unit: mg/kg/day 4.6 .51 6 .4 .16 6 8 166 1.5 42.0 66 67 10.9 6 81 18 1.1 9.0 4.7 4.3 .3 7 114 53 51 22 1.2 9.8 4.7 5.1 .9 7 143 81 61 22 1.0 8.1 4.3 3.8 .4 8 149 50 80 26 1.1 9.0 4.6 4.4 .4 10 129 60 68 14.7 4 22 3..3 4 1.1 .08 4 9.0 .69 4 4.6 .19 4 4.4 .54 4 .5 .27 4 8 134 1.4 15.6 44 61 14.0 4 Dose Level: 0,.15 Dosage Unit: mg/kg/day 62 15 1.1 9.2 4.8 4.4 .6 7 153 42 55 20 1.1 9.3 4.9 4.4 .3 7 122 35 74 18 1.0 8.7 3.8 4.9 .4 8 143 77 49 24 1.0 8.9 4.6 4.3 .5 22 151 67 45 17 1.0 9.0 4.3 4.7 .4 10 125 43 74 26 1.0 9.3 4.2 5.1 .4 8 143 72 60 20 1.0 9.1 4.4 4.6 .4 10 140 56 12.4 4. 2 .05 .24 .41 .32 .10 5.8 13.1 18.0 6666666666 003272 607 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M T-6295.7 TRIG MG/DL Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 105534 105536 105540 105542 105551 84 22 1.2 9.8 4.8 5.0 .3 9 142 62 89 18 1.4 9.5 5.0 4.5 .3 6 131 76 89 14 1.2 9.6 4.5 5.1 .3 6 65 51 63 20 1.4 10.0 5.2 4.8 .3 13 105 53 93 32 1.3 9.1 4.5 4.6 .3 7 115 78 56 26 .9 8.8 4.6 4.2 .5 24 109 42 MEAN S.D. N 79 22 1.2 9.5 4.8 4.7 .3 11 111 60 15.5 6.3 .19 .45 .29 .33 .08 7.0 26.6 14.4 6666666666 003273 608 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group : 1 Dose Level !: 0 Dosage Unit: mg/kg/day 105529 105530 105531 105535 105544 105549 36 55 220 81 57 78 322 123 35 43 292 84 53 38 583 161 40 38 274 164 44 74 284 50 3 188 9 1481 6 128 7 2407 5 146 4 368 387 292 410 350 510 269 8 264 0 144 45 259 10 224 25 327 0 198 MEAN S.D. N 44 9.1 6 54 17.9 6 329 128.7 6 110 46.5 6 6 786 370 2..2 947..2 87..4 666 15 17. 5 6 236 62 6 Group: 2 Dose Level:: 0..03 Dosage Unit: mg/kg/day 105537 105541 105547 105550 39 72 219 220 39 80 238 73 30 50 168 53 64 114 307 67 2 247 269 2 250 348 3 165 454 11 217 487 23 190 2 249 23 330 25 306 MEAN S.D. N 43 14.6 4 79 26.6 4 233 57.5 4 103 78.3 4 4 220 390 4. 4 39. 4 99. 8 444 18 10. 9 4 269 62 4 Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105532 105538 105539 105545 105548 105552 30 34 235 37 57 531 23 52 157 56 153 229 38 54 404 40 54 390 98 85 69 42 68 82 1 196 447 130 245 4 149 426 41 261 3 107 290 26 213 2 345 520 25 319 7 230 329 0 214 7 227 640 18 443 MEAN 37 67 324 74 4 209 442 40 282 S.D. 11.1 42.8 140.3 19.2 2.5 81.8 127.6 46.1 87 N 666666666 co,' vF 609 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 35 43 38 34 33 42 31 41 20 40 50 71 34 9..8 6 45 13. 0 6 Dosage Unit: mg/kg/day 296 106 447 43 668 54 294 52 280 58 346 63 1 1 2 2 2 2 388 150.1 6 63 22.3 6 2 .5 6 1132 476 367 141 105 276 416 377. 0 6 389 482 343 480 225 353 379 96.5 6 35 0 18 35 16 12 19 13.6 6 281 338 221 292 169 279 263 59 6 003275 610 000276 Appendix 4 Individual Clinical Chemistry Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level: 0 10.2 11.1 10.3 11.0 8.1 10.7 5.5 6.0 4.8 6.8 5.6 5.5 10.2 1.11 6 5.7 .66 6 Dose Level: 0..03 9.7 11.5 8.8 10.9 4.5 3.6 4.5 4.0 10.2 1.21 4 4.2 .44 4 Dose Level: 0 .15 9.7 10.7 9.2 10.1 10.4 9.9 5.4 5.0 5.4 4.1 5.2 6.0 10.0 .53 6 5.2 .63 6 Dosage Unit: mg/kg/day 151 5.0 109 168 6.7 125 160 5.1 116 166 5.7 125 160 4.8 118 162 6.1 117 161 5.9 6 5.6 .74 6 118 6 6 Dosage Unit: mg/kg/day 156 4.6 110 170 6.5 122 154 4.5 113 165 5.4 124 161 7.5 4 5.2 .93 4 117 6 4 Dosage Unit: mg/kg/day 160 5.2 116 161 6.2 121 156 5.3 116 156 5.6 118 160 5.7 125 165 6.3 125 160 3.4 6 5.7 .45 6 120 4 6 611 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ' CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level : 0.75 10.4 10.5 10.7 11.5 10.6 9.7 4.9 4.2 5.0 5.8 5.3 5.2 10.6 .58 6 5.1 .53 6 Dosage Unit: mg/kg/day 159 5.4 122 165 6.2 124 160 5.9 114 170 6.6 117 163 5.8 118 157 5.1 115 162 4.7 6 5.8 .54 6 118 3 6 Covance 6329-223 3M T-6295.7 LLznm 612 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T--6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL 'T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL TRIG MG/DL Covance 6329-223 3M T-6295.7 HDL MG/DL Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level: 0 57 22 74 16 52 25 55 19 60 20 65 20 60 8.0 6 20 3..0 6 Dose Level: 0..03 56 18 63 19 60 22 66 17 61 4.3 4 19 2. 2 4 Dose Level: 0..15 58 21 62 16 71 24 74 17 65 27 48 25 63 9.4 6 22 4.,5 6 Dosage Unit: mg/kg/day 1.0 7.7 4.6 1.2 8.9 5.0 1.1 7.9 4.7 1.0 8.2 4.6 1.2 8.1 5.0 1.3 8.6 4.9 1.1 .12 6 8.2 .45 6 4.8 .19 6 Dosage Unit: mg/kg/day 1.1 8.3 5.0 1.3 9.6 5.2 1.1 7.9 5.0 1.5 9.4 5.5 1.2 .19 4 8.8 .83 4 5.2 .24 4 Dosage Unit: mg/kg/day 1.1 8.4 5.3 .9 8.2 4.7 1.3 9.3 5.4 1.1 9.6 4.7 1.4 8.5 5.0 1.1 8.6 4.8 1.2 .18 6 8.8 .55 6 5.0 .31 6 3.1 3.9 3.2 3.6 3.1 3.7 3.4 .34 6 3.3 4.4 2.9 3.9 3.6 .66 4 3.1 3.5 3.9 4.9 3.5 3.8 3.8 .61 6 1.2 1.2 .4 .6 .4 .3 .7 .41 6 .5 .3 .4 .4 .4 .08 4 .7 .3 .4 .2 .6 .6 .5 .20 6 8 11 12 11 9 10 10 1.5 6 115 178 183 124 147 178 154 29.9 6 7 136 8 127 8 117 6 98 7 120 1.0 16.3 44 11 7 10 9 11 14 10 2.3 6 191 135 145 129 136 157 149 22.8 6 68 82 39 78 42 54 60 18.3 6 49 97 49 44 60 24.9 4 49 69 73 74 64 59 65 9.5 6 58 77 84 57 70 67 69 10.6 6 52 45 42 43 46 4.5 4 74 60 56 49 53 36 55 12.5 6 003278 613 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL TRIG MG/DL Covance 6329-223 3M T-6295.7 HDL MG/DL Group : 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 80 22 98 23 60 21 55 17 91 19 72 19 76 17.0 6 20 2.2 6 Dosage Unit: mg/kg/day 1.6 9.4 5.4 1.4 9.0 4.8 1.2 9.0 4.2 1.0 9.0 4.6 1.2 8.7 5.1 1.3 9.2 5.4 1.3 .20 6 9.0 .23 6 4.9 .48 6 4.0 4.2 4.8 4.4 3.6 3.8 4.1 .43 6 .2 11 57 51 16 .2 14 29 29 9 .3 17 65 89 18 .3 8 75 41 25 .2 24 76 58 27 .2 13 87 95 20 .2 14 65 60 19 .05 5.5 20.3 26.3 6 66666 003279 614 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 153 26-WEEK CAPSULE 'rOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level:: 0 29 31 34 51 37 29 23 22 30 30 33 95 31 4.9 6 43 27. 3 6 Dose Level :: 0 .03 22 13 35 59 35 43 28 28 30 6.3 4 36 19. 8 4 Dose Level:: 0.15 43 72 28 43 33 40 20 36 50 75 63 63 40 15.7 6 55 17. 2 6 Dosage Unit: mg/kg/day 723 490 666 842 1370 659 156 125 128 79 238 126 2 2 8 3 1 1 792 305.3 6 142 53.1 6 3 2. 6 6 Dosage Unit: mg/kg/day 606 778 1093 258 132 109 163 88 4 3 1 1 684 348.2 4 123 32.2 4 2 1.,5 4 Dosage Unit: mg/kg/day 740 848 720 897 1241 673 160 143 129 70 121 262 4 1 2 1 7 8 853 207.5 6 148 63.8 6 4 3. 1 6 157 130 194 135 184 191 165 28..5 6 92 144 188 108 133 42,.6 4 218 178 201 122 213 225 193 38. 4 6 527 290 457 408 226 446 392 112. 8 6 403 713 420 344 470 165. 2 4 348 514 356 479 402 475 429 69. 9 6 28 27 12 20 12 39 23 10..5 6 14 100 19 31 41 40..0 4 30 9 36 28 36 860 166 339. 9 6 377 203 285 307 174 309 276 74 6 273 502 360 220 339 123 4 211 392 274 346 282 365 312 67, 6 003280 615 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT AtK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level: 0.75 28 24 31 39 52 85 44 33 40 46 37 85 39 8. 8 6 52 26. 6 6 Dosage Uni t : mg/ kg/day 1262 239 902 415 377 683 168 109 88 98 70 141 2 2 5 2 2 2 646 384.1 6 112 36.1 6 2 1.2 6 180 219 954 207 267 285 352 297. 5 6 758 499 504 494 439 406 517 124.5 6 61 9 25 33 25 36 32 17.2 6 475 359 371 340 346 296 364 59.9 6 003281 616 003282 Appendix 4 Individual Clinical Chemistry Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOSj T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level: 0 9.0 11.0 10.3 9.8 9.9 10.8 6.6 6.2 6.8 6.9 6.9 6.3 10.1 .73 6 6.6 .31 6 Dose Level: 0,.03 10.2 11.3 10.4 11.2 6.6 6.6 7.2 4.7 10.8 .56 4 6.3 1.09 4 Dose Level: 0 .15 9.6 10.1 11.3 10.9 9.9 10.3 5.7 7.2 6.9 6.2 8.6 6.5 10.4 .64 6 6.8 1.01 6 Dosage Unit: mg/kg/day 154 4.7 116 160 5.4 116 150 5.3 110 151 5.3 112 163 5.8 121 164 6.1 119 157 6.1 6 5.4 .48 6 116 4 6 Dosage Unit: mg/kg/day 154 5.0 113 163 6.1 114 159 4.9 118 161 6.1 122 159 3.9 4 5.5 .67 4 117 4 4 Dosage Unit: mg/kg/day 161 5.7 120 154 4.8 119 159 6.0 114 158 5.3 116 161 5.6 109 154 5.8 112 158 3.2 6 5.5 .43 6 115 4 6 617 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER ` CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 11.4 10.4 9.5 10.5 11.4 11.3 7.9 6.7 4.3 5.9 9.1 7.2 10.8 .76 6 6.8 1.66 6 Dosage Unit: mg/kg/day 171 6.6 128 150 6.4 111 153 4.8 107 153 5.8 108 160 5.1 109 163 6.2 114 158 7.9 6 5.8 .73 6 113 7 6 Covance 6329-223 3M T-6295.7 003283 618 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN 1MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL TRIG MG/DL Covance 6329-223 3M T-6295.7 HDL MG/DL Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level : 0 48 21 74 22 62 25 57 16 57 23 47 15 58 9.9 6 20 4.,0 6 Dose Level : 0. 03 46 18 70 25 72 12 68 24 64 12.1 4 20 6..0 4 Dose Level : 0. 15 49 20 53 23 62 18 59 24 58 23 60 27 57 4.9 6 22 3.,1 6 Dosage Unit: mg/kg/day .9 7.6 4.3 1.3 9.6 5.6 1.2 8.2 4.6 1.2 9.2 4.4 1.1 9.4 4.6 1.1 9.3 4.8 1.1 .14 6 8.9 .80 6 4.7 .47 6 Dosage Unit: mg/kg/day 1.0 8.6 4.4 1.3 8.9 4.6 .9 8.3 3.8 1.1 8.5 4.7 1.1 .17 4 8.6 .25 4 4.4 .40 4 Dosage Unit: mg/kg/day 1.1 9.2 5.1 1.0 8.5 4.6 1.2 8.8 4.2 1.0 8.3 4.7 1.1 8.7 4.3 1.0 9.0 4.1 1.1 .08 6 8.8 .33 6 4.5 .37 6 3.3 4.0 3.6 4.8 4.8 4.5 4.2 .63 6 4.2 4.3 4.5 3.8 4.2 .29 4 4.1 3.9 4.6 3.6 4.4 4.9 4.2 .48 6 1.0 .3 .6 .4 .6 .3 .5 .27 6 .4 1.0 .2 .5 .5 .34 4 .6 .3 .4 .5 .4 .6 .5 .12 6 7 9 9 9 9 11 9 1.3 6 80 175 177 226 143 175 163 48..5 6 53 65 70 175 59 56 80 47..1 6 6 9 10 9 8 1.7 4 102 128 82 127 110 22.,1 4 61 123 65 77 82 28.,5 4 8 7 9 12 15 8 10 3.1 6 133 100 144 136 107 162 130 23. 2 6 54 57 72 83 86 60 69 13. 7 6 39 73 64 56 42 81 59 16..8 6 43 61 41 42 47 9..5 4 33 37 56 37 48 34 41 9. 2 6 003284 619 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL TRIG MG/DL Covance 6329-223 3M T-6295.7 HDL MG/DL Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 105534 105536 105540 105542 105551 81 21 1.2 9.6 5.1 4.5 .3 15 100 62 25 74 12 1.4 9.1 4.6 4.5 .3 9 128 69 23 70 13 1.1 9.0 3.9 5.1 .2 8 62 44 20 62 15 1.1 8.7 4.6 4.1 .3 8 80 67 16 87 18 1.1 8.4 4.2 4.2 .4 9 77 84 25 46 26 1.0 8.6 4.6 4.0 .4 43 99 55 28 MEAN S.D. N 70 18 1.2 8.9 4.5 4.4 .3 15 91 64 23 14.6 5.3 .14 .43 .41 .40 .08 13.8 23.1 13.5 4 66666666666 S82C00 620 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 1 105529 105530 QS 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level: 0 52 159 33 82 30 51 31 48 37 44 33 79 36 8.2 6 77 43. 3 6 Dose Level:; 0,.03 54 88 33 70 17 18 46 146 38 16.2 4 80 52. 8 4 Dose Level:! 0..15 36 47 31 53 24 38 61 131 26 75 38 52 36 13.4 6 66 34. 1 6 Dosage Unit: mg/kg/day 175 78 305 115 277 82 593 171 266 176 272 53 3 1 2 2 1 2 315 143.3 6 112 51.2 6 2 .8 6 Dosage Unit: mg/kg/day 221 254 233 70 280 42 312 68 3 2 2 1 262 42.2 4 108 97.8 4 2 .8 4 Dosage Unit: mg/kg/day 259 100 498 78 169 68 228 38 401 67 292 78 2 3 3 2 1 8 308 120.9 6 72 20.3 6 3 2.5 6 192 377 156 362 155 169 235 105..0 6 395 293 79 253 255 131..7 4 268 118 201 330 126 412 242 116. 5 6 395 296 383 361 499 302 373 74..3 6 249 358 394 513 378 108..8 4 371 405 280 494 310 733 432 165. 5 6 11 - 45 8 25 0 18 17..7 5 285 175 255 244 342 232 256 55..7 6 25 3 11 33 18 13..5 4 182 276 302 341 275 67. 7 4 23 45 34 28 0 19 25 15. 2 6 212 264 211 322 208 541 293 129. 4 6 98200 621 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group : 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 33 45 73 42 34 41 30 40 22 62 46 60 40 18. 1 6 48 10. 0 6 Dosage Unit : mg/kg/day 285 107 359 44 616 47 230 44 216 57 310 66 1 2 7 2 1 1 336 146.9 6 61 24.2 6 2 2.3 6 297 3173 99 139 154 306 695 1217. 1 6 374 554 344 404 232 373 380 104.1 6 33 6 23 36 31 30 26 10.9 6 284 406 238 270 178 308 281 76.1 6 003287 622 003288 Appendix 4 Individual Clinical Chemistry Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level: 0 9.4 11.7 10.1 10.7 10.1 9.4 5.2 6.0 5.8 5.8 5.2 5.8 10.2 .87 6 5.6 .34 6 Dose Level: 0,.03 8.4 10.9 10.0 10.0 4.0 4.9 3.0 4.6 9.8 1.04 4 4.1 .84 4 Dose Level: 0,.15 9.5 9.3 9.7 9.9 10.4 10.2 5.0 3.8 5.7 4.0 5.1 6.3 9.8 .42 6 5.0 .96 6 Dosage Unit: mg/kg/day 144 4.7 107 169 6.6 124 155 5.8 116 163 6.9 125 159 5.6 125 161 6.5 116 158 8.5 6 6.0 .81 6 119 7 6 Dosage Unit: mg/kg/day 148 5.1 108 163 6.1 118 151 5.3 113 159 5.8 124 155 6.9 4 5.6 .46 4 116 6 4 Dosage Unit: mg/kg/day 153 4.7 110 152 5.3 118 154 5.8 115 152 5.7 114 158 4.8 120 154 5.9 118 154 2.2 6 5.4 .52 6 116 3 6 623 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level : 0.75 10.6 11.7 10.5 10.1 10.6 9.7 5.0 6.0 5.0 4.0 4.3 5.3 10.5 .67 6 4.9 .71 6 Dosage Unit: mg/kg/day 158 5.3 116 166 7.1 114 153 7.1 116 153 5.9 111 161 6.5 124 156 5.7 114 158 5.0 6 6.3 .75 6 116 4 6 Covance 6329-223 3M T-6295.7 003289 624 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL TRIG MG/DL Covance 6329-223 3M T-6295.7 HDL MG/DL Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level : 0 64 18 68 14 51 25 59 16 57 21 64 17 60 6.1 6 18 3. 9 6 Dose Level : 0. 03 62 18 77 12 59 27 57 16 64 9.1 4 18 6..3 4 Dose Level : 0. 15 70 15 71 13 83 18 68 16 72 19 57 20 70 8.3 6 17 2. 6 6 Dosage Unit: mg/kg/day 1.1 8.5 4.9 1.2 9.1 4.9 1.0 7.7 4.6 .8 7.7 4.5 1.2 8.4 5.1 1.2 8.1 4.6 1.1 .16 6 8.2 .54 6 4.8 .23 6 Dosage Unit: mg/kg/day 1.2 8.6 4.9 1.2 9.1 4.8 1.0 8.0 4.8 1.4 9.5 5.5 1.2 .16 4 8.8 .65 4 5.0 .34 4 Dosage Unit: mg/kg/day 1.1 8.6 5.2 .8 8.2 4.4 1.2 8.5 5.0 1.1 9.0 5.2 1.3 8.4 4.8 1.1 8.2 4.7 1.1 .17 6 8.5 .30 6 4.9 .31 6 3.6 4.2 3.1 3.2 3.3 3.5 3.5 .40 6 3.7 4.3 3.2 4.0 3.8 .47 4 3.4 3.8 3.5 3.8 3.6 3.5 3.6 .17 6 .9 .8 .5 .5 .3 .4 .6 .23 6 .3 .2 .4 .3 .3 .08 4 .5 .2 .3 .3 .4 .4 .4 .10 6 5 127 7 166 5 186 6 112 6 165 6 158 6 152 ,8 27..5 66 5 135 4 104 5 98 5 102 5 110 .5 17..0 44 8 190 5 136 7 119 5 137 5 151 5 149 6 147 1. 3 24. 0 66 45 55 37 35 41 55 45 8..7 6 28 35 41 27 33 6..6 4 22 51 31 45 32 35 36 10. 4 6 56 66 82 53 67 54 63 11 6 47 42 38 41 42 3 4 73 53 48 39 42 32 48 14 6 003290 625 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL TRIG MG/DL Covance 6329-223 3M T-6295.7 HDL MG/DL Group : 4 105506 a 105507 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 107 28 93 22 66 23 78 27 67 16 76 12.6 4 22 4.5 4 Dosage Unit: mg/kg/day 1.8 9.2 4.4 1.4 9.3 4.8 .9 8.0 4.2 1.3 8.8 5.2 1.4 9.8 5.4 1.2 .24 4 9.0 .77 4 4.9 .53 4 4.8 4.5 3.8 3.6 4.4 4.1 .44 4 .2 58 67 75 11 .2 28 28 22 8 .2 18 59 36 20 .2 7 38 19 10 .3 19 69 44 15 .2 18 48 30 13 .05 8.6 18.8 11.8 5 44444 a Unscheduled sacrifice on Day 179. 003291 626 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 1 Dose Level;: 0 Dosage Unit: mg/kg/day 105508 105517 105519 105520 105526 105527 28 32 756 169 2 122 524 15 373 35 52 420 126 5 106 308 37 210 41 27 628 149 10 526 440 19 281 23 26 776 72 3 207 388 30 298 30 26 1322 266 7 159 243 22 194 33 69 510 118 11 140 454 51 327 MEAN S.D. N 32 6.2 6 39 17. 9 6 735 318.7 6 150 65.6 6 6 210 393 3,,7 158,.7 102.,8 666 29 13. 4 6 280 68 6 Group: 2 Dose Level ;; 0 .03 Dosage Unit : mg/kg/day 105514 105515 105516 105521 19 16 548 136 34 35 552 100 29 34 1085 182 27 31 233 87 2 93 379 6 219 646 2 143 391 4 96 354 15 260 37 443 15 329 27 224 MEAN S.D. N 27 6.2 4 29 8. 8 4 604 353.5 4 126 42.6 4 4 138 442 1. 9 58..8 136. 5 444 24 10. 6 4 314 96 4 Group: 3 Dose Level ; 0 .15 Dosage Unit: mg/kg/day 105505 105510 105518 105523 105524 105528 30 39 650 171 4 118 412 36 234 21 20 634 133 3 102 431 7 333 39 51 558 115 7 116 336 36 256 22 58 697 95 3 101 472 36 337 50 69 1035 125 13 296 397 37 277 51 43 557 250 5 314 240 27 184 MEAN 36 47 688 148 6 174 381 30 270 S.D. 13.3 16. 9 178.3 55.8 3. 8 101.,5 82. 3 11. 8 59, N 666666666 Li N 627 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 4 105506 a 105507 105511 105512 105522 MEAN S.D. N Dose Level: 0.75 73 29 30 46 41 25 36 44 30 73 34 5. 3 4 47 19.7 4 Dosage Unit : mg/kg/day 876 134 208 110 344 101 422 71 581 132 10 2 4 3 2 389 155.7 4 104 25.3 4 3 1.0 4 4040 192 101 175 258 182 64. 5 4 738 474 524 379 408 446 65.3 4 67 17 27 32 68 36 22.2 4 432 344 339 297 299 320 25.2 4 a Unscheduled sacrifice on Day 179. 003293 628 003294 Appendix 4 Individual Clinical Chemistry Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level : 0 10.1 10.9 10.2 9.7 10.5 9.9 6.8 5.5 6.5 6.2 7.7 5.6 10.2 .43 6 6.4 .82 6 Dose Level: 0,.03 9.9 9.9 9.9 10.3 5.7 5.3 7.1 4.9 10.0 .20 4 5.8 .96 4 Dose Level: 0 .15 10.8 9.7 10.2 10.2 10.1 9.7 5.0 6.5 6.1 6.3 7.5 5.8 10.1 .41 6 6.2 .82 6 Dosage Unit: mg/kg/day 156 4.7 111 160 5.3 113 149 5.2 112 151 5.2 109 159 5.2 112 150 4.9 110 154 4.8 6 5.1 .23 6 111 1 6 Dosage Unit: mg/kg/day 157 5.1 112 155 4.8 107 154 4.7 109 157 5.4 108 156 1.5 4 5.0 .32 4 109 2 4 Dosage Unit: mg/kg/day 157 4.8 112 152 4.9 113 147 5.4 107 158 5.2 112 158 5.2 110 150 4.8 106 154 4.7 6 5.0 .25 6 110 2 6 629 Covance G329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105506 a 105507 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 10.6 10.1 9.6 10.3 11.1 6.9 7.2 4.4 6.1 6.7 10.3 .62 4 6.1 1.22 4 Dosage Unit: mg/kg/day 157 7.5 111 144 5.5 99 152 5.2 111 157 5.6 109 158 5.4 106 153 6.4 4 5.4 .17 4 106 5 4 a Unscheduled sacrifice on Day 179. Covance 6329-223 3M T-6295.7 00329S 630 ANIMAL NUMBER Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group : 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T--6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL TRIG MG/DL Covance 6329-223 3M T-6295.7 HDL MG/DL Dose Level: 0 Dosage Unit: mg/kg/day 35 23 58 21 68 22 44 16 75 22 65 14 58 15.2 6 20 3..7 6 Dose Level : 0,.03 62 18 58 18 53 19 44 25 54 7.8 4 20 3..4 4 Dose Level: 0,.15 .8 8.0 4.4 1.3 9.6 5.5 1.2 8.4 4.5 1.2 9.4 4.7 1.2 9.5 4.4 1.0 8.7 4.6 1.1 .18 6 8.9 .66 6 4.7 .42 6 Dosage Unit: mg/kg/day 1.1 9.1 4.6 1.2 9.3 4.7 .8 7.6 3.7 1.0 8.5 4.6 1.0 .17 4 8.6 .76 4 4.4 .47 4 Dosage Unit: mg/kg/day 3.6 4.1 3.9 4.7 5.1 4.1 4.2 .55 6 4.5 4.6 3.9 3.9 4.2 .38 4 .9 .3 .4 .3 .4 .2 .4 .25 6 .5 .8 .2 .5 .5 .24 4 5 87 6 181 6 176 6 226 7 143 6 149 6 160 .6 46.5 66 4 99 6 143 4 109 7 138 5 122 1.5 21.6 44 46 48 74 72 55 44 56 13.3 6 53 66 31 45 49 14.7 4 32 71 59 60 43 73 56 16.0 6 33 54 42 37 42 9.1 4 80 17 1.1 9.2 5.0 4.2 .4 10 130 44 25 63 17 .9 8.6 4.6 4.0 .3 7 98 26 34 66 18 1.1 9.0 4.3 4.7 .4 6 154 68 58 56 21 1.0 8.4 4.7 3.7 .5 11 137 56 38 55 16 .9 8.5 4.3 4.2 .3 7 108 37 38 66 24 1.0 9.6 4.0 5.6 .3 7 149 61 25 64 9.0 6 19 3.,1 6 1.0 .09 6 8.9 .47 6 4.5 .35 6 4.4 .67 6 .4 .08 6 8 129 2.0 22.3 66 49 15.8 6 36 12.1 6 96ZC00 631 ANIMAL NUMBER GLU MG/DL Appendix 4 Individual Clinical Chemistry Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL TRIG MG/DL Covance 6329-223 3M T-6295.7 HDL MG/DL Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 105534 105536 105540 105542 105551 78 23 1.2 9.1 4.8 4.3 74 22 1.4 9.4 4.8 4.6 86 12 1.2 9.9 4.0 5.9 67 18 1.1 9.1 4.7 4.4 80 22 1.1 9.2 4.4 4.8 55 25 .9 8.8 4.6 4.2 .2 5 88 .2 6 93 .2 5 67 .3 12 76 .2 4 66 .4 11 102 46 22 77 15 34 21 45 11 67 26 50 31 MEAN S.D. N 73 11.0 6 20 4.7 6 1.2 .16 6 9.2 .37 6 4.6 .31 6 4.7 .63 6 .2 .08 6 7 82 53 21 3.4 14.7 15.8 7 6666 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group: 1 105529 105530 105531 105535 105544 L05549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level :: 0 91 262 30 55 25 42 37 56 39 61 26 47 41 25.0 6 87 85. 9 6 Dose Level: 0,.03 58 61 34 60 26 55 50 111 42 14.6 4 72 26. 3 4 Dose Level: 0..15 34 38 29 32 21 43 59 126 42 35 35 43 37 13.0 6 53 36. 1 6 Dosage Unit: mg/kg/day 169 86 274 113 243 81 554 172 237 182 222 48 10 2 4 5 7 2 283 137.1 6 114 53.3 6 5 3,,1 6 Dosage Unit: mg/kg/day 207 260 218 70 296 50 236 65 3 2 5 15 239 39.7 4 111 99.5 4 6 6. 0 4 Dosage Unit : mg/kg/day 228 102 363 69 118 74 219 41 303 65 295 76 5 5 2 3 14 13 254 85.3 6 71 19.7 6 7 5. 2 6 151 197 84 287 134 422 212 123..4 6 2745 209 147 190 823 1281..8 4 167 95 238 321 109 164 182 84. 7 6 350 282 407 351 530 345 378 84..6 6 254 337 347 496 358 100. 7 4 372 430 302 514 335 683 439 140. 9 6 19 16 103 14 41 0 32 37,.1 6 14 12 8 41 19 15. 0 4 56 52 42 29 0 17 33 21. 6 6 252 158 274 234 355 275 258 64,.1 6 184 252 265 341 260 64. 4 4 204 272 232 323 226 505 294 111. 7 6 003298 633 ANIMAL NUMBER Appendix 4 Individual Clinical Chemistry Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L P AMYL U/L Covance 6329-223 3M T-6295.7 Group : 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 33 43 33 34 31 38 25 37 32 59 44 53 33 6. 2 6 44 9. 9 6 Dosage Unit: mg/kg/day 243 107 245 43 659 58 217 48 212 63 320 65 4 1 4 2 5 4 316 172.4 6 64 22.7 6 3 1.5 6 253 203 189 296 515 251 284 119.3 6 337 467 408 399 279 358 375 64.9 6 29 9 19 68 42 20 31 21.2 6 256 338 277 252 213 300 273 43.1 6 003299 634 003300 Appendix 4 Individual Clinical Chemistry Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level : 0 9.1 11.1 9.8 10.6 10.2 10.1 4.5 6.1 5.2 6.1 5.7 4.1 10.2 .68 6 5.3 .84 6 Dose Level : 0,.03 9.2 10.9 9.1 9.4 4.2 4.2 5.0 4.3 9.6 .84 4 4.4 .39 4 Dose Level: 0,.15 9.7 9.6 9.8 9.9 9.6 10.0 5.4 3.3 5.8 3.7 4.6 5.9 9.8 .16 6 4.8 1.10 6 Dosage Unit: mg/kg/day 142 4.5 102 159 6.1 112 155 5.1 108 159 5.0 112 160 5.4 115 158 5.7 115 156 6.8 6 5.3 .56 6 111 5 6 Dosage Unit: mg/kg/day 148 3.9 106 163 6.1 114 149 4.5 110 149 4.5 107 152 7.2 4 4.8 .94 4 109 3 4 Dosage Unit: mg/kg/day 155 4.8 110 149 4.4 108 155 5.1 110 156 5.1 112 151 5.0 113 158 5.5 110 154 3.3 6 5.0 .37 6 110 1 6 635 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Chemistry Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level : 0.75 9.3 10.8 10.9 9.9 11.0 10.0 4.7 5.3 5.3 4.4 6.6 5.0 10.3 .69 6 5.2 .76 6 Dosage Uni t: mg/ kg/day 148 4.3 109 160 6.6 113 162 5.9 112 155 5.0 106 158 5.7 107 155 4.9 113 156 4.9 6 5.4 .82 6 110 3 6 Covance 6329-223 3M T-6295.7 TOCCOO 636 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 105526 59 12 1.1 7.9 4.6 3.3 .6 11 112 43 49 55 19 1.0 8.2 4.7 3.5 .4 13 152 44 67 MEAN S.D. N 57 16 1.0 8.0 4.6 3.4 .5 12 132 44 58 2.8 4.9 .07 .21 .07 .14 .14 1.4 28.3 .7 12.7 22222222222 Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 105523 61 17 .8 8.7 5.1 3.6 .8 16 184 37 75 78 17 1.0 9.3 5.1 4.2 .5 16 131 41 47 MEAN S.D. N 70 17 .9 9.0 5.1 3.9 .6 16 158 39 61 12.0 .0 .14 .42 .00 .42 .21 .0 37.5 2.8 19.8 22222222222 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 105522 70 13 1.0 8.7 4.3 4.4 76 16 1.1 8.7 4.8 3.9 .6 12 140 46 33 .6 17 134 92 22 MEAN S.D. N 73 14 1.0 8.7 4.6 4.2 .6 14 137 69 28 4.2 2.1 .07 .00 .35 .35 .00 3.5 4.2 32.5 7.8 22222222222 ooaao2 ANIMAL NUMBER APPENDIX 4 Individual clinical Chemistry Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-62951 IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group: 1 105520 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level: 0 19 23 24 28 22 3.5 2 26 3.5 2 Dose Level: 0.15 43 45 31 42 37 8.5 2 44 2.1 2 Dose Level: 0.75 36 28 29 68 32 4.9 2 48 28.3 2 Dosage Unit: mg/kg/day 709 1156 62 237 3 4 932 316.1 2 150 123.7 2 4 .7 2 Dosage Unit: mg/kg/day 917 186 669 89 11 13 793 175.4 2 138 68.6 2 12 1.4 2 Dosage Unit: mg/kg/day 538 127 499 159 1 2 518 27.6 2 143 22.6 2 2 .7 2 84 194 139 77.8 2 177 146 162 21.9 2 177 223 200 32.5 2 400 276 338 87.7 2 424 484 454 42.4 2 543 467 505 53.7 2 30 41 36 7.8 2 292 209 250 58.7 2 48 45 46 2.1 2 244 332 288 62.2 2 23 53 38 21.2 2 362 329 346 23.3 2 003303 APPENDIX 4 Individual clinical Chemistry Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: i 105520 105526 MEAN S.D. H Group : 3 105505 105523 MEAN S.D. N Group : 4 105511 I05S22 MEAN S.D. N Dose Level: 0 9.6 10.4 5.5 7.1 10.0 .57 2 6.3 1.13 2 Dose Level : 0 .15 11.5 10.4 6.6 6.6 11.0 .78 2 6.6 .00 2 Dose Level: 0..75 10.6 10.9 5.4 7.0 10.8 .21 2 6.2 1.13 2 Dosage Unit: mg/kg/day 150 4.6 112 154 5.3 110 152 2.8 2 5.0 .49 2 111 1.4 2 Dosage Unit: mg/kg/day 156 5.5 110 154 5.1 106 155 1.4 2 5.3 .28 2 108 2.8 2 Dosage Unit: mg/kg/day 157 5.4 112 161 5.5 110 159 2.8 2 5.4 .07 2 111 1.4 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Females Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 105529 105549 Dose Level : 0 51 19 67 12 Dosage Unit: mg/kg/day .7 8.3 4.4 .9 8.9 4.7 3.9 4.2 .7 13 86 108 .1 15 152 37 33 74 MEAN S.D. N 59 16 .8 8.6 4.6 4.0 .4 14 119 72 54 11.3 4.9 .14 .42 .21 .21 .42 1.4 46.7 50.2 29.0 222 22222222 Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105539 105552 76 19 1.0 8.6 4.1 4.5 .6 14 142 59 61 77 16 1.0 8.8 4.0 4.8 .6 13 148 52 26 MEAN S.D. N 76 18 1.0 8.7 4.0 4.6 .6 14 145 56 44 .7 2.1 .00 .14 .07 .21 .00 .7 4.2 4.9 24.7 222 222222 22 Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 105542 82 21 1.1 9.6 5.0 4.6 68 25 .8 9.0 4.2 4.8 .6 14 135 .5 24 131 62 25 93 42 MEAN S.D. N 75 23 1.0 9.3 4.6 4.7 .6 19 133 78 34 9.9 2.8 .21 .42 .57 .14 .07 7.1 2.8 21.9 12.0 22 2 2 2 2 222 22 003305 ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Females Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group: i 105529 105549 MEAIJ S.D. N Group: 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level : 0 35 120 34 86 34 .7 2 103 24.0 2 Dose Level: 0.15 19 43 33 54 26 9.9 2 48 7.8 2 Dose Level: 0.75 23 38 23 61 23 .0 2 50 16.3 2 Dosage Unit: mg/kg/day 161 81 208 41 4 5 184 33.2 2 61 28.3 2 4 .7 2 Dosage Unit: mg/kg/day 113 69 251 72 1 7 182 97.6 2 70 2.1 2 4 4.2 2 Dosage Unit: mg/kg/day 241 121 200 68 2 5 220 29.0 2 94 37.5 2 4 2.1 2 157 117 137 28.3 2 117 1197 657 763.7 2 144 186 165 29.7 2 377 309 343 48.1 2 313 658 486 244.0 2 394 296 345 69.3 2 26 0 13 18.4 2 257 232 244 17.7 2 48 17 32 21.9 2 235 466 350 163.3 2 35 41 38 4.2 2 289 222 256 * 47.4 2 003306 ocroo APPENDIX 4 Individual Clinical Chemistry Data Females Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL HA MMOL/L K MMOL/L CL MMOL/L Group : 1 105529 I5549 MEAN S.D. U Group : 3 105539 I5552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level : 0 9.7 5.9 9.9 3.7 9.8 .14 2 4.8 1.56 2 Dose Level: 0.15 9.9 5.7 9.7 5.3 9.8 .14 2 5.5 .28 2 Dose Level: 0.75 10.4 10.2 5.4 6.3 10.3 .14 2 5.8 .64 2 Dosage Unit: mg/kg/day 145 5.0 103 152 5.9 112 148 4.9 2 5.4 .64 2 108 6.4 2 Dosage Unit: mg/kg/day 155 5.5 112 150 5.5 109 152 3.5 2 5.5 .00 2 110 2.1 2 Dosage Unit: mg/kg/day 152 5.2 111 152 4.9 108 152 .0 2 5.0 .21 2 110 2.1 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Males Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 105526 116 15 1.2 8.8 4.9 3.9 86 17 1.0 8.6 4.8 3.8 .5 .4 8 114 28 73 9 155 38 81 MEAN S.D. N 101 21.2 2 16 1.4 2 1.1 .14 2 8.7 .14 2 4.8 .07 2 3.8 .07 2 .4 .07 2 8 134 .7 29.0 22 33 7.1 2 77 5.7 2 Group: 3 105505 105523 Dose Level : 0.15 79 17 83 17 Dosage Unit: mg/kg/day 1.2 9.1 5.3 1.0 8.9 5.2 3.8 3.7 .8 5 193 .4 11 128 44 103 52 65 MEAN S.D. N 81 2.8 2 17 .0 2 1.1 .14 2 9.0 .14 2 5.2 .07 2 3.8 .07 2 .6 .28 2 8 160 4.2 46.0 22 48 5.7 2 84 26.9 2 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 105522 61 16 1.0 8.6 4.4 4.2 .4 7 132 56 54 84 18 1.0 9.1 4.9 4.2 .4 15 139 71 51 MEAN S.D. N 72 17 1.0 8.8 4.6 4.2 .4 11 136 64 52 16.3 1.4 .00 .35 .35 .00 .00 5.7 4.9 10.6 2.1 22222222222 003308 ANIMAL NUMBER APPENDIX 4 Individual clinical Chemistry Data Males Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3H Study No. T-6295.7 P AMYL U/L Group: l 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 24 27 30 28 27 4.2 2 28 .7 2 Dose Level: 0.15 49 40 19 40 34 21.2 2 40 .0 2 Dose Level: 0.75 42 33 49 73 46 4.9 2 53 28.3 2 Dosage Unit: mg/kg/day 664 1137 68 220 2 6 900 334.5 2 144 107.5 2 4 2.8 2 Dosage Unit: mg/kg/day 882 186 793 98 6 1 838 62.9 2 142 62.2 2 4 3.5 2 Dosage Unit: mg/kg/day 736 156 625 176 1 6 680 78.5 2 166 14.1 2 4 3.5 2 145 209 177 45.3 2 189 124 156 46.0 2 178 336 257 111.7 2 409 307 358 72.1 2 422 503 462 57.3 2 628 460 544 118.8 2 33 52 42 13.4 2 306 234 270 50 2 22 52 37 21.2 2 241 353 297 79 2 17 48 32 21.9 2 410 333 372 54 2 003309 OTceoo APPENDIX 4 Individual Clinical Chemistry Data Males Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group : i 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level : 0 9.9 10.4 6.2 7.1 10.2 .35 2 6.6 .64 2 Dose Level : 0.15 11.3 10.5 6.5 6.8 10.9 .57 2 6.6 .21 2 Dose Level : 0.75 10.4 11.3 6.2 7.8 10.8 .64 2 7.0 1.13 2 Dosage Unit: mg/kg/day 152 5.0 117 157 5.0 117 154 3.5 2 5.0 .00 2 117 .0 2 Dosage Unit: mg/kg/day 160 5.2 118 159 5.1 116 160 .7 2 5.2 .07 2 117 1.4 2 Dosage Unit: mg/kg/day 159 5.0 118 164 5.4 114 162 3.5 2 5.2 .28 2 116 2.8 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual clinical Chemistry Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 Dose Level : 0 Dosage unit: mg/kg/day 105529 105549 48 20 .7 8.5 4.5 4.0 .8 8 94 61 52 68 15 1.2 9.4 4.7 4.7 .3 10 168 53 88 MEAN S.D. N 58 14.1 2 18 3.5 2 1.0 .35 2 9.0 .64 2 4.6 .14 2 4.4 .49 2 .6 .35 2 9 131 1.4 52.3 22 57 5.7 2 70 25.5 2 Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105539 105552 83 19 i.i 8.8 4.0 4.8 .5 12 163 72 91 91 21 .9 9.2 4.2 5.0 .3 10 138 70 52 MEAN S.D. N 87 20 1.0 9.0 4.1 4.9 .4 11 150 71 72 5.7 1.4 .14 .28 .14 .14 .14 1.4 17.7 1.4 27.6 22222222222 Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 105542 92 22 1.3 9.8 5.0 4.8 .2 19 151 61 54 91 22 1.2 9.0 4.4 4.6 .3 11 147 129 73 MEAN S.D. N 92 22 1.2 9.4 4.7 4.7 .2 15 149 95 64 .7 .0 .07 .57 .42 .14 .07 5.7 2.8 48.1 13.4 22222222222 TTC-00 ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group : 1 105529 105549 MEAN S.D. M Group : 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 42 158 29 74 36 9.2 2 116 59.4 2 Dose Level : 0.15 24 61 37 71 30 9.2 2 66 7.1 2 Dose Level : 0.75 28 41 22 39 25 4.2 2 40 1.4 2 Dosage Unit: mg/kg/day 160 73 203 44 2 3 182 30.4 2 58 20.5 2 2 .7 2 Dosage Unit: mg/kg/day 113 77 262 83 1 5 188 105.4 2 80 4.2 2 3 2.8 2 Dosage Unit: mg/kg/day 249 121 224 74 2 1 236 17.7 2 98 33.2 2 2 .7 2 204 132 168 50.9 2 120 663 392 384.0 2 168 129 148 27.6 2 363 295 329 48.1 2 311 654 482 242.5 2 385 277 331 76.4 2 21 0 10 14.8 2 46 21 34 17.7 2 113 19 66 66.5 2 261 222 242 27.6 2 235 458 346 157.7 2 289 212 250 54.4 2 Cw M CTCCOO APPENDIX 4 Individual Clinical Chemistry Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL HUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group : 1 105529 105549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level: 0 9.6 4.8 9.8 4.4 9.7 .14 2 4.6 .28 2 Dose Level: 0.15 9.5 10.2 5.6 5.2 9.8 .49 2 5.4 .28 2 Dose Level: 0.75 10.2 11.0 4.9 5.9 10.6 .57 2 5.4 .71 2 Dosage Unit: mg/kg/day 147 4.5 111 153 4.8 118 150 4.2 2 4.6 .21 2 114 4 2 Dosage Unit: mg/kg/day 148 4.9 117 155 5.9 120 152 4.9 2 5.4 .71 2 118 2 2 Dosage Unit: mg/kg/day 155 4.8 116 166 6.2 125 160 7.8 2 5.5 .99 2 120 6 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Males Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance G329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group: 1 105520 105526 MEAN S.D. N Dose Level : 0 80 13 54 18 67 18.4 2 16 3.5 2 Dosage Unit : mg/kg/day 1.3 8.8 4.8 1.1 8.2 4.6 1.2 .14 2 8.5 .42 2 4.7 .14 2 4.0 3.6 3.8 .28 2 .7 .1 .4 .42 2 3 112 2 149 2 130 .7 26.2 22 25 47 36 15.6 2 54 75 64 14.8 2 Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 105523 76 18 .9 9.0 5.2 3.8 .5 11 203 38 94 72 20 1.1 8.7 4.9 3.8 .3 7 132 57 57 MEAN S.D. N 74 2.8 2 19 1.4 2 1.0 .14 2 8.8 .21 2 5.0 .21 2 3.8 .00 2 .4 .14 2 9 168 2.8 50.2 22 48 13.4 2 76 26.2 2 Group: 4 105511 105522 Dose Level : 0.75 63 20 76 IS Dosage Unit: mg/kg/day 1.0 8.8 4.5 1.3 8.9 5.1 4.3 3.8 .4 5 135 58 45 .2 10 143 91 35 MEAN S.D. N 70 9.2 2 18 3.5 2 1.2 .21 2 8.8 .07 2 4.8 .42 2 4.0 .35 2 .3 .14 2 8 139 3.5 5.7 22 74 23.3 2 40 7.1 2 003314 ANIMAL NUMBER APPENDIX 4 individual Clinical Chemistry Data Males Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group: i IU5520 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 19 31 37 39 28 12.7 2 35 5.7 2 Dose Level :: 0.15 31 42 22 36 26 6.4 2 39 4.2 2 Dose Level: 0.75 41 39 36 69 38 3.5 2 54 21.2 2 Dosage Unit: mg/kg/day 552 1131 60 188 4 10 842 409.4 124 90.5 2 7 4.2 2 Dosage Unit: mg/kg/day 925 195 776 96 2 6 850 105.4 2 146 70.0 2 4 2.8 2 Dosage Unit: mg/kg/day 821 158 557 169 3 4 689 186.7 2 164 7.8 2 4 .7 2 151 201 176 35.4 2 157 125 141 22.6 2 167 294 230 89.8 2 368 267 318 71.4 2 414 475 444 43.1 2 572 453 512 84.1 2 31 41 36 7.1 2 277 201 239 53 2 41 37 39 2.8 2 232 338 285 75 2 18 52 35 24.0 2 377 331 354 32 2 STDDOO S *OO APPENDIX 4 Individual Clinical Chemistry Data Males Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105520 105526 MEAN S.D. U Group: 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level : 0 10.3 10.0 5.2 6.8 10.2 .21 2 6.0 1.13 2 Dose Level: 0 ..15 12.0 10.3 6.2 6.5 11.2 1.20 2 6.4 .21 2 Dose Level: 0 ..75 10.8 11.6 5.7 7.0 11.2 .57 2 6.4 .92 2 Dosage Unit: mg/kg/day 157 5.9 116 150 5.6 115 154 4.9 2 5.8 .21 2 116 .7 2 Dosage Unit: mg/kg/day 164 5.9 123 154 5.4 114 159 7.1 2 5.6 .35 2 118 6 2 Dosage Unit: mg/kg/day 158 5.4 115 163 5.9 112 160 3.5 2 5.6 .35 2 114 2 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Females Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN 1MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 105529 105549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 45 23 67 16 56 15.6 2 20 4.9 2 Dose Level : 0.15 78 19 71 23 74 4.9 2 21 2.8 2 Dose Level : 0.75 95 20 90 26 92 3.5 2 23 4.2 2 Dosage Unit: mg/kg/day .8 8.1 4.2 .8 9.3 4.6 .8 8.7 4.4 .00 .85 .28 222 Dosage Unit: mg/kg/day .8 8.7 4.0 1.0 9.1 4.0 .9 8.9 4.0 .14 .28 .00 222 Dosage Unit: mg/kg/day .9 9.2 4.7 1.1 8.7 4.1 1.0 .14 2 9.0 .35 2 4.4 .42 2 3.9 4.7 4.3 .57 2 4.7 5.1 4.9 .28 2 4.5 4.6 4.6 .07 2 1.0 .2 .6 .57 2 .5 .2 .4 .21 2 .1 .1 .1 .00 2 7 10 8 2.1 2 88 170 129 58.0 2 5 148 5 139 5 144 .0 6.4 22 4 145 7 144 6 144 2.1 .7 22 42 53 48 7.8 2 67 51 59 11.3 2 47 92 70 31.8 2 43 80 62 26.2 2 68 36 52 22.6 2 53 59 56 4.2 2 ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Females Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M study NO. T-6295.7 P AMYL U/L Group: 1 105529 105549 MEAN S.D. II Group: 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level :: U 47 128 33 79 40 9.9 2 104 34.6 2 Dose Level : 0,.15 27 60 47 57 37 14.1 2 58 2.1 2 Dose Level : 0..75 42 51 16 36 29 18.4 2 44 10.6 2 Dosage Unit: mg/kg/day 138 70 1fift 45 2 4 163 35.4 2 58 17.7 2 3 1.4 2 Dosere Unit: mg/kg/day 105 77 4 238 76 14 172 94.0 2 76 .7 2 9 7.1 2 Dosage Unit: mg/kg/day 244 108 208 66 6 4 226 25.5 2 87 29.7 2 5 1.4 2 167 435 301 189.5 2 113 2316 1214 1557.8 2 165 120 142 31.8 2 328 290 309 26.9 2 287 649 468 256.0 2 396 235 316 113.8 2 18 0 9 12.7 2 232 218 225 9.9 2 50 98 74 33.9 2 214 465 340 177.5 2 34 31 32 2.1 2 295 177 23 6 83.4 2 stceo o GTCCOO APPENDIX 4 Individual Clinical Chemistry Data Females Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTAME SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 105529 105549 MEAN S. D. N Group: 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level: 0 9.3 10.4 4.6 4.2 9.8 .78 2 4.4 .28 2 Dose Level: 0.15 9.5 5.3 9.5 5.2 9.5 .00 2 5.2 .07 2 Dose Level: 0.75 10.4 10.4 5.8 4.6 10.4 .00 2 5.2 .85 2 Dosage Unit: mg/kg/day 144 4.3 107 155 5.6 114 150 7.8 2 5.0 .92 2 110 4.9 2 Dosage Unit.- mg/kg/day 152 5.4 115 148 4.1 107 150 2.8 2 4.8 .92 2 111 5.7 2 Dosage Unit: mg/kg/day 154 6.1 121 157 6.0 117 156 2.1 2 6.0 .07 2 119 2.8 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Males Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN 1MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 74 19 68 16 71 4.2 2 18 2.1 2 Dose Level : 0.15 45 26 78 30 62 23.3 2 28 2.8 2 Dose Level : 0.75 55 18 76 19 66 14.8 2 18 .7 2 Dosage Unit: mg/kg/day 1.3 8.5 4.7 1.2 8.6 4.9 1.2 .07 2 8.6 .07 2 4.8 .14 2 Dosage Unit: mg/kg/day 1.3 9.0 5.2 1.6 8.4 5.0 1.4 .21 2 8.7 .42 2 5.1 .14 2 Dosage Unit: mg/kg/day 1.2 8.2 4.4 1.7 8.9 5.0 1.4 .35 2 8.6 .49 2 4.7 .42 2 3.8 3.7 3.8 .07 2 3.8 3.4 3.6 .28 2 3.8 3.9 3.8 .07 2 .8 .0 .4 .57 2 1.2 .2 .7 .71 2 .6 .2 .4 .28 2 5 109 6 158 6 134 .7 34.6 22 67 36 52 21.9 2 8 209 6 117 7 163 1.4 65.1 22 48 74 61 18.4 2 6 137 54 9 136 127 8 136 2.1 .7 22 90 51.6 2 57 81 69 17.0 2 91 54 72 26.2 2 44 34 39 7.1 2 ozceoo ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Males Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group: 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level:. 0 34 34 42 43 38 5.7 2 38 6.4 2 Dose Level :: 0.15 60 63 46 73 53 9.9 2 68 7.1 2 Dose Level : 0.75 76 59 46 92 61 21.2 2 76 23.3 2 Dosage Unit: mg/kg/day 499 1046 50 199 3 5 772 386.8 2 124 105.4 2 4 1.4 2 Dosage Unit: mg/kg/day 995 189 770 92 6 6 882 159.1 2 140 68.6 2 6 .0 2 Dosage Unit: mg/kg/day 844 156 573 158 3 1 708 191.6 2 157 1.4 2 2 1.4 2 860 1071 966 149.2 2 515 624 570 77.1 2 787 1308 1048 368.4 2 512 462 487 35.4 2 1618 976 1297 454.0 2 727 523 625 144.2 2 90 98 94 5.7 2 380 352 366 19.8 2 871 549 710 227.7 2 1193 731 962 326.7 2 36 25 30 7.8 2 503 382 442 85.6 2 003321 003322 APPENDIX 4 Individual clinical Chemistry Data Males Day 322 26-WEEK c a p s u l e t o x i c i t y s t u d y w i t h p e r f l u o r o o c t a n e s u l f o n i c a c i d POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group : 1 I05S20 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level : 0 10.1 10.8 5.0 5.8 10.4 .49 2 5.4 .57 2 Dose Level : 0.15 11.6 10.3 6.3 5.4 11.0 .92 2 5.8 .64 2 Dose Level : 0.75 9.9 11.2 5.0 6.6 10.6 .92 2 5.8 1.13 2 Dosage Unit: mg/kg/day 148 4.9 107 153 5.1 106 150 3.5 2 5.0 .14 2 106 2 Dosage Unit: mg/kg/day 154 5.1 104 154 5.0 108 154 .0 2 5.0 .07 2 106 2 2 Dosage Unit: mg/kg/day 151 5.1 108 158 5.6 108 154 4.9 2 5.4 .35 2 108 2 Covance S329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 105549 MEAN S.D. N 44 16 1.4 8.4 4.4 4.0 .9 6 89 48 41 64 14 1.1 8.5 4.3 4.2 .1 13 148 36 74 54 15 1.2 8.4 4.4 4.1 .5 10 118 42 58 14.1 1.4 .21 .07 .07 .14 .57 222 222 4.9 41.7 22 8.5 23.3 -> 2 Group: 3 Dose Level : 0.15 Dosage Unit: mg/ kg/day 105539 105552 69 27 1.4 8.2 3.8 4.4 .5 11 141 102 74 58 28 1.2 9.3 4.0 5.3 .5 6 154 69 46 MEAN S.D. N 64 7.8 2 28 .7 2 1.3 .14 2 8.8 .78 2 3.9 .14 2 4.8 .64 2 .5 .00 2 8 148 3.5 9.2 22 86 23.3 2 60 19.8 2 Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 105542 86 25 1.6 9.1 4.6 4.5 .1 84 12 1.4 8.2 4.0 4.2 .0 8 139 68 60 5 119 81 60 MEAN S.D. N 85 1.4 2 18 9.2 2 1.5 .14 2 8.7 .64 2 4.3 .42 2 4.4 .21 2 .0 .07 2 6 129 2.1 14.1 22 74 9.2 2 60 .0 2 003323 ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PEFFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ,RLK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No, T-6295.7 P AMYL U/L Group : 1 105529 105549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level:; 0 66 97 46 77 56 14.1 2 87 14.1 2 Dose Level : 0..15 36 71 60 85 48 17.0 2 78 9.9 2 Dose Level:; 0..75 43 70 46 155 44 2.1 2 112 60.1 2 Dosage Unit: mg/kg/day 143 82 169 39 2 5 156 18.4 2 60 30.4 2 4 2.1 2 Dosage Unit: mg/kg/day 114 67 205 79 4 9 160 64.3 2 73 8.5 2 6 3.5 2 Dosage Unit: mg/kg/day 250 105 220 55 2 I 235 21.2 2 80 35.4 2 2 .7 2 1212 1024 1118 132.9 2 602 1513 1058 644.2 2 1471 659 1065 574.2 2 390 342 366 33.9 2 386 722 554 237.6 2 448 450 449 1.4 2 0 277 0 260 0 268 .0 12.0 22 63 83 73 14.1 2 288 524 406 166.9 2 33 94 64 43.1 2 337 339 338 1.4 2 003324 003325 APPENDIX 4 Individual clinical Chemistry Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group : 1 I5529 105549 MEAN S.D . 11 Group: 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 9.8 5.0 9.6 4.4 9.7 .14 2 4.7 .42 2 Dose Level : 0.15 9.4 10.2 4.8 5.5 9.8 .57 2 5.2 .49 2 Dose Level : 0.75 10.3 10.3 4.4 4.1 10.3 .00 2 4.2 .21 2 Dosage Unit: mg/kg/day 146 5.1 100 148 4.8 107 147 1.4 2 5.0 .21 2 104 4 2 Dosage Unit: mg/kg/day 148 5.2 107 154 5.1 109 151 4.2 2 5.2 .07 2 108 1 2 Dosage Unit: mg/kg/day 154 5.2 109 158 5.8 111 156 2.8 2 5.5 .42 2 110 1 2 Covance G329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Males Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 105520 105526 MEAN S.D. n Group : 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 74 17 71 24 72 2.1 2 20 4.9 2 Dose Level : 0.15 73 23 76 28 74 2.1 2 26 3.5 2 Dose Level : 0.75 63 19 76 17 70 9.2 2 18 1.4 2 Dosage Unit: mg/kg/day 1.3 8.9 5.0 1.3 8.9 5.3 1.3 .00 2 8.9 .00 2 5.2 .21 2 Dosage Unit: mg/kg/day 1.2 9.0 5.4 1.1 8.1 4.9 1.2 .07 2 8.6 .64 2 5.2 .35 2 Dosage Unit: mg/kg/day l.i 8.3 4.5 1.3 8.5 5.0 1.2 .14 2 8.4 .14 2 4.8 .35 2 3.9 3.6 3.8 .21 2 3.6 3.2 3.4 .28 2 3.8 3.5 3.6 .21 2 .7 .3 .5 .28 2 1.1 .5 .8 .42 2 .6 .3 .4 .21 2 5 105 6 148 6 126 .7 30.4 22 7 206 6 127 6 166 .7 55.9 22 6 116 3 122 4 119 2.1 4.2 22 35 46 40 7.8 2 33 64 48 21.9 2 36 66 51 21.2 2 51 71 61 14.1 2 93 54 74 27.6 2 41 34 38 4.9 2 9ZCCOO ANIMAL NUMBER APPENDIX 4 Individual clinical Chemistry Data Males Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group : 1 105520 105526 MEAN S.D. H Group : 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level: 0 46 45 53 38 50 4.9 2 42 4.9 2 Dose Level: 0.15 64 63 55 70 60 6.4 2 66 4.9 2 Dose Level: 0.75 62 48 58 84 60 2.8 2 66 25.5 2 Dosage Unit: mg/kg/day 387 1040 53 222 3 8 714 461.7 2 138 119.5 2 6 3.5 2 Dosage Unit: mg/kg/day 915 188 725 98 9 8 820 134.4 2 143 63.6 2 8 .7 2 Dosage Unit: mg/kg/day 765 154 479 156 6 2 622 202.2 2 155 1.4 2 4 2.8 2 2123 2151 2137 19.8 2 1243 1747 1495 356.4 2 617 2004 1310 980.8 2 388 363 376 17.7 2 1640 948 1294 489.3 2 616 415 516 142.1 2 38 37 38 .7 2 298 246 272 36.8 2 793 365 579 302.6 2 1207 710 958 351.4 2 35 31 33 2.8 2 414 302 358 79.2 2 003327 8ZCC00 APPENDIX 4 Individual Clinical Chemistry Data Males Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group: 1 I0S520 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 10.3 11.0 4.2 5.2 10.6 .49 2 4.7 .71 2 Dose Level : 0.15 11.9 9.9 5.7 5.5 10.9 1.41 2 5.6 .14 2 Dose Level : 0.75 10.2 10.9 5.2 4.6 10.6 .49 2 4.9 .42 2 Dosage Unit: mg/kg/day 154 5.3 111 157 5.5 111 156 2.1 2 5.4 .14 2 111 .0 2 Dosage Unit: mg/kg/day 160 5.8 113 150 5.1 109 155 7.1 2 5.4 .49 2 111 2.8 2 Dosage Unit: mg/kg/day 153 5.9 113 156 5.0 108 154 2.1 2 5.4 .64 2 110 3.5 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Females Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN 1MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 105529 105549 MEAN S.D. N Group : 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 54 21 56 18 55 1.4 2 20 2.1 2 Dose Level : 0.15 66 22 80 26 73 9.9 2 24 2.8 2 Dose Level : 0.75 91 21 85 25 88 4.2 2 23 2.8 2 Dosage Unit: mg/kg/day .9 8.9 4.7 1.1 9.0 4.7 1.0 .14 2 9.0 .07 2 4.7 .00 2 Dosage Unit: mg/kg/day 1.1 8.3 3.8 1.0 9.1 4.0 X. .07 2 8.7 .57 2 3.9 .14 2 Dosage Unit: mg/kg/day 1.2 9.2 4.9 1.1 8.1 4.0 1.2 .07 2 8.7 .78 2 4.4 .64 2 4.2 4.3 4.2 .07 2 4.5 5.1 4.8 .42 2 4.3 4.1 4.2 .14 2 1.1 .4 .8 .49 2 .8 .7 .8 .07 2 .3 .4 .4 .07 2 5 112 6 162 137 .7 35.4 22 6 13 6 6 138 6 137 .0 1.4 22 13 5 9 5.7 2 152 131 142 14.8 2 56 42 49 9.9 2 66 43 54 16.3 2 55 95 75 28.3 2 40 79 60 27.6 2 71 36 54 24.7 2 55 66 60 7.8 2 003329 ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Females Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group: 1 105529 105549 MEAN S.D. N Group : 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level:: 0 110 297 61 106 86 34.6 2 202 135.1 2 Dose Level :: 0..15 37 61 62 95 50 17.7 2 78 24.0 2 Dose Level:: 0..75 67 78 45 83 56 15.6 2 80 3.5 2 Dosage Unit: mg/kg/day 157 109 167 45 7 5 162 7.1 2 77 45.3 2 6 1.4 2 Dosage Unit: mg/kg/day 109 78 8 188 80 15 148 55.9 2 79 1.4 2 12 4.9 2 Dosage Unit: mg/kg/day 243 117 213 56 5 3 228 21.2 2 86 43.1 2 4 1.4 2 2978 1838 2408 806.1 2 733 1009 871 195.2 2 2353 1241 1797 786.3 2 459 338 398 85.6 2 304 630 467 230.5 2 527 431 479 67.9 2 33 0 16 23.3 2 336 265 300 50.2 2 42 52 47 7.1 2 231 459 345 161.2 2 47 47 47 .0 2 412 329 370 58.7 2 003330 00333 APPENDIX 4 Individual Clinical Chemistry Data Females Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group : 1 105529 105549 MEAN S.D. N Group : 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 9.7 10.1 5.6 4.2 9.9 .28 2 4.9 .99 2 Dose Level : 0.15 9.0 4.8 9.9 4.7 9.4 .64 2 4.8 .07 2 Dose Level : 0.75 10.5 10.0 4.6 4.3 10.2 .35 2 4.4 .21 2 Dosage Unit: mg /kg/day 144 4.3 103 151 5.6 109 148 4.9 2 5.0 .92 2 106 4 2 Dosage Unit: mg/kg/day 146 4.9 108 151 5.9 111 148 3.5 2 5.4 .71 2 110 2 2 Dosage Unit: mg/kg/day 153 5.3 111 157 5.6 113 155 2.8 2 5.4 .21 2 112 1 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 80 12 68 16 74 8.5 2 14 2.8 2 Dose Level : 0.15 88 15 94 17 91 4.2 2 16 1.4 2 Dose Level : 0.75 64 13 75 14 70 7.8 2 14 .7 2 Dosage Unit: mg/kg/day 1.2 8.9 5.2 1.2 8.5 4.9 1.2 .00 2 8.7 .28 2 5.0 .21 2 Dosage Unit: mg/kg/day 1.2 9.3 5.4 1.1 8.9 5.5 1.2 .07 2 9-1 .28 2 5.4 .07 2 Dosage Unit: mg/kg/day 1.0 8.5 4.5 1.3 9.3 5.4 1.2 .21 2 8.9 .57 2 5.0 .64 2 3.7 3.6 3.6 .07 2 3.9 3.4 3.6 .35 2 4.0 3.9 4.0 .07 2 .8 .3 .6 .35 2 .6 .3 .4 .21 2 .8 .3 .6 .35 2 3 122 3 142 3 132 .0 14.1 22 5 216 6 139 6 178 .7 54.4 22 4 122 3 114 4 118 ,7 5.7 22 31 32 32 .7 2 56 61 58 3.5 2 39 43 41 2.8 2 106 55 80 36.1 2 37 81 59 31.1 2 44 26 35 12.7 2 003332 ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group : 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level : 0 19 21 29 26 24 7.1 2 24 3.5 2 Dose Level: 0.15 29 46 21 45 25 5.7 2 46 .7 2 Dose Level : 0.75 37 32 30 50 34 4.9 2 41 12.7 2 Dosage Unit: mg/kg/day 394 59 847 189 2 10 620 320.3 2 124 91.9 2 6 5.7 2 Dosage Unit: mg/kg/day 971 198 771 101 2 1 871 141.4 2 150 68.6 2 2 .7 2 Dosage Unit: mg/kg/day 458 129 379 148 1 0 418 55.9 2 138 13.4 2 0 .7 2 77 126 102 34.6 2 163 119 141 31.1 2 179 225 202 32.5 2 319 276 298 30.4 2 413 487 450 52.3 2 480 364 422 82.0 2 11 21 16 7.1 2 246 220 233 18.4 2 14 17 16 2.1 2 235 353 294 83.4 2 20 13 16 4.9 2 326 263 294 44.5 2 003333 YCCOQ APPENDIX 4 Individual Clinical Chemistry Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PEP.FLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL HA MMOL/L K MMOL/L CL MMOL/L Group: 1 105520 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. H Group : 4 105511 105522 MEAN S.D. N Dose Level : 0 10.4 10.1 5.7 6.4 10.2 .21 2 6.0 .49 2 Dose Level : 0.15 12.6 10.9 6.6 7.2 11.8 1.20 2 6.9 .42 2 Dose Level : 0.75 10.0 11.1 3.9 6.7 10.6 .78 2 5.3 1.98 2 Dosage Unit: mg/kg/day 156 5.7 113 150 5.1 109 153 4.2 2 5.4 .42 2 111 2 2 Dosage Unit: mg/kg/day 167 6.3 118 161 5.6 113 164 4.2 2 6.0 .49 2 116 3 2 Dosage Unit: mg/kg/day 152 4.6 113 158 5.4 109 155 4.2 2 5.0 .57 2 111 2 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; '-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group: 1 105529 105549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level : 0 48 17 79 17 64 21.9 2 17 .0 2 Dose Level: 0.15 79 16 78 18 78 .7 2 17 1.4 2 Dose Level: 0.75 98 17 101 21 100 2.1 2 19 2.8 2 Dosage Unit: mcr/kg/day .9 8.3 4.6 1.0 8.7 4.6 1.0 .07 2 8.5 .28 2 4.6 .00 2 Dosage Unit: mg/kg/day 1.0 8.4 4.1 .9 9.0 4.1 1.0 .07 2 8.7 .42 2 4.1 .00 2 Dosage Unit: mg/kg/day 1.1 9.1 4.9 1.0 8.2 4.1 1.0 .07 2 8.7 .64 2 4.5 .57 2 3.7 4.1 3.9 .28 2 4.3 4.9 4.6 .42 2 4.2 4.1 4.2 .07 2 1.0 .3 .6 .49 2 .6 .5 .6 .07 2 .2 .3 .2 .07 2 7 99 4 142 6 120 2.1 30.4 22 60 52 56 5.7 2 4 144 6 144 5 144 1.4 .0 22 83 59 71 17.0 2 5 137 42 3 139 114 4 138 1.4 1.4 22 78 50.9 2 34 67 50 23.3 2 58 36 47 15.6 2 55 72 64 12.0 2 003335 ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group : 1 105529 I5549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level :: 0 56 183 30 85 43 18.4 2 134 69.3 2 Dose Level :: 0.15 25 34 40 66 32 10.6 2 50 22.6 2 Dose Level: 0.75 25 64 25 43 25 .0 2 54 14.8 2 Dosage Unit: mg/kg/day 139 96 174 49 6 3 156 24.7 2 72 33.2 2 4 2.1 2 Dosage Unit : mg/kg/day 94 76 4 186 81 10 140 65.1 2 78 3.5 2 7 4.2 2 Dosage Unit: mg/kg/day 248 124 216 63 0 3 232 22.6 2 94 43.1 2 2 2.1 2 200 244 222 31.1 2 112 254 183 100.4 2 134 114 124 14.1 2 293 244 268 34.6 2 242 436 339 137.2 2 360 233 296 89.8 2 9 12 10 2.1 2 216 192 204 17.0 2 15 11 13 2.8 2 189 312 250 87.0 2 13 23 18 7.1 2 277 183 230 66.5 2 003336 APPENDIX 4 Individual clinical Chemistry Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group : 1 105529 105549 MEAN S.D. H Group : 3 105539 105552 MEAN S.D11 Group: 4 105533 105542 MEAN S.D. N Dose Level : 0 9.6 10.2 4.9 5.4 9.9 .42 2 5.2 .35 2 Dose Level : 0.15 9.5 10.1 5.3 5.0 9.8 .42 2 5.2 .21 2 Dose Level : 0.75 10.3 10.5 5.1 5.6 10.4 .14 2 5.4 .35 2 Dosage Unit: mg/kg/day 144 4.9 105 152 5.1 110 148 5.7 2 5.0 .14 2 108 3 2 Dosage Unit: mg/kg/day 151 5.4 ill 153 5.9 112 152 1.4 2 5.6 .35 2 112 2 Dosage Unit: mg/kg/day 155 5.6 114 154 6.8 118 154 .7 2 6.2 .85 2 116 2 2 Covance 6329-223 3M Study No. T-6295.7 eccoo vi ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN 1MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG MG/DL HDL MG/DL Group : 1 105520 105526 MEAN S.D. N Dose Level : 0 79 14 86 18 82 4.9 2 16 2.8 2 Dosage Unit: mg/kg/day 1.2 8.7 4.6 1.3 8.9 4.8 1.2 .07 2 8.8 .14 2 4.7 .14 2 4.1 4.1 4.1 .00 2 .5 .2 .4 .21 2 6 119 5 150 6 134 .7 21.9 22 30 32 31 1.4 2 63 77 70 9.9 2 Group: 3 105505 105523 Dose Level : 0.15 77 19 81 19 Dosage Unit: mg/kg/day 1.2 8.6 4.9 1.1 9.0 5.3 3.7 3.7 .6 .3 5 200 3 132 31 114 40 69 MEAN S.D. N 79 2.8 2 19 .0 2 1.2 .07 2 8.8 .28 2 5.1 .28 2 3.7 .00 2 .4 .21 2 4 166 1.4 48.1 22 36 6.4 2 92 31.8 2 Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 105522 75 16 1.4 9.5 5.0 4.5 .8 4 145 37 67 83 16 1.4 9.3 5.2 4.1 .3 10 132 52 47 MEAN S.D. N 79 5.7 2 16 .0 2 1.4 .00 2 9.4 .14 2 5.1 .14 2 4.3 .28 2 .6 .35 2 7 138 4.2 9.2 22 44 10.6 2 57 14.1 2 003338 ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group : 1 105520 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level : 0 19 20 28 30 24 6.4 2 25 7.1 2 Dose Level : 0.15 31 36 30 33 30 .7 2 34 2.1 2 Dose Level : 0.75 45 37 27 42 36 12.7 2 40 3.5 2 Dosage Unit: mg/kg/day 309 49 701 183 1 19 505 277.2 2 116 94.8 2 10 12.7 2 Dosage Unit: mg/kg/day 846 178 662 93 1 5 754 130.1 2 136 60.1 2 3 2.8 2 Dosage Unit: mg/kg/day 467 149 342 147 0 0 404 88.4 2 148 1.4 2 0 .0 2 78 144 111 46.7 2 130 212 171 58.0 2 165 165 165 .0 2 265 259 262 4.2 2 357 446 402 62.9 2 519 362 440 111.0 2 10 17 14 4.9 2 203 201 202 1 2 12 13 12 .7 2 206 321 264 81 2 22 11 16 7.8 2 334 260 297 52 2 003339 003340 APPENDIX 4 Individual Clinical Chemistry Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA 1MMOL/L K MMOL/L CL MMOL/L Group : 1 I0S520 105526 MEAN S.D. U Group : 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 10.8 10.5 6.5 6.6 10.6 .21 2 6.6 .07 2 Dose Level : U .15 11.4 11.0 6.3 7.6 11.2 .28 2 7.0 .92 2 Dose Level : 0.75 12.0 11.8 5.4 6.2 11.9 .14 2 5.8 .57 2 Dosage Unit: mg/kg/day 162 6.4 120 157 5.6 111 160 3.5 2 6.0 .57 2 116 6 2 Dosage Unit: mg/kg/day 164 5.8 117 169 6.9 122 166 3.5 2 6.4 .78 2 120 3 2 Dosage Unit: mg/kg/day 174 6.0 121 169 6.2 116 172 3.5 2 6.1 .14 2 118 3 2 Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER GLU MG/DL APPENDIX 4 Individual Clinical Chemistry Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS UN MG/DL CREAT MG/DL T PRO G/DL ALB G/DL GLOB G/DL T BILI MG/DL SBA UMOL/L CHOL MG/DL Covance 6329-223 3M Study No. T-6295.7 TRIG HG/DL HDL MG/DL Group : 1 105529 105549 MEAN S.D. N Group : 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 67 17 53 16 60 9.9 2 16 .7 2 Dose Level : 0.15 71 19 74 17 72 2.1 2 18 1.4 2 Dose Level : 0.75 100 19 93 19 96 4.9 2 19 .0 2 Dosage Unit: mg/kg/day .9 8.2 4.4 1.0 8.8 4.4 1.0 .07 2 8.5 .42 2 4.4 .00 2 Dosage Unit: mg/kg/day 1.1 8.5 3.9 .8 8.2 3.6 1.0 .21 2 8.4 .21 2 3.8 .21 2 Dosage Unit: mg/kg/day 1.2 9.0 4.6 1.2 7.9 4.0 1.2 .oo 2 8.4 .78 2 4.3 .42 2 3.8 4.4 4.1 .42 2 4.6 4.6 4.6 .00 2 4.4 3.9 4.2 .35 2 .8 .3 .6 .35 2 .5 .6 .6 .07 2 .3 .3 .3 .00 2 6 96 5 152 6 124 .7 39.6 22 55 51 53 2.8 2 5 147 5 129 5 138 .0 12.7 22 73 46 60 19.1 2 6 145 40 4 147 112 5 146 1.4 1.4 22 76 50.9 2 44 83 64 27.6 2 86 37 62 34.6 2 68 79 74 7.8 2 003341 \ ANIMAL NUMBER APPENDIX 4 Individual Clinical Chemistry Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS AST/SGOT ALT/SGPT ALK PHOS IU/L IU/L IU/L GGT IU/L SDH IU/L CK IU/L AMYLASE LIPASE IU/L IU/L Covance 6329-223 3M Study No. T-6295.7 P AMYL U/L Group : 1 105529 105549 MEAN S.D. N Group : 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level: 0 53 191 30 49 42 16.3 2 120 100.4 2 Dose Level : 0.15 27 31 26 37 26 .7 2 34 4.2 2 Dose Level : 0.75 36 79 19 39 28 12.0 2 59 28.3 2 Dosage Unit: mg/kg/day 131 93 171 45 0 0 151 28.3 2 69 33.9 2 0 .0 2 Dosage Unit: mg/kg/day 96 76 195 82 2 1 146 70.0 2 79 4.2 2 2 .7 2 Dosage unit: mg/kg/day 240 117 186 61 3 0 213 38.2 2 89 39.6 2 2 2.1 2 216 93 154 87.0 2 80 109 94 20.5 2 164 97 130 47.4 2 316 245 280 50.2 2 252 454 353 142.8 2 372 250 311 86.3 2 11 12 12 .7 2 232 192 212 28.3 2 14 8 11 4.2 2 195 327 261 93.3 2 12 18 15 4.2 2 286 195 240 64.3 2 003342 003343 APPENDIX 4 Individual Clinical Chemistry Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER CA MG/DL I PHOS MG/DL NA MMOL/L K MMOL/L CL MMOL/L Group : 1 105529 105549 MEAN S.D. n Group: 3 105539 105552 MEAN S.D. H Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 10.1 10. L 5.2 5.6 10.1 .0u 2 5.4 .28 2 Dose Level : 0.15 9.8 10.2 5.4 4.9 10.0 .28 2 5.2 .35 2 Dose Level : 0.75 10.3 10.7 5.9 5.4 10.5 .28 2 5.6 .35 2 Dosage Unit: mg 'kg/day 150 5.1 108 152 .n 111 151 1.4 2 5.2 .14 2 110 2 2 Dosage Unit: mg /kg./day 155 5.4 112 157 6.1 117 156 1.4 2 5.8 .49 2 114 3 2 Dosage unit: mg /kg/day 159 5.6 115 165 6.7 124 162 4.2 2 6.2 .78 2 120 6 2 Covance 6329-223 3M Study No. T-6295.7 CO o 003344 Appendix 4 Individual Clinical Urinalysis Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group i 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level;: 0 37.0 28.0 47.0 75.0 32.0 30.0 1.025 1.032 1.025 1.018 1.030 1.023 41.5 17.76 6 1.026 .0050 6 Dose Level: 67.0 46.0 52.0 45.0 1.019 1.023 1.020 1.023 52.5 10.15 4 1.021 .0021 4 Dose Level:: 0.15 228.0 52.0 93.0 43.0 46.0 125.0 1.007 1.025 1.020 1.026 1.025 1.013 97.8 71.41 6 1.019 .0078 6 Dosage 8.0 7.0 8.0 7.5 7.5 6.0 7.3 .75 6 Dosage 7.0 7.5 7.0 8.0 7.4 .48 4 Dosage 7.0 7.0 7.0 7.0 7.5 7.0 7.1 .20 6 637 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Covance 6329-223 3M T-6295.7 Group: 4 Dose Level:: 0.75 Dosaaggee Unit: mg/kg/day 105506 43.0 1.026 7.0 105507 59.0 1.022 7.5 105509 68.0 1.018 7.0 105511 173.0 1.008 7.0 105512 92.0 1.013 7.5 I 105522 66.0 1.022 7.0 MEAN S.D. N 83.5 46.63 6 1.018 .0066 6 7.2 .26 6 003345 638 Appendix 4 Individual Clinical Urinalysis Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105508 105517 105519 105520 105526 105527 Group: 2 105514 105515 105516 105521 Group: 3 105505 105510 105518 105523 105524 105528 Group: 4 105506 105507 105509 105511 105512 105522 Dose Level : 0 0_ 10 00+ 10 + 0 Dose Level: 0.03 0_ 010 10 Dose Level : 0.15 010 30 + 10 10 0 Dose Level: 0.75 10 010 0010 - Dosage Unit: mg/kg/day +++ _ +++ - -- +++ +- ++ +++ - Dosage Unit: mg/kg/day __ _ - -- -+ -- Dosage Unit: mg/kg/day __ --- -- M* -- - +++ - - " Dosage Unit: mg/kg/day _ -- --- -- + ++ - - + - _ - - - - _ - - _ - _ _ _ - Covance 6329-223 3M T-6295.7 003346 639 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Males Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 COMMENTS Covance 6329-223 3M T-6295.7 Group: 1 105508 105517 105519 105520 105526 105527 Dose Level: 0 00 00 00 00 00 00 Dosage Unit: mg/kg/day 030 230 030 120 120 010 2B4D 2B4D 4B4E 4B4D 4B3D 4B3E 0 0 0 0 0 0 DK _ DK PQ CL BK CK BK Group: 2 Dose Level: 0.03 Dosage Unit: mg/kg/day 105514 105515 0 0 0 0 1 0 3 3 0 0 4B2E 4B4D 0 4E CK CL _ _ 105516 0 0 0 3 0 4B2D 0 CK 105521 0 0 0 3 0 4B4D 0 BL - Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 105510 0 0 0 0 1 0 2 3 0 0 3B 4B4D 0 4E BK BL _ _ 105518 105523 105524 0 0 0 0 0 0 4 0 0 3 3 3 0 0 0 4B 4B2D 3B4D 0 0 0 DL BL CK _ _ 105528 0 0 1 3 0 4B 0 BK - Group: 4 105506 105507 105509 105511 105512 105522 Dose Level: 0.75 20 01 01 00 00 01 Dosage Unit: mg/kg/day 130 030 430 130 130 120 2B2D 4B4D 4B1E 4B 2B 2B 0 0 0 0 0 0 CK _ CL Q BK Q BK Q BK BJ - frncoo 640 003348 Appendix 4 Individual Clinical Urinalysis Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOSi T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group : 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level:; 0 52.0 100.0 57.0 45.0 240.0 50.0 1.017 1.020 1.020 1.023 1.007 1.023 90.7 75.84 6 1.018 .0060 6 Dose Level:i 0.03 225.0 48.0 45.0 52.0 1.007 1.023 1.024 1.023 92.5 88.38 4 1.019 .0082 4 Dose Level:: 0.15 140.0 61.0 53.0 62.0 64.0 51.0 1.012 1.023 1.026 1.018 1.020 1.025 71.8 33.80 6 1.021 .0052 6 Dosaaggee Unit: mg/kg/day 7.0 7.0 7.5 7.0 7.5 8.0 7.3 .41 6 Dosage mg/kg/day 7.5 7.0 7.0 7.0 7.1 .25 4 Dosaaggee Unit: mg/kg/day 8.0 7.5 8.0 7.0 8.0 8.0 7.8 .42 6 641 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Covance 6329-223 3M T-6295.7 Group : 4 Dose Level:r 0.75 Dosage 105533 35.0 1.026 7.5 105534 59.0 1.024 8.0 I 105536 64.0 1.023 7.5 105540 247.0 1.007 7.0 105542 72.0 1.019 7.0 105551 51.0 1.021 7.0 MEAN S.D. N 88.0 78.91 6 1.020 .0068 6 7.3 .41 6 003349 642 Appendix 4 Individual Clinical Urinalysis Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105529 105530 105531 105535 105544 105549 Group : 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0 010 0000 Dose Level: 0.03 0_ 010 0 Dose Level: 0.15 0 010 000 Dose Level: 0.75 10 _ 0 0000- Dosage Unit: mg/kg/day ++ _ -- -- ++ - -- _ + - - + " Dosage Unit: mg/kg/day _ _ +++ +- - - - ++ " Dosage Unit: mg/kg/day _ +- -- ++ +- - ++ - - Dosage Unit : mg/kg/day +++ _ _ --- - -- --- -- +- - - _ - " _ - - - _ - Covance 6329-223 3M T-6295.7 000350 643 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Females Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APPI COMMENTS Covance 6329-223 3M T-6295.7 Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105529 0 1 1 3 1H 3B4D 0 BK P 105530 0 0 0 3 0 4B 0 DL _ 105531 0 0 1 3 0 4B4D 0 CK _ 105535 0 0 0 3 0 2B2D 0 CL - 105544 0 0 2 3 0 4B 0 AK - 105549 0 0 0 1 0 4B1D IE BK - Group : 2 105537 105541 105547 105550 Dose Level: 0.03 00 01 00 00 Dosage Unit: mg/kg/day 130 130 030 12 0 4B4D 4B2D 2B 4B1E 0 0 0 0 BK _ DL _ DL _ CK - Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105532 0 0 2 2 0 1D4F 0 BJ _ 105538 0 0 1 2 0 1B1E IF CK _ 105539 0 0 1 3 0 4B 0 CK _ 105545 0 0 1 2 0 4B 0 CK P 105548 0 0 0 3 0 2B 0 CL _ 105552 0 0 2 3 0 4B 0 CL - Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0.75 01 00 00 00 01 00 Dosage Unit: mg/kg/day 230 12 0 130 430 130 130 2B4D 4B4D 3B3D 0 4B1E 4B1D 0 0 0 0 0 0 DK _ CL CL _ AK _ CK _ CK - 003351 644 Appendix 4 Individual Clinical Urinalysis Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group : 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. Dose Level :: 0 56.0 47.0 48.0 66.0 26.0 58.0 1.023 1.025 1.021 1.013 1.006 1.017 50.2 13.75 6 1.018 .0071 6 Dose Level:: 0.03 62.0 108.0 38.0 82.0 1.020 1.017 1.028 1.019 72.5 29.73 4 1.021 .0048 4 Dose Level:: 0.15 307.0 34.0 70.0 54.0 37.0 64.0 1.002 1.023 1.017 1.019 1.028 1.025 94.3 105.16 1.019 .0092 Dosage Unit: mg/kg/day 8.0 7.0 8.0 7.0 7.5 7.5 7.5 .45 6 Dosage Unit: mg/kg/day 7.0 7.5 8.0 7.5 7.5 .41 4 Dosage Unit: mg/kg/day 7.0 7.5 7.5 7.5 7.0 7.0 7.2 .27 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 50.0 52.0 36.0 110.0 146.0 80.0 1.023 1.026 1.023 1.008 1.007 1.018 79.0 42.12 6 1.018 .0082 6 Dosage 8.0 8.0 8.0 6.5 7.0 6.5 7.3 .75 6 Covance 6329-223 3M T-6295.7 003353 646 Appendix 4 Individual Clinical Urinalysis Data Hales Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105508 105517 105519 105520 105526 105527 Group: 2 105514 105515 105516 105521 Group: 3 105505 105510 105518 105523 105524 105528 Group: 4 105506 105507 105509 105511 105512 105522 Dose Level: 0 0_ 00000- Dose Level: 0.03 0_ 0 .00- Dose Level: 0.15 0_ 00000 Dose Level: 0.75 0_ 00000- Dosage Unit: mg/kg/day + ++ - +++ + - _ - - _ - Dosage Unit: mg/kg/day _ __ ----- - Dosage Unit: mg/kg/day __ -- +- -- ++ - - --- Dosage Unit: mg/kg/day ++ - - + + +++ _ - _ - _ - - _ _ - _ _ _ - - _ _ _ _ _ - Covance 6329-223 3M T-6295.7 000354 647 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Males Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APPI COMMENTS Covance 6329-223 3M T-6295.7 Group: 1 105508 105517 105519 105520 105526 105527 Dose Level: 0 00 00 00 00 00 00 Dosage Unit : rog/kg/day 1 2 0 4D 1 2 0 - ID 0 2 0 3E3F 1 100 0 1 0 IBID 0 1 0 4D 0 0 0 0 0 0 BK _ CK BK BJ P BJ BJ P Group: 2 Dose Level: 0.03 Dosage Unit : mg/kg/day 105514 1 0 1 2 0 2E 0 BK PQ 105515 0 0 0 3 0 4B4D 0 BK P 105516 0 0 1 2 0 4B1D 0 CK - 105521 0 0 0 2 0 4B2D IE BL - Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 0 0 0 0 0 IB 0 AJ Q 105510 0 0 0 3 0 4D 0 BK 105518 0 0 0 1 0 3D 0 BK PQ 105523 0 0 1 2 0 2D3E 0 BK Q 105524 0 1 1 1 0 0 0 CK 105528 0 0 0 2 0 4B1E 0 BK Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105506 0 0 1 2 0 0 0 BK P 105507 0 0 0 1 0 3B4D 0 BK Q 105509 0 0 1 1 0 0 0 BK Q 105511 0 0 0 3 0 IB 0 BJ Q 105512 0 0 0 3 0 2B 0 BJ 105522 0 0 0 2 0 0 0 BK PQ 003355 648 003356 Appendix 4 Individual Clinical Urinalysis Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group : 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level:: 0 14.0 20.0 31.0 564.0 38.0 44.0 1.010 1.003 1.026 1.001 1.020 1.021 118.5 218.53 6 1.014 .0103 6 Dose Level:: 0.03 170.0 46.0 76.0 55.0 1.011 1.020 1.016 1.024 86.8 56.91 4 1.018 .0056 4 Dose Level:: 0.15 78.0 186.0 66.0 85.0 47.0 40.0 1.014 1.006 1.019 1.012 1.024 1.026 83.7 53.05 6 1.017 .0076 6 Dosage 8.5 8.0 8.0 7.5 8.0 8.0 8.0 .32 6 Dosage 7.5 8.0 8.0 7.5 7.8 .29 4 Dosage 7.5 7.5 7.0 7.5 8.0 7.5 7.5 .32 6 mg/kg/day mg/kg/day mg/kg/day 649 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Covance 6329-223 3H T-6295.7 Group: 4 Dose Level;: 0.75 Dosaggee Unit: mg/kg/day 105533 38.0 1.024 8.0 105534 32.0 1.026 8.5 I 105536 44.0 1.028 8.0 105540 417.0 1.003 8.0 105542 34.0 1.025 7.0 105551 36.0 1.026 7.0 MEAN S.D. N 100.2 155.27 6 1.022 .0094 6 7.8 .61 6 003357 650 Appendix 4 Individual Clinical Urinalysis Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105529 105530 105531 105535 105544 105549 Group: 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0 0_ 10 0000 Dose Level: 0.03 0_ 000 Dose Level: 0.15 000000 Dose Level: 0.75 0_ 10 0000- Dosage Unit: mg/kg/day _- -- -- -+- _ ++ - +++ - Dosage Unit : mg/kg/day _ -- -- - -- Dosage Unit: mg/kg/day __ --- - -- -- - - - - - Dosage Unit: mg/kg/day +_+ ----- - +++ - - --- _ - - _ - _ " - Covance 6329-223 3M T-6295.7 003358 651 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Females Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APPI COMMENTS Covance 6329-223 3M T-6295.7 Group : 1 105529 105530 105531 105535 105544 105549 Group: 2 105537 105541 105547 105550 Group : 3 105532 105538 105539 105545 105548 105552 Group : 4 105533 105534 105536 105540 105542 105551 Dose Level: 0 00 00 01 00 00 01 Dose Level 0.03 00 00 00 00 Dose Level: 0.15 01 00 00 00 00 00 Dose Level : 0.75 01 00 00 00 01 01 Dosage Unit: mg/kg/day 210 030 02 0 110 02 0 030 Dosage Unit : mg/kg/day 12 0 12 0 010 010 Dosage Unit: mg/kg/day 12 0 210 030 130 030 110 Dosage Unit: mg/kg/day 130 110 010 120 110 12 0 1E2F 4B 3B4D 0 3B3D 1E1F 4B 4B4D 2D IB 4B2E 3B 4B3E 4B4D 3B1D 3B1D 3B3D 2B4D 4B1D 0 3D 4B1D 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 IE IE 0 3E 0 0 0 BJ BLM CL AK BK BK BK BK BK BK BK BK BK BL BK BL BK BK BL AK BK BK P - - _ - P - _ - - - - _ P - P - 003359 652 003360 Appendix 4 Individual Clinical Urinalysis Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group : 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level;: 0 40.0 67.0 54.0 65.0 179.0 60.0 1.025 1.017 1.017 1.014 1.010 1.022 77.5 50.66 6 1.018 .0054 6 Dose Leveli: 0.03 44.0 69.0 28.0 108.0 1.010 1.020 1.028 1.016 62.2 34.86 4 1.018 .0076 4 Dose Level !: 0.15 192.0 53.0 82.0 131.0 25.0 84.0 1.006 1.021 1.014 1.006 1.031 1.014 94.5 59.43 6 1.015 .0095 6 Dosage 8.0 8.0 8.0 7.5 8.0 8.5 8.0 .32 6 Dosage 8.5 8.0 7.5 8.0 8.0 .41 4 Dosage 8.0 8.0 8.0 7.5 8.0 7.0 7.8 .42 6 mg/kg/day rag/kg/day mg/kg/day 653 Covance 6329-223 3H T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level: 0.75 50.0 66.0 34.0 107.0 89.0 62.0 1.020 1.018 1.023 1.009 1.013 1.019 68.0 26.39 6 1.017 .0051 6 Dosage Unit: mg/kg/day 7.5 8.0 8.0 8.0 7.5 8.5 7.9 .38 6 Covance 6329-223 3M T-6295.7 003361 654 Appendix 4 Individual Clinical Urinalysis Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105508 105517 105519 105520 105526 105527 Groups 2 105514 105515 105516 105521 Group: 3 105505 105510 105518 105523 105524 105528 Groups 4 105506 105507 105509 105511 105512 105522 Dose Levels 0 10 10 00010 Dose Levels 0.03 0_ 10 10 0 Dose Levels 0.15 0_ 00010 0- Dose Levels 0.75 10 _ 10 10 0010 - Dosage Units mg/kg/day ++ + +++ + - _ - - _ - - Dosage Units mg/kg/day ___ ++ ++ -- - - Dosage Units mg/kg/day __ - - + +++ + - - - - +++ - - Dosage Units mg/kg/day +++ - - _ - --- - +++ - - - +++ _ - - - - - - _ - - __ - Covance 6329-223 3M T-6295.7 29i)9 655 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Males Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 COMMENTS Covance 6329-223 3M T-6295.7 Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105508 0 0 0 3 0 2B3D 0 CK Q 105517 0 1 1 2 0 2B2D 0 CK 105519 0 0 1 1 0 2E 0 CK _ 105520 0 0 1 2 0 2B3D 0 BK - 105526 0 0 1 2 0 2B 0 BJ - 105527 0 0 1 3 0 2B4D 0 CK - Group: 2 Dose Level : 0.03 Dosage Unit: mg/kg/day 105514 0 0 1 2 0 105515 0 0 1 3 0 105516 0 0 1 2 0 105521 0 0 0 3 0 Group: 3 Dose Level : 0.15 Dosage Unit : mg/kg/day 2B1E 2B4D 4D 3B1D 0 0 0 0 AJ Q CK CK P BK - 105505 0 1 0 3 0 4B1D 0 AK Q 105510 0 0 0 1 0 3B4D IE CK 105518 0 0 1 3 0 4B3D 0 BK _ 105523 0 1 1 2 0 2B 0 AK - 105524 0 0 1 2 0 2B4D 0 CK P 105528 0 0 1 2 0 3B1E 0 BK P Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105506 0 0 1 1 0 4D 0 CK Q 105507 0 0 1 2 0 4D 0 CK PQ 105509 0 1 1 1 0 0 0 CK P 105511 0 0 1 1 0 2B1D 0 BK Q 105512 0 0 1 2 0 ID 0 BJ 105522 0 1 0 3 0 1B3D 0 BK - 003363 656 003364 Appendix 4 Individual Clinical Urinalysis Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group : 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level : 0 62.0 68.0 31.0 195.0 60.0 30.0 1.020 1.022 1.024 1.005 1.016 1.026 74.3 61.32 6 1.019 .0076 6 Dose Levels: 0.03 97.0 18.0 50.0 49.0 1.015 1.028 1.018 1.021 53.5 32.58 4 1.020 .0056 4 Dose Level:: 0.15 98.0 56.0 47.0 98.0 30.0 45.0 1.010 1.022 1.022 1.016 1.028 1.020 62.3 28.86 6 1.020 .0061 6 Dosage 8.0 8.5 8.0 8.0 8.0 8.5 8.2 .26 6 Dosage 8.0 8.0 7.5 7.0 7.6 .48 4 Dosage 7.5 8.0 8.0 8.0 7.5 8.0 7.8 .26 6 mg/kg/day mg/kg/day mg/kg/day 657 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level: 0.75 45.0 115.0 42.0 158.0 99.0 27.0 1.020 1.011 1.024 1.010 1.007 1.030 81.0 51.27 6 1.017 .0091 6 Dosage Unit: mg/kg/day 7.5 8.0 7.5 8.0 7.5 7.0 7.6 .38 6 Covance 6329-223 3M T-6295.7 003365 658 Appendix 4 Individual Clinical Urinalysis Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105529 105530 105531 105535 105544 105549 Group: 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level : 0 10 _ 10 00010 Dose Level: O'.03 10 _ 10 10 10 Dose Level: 0.15 10 10 10 010 10 Dose Level: 0.75 10 _ 010 0010 - Dosage Unit: mg/kg/day ++++ - + - ++ _ +++ - - - - Dosage Unit: mg/kg/day __ ++++ - ++++ - Dosage Unit: mg/kg/day +_ -_ +++ - ++++ +++ _ _ - Dosage Unit: mg/kg/day +_ - +- - _ __ +++ - _ - - _ - _ _ - - _ - Covance 6329-223 3M T-6295.7 003366 659 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Females Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 COMMENTS Covance 6329-223 3m T-6295.7 Group: 1 105529 105530 105531 105535 105544 105549 Group: 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level : 0 00 10 01 00 00 00 Dose Level: 0.03 00 01 01 01 Dose Level : 0.15 04 00 01 00 01 01 Dose Level : 0.75 11 00 01 01 01 01 Dosage Unit: mg/kg/day 12 0 130 120 12 0 110 130 Dosage Unit: mg/kg/day 120 13 0 11 0 210 Dosage Unit: mg/kg/day 210 120 210 110 130 020 Dosage Unit: mg/kg/day 120 230 110 130 130 130 4D 4B 2B3D 0 4D1E 2B1D 2B4D 4B4D 4B2D 2D 0 3B3D 4D 4B1D 4D 2B2D 4B2D 4D 3D1E IB 2B3D 2B4D 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 CK P CK CK _ BJ P BK CK - BK P CK P CK P CK P BJ P CK CK P BK CK P CK CK __ BK P CK P BK AJ P CK P 003367 660 003368 Appendix 4 Individual Clinical Urinalysis Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group : 2 105514 105515 105516 105521 a MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level;: 0 46.0 40.0 60.0 43.0 52.0 44.0 1.023 1.026 1.017 1.023 1.026 1.031 47.5 7.31 6 1.024 .0046 6 Dose Level:: 0.03 29.0 66.0 46.0 122.0 1.010 1.017 1.025 1.019 65.8 40.43 4 1.018 .0062 4 Dose Level:: 0.15 241.0 48.0 106.0 72.0 42.0 98.0 1.005 1.010 1.017 1.010 1.021 1.018 101.2 73.16 6 1.014 .0061 6 Dosage Unit: mg/kg/day 8.0 6.0 8.0 7.5 7.5 8.0 7.5 .77 6 Dosage Unit: mg/kg/day 8.0 8.0 7.5 7.5 7.8 .29 4 Dosage Unit: mg/kg/day 7.0 7.0 8.0 7.0 7.5 8.0 7.4 .49 6 a Sample collected on Day 92. 661 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Covance 6329-223 3H T-6295.7 Group: 4 Dose Level;! 0.75 Dosage Unit: mg/kg/day 105506 42.0 1.021 6.5 105507 28.0 1.030 8.0 '! 105509 48.0 1.021 8.0 105511 70.0 1.017 8.0 105512 82.0 1.010 6.0 105522 54.0 1.023 7.0 MEAN S.D. N 54.0 19.47 6 1.020 .0066 6 7.2 .88 6 Co C..' CO CS 662 003370 Appendix 4 Individual Clinical Urinalysis Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105508 105517 105519 105520 105526 105527 Group: 2 105514 105515 105516 105521 a Group: 3 105505 105510 105518 105523 105524 105528 Group: 4 105506 105507 105509 105511 105512 105522 Dose Level: 0 10 _ 10 10 10 10 10 - Dose 0 10 10 0 Level: _ - - 0.03 Dose Level: 0.15 0_ 00010 0- Dose Level : 0.75 10 _ 10 00010 - Dosage Unit : mg/kg/day ++++ + ++++ + - - Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day ++ Dosage Unit: mg/kg/day ++++ ++ - a Sample collected on Day 92. 663 Covance 6329-223 3M T-6295.7 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Males Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 COi Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105508 0 0 0 3 0 3D2F 0 CK 105517 0 0 2 3 0 4B 0 CK P 105519 105520 105526 0 0 0 0 0 0 0 0 0 3 3 2 0 0 0 3B1D 4B4D 1B4D IF IE 0 BK BK CK _ _ 105527 0 0 0 2 0 4B4D 3E CL - Group: 2 Dose Level : 0.03 Dosage Unit: mg/kg/day 105514 105515 105516 105521 a Group: 3 00 00 00 00 Dose Level: 0.15 030 030 130 010 Dosage Unit: mg/kg/day 4B2E 4B1D ID 4B2E 0 0 0 0 BK Q BK CK _ CK Q 105505 105510 0 0 0 1 1 0 2 3 0 0 00 3B 0 AJ PQ BK PQ 105518 0 0 0 3 0 2B1E 0 BL 105523 0 1 0 3 0 4B 0 AK PQ 105524 0 0 1 2 0 0 0 CK P 105528 0 0 0 2 0 3B2E IF BK Q Group: 4 Dose Level: 0.75 Dosage Unit : mg/kg/day 105506 0 1 1 2 0 0 0 CK PQ 105507 105509 0 0 0 0 0 0 1 3 0 0 4B4D IB IE 0 CIi BJ _ 105511 0 0 0 2 0 3B1E 0 BL Q 105512 0 0 1 2 0 0 0 BJ p 105522 0 0 1 1 0 4D 0 BJ Q a Sample collected on Day 92, Covance 6329-223 3m T-6295.7 003371 664 003372 Appendix 4 Individual Clinical Urinalysis Data Females Day 91 WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS ; T--6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level : 0 45.0 67.0 62.0 229.0 65.0 92.0 1.016 1.020 1.019 1.006 1.018 1.012 93.3 68.15 6 1.015 .0053 6 Dose Level: 0.03 104.0 31.0 60.0 64.0 1.017 1.021 1.014 1.021 64.8 30.02 4 1.018 .0034 4 Dose Level : 0.15 102.0 74.0 56.0 48.0 61.0 38.0 1.011 1.012 1.026 1.014 1.020 1.028 63.2 22.56 6 1.018 .0073 6 Dosage unit: mg/kg/day 8.0 8.0 8.0 8.0 8.0 8.0 8.0 .00 6 Dosage Unit: mg/kg/day 7.0 7.5 7.0 8.0 7.4 .48 4 Dosage Unit: mg/kg/day 8.0 7.0 7.5 6.5 8.0 8.0 7.5 .63 6 665 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Covance 6329-223 3M T-6295.7 Group: 4 Dose Level ;! 0.75 Dosag< mg/kg/day 105533 30.0 1.025 8.0 105534 46.0 1.023 8.0 I 105536 268.0 1.005 8.0 105540 295.0 1.005 8.0 105542 38.0 1.022 7.0 105551 46.0 1.024 7.5 MEAN S.D. N 120.5 125.14 6 1.017 .0096 6 7.8 .42 6 003373 666 Appendix 4 Individual Clinical Urinalysis Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105529 105530 105531 105535 105544 105549 Group : 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level: 0 10 _ 10 10 10 10 0 Dose Level : 0.03 0_ 10 030 - Dose Level: 0.15 10 _ 010 010 - ' 10 Dose Level: 0.75 10 10 0010 10 - Dosage Unit: mg/kg/day ___ - - +++ ------- - Dosage Unit: mg/kg/day __ +---* +++ Dosage Unit: mg/kg/day ___ +-+ --+-+--" Dosage Unit: mg/kg/day +_ -- --- ++ -- _ - - _ - _ - _ - - Covance 6329-223 3M T-6295.7 003374 667 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Females Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 COMMENTS Covance 6329-223 3M T-6295.7 Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 0 0 0 3 0 105530 4 0 0 3 0 105531 0 0 0 3 0 105535 0 0 1 3 0 105544 0 0 0 3 0 105549 0 0 1 3 0 Group : 2 Dose Level: 0.03 Dosage Unit: mg/kg/day 105537 0 0 1 2 0 105541 0 0 1 3 0 105547 0 0 0 3 0 105550 4 0 1 3 0 Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105532 0 1 4 3 0 105538 0 0 2 3 0 105539 0 0 0 2 0 105545 0 0 1 1 0 105548 0 0 1 1 0 105552 0 0 1 1 0 Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105533 0 3 1 3 0 105534 0 0 0 2 0 105536 0 0 1 2 0 105540 0 0 2 3 0 105542 0 2 1 3 0 105551 0 0 1 3 0 3B4D 3B4D 4B2E 2B1F 2B 2B1D 3BID 4B4D 3B1D 3B 1B4D 3D 4B2E 0 4B4D 4B1D 4D 4B4D 3D 0 2B2D 3B1D 0 0 0 0 0 IE IE 1E1F 0 0 0 0 0 0 0 IE 0 0 0 0 0 0 BK BL BL BJ BL BK BK BL BL CL BK BK BL BK BL CL CK BL AJ AK BK BL _ _ _ - _ _ P P _ _ - - P _ _ P 003375 668 Appendix 4 Covance 6329-223 3M T-6295.7 Individual Clinical Urinalysis Data Males Day 153 * 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group : 2 105514 105515 105516 105521 MEAN S.D. N Group: 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level:: 0 68.0 76.0 210.0 34.0 320.0 80.0 1.017 1.013 1.004 1.019 1.005 1.021 131.3 110.42 6 1.013 .0072 6 Dose Level:: 0.03 56.0 46.0 34.0 84.0 1.017 1.020 1.028 1.017 55.0 21.32 4 1.020 .0052 4 Dose Level:: 0.15 360.0 92.0 66.0 140.0 44.0 125.0 1.004 1.009 1.014 1.008 1.022 1.011 137.8 114.54 6 1.011 .0062 6 Dosage 7.5 7.0 7.5 6.5 6.5 7.5 7.1 .49 6 Dosage 7.5 7.0 7.0 8.0 7.4 .48 4 Dosage 7.5 7.0 7.0 7.0 7.0 7.0 7.1 .20 6 mg/kg/day mg/kg/day mg/kg/day 003376 669 Appendix 4 Individual Clinical Urinalysis Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group : 4 105506 105507 105509 105511 105512 105522 MEAN S.D. N Dose Level : 0.75 80.0 200.0 32.0 390.0 280.0 98.0 1.012 1.008 1.026 1.003 1.005 1.013 180.0 136.48 6 1.011 .0082 6 Dosage 7.0 7.5 6.0 7.0 7.5 7.5 7.1 .58 6 mg/kg/day Covance 6329-223 3M T-6295.7 003377 670 Appendix 4 Individual Clinical Urinalysis Data Males Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105508 105517 105519 105520 105526 105527 Group: 2 105514 105515 105516 105521 Group: 3 105505 105510 105518 105523 105524 105528 Group: 4 105506 105507 105509 105511 105512 105522 Dose Level : 0 0_ 00000 Dose Level: 0.03 0 00- 0- Dose Level: 0.15 0_ 00000" Dose 0 0 10 0 0 0 Level: _ - 0.75 Dosage Unit: mg/kg/day _ ++ - - - ++++ 4- - - - Dosage Unit: mg/kg/day ++ _ + -- --- -* Dosage Unit: mg/kg/day ___ -- +- -- ++ - - Dosage Unit: mg/kg/day +++ - ++ - _ - - --- -- - _ - - - - _ - " _ _ - Covance 6329-223 3M T-6295.7 003378 671 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Hales Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 COMMENTS Covance 6329-223 3M T-6295.7 Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105508 0 0 1 3 0 105517 0 0 1 2 0 105519 0 0 0 2 0 105520 0 0 1 3 0 105526 0 0 1 3 0 105527 0 0 0 3 0 Group : 2 Dose Level : 0.03 Dosage Unit : mg/kg/day 4B 0 0 0 0 4B4D 0 0 0 0 0 0 BK Q BK P AJ _ BK _ AK BL Q 105514 0 0 0 3 0 3B1D IE BK PQ 105515 0 0 1 3 0 IBID IE BK PQ 105516 0 0 1 3 0 4B1D 0 BK PQ 105521 0 0 1 3 0 4B4D 0 BL Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 0 0 1 3 0 105510 0 0 1 3 0 105518 0 0 0 3 0 105523 0 1 1 3 0 105524 0 0 1 2 0 105528 0 1 1 3 0 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 0 0 4B 0 0 0 0 0 0 0 0 0 AK _ BK _ BK _ BK Q BK BK Q 105506 0 0 1 3 0 2B 0 BK Q 105507 0 0 0 2 0 0 0 AK 105509 0 1 1 3 0 0 0 BK P 105511 0 0 0 2 0 0 0 AK 105512 0 0 1 2 0 0 0 AK _ 105522 0 0 1 3 0 0 0 BK - 6 C C 00 672 003380 Appendix 4 Individual Clinical Urinalysis Data Females Day 153 WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group : 2 105537 105541 105547 105550 MEAN S.D. N Group : 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level: 0 44.0 36.0 36.0 145.0 100.0 150.0 1.022 1.024 1.023 1.006 1.011 1.007 85.2 53.91 6 1.016 .0084 6 Dose Level: 0.03 110.0 40.0 26.0 66.0 1.013 1.020 1.017 1.016 60.5 36.93 4 1.016 .0029 4 Dose Level: 0.15 44.0 46.0 54.0 46.0 28.0 26.0 1.023 1.027 1.018 1.018 1.022 1.027 40.7 11.15 6 1.022 .0040 6 Dosage Unit: mg/kg/day 7.5 8.0 7.5 7.0 7.5 7.5 7.5 .32 6 Dosage Unit: mg/kg/day 7.0 7.0 6.5 7.5 7.0 .41 4 Dosage Unit: mg/kg/day 7.0 7.0 7.0 7.0 7.5 7.0 7.1 .20 6 673 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level:: 0.75 30.0 52.0 110.0 270.0 36.0 36.0 1.025 1.011 1.012 1.005 1.021 1.026 89.0 93.46 6 1.017 .0085 6 Dosage Unit: mg/kg/day 7.0 8.0 7.5 6.0 7.0 7.0 7.1 .66 6 Covance G329-223 3M T-6295.7 T8CEO0 674 Appendix 4 Individual Clinical Urinalysis Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105529 105530 105531 105535 105544 105549 Group: 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level : 0 10 _ 10 0000- Dose Level : 0.03 0_ 30 10 0 Dose Level: 0.15 0_ 00010 0- Dose Level: 0.75 0 00000- Dosage Unit: mg/kg/day + _ +++ -- ++- -- - Dosage Unit : mg/kg/day + ++ ++++ + _ - _ +++ - - Dosage Unit: mg/kg/day + +++ + ++ +++ +++ - - _ - Dosage Unit: mg/kg/day +++ - - + ++ + _ _ - - __ - - _ - - _ _ _ - _ _ _ - Covance 6329-223 3M T-6295.7 003352 675 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Females Day 153 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APPl COMMENTS Covance G329-223 3M T-6295.7 Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 2 1 0 3 0 105530 0 1 0 3 0 105531 0 0 0 2 0 105535 0 0 1 2 0 105544 0 0 1 3 0 105549 0 0 2 3 0 Group: 2 Dose Level : 0.03 Dosage Unit : mg/kg/day 105537 0 0 1 3 0 105541 4 1 1 3 0 105547 0 1 1 3 0 105550 0 0 2 3 0 Group: 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105532 0 4 2 2 0 105538 0 0 1 1 0 105539 0 1 3 3 0 105545 0 0 2 3 0 105548 0 1 1 3 0 105552 0 0 1 3 0 Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 0 1 1 3 0 105534 0 0 1 3 0 105536 0 1 1 2 0 105540 0 1 2 1 0 105542 0 2 1 3 0 105551 0 1 1 3 0 3B1D 4B4D 4B4D 0 4B 0 2B4D 0 3B2E 0 0 ID ID 4D 4B4D 4D 2B2D 2B4D 4B3D 0 2B4D 3B4D 0 0 2E4F 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 IE 0 0 0 BL BL BL BK BL BK BK CK BL BK BK CK BK BK BL CK BK BK BL AK BK CK _ _ P_ - _ P P - P P P P _ _ _ _ _ - 0033S3 676 003384 Appendix 4 Individual Clinical Urinalysis Data Males Day 182 WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) :IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 1 105508 105517 105519 105520 105526 105527 MEAN S.D. N Group : 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105505 105510 105518 105523 105524 105528 MEAN S.D. N Dose Level: 0 184.0 49.0 62.0 102.0 242.0 58.0 1.006 1.021 1.012 1.013 1.006 1.023 116.2 79.33 6 1.014 .0072 6 Dose Level: 0.03 94.0 52.0 54.0 102.0 1.014 1.019 1.018 1.016 75.5 26.20 4 1.017 .0022 4 Dose Level: 0.15 368.0 122.0 78.0 21.0 49.0 96.0 1.003 1.012 1.016 1.017 1.015 1.016 122.3 125.43 6 1.013 .0053 6 Dosage Unit: mg/kg/day 8.0 7.5 8.0 8.0 8.0 8.0 7.9 .20 6 Dosage Unit: mg/kg/day 8.0 7.5 8.0 8.0 7.9 .25 4 Dosage Unit: mg/kg/day 8.0 8.0 8.5 6.0 6.5 8.0 7.5 1.00 6 677 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical Urinalysis Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 4 105507 105511 105512 105522 MEAN S.D. N Dose Level:: 0.75 280.0 96.0 36.0 72.0 1.005 1.017 1.018 1.012 121.0 108.83 4 1.013 .0059 4 Dosage Unit: mg/kg/day 7.5 8.0 6.5 7.0 7.2 .65 4 Covance 6329-223 3M T-6295.7 c o (4 0> 00 01 678 Appendix 4 Individual Clinical Urinalysis Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105508 105517 105519 105520 105526 105527 Group: 2 105514 105515 105516 105521 Group : 3 105505 105510 105518 105523 105524 105528 Group: 4 105507 105511 105512 105522 Dose Level : 0 10 _ 10 10 10 10 10 Dose Level: 0.03 10 _ 10 10 10 Dose Level: 0.15 10 _ 10 10 10 10 10 " Dose Level: 0.75 10 10 10 10 Dosage Unit: mg/kg/day ___ -- -- - - --- -- + - - Dosage Unit: mg/kg/day __ --- -- ~-- Dosage Unit: mg/kg/day ___ -- - -- ++ -~ - Dosage Unit: mg/kg/day __ ------- _ - _ - - - - _ _ - Covance 6329-223 3M T-6295.7 S 8 00 679 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Males Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APPI COMMENTS Covance 6329-223 3M T-6295.7 Group : 1 Dose Level: 0 Dosage Unit: mg/kg/day 105508 0 0 0 3 0 105517 0 0 0 2 0 105519 0 0 0 3 0 105520 0 0 0 3 0 105526 0 1 0 3 0 105527 0 0 0 3 0 Group: 2 Dose Level : 0.03 Dosage Unit: mg/kg/day 105514 0 0 0 2 0 105515 0 0 0 3 0 105516 0 0 1 3 0 105521 0 0 0 3 0 Group: 3 Dose Level: 0.15 Dosage Unit : mg/kg/day 105505 0 0 0 3 0 105510 0 0 1 3 0 105518 0 0 0 3 0 105523 0 0 0 1 0 105524 0 0 0 3 0 105528 0 0 0 1 0 Group: 4 Dose Level: 0.75 Dosage Unit : mg/kg/day 105507 0 0 0 1 0 105511 0 0 1 2 0 105512 0 0 0 2 0 105522 0 0 1 2 0 2B1E 3B3D 4B 3B1D 2B 4B4D 2B2E 4B1E 2B 4B 2B 2B1E 4B4D IB 0 4B1E 0 4B 0 2D 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 BK BL BK BL AK BL BK BK BK BL AK BK BK BJ BK BL AJ BK BJ BK DOO 003387 680 003388 Appendix 4 Individual Clinical Urinalysis Data Females Day 182 WEEK CAPSULE 1TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105529 105530 105531 105535 105544 105549 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105539 105545 105548 105552 MEAN S.D. N Dose Level : 0 50.0 1.020 62.0 1.015 57.0 1.023 159.0 1.009 86.0 1.017 100.0 1.013 85.7 40.59 6 1.016 .0050 6 Dose Level: 0.03 108.0 38.0 95.0 64.0 1.013 1.020 1.009 1.020 76.2 31.48 4 1.016 .0054 4 Dose Level: 0.15 118.0 61.0 70.0 66.0 82.0 43.0 1.010 1.021 1.022 1.013 1.014 1.023 73.3 25.33 6 1.017 .0055 6 Dosage Unit: mg/kg/day 8.0 8.0 8.5 8.0 8.0 8.0 8.1 .20 6 Dosage Unit: mg/kg/day 7.0 7.5 8.0 8.0 7.6 .48 4 Dosage Unit: mg/kg/day 8.0 8.0 8.0 7.5 8.0 8.0 7.9 .20 6 681 Covance 6329-223 3M T-6295.7 Appendix 4 Individual Clinical urinalysis Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U VOL ML SP GR U PH Group: 4 105533 105534 105536 105540 105542 105551 MEAN S.D. N Dose Level:i 0.75 47.0 82.0 72.0 450.0 84.0 56.0 1.016 1.015 1.017 1.003 1.018 1.018 131.8 156.54 6 1.014 .0058 6 Dosagi 7.5 8.0 8.0 7.5 8.0 8.0 7.8 .26 6 mg/kg/day Covance 6329-223 3M T-6295.7 0033S9 682 Appendix 4 Individual Clinical Urinalysis Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105529 105530 105531 105535 105544 105549 Group : 2 105537 105541 105547 105550 Group: 3 105532 105538 105539 105545 105548 105552 Group: 4 105533 105534 105536 105540 105542 105551 Dose Level : 0 10 _ 10 10 10 10 10 Dose Level: 0.03 10 _ 10 _ 10 10 Dose Level: 0.15 10 _ 10 10 10 10 10 Dose Level: 0.75 30 _ 10 10 10 10 10 - Dosage Unit: mg/kg/day __ - -- --_ --- -- - + Dosage Unit: mg/kg/day ++ _ ++ - -- _ - " Dosage Unit: mg/kg/day __ -- ------- * Dosage Unit: mg/kg/day +++ _ - _ - +++ + - - - -- _ - - _ _ - _ _ - - _ _ - Covance 6329-223 3M T-6295.7 06PC00 683 ANIMAL NUMBER Appendix 4 Individual Clinical Urinalysis Data Females Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 COMMENTS Covance 6329-223 3M T-6295.7 Group: 1 105529 105530 105531 105535 105544 105549 Dose Level : 0 00 00 00 00 00 01 Dosage Unit: mg/kg/day 130 030 1 3 1G 130 130 130 4B1D 4B2D 4B1E 4D 4B 2B1D 0 0 0 0 0 0 BL BL BK BK BL _ _ _ _ BK - Group: 2 105537 105541 105547 105550 Dose Level : 0.03 01 01 00 00 Dosage Unit: mg/kg/day 130 130 130 13 0 3B2E 3B1E 4B 4B1E 0 0 0 0 BK BL _ _ BK P BL Group ! 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105532 105538 105539 0 0 0 3 0 0 0 1 0 3 2 1 0 0 0 2B2E 4B2E 3B1E 0 IF 0 BK BL BL _ _ 105545 105548 0 0 0 0 1 1 2 3 0 0 2B2D 3B 0 0 BK BK _ 105552 0 1 1 3 0 3B3D 0 BL - Group: 4 Dose Level: 0.75 Dosage Unit : mg/kg/day 105533 105534 105536 105540 105542 105551 2 0 0 0 0 0 0 1 0 0 0 1 1 1 2 1 0 1 3 3 2 2 3 3 0 0 0 0 0 0 0 3B 4B3D IB 4B 3B3D 0 0 0 0 0 0 BK BL BL AK BK BL _ _ _ _ - 003391 684 APPENDIX 4 Individual clinical Urinalysis Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level: 0 162.0 197.0 1.010 1.010 179.5 24.75 2 1.010 .0000 2 Dose Level: 0.15 296.0 183.0 1.005 1.009 239.5 79.90 2 1.007 .0028 2 Dose Level: 0.75 62.0 113.0 1.011 1.015 87.5 36.06 2 1.013 .0028 2 Dosage Unit: mg/kg/day 7.5 7.0 7.2 .35 2 Dosage Unit: mg/kg/day 7.5 7.5 7.5 .00 2 Dosage Unit: mg/kg/day 6.5 7.5 7.0 .71 2 Covance 6329-223 3M Study No. T-6295.7 C6PC00 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group : 1 105520 105526 Group : 3 105505 105523 Group : 4 105511 105522 Dose Level: 0 0 0 Dose Level: 0.15 0 0 Dose Level: 0.75 0 0 Dosage Unit: mg/kg/day -- Dosage Unit: mg/kg/day - - Dosage Unit: mg/kg/day -+ Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Males Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 URINE APP1 COMMENTS Covance 6329-223 3M Study No. T-6295.7 Group : 1 Dose Level .- 0 Dosage Unit: mg/kg/day 105520 i) 1 0 1 0 4B BK _ 105526 0 0 1 2 0 4B BJ Q Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 0 0 0 2 0 2B AJ _ 105523 U 0 0 2 0 2B AK Q Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 0 0 1 3 0 3B BK _ 105522 0 0 0 3 0 3B BK - 003394 003395 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group: i 105529 105549 MEAH S.D. N Group: 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level :: 0 88.0 198.0 1.020 1.009 143.0 77.78 2 1.014 .0078 2 Dose Level: 0.15 178.0 64.0 1.015 1.015 121.0 80.61 2 1.015 .0000 2 Dose Level : 0.75 63.0 115.0 1.015 1.015 89.0 36.77 2 1.015 .0000 2 Dosage Unit: mg/kg/day 8.0 7.5 7.8 .35 2 Dosage Unit: mg/kg/day 7.5 7.0 7.2 .35 2 Dosage Unit: mg/kg/day 7.0 8.0 7.5 .71 2 Covance S329-223 3M Study No. T-6295.7 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Covance 6329-223 3M Study No. T-6295.7 Group : 1 105529 105549 Dose Level: 0 0_ 0- Dosage Unit: mg/kg/day __ -+ _ - ! Group : 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105539 105552 10 10 _ - _ + -M-+ -- Group : 4 105533 105542 Dose Level : 0.75 0_ 0- Dosage Unit: mg/kg/day +_ -- - 9Greoo ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Females Day 217 26-WEEK CAPSULE TOXICITY :STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T- 6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 URINE APPI COMMENTS Covance 6329-223 3M Study No. T-6295.7 Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 0 0 1 3 0 105549 0 0 0 3 0 Group : 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105539 4 0 1 3 0 105552 0 0 1 3 0 Group : 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 0 0 1 3 0 105542 0 0 0 3 0 4B 3B 4B3E 4B 4B 3B CK AK BK BK BK BK - " _ - P - 003397 003398 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group: 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group : 4 105511 105522 MEAN S.D. N Dose Level:: 0 202.0 189.0 1.008 1.010 195.5 9.19 2 1.009 .0014 2 Dose Level : 0.15 290.0 102.0 1.005 1.014 196.0 132.94 2 1.010 .0064 2 Dose Level : 0.75 62.0 104.0 1.014 1.020 83.0 29.70 2 1.017 .0042 2 Dosage Unit: mg/kg/day 7.5 8.0 7.8 .35 2 Dosage Unit: mg/kg/day 7.5 7.5 7.5 .00 2 Dosage Unit: mg/kg/day 7.5 8.0 7.8 .35 2 Covance 6329-223 3M Study No. T-6295.7 003399 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105520 105526 Group: 3 105505 105523 Group: 4 105511 105522 Dore Level : 0 0_ 0 Dore Level : 0.15 0_ 0- Dore Level : 0.75 0_ 10 - Dosage Unit: mg/kg/day __ *" Dosage Unit: mg/kg/day _ ~-- Dosage Unit: mg/kg/day -- _ - - _ - Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Males Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 Covance 6329-223 3M Study No. T- 6295.7 COMMENTS Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105520 0 0 1 3 0 105526 O 0 0 3 0 Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 0 0 0 3 0 105523 0 1 1 2 1H Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105511 0 0 1 2 0 105522 0 0 0 3 0 0 ID 0 2B2F 3D 4B 0 0 0 0 0 0 AJ Q AJ AJ _ AJ PQ BJ _ BL - 003400 003401 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105529 105549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level:: 0 46.0 188.0 1.026 1.010 117.0 100.41 - 1.018 .0113 2 Dose Level: 0.15 176.0 87.0 1.015 1.018 131.5 62.93 2 1.016 .0021 2 Dose Level: 0.75 57.0 126.0 1.014 1.019 91.5 48.79 2 1.016 .0035 2 Dosage Unit : mg/kg/day 8.0 8.0 8.0 .00 2 Dosage Unit : mg/kg/day 7.0 7.5 7.2 .35 2 Dosage Unit : mg/kg/day 7.5 8.0 7.8 .35 2 Covance 6329-223 3M Study No. T-6295.7 003402 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group : i 105529 105549 Dose Level : 0 10 _ 0 Dosage Unit:: mg/kg/day __ -- Group : 3 Dore Level : 0.15 Dosage Unit: mg''kg/day 105539 0 _ _ 105552 0 - - _ - Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 105542 10 0 - +__ --- _ Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Females Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTAHE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PEP. HPF PER HPF PER HPF PER HPF PER LPF PER LPFi PER LPF2 URINE APP1 covance 6329-223 3M study No. T-6295.7 COMMENTS Group: 1 Dos Level: 0 Dosage Unit: mg/kg/day 105529 0 0 0 3 0 3BlD IE EK 105549 0 0 1 3 0 2B 0 BJ - Group: 3 Dos Level: 0.15 Dosage Unit: mg./kg/day 105539 0 0 1 3 0 105552 0 0 1 1 0 IB 4B1E 0 0 BJ _ BL - Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105533 0 11 3 0 2B1D 0 BK _ 105542 0 0 1 2 0 3B2E 2F BL - 003403 003404 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level !: 0 248.0 320.0 1.004 1.003 284.0 50.91 2 1.004 .0007 2 Dose Level :: 0.15 354.0 114.0 1.004 1.010 234.0 169.71 2 1.007 .0042 2 Dose Level : 0.75 32.0 103.0 1.026 1.011 67.5 50.20 2 1.018 .0106 2 Dosage unit: mg/kg/day 6.5 7.0 6.8 .35 2 Dosage Unit: mg/kg/day 7.5 7.0 7.2 .35 2 Dosage Unit : mg/kg/day 6.5 7.5 7.0 .71 2 Covance 6329-223 3M Study No. T-6295.7 003405 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOP.OOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-629S) IN CYHOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group : 1 105520 105526 Dose Level: 0 I.) _ 0- Dosage Unit: met/kg /day __ -- Group : 3 Dose Levelt 0.15 Dosage Unit : mg/kg/day 105505 0 _ _ _ 105523 10 - - +++ Group: 4 Dose Level : 0.75 Dosage Unit : mg"kg/day 105511 10 _ 105522 0 - - _ _ _ - - _ Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical urinalysis Data Males Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYHOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PEP. LPF1 URINE APP1 COMMENTS Covance 6329-223 3M Study No. T- 6295.7 Group: 1 105520 105526 Group: 3 105505 105523 Group: 4 105511 105522 Dose Level: 0 00 00 Dose Level: 0.15 00 00 Dose Level: 0.75 00 00 Dosage Unit: mg/kg/day 030 120 Dosage Unit: mg/kg/day 030 030 Dosage Unit: mg/kg/day 020 030 0 0 0 0 1B4E IB AJ AJ AJ BJ BJ BJ .. _ PQ _ - 003406 003407 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-62951 IN CYNOMOLGUS ANIMAL HUMBER U VOL ML SP GR U PH Group : 1 105529 105549 MEAN S.D. U Group : 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 118.0 165.0 1.007 1.005 141.5 33.23 2 1.006 .0014 2 Dose Level : 0.15 90.0 37.0 1.016 1.023 63.5 37.48 2 1.020 .0050 2 Dose Level : 0.75 23.0 106.0 1.011 1.010 64.5 58.69 2 1.010 .0007 2 Dosage Unit : mg/kg/day 7.5 8.0 7.8 .35 2 Dosage Unit : mg/kg/day 7.5 7.5 7.5 .00 2 Dosage Unit: mg/kg/day 8.0 6.5 7.2 1.06 2 Covance 6329-223 3M Study No. T-6295.7 003408 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTAHE SULFONIC ACID POTASSIUM SALT (PFOS; T-629S) IN CYHOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU u KET U BILI U BLOOD UROBILI Group: 1 105529 105549 Group: 3 105539 105552 Group: 4 105533 105542 Do? Level: 0 0_ 0- Do?e Level: 0.15 10 _ 10 - Dose Level: 0.75 10 _ 0- Dosage Unit: mg<'kg/day _ -- Dosage Unit: mg 'kg- day __ ++ - Dosage Unit: mg /kg day _ ++ - - _ _ _ Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Females Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS PER HPF PEP. HPF PER HPF PER HPF PEP. LPF PER LPF1 URINE APP1 COMMENTS Covance 6329-223 3M Study No. T-6295.7 Group: 1 105529 105549 Group: 3 105539 105552 Group: 4 105533 105542 Dose Level: 0 00 00 Dose Level: 0.15 01 00 Dose Level: 0.75 00 00 Dosage Unit: mg/kg .'day 13 13 0 0 Dosage Unit: mg/kg/day 13 13 0 0 Dosage Unit: mg ./kg/day 03 0 13 0 0 ID 1B2E 4B 4B IB AJ AJ BJ BL BL BJ P 00349 003410 APPENDIX 4 Individual clinical Urinalysis Data Males Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group: 1 105520 105526 MEAN S.D. N Group : 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level:: 0 116.0 476.0 1.015 1.002 296.0 254.56 2 1.008 .0092 2 Dose Level: 0.15 166.0 33.0 1.009 1.023 99.5 94.05 2 1.016 .0099 2 Dose Level: 0.75 51.0 44.0 1.013 1.026 47.5 4.95 2 1.020 .0092 2 Dosage Unit: mg/kg/day 6.5 7.0 6.8 .35 2 Dosage Unit : mg/kg/day 7.0 6.0 6.5 .71 2 Dosage Unit : mg/kg/day 6.0 6.0 6.0 .00 2 Covance 6329-223 3M Study No. T-6295.7 003411 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group : 1 105520 105526 Group : 3 105505 105523 Group : 4 105511 105522 Dose Level : 0 0 0- Dose Level : 0.15 0_ 0- Dose Level: 0.75 0 0- Dosage Unit: mg/kg/day +++ _ -- Dosage Uni t: mg/kg/day __ +++ - Dosage Unit : mg/kg/day _ ++++ - _ - _ - _ - Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Hales Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOF.OOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-629S) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 URINE APP1 COMMENTS Covance 6329-223 3M Study No. T- 6295.7 Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105520 0 0 1 1 0 IB BJ _ 105526 0 0 1 1 0 0 AJ Q Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 0 1 1 3 0 3B BJ 105523 0 0 1 3 0 2B BJ - Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105511 0 1 1 2 0 2B BJ Q 105522 0 0 0 2 0 0 BJ Q 003412 003413 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-629S) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105529 IU5549 MEAN S.D. N Group : 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 87.0 354.0 1.010 1.003 220.5 188.80 2 1.006 .0050 2 Dose Level :: 0.15 76.0 42.0 1.015 1.021 59.0 24.04 2 1.018 .0042 2 Dose Level : 0.75 71.0 113.0 1.017 1.012 92.0 29.70 2 1.014 .0035 2 Dosage Unit : mg/kg'day 8.0 8.0 8.0 .00 2 Dosage Unit: mg/kg/day 7.0 6.0 6.5 .71 2 Dosage Unit: mg/kg/day 6.5 7.0 6.8 .35 2 Covance 6329-223 3M Study No. T-6295.7 003414 APPENDIX 4 Individual clinical Urinalysis Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 105529 105549 Group : 3 105539 105552 Group : 4 105533 105542 Dose Level: 0 0 10 Dose Level: 0.15 0 0 Dose Level: 0.75 10 0 Dosage Unit:: mg/kg/day ++ Dosage Unit: mg/kg/day ++ +++++ - Dosage Unit: mg/kg/day ++ ++ Covance 6329-223 3M Study No. T-6295.7 II ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Females Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOP.OOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 URINE APPI COMMENTS Covance 6329-223 3M Study No. T-6295.7 Group : 1 Dose Level : n Dosage Unit: mg/kg/day 105529 0 1 1 2 0 2B BJ - 105549 0 0 1 3 0 0 AJ - Group : 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105539 0 1 1 3 0 ID BK 105552 0 0 i 3 0 IB CJ Group: 4 105533 105542 Dose Level : 0.75 01 01 Dosage Unit: mg/kg/day 12 0 11 0 0 0 BO _ BJ - 003415 003416 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105520 105526 MEAN S.D. H Group : 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level :: 0 149.0 264.0 1.019 1.015 206.5 81.32 2 1.017 .0028 2 Dose Level : 0.15 82.0 67.0 1.018 1.018 74.5 10.61 2 1.018 .0000 2 Dose Level : 0.75 100.0 80.0 1.015 1.022 90.0 14.14 2 1.018 .0050 2 Dosage Unit: mg/kg/day 8.0 7.5 7.8 .35 2 Dosage Unit: mg/kg/day 8.0 7.0 7.5 .71 2 Dosage Unit: mg/kg/day 7.5 6.0 6.8 1.06 2 Covance 6329-223 3M Study No. T-6295.7 003417 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group : 1 105520 105526 Group: 3 105505 105523 Group : 4 I0551I 105522 Dose Level : 0 10 ++++ 10 + Dose Level: 0.15 0+ 10 - Dose Level : 0.75 10 _ 10 + Dosage Unit : mg/kg/day + -+ Dosage Unit : mg/kg/day -+ ++ +++ Dosage Unit : mg/kg/day _ ++ - +++ _ - - - _ - Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Males Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 Covance 6329-223 3M Study No. T-6295.7 COMMENTS Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 0 1 1 3 0 3B1E IK BL _ 105526 0 1 3 0 3B1K BL Q Group : 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 0 0 1 2 0 3B3D 0 BL _ 105523 0 1 1 3 0 3B3D 0 CK - Group: 4 105511 105522 Dose Level : 0.75 00 00 Dosage Unit: mg/kg/day 03 0 130 4B3D 3B 0 0 BK _ BL - 003418 003419 APPENDIX 4 Individual clinical Urinalysis Data Females Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : i 105529 105549 MEAN S.D. n Group: 3 105539 105552 MEAN S.D. N Group: 4 105533 105542 MEAN S.D. N Dose Level:: 0 166.0 150.0 1.011 1.011 158.0 11.31 2 1.011 .0000 2 Dose Level:: 0.15 78.0 59.0 1.020 1.022 68.5 13.44 2 1.021 .0014 2 Dose Level: 0.75 43.0 109.0 1.018 1.019 76.0 46.67 2 1.018 .0007 2 Dosage Unit: mg/kg/day 8.0 8.0 8.0 .00 2 Dosage Unit: mg/kg/day 7.0 7.0 7.0 .00 2 Dosage Unit: mg/kg/day 6.5 7.5 7.0 .71 2 Covance 6329-223 3M Study No. T-6295.7 003420 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL HUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UP.OBILI Group: 1 105529 105549 Group: 3 105539 105552 Group: 4 105533 105542 Dose Level: 0 0 0 f Dose Level: 0.15 10 10 + Dose Level: 0.75 10 10 + Dosage Unit: mg/kg/day _+ "+ Dosage Unit: mg/kg/day _ ++ " -M-+ Dosage Unit: mg/kg/day _ +- ++ + _ - _ " _ - Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Females Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 Covance 6329-223 3M Study No. T-6295.7 COMMENTS Group: 1 Dore Level : 0 Dosage Unit: mg/kg/day 105529 U 0 0 3 0 4B2D 3K BL _ 105549 f! 0 1 3 0 4B1D 0 BL - Group : 3 Dore Level : 0.15 Dosage Unit: mg/kg/day 105539 0 1 3 0 4K 0 BK _ 105552 li 0 1 3 0 3B1D 0 BL - Group: 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105533 0 I 1 3 0 105542 0 0 0 3 0 2B 3B3K 0 0 BK _ BL - 003421 003422 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level : 0 100.0 270.0 1.012 1.008 185.0 120.21 2 1.010 .0028 2 Dose Level : 0.15 286.0 78.0 1.004 1.011 182.0 147.08 2 1.008 .0050 2 Dose Level: 0.75 90.0 78.0 1.008 1.015 84.0 8.49 2 1.012 .0050 2 Dosage Unit: mg/kg/day 8.0 8.0 8.0 .00 2 Dosage Unit: mg/kg/day 8.0 8.0 8.0 .00 2 Dosage Unit: mg/kg/day 8.0 8.0 8.0 .00 2 Covance 6329-223 3M Study No. T-6295.7 003423 APPENDIX 4 Individual clinical Urinalysis Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group: 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 105526 0 0 Group : 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 105523 0 10 Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105511 105522 0 0 - --- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Males Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APPI Covance 6329-223 3M Study No. T-6295.7 COMMENTS Group : 1 105520 105526 Dose Level : 0 00 00 Dosage Unit: mg/kg/day 030 130 IBID 0 0 0 BK _ AJ - J Group: 3 Dor. Level : 0.15 Dosage Unit: mg/kg/day 105505 0 0 0 2 0 0 0 AJ 0 , 105523 0 0 0 3 0 4B1D 0 BK Group: 4 Do:? Level : 0.75 Dosage Unit: mg/kg/day 105511 0 0 1 3 0 0 0 BJ Q 105522 0 0 0 3 0 2B4D 0 BJ 003424 003425 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105529 105549 MEAN S.D. N Group : 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level : 0 98.0 330.0 1.013 1.005 214.0 164.05 2 1.009 .0057 2 Dose Level : 0.15 198.0 92.0 1.008 1.014 145.0 74.95 2 1.011 .0042 2 Dose Level : 0.75 60.0 176.0 1.002 1.008 118.0 82.02 2 1.005 .0042 2 Dosage Unit : mg/kg/day 8.0 8.0 8.0 .00 2 fLy Dosage Unit: mg/kg/day 7.5 8.0 7.8 .35 2 Dosage unit : mg/kg/day 8.0 8.0 8.0 .00 2 Covance 6329-223 3M Study No. T-629S.7 003426 APPENDIX 4 Individual clinical Urinalysis Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG./DL U GLU U KET U BILI U BLOOD UROBILI Group : 1 Dose Level : 0 Dosage Unit: mg/kg/day 105529 105549 0 10 _ - _ _ +++ Group : 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105539 0 _ _ 105552 0 - - - - Group : 4 105533 105542 Dose Level : 0.75 0_ 0- _ - Dosage Unit : mg/kg/day _ -+ _ - _ - _ - Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Females Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPFl PER LPF2 URINE APP'l Covance 6329-223 3M Study No. T-6295.7 COMMENTS Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105529 0 0 1 3 0 105549 0 1 1 3 0 Group: 3 Dose Level: 0 .15 Dosage Unit: mg/kg/day 105539 0 i 1 3 0 105552 0 0 1 3 0 Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105533 0 0 1 3 0 105542 0 0 0 3 0 2B4D 0 0 3B 2B 4B 0 0 0 0 0 0 BE _ AJ - AJ _ BE - AK _ AL - 003427 00342S APPENDIX 4 Individual Clinical Urinalysis Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group : 1 105520 105526 MEAN S.D. N Group: 3 105505 105523 MEAN S.D. N Group: 4 105511 105522 MEAN S.D. N Dose Level: 0 480.0 380.0 1.005 1.005 430.0 70.71 2 1.005 .0000 2 Dose Level: 0.15 405.0 195.0 1.004 1.008 300.0 148.49 2 1.006 .0028 2 Dose Level: 0.75 345.0 100.0 1.005 1.015 222.5 173.24 2 1.010 .0071 2 Dosage 8.0 8.0 8.0 .00 2 Dosage 7.5 8.0 7.8 .35 2 Dosage 8.0 8.0 8.0 .00 2 mg/kg/day mg/kg/day mg/kg/day Covance 6329-223 3M Study No. T-6295.7 003429 APPENDIX 4 Individual Clinical Urinalysis Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD ' Group : 1 105520 105526 Group : 3 105505 105523 Group : 4 105511 105522 Dose Level : 0 0 Dose Level : 0.15 0 0 Dose Level : 0.75 0 0 Dosage Unit:: mg/kg/day -- Dosage Unit: mg/kg/day - - Dosage Unit: mg/kg/day -- Covance 6329-223 3M Study No. T-6295.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Males Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 Covance 6329-223 3M Study No. T-6295.7 COMMENTS Group: 1 105520 105526 Dose Level: 0 0 00 Dosage Unit: mg/kg/day 1i0 030 IB IB 0 0 AJ _ AJ Q Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 0 0 0 2 0 0 0 AJ _ 105523 0 0 0 1 0 2B 0 AJ Q Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105511 0 0 1 0 IB 0 AJ Q 105522 0 0 0 1 0 2B1D 2E BK 003430 003431 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-629S) IN CYNOMOLGUS ANIMAL NUMBER U VOL ML SP GR U PH Group: i 105529 106549 MEAN S.D. N Group: 3 105539 105552 MEAN S.D. N Group : 4 105533 105542 MEAN S.D. N Dose Level:: 0 105.0 160.0 1.015 1.007 132.5 38.89 2 1.011 .0057 2 Dose Level: 0.15 85.0 50.0 1.017 1.019 67.5 24.75 2 1.018 .0014 2 Dose Level : 0.75 42.0 156.0 1.017 1.010 99.0 80.61 2 1.014 .0050 2 Dosage Unit : mg/kg/day 8.0 8.0 8.0 .00 2 Dosage Unit : mg/kg/day 8.0 8.0 8.0 .00 2 Dosage Unit: mg/kg/day 8.0 8.0 8.0 .00 2 Covance 6329-223 3M Study No. T-6295.7 003432 APPENDIX 4 Individual Clinical Urinalysis Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS ANIMAL NUMBER U PRO MG/DL U GLU U KET U BILI U BLOOD UROBILI Group : 1 105529 105549 Group: 3 105539 105552 Group : 4 105533 105542 Dose Level:: 0 0 0 Dose Level :; 0.15 10 10 Dose Level : 0.75 0 0 Dosage Unit : mg/kg/day " - Dosage Unit : mg/kg/day -- Dosage unit : mg/kg/day - +++ Covance 6329-223 3M Study No. T-629S.7 ANIMAL NUMBER APPENDIX 4 Individual Clinical Urinalysis Data Females Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS RBC WBC EPITH BACT CASTS CRYSTALS CRYSTALS PER HPF PER HPF PER HPF PER HPF PER LPF PER LPF1 PER LPF2 URINE APP1 Covance 6329-223 3M Study No. T-6295.7 COMMENTS Group: 1 Dose Level: 0 Dosage Unit: mg/kg/day 105529 0 1 0 2 0 2B2D IF BJ _ 105549 0 0 0 2 0 2B 0 BJ Group: 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105539 0 0 u 2 0 3B1E 0 BK 105552 0 0 0 2 0 2B2E 0 BL - Group: 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105533 0 0 0 2 0 3B3D 0 BL _ 105542 0 1 1 1 0 3B 0 AL - 003433 APPENDIX 5 Covance 6329-223 3M T-6295.7 Individual Palmitoyl CoA Oxidase Determinations Individual Anatomic Pathology Data 685 0 0 3 4 3 4 003435 Appendix 5 Individual Palmitoyl CoA Oxidase Determinations Terminal Sacrifice Males 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER PCOAO IU/G Group: 1 105508 105517 105519 105527 MEAN S.D. N Group: 2 105514 105515 105516 105521 MEAN S.D. N Group : 3 105510 105518 105524 105528 MEAN S.D. N Dose Level 4 4 6 7 5 1.5 4 Dose Level 4 5 4 6 5 1.0 4 Dose Level 6 6 5 5 6 .6 4 Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day 686 Covance 6329-223 3M T-6295.7 Appendix 5 Individual Palmitoyl CoA Oxidase Determinations Terminal Sacrifice Hales 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER PCOAO IU/G Group: 4 105507 105512 MEAN S.D. N Dose Level: 0.75 8 6 7 1.4 2 Dosage Unit: mg/kg/day Covance 6329-223 3M T-6295.7 003436 687 Appendix 5 Individual Palmitoyl CoA Oxidase Determinations Terminal Sacrifice Females 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER PCOAO IU/G Group: 1 105530 105531 105535 105544 MEAN S.D. N Group: 2 105537 105541 105547 105550 MEAN S.D. N Group: 3 105532 105538 105545 105548 MEAN S.D. N Dose Level: 0 3 4 4 5 4 .8 4 Dose Level 4 4 2 5 4 1.3 4 Dose Level: 0.15 5 5 6 7 6 1.0 4 Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Dosage Unit: mg/kg/day Covance 6329-223 3M T-6295.7 003437 688 Appendix 5 Individual Palmitoyl CoA Oxidase Determinations Terminal Sacrifice Females 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER PCOAO IU/G Group: 4 105534 105536 105540 105551 MEAN S.D. N Dose Level: 0.75 6 7 6 5 6 .8 4 Dosage Unit: mg/kg/day Covance 6329-223 3M T-6295.7 003438 689 APPENDIX 5 Individual Anatomic Pathology Data Unscheduled Deaths 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 1 ANIMAL NUMBER: 105506 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (M) DATE OF DEATH: 02/20/99 STUDY DAY OF DEATH: 179 STUDY WEEK OF DEATH: 26 TERMINAL BODY WEIGHT: 3625.0 GRAMS DATE AND TIME OF NECROPSY: 02/20/99 12:40 PROSECTOR: DAVID SCHUETTE RECORDER: NANCY DIEDRICH POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NANCY DIEDRICH ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TTl) GALLBLADDER (GB) BILE(VOLUME) (BI) .4730 .3840 65.9350 1.2760 1.2520 6.1230 5.9240 88.6340 7.0730 7.0020 6.7010 .1980 .2070 .0130 % .0106 % 1.8189 % .0352 % .0345 % .1689 .1634 % 2.4451 % .1951 % .1932 % .1849 .0055 % .0057 % .0072 .0058 1.0000 .0194 .0190 .0929 .0898 1.3443 .1073 .1062 .1016 .0030 .0031 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NOT SCHEDULED NOT SCHEDULED NECROPSY OBSERVATIONS HISTOPATHOLOGY BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MODERATELY SEVERE BRAIN (BR) : -INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR,-MINIMAL -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL -INFILTRATE, LYMPHOHISTIOCYTIC, MENINGEAL,-SLIGHT KIDNEY (KD) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL -CAST, PROTEINACEOUS,-SLIGHT 003439 690 APPENDIX 5 Individual Anatomic Pathology Data Unscheduled Deaths 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT <PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 2 ANIMAL NUMBER: 105506 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (M) DATE OF DEATH: 02/20/99 STUDY DAY OF DEATH:I: 179 STUDY WEEK OF DEATH: 26 TERMINAL BODY WEIGHT: 3625.0 GRAMS DATE AND TIME OF NECROPSY: 02/20/99 12:40 PROSECTOR: DAVID SCHUETTE RECORDER: NANCY DIEDRICH POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NANCY DIEDRICH NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -HYPERTROPHY, HEPATOCELLULAR,-MODERATE, DIFFUSE -STASIS, BILE,-SLIGHT, MULTI-FOCAL THYMUS (TH) : -CYST,-PRESENT -ATROPHY,-MODERATELY SEVERE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL ESOPHAGUS (ES) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT THYROID (TY) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT -CYST, ULTIMOBRANCHIAL,-PRESENT ADRENAL, CORTEX (AC) : -MINERALIZATION, VASCULAR,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT SPINAL CORD (SC) : -INFILTRATION, LYMPHOHISTIOCYTIC MENINGEAL/PERIVASCULAR,SLIGHT DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT 003440 691 APPENDIX 5 Individual Anatomic Pathology Data Unscheduled Deaths 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 3 ANIMAL NUMBER: 105506 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (M) DATE OF DEATH: 02/20/99 STUDY DAY OF DEATH: 179 STUDY WEEK OF DEATH: 26 TERMINAL BODY WEIGHT: 3625.0 GRAMS DATE AND TIME OF NECROPSY: 02/20/99 12:40 PROSECTOR: DAVID SCHUETTE RECORDER: NANCY DIEDRICH POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NANCY DIEDRICH NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS CAUSE OF DEATH (CD) : -UNDETERMINED, -PRESENT THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , LUNG (LU) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP), LN, MESENTERIC (MS), PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM) , NERVE, SCIATIC (SN) , STOMACH, GL (ST), PANCREAS (PA), CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE) 003441 692 APPENDIX 5 Individual Anatomie Pathology Data Unscheduled Deaths 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 4 ANIMAL NUMBER: 105509 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (D) DATE OF DEATH: 01/27/99 STUDY DAY OF DEATH: 155 STUDY WEEK OF DEATH: 23 TERMINAL BODY WEIGHT: NOT ENTERED DATE AND TIME OF NECROPSY: 01/27/99 10:21 PROSECTOR: NANCY DIEDRICH RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NOT AVAILABLE *** ORGAN WEIGHTS WERE NOT RECORDED *** NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION(S) ; ALL LOBES TO EACH OTHER AND PLEURA: MULTIPLE INDISTINCT ADHESIONS; CANNOT DISTINGUISH LOBES FROM ONE ANOTHER; COLLECTED -MOTTLED; ALL RIGHT LOBES: RED, DARK RED, AND TAN; LOBES APPEAR FIRM -EROSION(S)/ULCERATION(S); APPEARS TO BE RIGHT CAUDAL LOBE: SINGLE ULCERATED AREA, 2.5 X 1.5 CM; ULCERATED AREA EXTENDS DEEP INTO LUNG TISSUE; WALLS OF ULCERATION APPEAR GREEN, TAN, GRAY AND MOIST; COLLECTED INTACT LIVER (LI) : -MOTTLED; ALL LOBES: DARK BROWN AND TAN -LARGE; ALL LOBES: THICKENED BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MODERATELY SEVERE MARROW, FEMUR (FM) : >SECTION EXAMINED; TISSUE NOT PRESENT KIDNEY (KD) : -MINERALIZATION, PAPILLARY,-MODERATE LUNG (LU) : -FIBROSIS, PLEURAL/SUBPLEURAL, -MODERATE -INFILTRATE, MACROPHAGE, ALVEOLAR,-MODERATE -NECROSIS,-SEVERE -INFLAMMATION, ACUTE,-SEVERE -FIBRIN, PLEURAL,-MODERATELY SEVERE LIVER (LI) : -HYPERTROPHY, HEPATOCELLULAR,-SLIGHT, DIFFUSE -VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR,-MODERATE THYMUS (TH) : -ATROPHY,-MODERATE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL 003442 693 APPENDIX 5 Individual Anatomic Pathology Data Unscheduled Deaths 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 5 ANIMAL NUMBER: 105509 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (D) DATE OF DEATH: 01/27/99 STUDY DAY OF DEATH: 155 STUDY WEEK OF DEATH: 23 TERMINAL BODY WEIGHT: NOT ENTERED DATE AND TIME OF NECROPSY: 01/27/99 10:21 PROSECTOR: NANCY DIEDRICH RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NOT AVAILABLE NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY COLON (CO) : -DARK FOCUS(I)/AREA(S); WITHIN MUCOSA: SINGLE DARK BROWN AREA, 0.3 X 0.2 CM; COLLECTED ON ROUTINE SECTION LN, TRACHEOBRON (TB) : -LARGE; UP TO 1.0 X 0.9 X 0.5 CM (CAP 29) JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT COLON (CO) : >UNREMARKABLE CAUSE OF DEATH (CD) : -NECROSIS, PULMONARY,-PRESENT LN, TRACHEOBRON (TB) : -INFLAMMATION, ACUTE,-MODERATE 003443 694 APPENDIX 5 Individual Anatomic Pathology Data Unscheduled Deaths 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 6 ANIMAL NUMBER: 105509 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: UNSCHEDULED (D) DATE OF DEATH: 01/27/99 STUDY DAY OF DEATH: 155 STUDY WEEK OF DEATH: 23 TERMINAL BODY WEIGHT: NOT ENTERED DATE AND TIME OF NECROPSY: 01/27/99 10:21 PROSECTOR: NANCY DIEDRICH RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: NOT AVAILABLE THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB) , EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS) , TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU) , PANCREAS (PA) , JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , RECTUM (RE) , SKIN (SK) , MAMMARY, MALE (MM) , URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), GENERAL COMMENT (GC) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP) , LN, MESENTERIC (MS), ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), CECUM (CE) , RECTUM (RE), SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP), TESTIS (TE) 003444 695 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 1 ANIMAL NUMBER: 105508 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL JSACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH:: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT : 3285 .0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 10:24 PROSECTOR:: KEVIN BILLINGS RECORDER:: MICHELE ZIMA POST--FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .2650 .2010 62.3670 .8310 1.0370 5.8660 5.4930 59.3880 5.5360 5.1190 4.3000 .1520 .1390 .4890 1.6000 mL .0081 % .0061 % 1.8985 % .0253 % .0316 % .1786 .1672 1.8079 % .1685 % .1558 % .1309 % .0046 % .0042 % .0042 .0032 1.0000 .0133 .0166 .0941 .0881 .9522 .0888 .0821 .0689 .0024 .0022 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -RED FOCUS (I)/AREA(S) ; ALL LOBES: MULTIPLE DARK RED PINPOINT FOCI BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MODERATELY SEVERE KIDNEY (KD) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT -GLOMERULOSCLEROSIS,-MINIMAL LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,- SLIGHT LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL 003445 696 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 2 ANIMAL NUMBER: 105508 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3285.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 10:24 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY SPLEEN (SP) : -LARGE; 7.0 X 4.0 X 3.0 CM GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS SPLEEN (SP) : UNREMARKABLE LN, MESENTERIC (MS) : -HEMORRHAGE,-SLIGHT TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT COLON (CO) : -INFILTRATE, EOSINOPHILIC,-SLIGHT MAMMARY, MALE (MM) : SECTION EXAMINED; TISSUE NOT PRESENT PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC, -MINIMAL 003446 697 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covanee 6329-223 3M T-6295.7 PAGE: 3 ANIMAL NUMBER: 105508 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3285.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 10:24 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , LIVER (LI), GALLBLADDER (GB) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB) , EYE (EY) , BRAIN (BR) , HEART (HT) , GALLBLADDER (GB) , THYMUS (TH). ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU) , PANCREAS (PA) , JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , RECTUM (RE) , SKIN (SK) , URINARY BLADDER (UB) , SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE) 003447 698 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 4 ANIMAL NUMBER: 105517 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3055.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EPl) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .2840 .1430 62.4920 1.0930 1.2250 5.9980 5.7530 44.2710 8.0310 8.1690 5.8790 .1490 .1400 .6330 1.6000 mL .0093 % .0047 % 2.0456 % .0358 % .0401 % .1963 % .1883 % 1.4491 % .2629 % .2674 % .1924 % .0049 .0046 % .0045 .0023 1.0000 .0175 .0196 .0960 .0921 .7084 .1285 .1307 .0941 .0024 .0022 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MODERATE MARROW, FEMUR (FM) : SECTION EXAMINED; TISSUE NOT PRESENT LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR, MINIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL 003448 699 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 5 ANIMAL NUMBER: 105517 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3055.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS LN, MESENTERIC (MS) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT ADRENAL, CORTEX (AC) : -HYPERTROPHY, CORTICAL CELL,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL PANCREAS (PA) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL COLON (CO) : -PARASITISM, INTRAMUSCULAR, -PRESENT 003449 700 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 6 ANIMAL NUMBER: 105517 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH:1: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3055.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB) , EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP), THYMUS (TH), ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), JEJUNUM (JE), ILEUM (IL) , CECUM (CE) , RECTUM (RE), SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE) 003450 701 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 7 ANIMAL NUMBER: 105519 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3140.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 6:57 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EPO) RT EPIDIDYMIS (EP1) LF KIDNEY (KDO) RT KIDNEY (KDl) LIVER (LI) LF TESTIS (TEO) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .2820 .2330 62.8980 .7730 .8270 5.5490 5.3860 53.1740 2.7780 2.9990 5.5570 .1310 .1220 .7260 1.2000 mL .0090 % .0074 % 2.0031 % .0246 % .0263 t .1767 % .1715 % 1.6934 % .0885 % .0955 % .1770 % .0042 t .0039 % .0045 .0037 1.0000 .0123 .0131 .0882 .0856 .8454 .0442 .0477 .0883 .0021 .0019 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MODERATELY SEVERE MARROW, FEMUR (FM) : SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL KIDNEY (KD) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL 003451 702 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 8 ANIMAL NUMBER: 105519 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3140.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 6:57 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,SLIGHT LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL, MULTI-FOCAL GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC, -SLIGHT PARATHYROID (PT) : -CYST,-PRESENT ADRENAL, CORTEX (AC) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE CECUM (CE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE MAMMARY, MALE (MM) : >SECTION EXAMINED; TISSUE NOT PRESENT PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL EPIDIDYMIDES <EP) : -HYPOSPERMIA,-MODERATE TESTIS (TE) : -IMMATURE,-PRESENT 003452 703 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLU0R00CTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 9 ANIMAL NUMBER: 105519 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH; 27 TERMINAL BODY WEIGHT: 3140.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 6:57 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC) , ADRENAL, MEDULLA (MA) , AORTA (AO) , PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , HEART (HT) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), ESOPHAGUS (ES), THYROID (TY) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), COLON (CO), RECTUM (RE), SKIN (SK) , URINARY BLADDER (UB) , SEMINAL VESICLES (SV) 003453 704 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 10 ANIMAL NUMBER: 105527 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4680.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) ABSOLUTE ORGAN WEIGHT (GRAMS) .3120 .2600 64.8130 1.8660 1.7750 7.5090 7.3890 62.8470 11.5730 10.6940 6.0920 .2380 .2750 .6430 2.4000 mL ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) .0067 % .0056 % 1.3849 % .0399 % .0379 % .1604 % .1579 % 1.3429 % .2473 % .2285 % .1302 % .0051 % .0059 % ORGAN TO BRAIN WEIGHT RATIO .0048 .0040 1.0000 .0288 .0274 .1159 .1140 .9697 .1786 .1650 .0940 .0037 .0042 ORGAN STATUS WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-SLIGHT MARROW, FEMUR (FM) : SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,SLIGHT 003454 705 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 11 ANIMAL NUMBER: 105527 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4680.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY SKIN (SK) : -ABRASION(S)/ULCERATION(S); 2.0 CM FROM TIP OF TAIL: SINGLE RED, MOIST ABRADED AREA, 0.8 CM IN DIAMETER; COLLECTED GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -GRANULOMA,-MINIMAL, FOCAL THYMUS (TH) : -ATROPHY,-SEVERE SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL MUSCLE, SKELETAL (SM) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE SKIN (SK) : -HYPERPLASIA, EPIDERMAL (ACANTHOSIS),-MODERATE -INFLAMMATION, CHRONIC-ACTIVE,-SLIGHT -ULCERATION, -MODERATELY SEVERE URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL 003455 706 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 12 ANIMAL NUMBER: 105527 SEX: MALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4680.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP) , TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , KIDNEY (KD) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), PANCREAS (PA), JEJUNUM (JE) , CECUM (CE) , COLON (CO), RECTUM (RE), MAMMARY, MALE (MM), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE) 003456 707 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice Covance 6329-223 3M T-6295.7 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER: 105514 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL 1SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH : 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT : 3495..0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST : ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) .3620 .2420 62.4280 1.1580 1.0010 6.0230 6.1700 64.2170 6.7090 5.1600 4.7970 .3130 .3200 .0104 % .0069 % 1.7862 % .0331 % .0286 % .1723 % .1765 % 1.8374 % .1920 % .1476 % .1373 % .0090 % .0092 % .0058 .0039 1.0000 .0185 .0160 .0965 .0988 1.0287 .1075 .0827 .0768 .0050 .0051 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION (S) ; ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, AND CAUDAL LOBES TO DIAPHRAGM: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL THYMUS (TH) : -ATROPHY,-MODERATE 003457 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS.-T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 14 ANIMAL NUMBER: 105514 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3495.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE 2IMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL INFORMATION (XX) : >NOTE :>GALLBLADDER WEIGHT IS 0.7220 GRAMS BILE VOLUME IS 1.4000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) 003458 APPENDIX 5 Individual Anatomic Pathology Data Terminal sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS.-T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: IS ANIMAL NUMBER: 105515 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH:: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.,0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 6: 45 PROSECTOR: STEVE VAN ADESTINE RECORDER:: JOHN S.. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EPO) RT EPIDIDYMIS (EP1) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TEO) RT TESTIS (TE1) PANCREAS (PA) LF THYRO ID/PARA (TTO ) RT THYROID/PARA (TT1) .2770 .1900 63.7670 .7590 .8690 6.4220 6.2010 55.8260 2.7190 3.3300 5.0260 .1340 .1240 .0080 % .0055 % 1.8350 % .0218 % .0250 % .1848 % .1784 % 1.6065 % .0782 % .0958 % .1446 % .0039 .0036 % .0043 .0030 1.0000 .0119 .0136 .1007 .0972 .8755 .0426 .0522 .0788 .0021 .0019 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OB SERVA T ION S HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS GENERAL INFORMATION (XX) : >NOTE:GALLBLADDER WEIGHT IS 0.4620 GRAMS BILE VOLUME IS 1.2000 ML LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI--FOCAL 003459 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT lPFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 16 ANIMAL NUMBER: 105515 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 6:45 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (THI , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: THYMUS (TH) 003460 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice Covance 6329-223 3M T-6295.7 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS ANIMAL NUMBER: 105516 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH:: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT : 3170..0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT 1%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA ITT0) RT THYROID/PARA (TT1 ) .2940 .2410 67.0240 .8820 .7570 6.8380 7.0240 68.1040 3.3570 5.1290 3.0500 .2040 .1430 .0093 % .0076 % 2.1143 % .0278 % .0239 % .2157 % .2216 % 2.1484 .1059 % .1618 % .0962 % .0064 % .0045 % .0044 .0036 1.0000 .0132 .0113 .1020 .1048 1.0161 .0501 .0765 .0455 .0030 .0021 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY O B S E R V A T I I 5N S HISTOPATHOLOGY SPLEEN (SP) : -LARGE; 7.0 X 5.0 X 3.0 CM TESTIS (TE) : -LARGE; RIGHT: 2.5 X 1.5 X 1.4 CM (FOR COMPARISON, LEFT IS 2.0 X 1.5 X 1.0 CM) GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS SPLEEN (SP) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL THYMUS <TH) : -CYST,-PRESENT TESTIS (TE) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL 003461 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-629S.7 PAGE: 18 ANIMAL NUMBER: 105516 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3170.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL INFORMATION (XX) : >NOTE:^GALLBLADDER WEIGHT IS 0.6300 GRAMS BILE VOLUME IS 1.4000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (ID, CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER (LI) 003462 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295 ) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 19 ANIMAL NUMBER: 105521 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4385.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 10:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TEO) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) .3090 .2230 53.9580 2.8840 2.7980 7.1230 7.6030 60.2000 18.7540 18.8730 6.3800 .4490 .4660 .0070 % .0051 % 1.2305 % .0658 % .0638 .1624 % .1734 % 1.3729 % .4277 % .4304 % .1455 % .0102 % .0106 % .0057 .0041 1.0000 .0534 .0519 .1320 .1409 1.1157 .3476 .3498 .1182 .0083 .0086 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS . LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -VACUOLATION, HEPATOCELLULAR,-MINIMAL, MULTI-FOCAL -STASIS, BILE,-MODERATE, MULTI-FOCAL THYMUS (TH) : -ATROPHY,-MODERATELY SEVERE 003463 APPENDIX 5 Individual Anatomic Pathology Data Terminal sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 20 ANIMAL NUMBER: 105521 SEX: MALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4385.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 10:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL INFORMATION (XX) : >NOTE:GALLBLADDER WEIGHT IS 0.4810 GRAMS BILE VOLUME IS 1.4000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU) , HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) 003464 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 21 ANIMAL NUMBER: I0S510 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3180.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 9:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE 2IMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LP TESTIS <TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) .2490 .1600 56.7600 1.0910 1.0750 6.4950 6.1190 54.2060 6.0950 5.8860 3.8800 .1660 .1960 .0078 % .0050 % 1.7849 % .0343 % .0338 .2042 .1924 % 1.7046 % .1917 % .1851 % .1220 % .0052 % .0062 % .0044 .0028 1.0000 .0192 .0189 .1144 .1078 .9550 .1074 .1037 .0684 .0029 .0035 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION (S) ; BILATERAL CAUDAL LOBES TO PLEURA AND DIAPHRAGM: MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT ADIPOSE TISSUE (AT) : -RAISED FOCUS(I)/AREA(S); DIFFUSE, THROUGHOUT MESENTERY AND THORACIC CAVITY: MULTIPLE, TAN, FIRM NODULES, UP TO 0.6 CM IN DIAMETER WITHIN MESENTERY (CAP 29), UP TO 0.3 CM IN DIAMETER WITHIN THORACIC CAVITY (CAP 30) AND COLLECTED INTACT WITH LUNG ADHESIONS GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL ADIPOSE TISSUE (AT) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL 003465 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 22 ANIMAL NUMBER: 105510 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3180.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 9:48 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUEDI HISTOPATHOLOGY GENERAL INFORMATION (XX) : >NOTE:GALLBLADDER WEIGHT IS 0.6690 GRAMS BILE VOLUME IS 2.4000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT), LIVER (LI), GALLBLADDER 1GB), SPLEEN (SP), THYMUS !TH), LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID <TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL), CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER (LI), THYMUS (TH) 003466 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEX CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 23 ANIMAL NUMBER: 105518 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3070.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) .2790 .2460 62.8420 .8790 1.0970 5.6790 5.6110 57.5930 4.5720 4.6220 3.1580 .2450 .3110 .0091 % .0080 % 2.0470 % .0286 % .0357 % .1850 % .1828 % 1.8760 % .1489 % .1506 % .1029 % .0080 % .0101 % .0044 .0039 1.0000 .0140 .0175 .0904 .0893 .9165 .0728 .0735 .0503 .0039 .0049 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS GENERAL INFORMATION (XX) : >NOTE :>GALLBLADDER WEIGHT IS 0.5320 GRAMS BILE VOLUME IS 1.3000 ML THYMUS (TH) : -ATROPHY,-MINIMAL 003467 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 24 ANIMAL NUMBER: 105518 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3070.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE 2IMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN>, STOMACH, GL (ST), DUODENUM (DU) , PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER (LI) I. o CO > C) 05 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLU0R00CTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 25 ANIMAL NUMBER: 105524 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3035.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:42 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0)' RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) .2420 .1860 63.9330 .9350 .9840 5.0370 4.8440 52.5550 4.6940 4.2750 4.6550 .1210 .1330 .0080 % .0061 % 2.1065 % .0308 % .0324 % .1660 % .1596 % 1.7316 % .1547 % .1409 % .1534 % .0040 % .0044 % .0038 .0029 1.0000 .0146 .0154 .0788 .0758 .8220 .0734 .0669 .0728 .0019 .0021 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS GENERAL INFORMATION (XX) : >NOTE :>GALLBLADDER WEIGHT IS 0.9610 GRAMS BILE VOLUME IS 0.8000 ML THYMUS (TH) : -ATROPHY,-MINIMAL 003469 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS.-T-6295 ) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 26 ANIMAL NUMBER: 105524 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3035.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:42 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR IFE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE>, ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER (LI) 003470 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 27 ANIMAL NUMBER: 105528 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 10:19 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) .3070 .2620 69.8730 .9990 .9290 6.3390 6.3690 64.9760 5.0300 5.2350 5.8230 .2980 .3900 .0088 % .0075 % 2.0107 % .0287 % .0267 % .1824 % .1833 % 1.8698 % .1447 % .1506 % .1676 % .0086 % .0112 % .0044 .0037 1.0000 .0143 .0133 .0907 .0912 .9299 .0720 .0749 .0833 .0043 .0056 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS GENERAL INFORMATION (XX) : >NOTE:GALLBLADDER WEIGHT IS 0.5220 GRAMS BILE VOLUME IS 1.8000 ML LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -HYPERTROPHY, HEPATOCELLULAR,-SLIGHT, DIFFUSE THYMUS (TO) : -ATROPHY,-SLIGHT 003471 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 28 ANIMAL NUMBER: 105528 SEX: MALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH:I: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3475.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 10:19 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE. FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU) , HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) , 003472 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 29 ANIMAL NUMBER: 105507 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3870.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADl) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .4540 .3210 71.7900 2.0740 2.3260 6.5150 6.2950 112.4190 12.6370 12.5000 5.2280 .2850 .3460 .5330 2.0000 mL .0117 % .0083 % 1.8550 % .0536 % .0601 % .1683 % .1627 % 2.9049 .3265 % .3230 % .1351 % .0074 % .0089 % .0063 .0045 1.0000 .0289 .0324 .0908 .0877 1.5659 .1760 .1741 .0728 .0040 .0048 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-SLIGHT MARROW, FEMUR (FM) : >SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, LYMPHOHISTIOCYTIC, PERIVASCULAR,-MINIMAL -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-SLIGHT KIDNEY (KD) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL -MINERALIZATION, CORTEX,-MINIMAL 003473 724 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE; 30 ANIMAL NUMBER: 105507 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3870.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY LIVER (LI) : -MOTTLED; ALL LOBES: BROWN AND TAN LN, MESENTERIC (MS) : -DIFFUSELY RED; DARK RED ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: DARK BROWN GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS LIVER (LI) : -HYPERTROPHY, HEPATOCELLULAR,-MODERATE, DIFFUSE -VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR,-MODERATELY SEVERE THYMUS (TH) : -CYST.-PRESENT -ATROPHY,-MODERATELY SEVERE LN, MESENTERIC (MS) : UNREMARKABLE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT ADRENAL, CORTEX (AC) : UNREMARKABLE JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC, -MINIMAL 003474 725 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE! 31 ANIMAL NUMBER: 105507 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3870.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 8:11 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE), ADIPOSE TISSUE (AT), LN, TRACHEOBRQN (TB), LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , LUNG (LU) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP), TESTIS (TE) 003475 726 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 32 ANIMAL NUMBER: 105512 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2285.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF EPIDIDYMIS (EP0) RT EPIDIDYMIS (EP1) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF TESTIS (TE0) RT TESTIS (TE1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .2790 .2240 60.7370 .5450 .4350 4.5470 4.5140 58.1440 1.4310 1.3310 3.0430 .1190 .1260 .3100 1.2000 mL .0122 % .0098 % 2.6581 % .0239 % .0190 % .1990 % .1975 % 2.5446 % .0626 % .0582 % .1332 % .0052 % .0055 % .0046 .0037 1.0000 .0090 .0072 .0749 .0743 .9573 .0236 .0219 .0501 .0020 .0021 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LIVER (LI) : -MOTTLED; ALL LOBES: BROWN AND TAN BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MODERATE MARROW, FEMUR (FM) : SECTION EXAMINED: TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL LIVER (LI) : -HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR,-SLIGHT GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT 003476 727 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 33 ANIMAL NUMBER: 105512 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2285.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS THYMUS (TH) : -ATROPHY,-MODERATELY SEVERE LN, MESENTERIC (MS) : -HEMORRHAGE,-MINIMAL TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT -INFLAMMATION, ACUTE,-MINIMAL ADRENAL, CORTEX (AC) : >UNREMARKABLE SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT MAMMARY, MALE (MM) : SECTION EXAMINED; TISSUE NOT PRESENT PROSTATE (PR) : -INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL EPIDIDYMIDES (EP) : -HYPOSPERMIA,-SEVERE TESTIS (TE) : -IMMATURE,-PRESENT 003477 728 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 34 ANIMAL NUMBER: 105512 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH:I: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2285.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:21 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB) , EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU) , PANCREAS (PA) , JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO) , RECTUM (RE) , SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP) , TESTIS (TE) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , KIDNEY (KD) , LUNG (LU) , HEART (HT) , SPLEEN (SP) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK) , URINARY BLADDER (UB) , SEMINAL VESICLES (SV) i, 003478 729 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 35 ANIMAL NUMBER: 105530 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL ;SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT : 2755..0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 11:29 PROSECTOR:: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO O RGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .2480 .1640 60.5500 5.6520 5.4770 49.1800 .1220 .1280 4.2470 .2100 .2150 .5970 1.2000 mL .0090 % .0060 % 2.1978 % .2052 % .1988 % 1.7851 % .0044 % .0046 % .1542 % .0076 % .0078 % .0041 .0027 1.0000 .0933 .0905 .8122 .0020 .0021 .0701 .0035 .0036 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION(S) ; ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, AND CAUDAL LOBES TO DIAPHRAGM: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MINIMAL BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MODERATE KIDNEY (KD) : -GLOMERULOSCLEROSIS,-MINIMAL LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,MINIMAL -FIBROSIS, PLEURAL/SUBPLEURAL,-SLIGHT LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL 003479 730 APPENDIX 5 individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 36 ANIMAL NUMBER: 105530 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2755.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 11:29 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL THYROID (TY) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL MUSCLE, SKELETAL (SM) : -DEGENERATION,-SLIGHT -INFLAMMATION, GRANULOMATOUS,-MODERATE -REGENERATION, MYOFIBER,-MODERATELY SEVERE URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL 003480 731 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 37 ANIMAL NUMBER: 105530 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2755.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 11:29 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB) , EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT), LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC) , ADRENAL, MEDULLA (MA) , AORTA (AO) , PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST) , DUODENUM (DU) , PANCREAS (PA) , JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO) , RECTUM (RE) , SKIN (SK), MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA <VA) , CERVIX (CV) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB) , EYE (EY) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH), LN, MESENTERIC (MS), ESOPHAGUS (ES) , PARATHYROID (PT) , ADRENAL, CORTEX(AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO) , RECTUM (RE) , SKIN (SK) , MAMMARY, FEMALE (MF) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) 003481 732 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 38 ANIMAL NUMBER: 105531 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2625.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADl) BRAIN (BR) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .2360 .1480 54.3050 4.3520 4.2910 42.1310 .0990 .0930 3.9080 .1970 .1740 .7250 1.8000 mL .0090 % .0056 % 2.0688 % .1658 % .1635 % 1.6050 % .0038 % .0035 % .1489 % .0075 % .0066 .0043 .0027 1.0000 .0801 .0790 .7758 .0018 .0017 .0720 .0036 .0032 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY MARROW, FEMUR (FM) : SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-SLIGHT KIDNEY (KD) ; -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL ADRENAL, CORTEX (AC) : -HYPERTROPHY, CORTICAL CELL,-MINIMAL JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE G 034S2 733 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 39 ANIMAL NUMBER: 105531 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2625.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:15 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MINIMAL UTERUS (UT) : -AMYLOID, -SLIGHT THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST) , DUODENUM (DU) , PANCREAS (PA) , JEJUNUM (JE) , ILEUM (IL) , CECUM(CE) , COLON (CO) , RECTUM (RE) , SKIN (SK) , MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) ,VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: BONE, FEMUR (FE) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , LUNG (LU) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP), THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , OVARY (OV) , VAGINA (VA) ,CERVIX (CV) 003483 734 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 40 ANIMAL NUMBER: 105535 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL 1SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH:: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT : 3270..0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 8:13 PROSECTOR:: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST--FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADl) BRAIN (BR) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .3770 ,3150 51.9670 6.6940 6.1830 64.3990 .2280 .2100 5.0450 .4660 .4370 .6970 2.6000 mL .0115 .0096 % 1.5892 % .2047 .1891 % 1.9694 .0070 % .0064 % .1543 .0143 % .0134 % .0073 .0061 1.0000 .1288 .1190 1.2392 .0044 .0040 .0971 .0090 .0084 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION(S) ; ALL LOBES TO EACH OTHER, PLEURA, AND PERICARDIAL SAC: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT MARROW, FEMUR (FM) : SECTION EXAMINED; TISSUE NOT PRESENT LUNG (LU) : -FIBROSIS, PLEURAL/SUBPLEURAL,-SEVERE -FIBROSIS, INTERSTITIAL,-MODERATELY SEVERE LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -VACUOLATION, HEPATOCELLULAR,-MINIMAL, MULTI-FOCAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT 003484 735 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 41 ANIMAL NUMBER: 105535 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3270.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 8:13 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY STOMACH, GL (ST) : -RED FOCUS(I)/AREA(S); MUCOSA, FUNDIC: SINGLE RED FOCUS, 0.3 MM IN DIAMETER; FOCUS HAS A STELLATE PATTERN >NOTE:>FUNDIC MUCOSA, ALONG GREATER CURVATURE: SINGLE APPARENT HOOK WORM EMBEDDED INTO MUCOSA, 3.0 X 0.1 X 0.1 CM GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>ANIMAL APPEARS TO BE IN ESTROUS STOMACH, GL (ST) : UNREMARKABLE DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE CECUM (CE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT MAMMARY, FEMALE (MF) : -INFLAMMATION, ACUTE,-MINIMAL URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL UTERUS (UT) : -AMYLOID, -SLIGHT oo CO c0n0 736 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS.-T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 42 ANIMAL NUMBER: 105535 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3270.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 8:13 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE),MARROW, FEMUR (FM) , MARROW, STERNUM (SE) ,BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD), HEART (HT), LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) . MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: BONE, FEMUR (FE),MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , GALLBLADDER (GB),SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , PANCREAS (PA), COLON (CO), RECTUM (RE), SKIN (SK) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) 0034S6 737 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 43 ANIMAL NUMBER: 105544 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL lSACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT : 2635..0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:55 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TTl) GALLBLADDER (GB) BILE(VOLUME) (BI) .3120 .2440 59.7410 5.3110 5.2470 48.6600 .2260 .1380 4.5080 .1540 .1560 .3810 2.2000 mL .0118 % .0093 % 2.2672 % .2016 .1991 % 1.8467 % .0086 % .0052 .1711 % .0058 % .0059 t .0052 .0041 1.0000 .0889 .0878 .8145 .0038 .0023 .0755 .0026 .0026 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LIVER (LI) : -LIGHT FOCUS (I)/AREA (S) ; TRIM COMMENT: DIAPHRAGMATIC SURFACE OF LEFT LATERAL LOBE: SINGLE TAN AREA, 1.0 CM IN DIAMETER; SUBMITTED ON ROUTINE SECTION MARROW, STERNUM (SE) : -HYPOCELLULAR, MARROW,-SLIGHT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MODERATE LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL LN, MESENTERIC (MS) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE 003487 738 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 44 ANIMAL NUMBER: 105544 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2635.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:55 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT ESOPHAGUS (ES) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL PARATHYROID (PT) : SECTION EXAMINED; TISSUE NOT PRESENT MUSCLE, SKELETAL (SM) : -PARASITES, CYST,-PRESENT NOTE:HEAVY BURDEN, SARCOCYST-LIKE. DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT MAMMARY, FEMALE (MF) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT OVARY (OV) : -MINERALIZATION, -MODERATE 003488 739 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 45 ANIMAL NUMBER: 105544 SEX: FEMALE DOSE GROUP: 1 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2635.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:55 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB) , EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM),SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE),ILEUM (IL) ,CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) ,VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , BONE, STERNUM (SB) , EYE (EY) , KIDNEY (KD) , LUNG (LU) , HEART (HT) , SPLEEN (SP), THYMUS (TH) , THYROID (TY) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , SPINAL CORD (SC), NERVE, SCIATIC (SN),STOMACH, GL (ST), PANCREAS (PA), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), UTERUS (UT), VAGINA (VA),CERVIX (CV) 003489 740 APPENDIX 5 individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance G329-223 3M T-6295.7 PAGE: 46 ANIMAL NUMBER: 105537 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4055.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADl) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OV0) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .3730 .3030 61.3750 7.0240 6.6650 75.2140 .2790 .2280 6.1370 .3200 .3400 .5100 3.0000 mL .0092 % .0075 % 1.5136 % .1732 % .1644 1.8548 % .0069 .0056 % .1513 % .0079 % .0084 % .0061 .0049 1.0000 .1144 .1086 1.2255 .0045 .0037 .1000 .0052 .0055 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -ANIMAL OBESE 003490 741 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 47 ANIMAL NUMBER: I05S37 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4055.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%> ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO ) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OV0) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0 ) RT THYROID/PARA (TT1 ) .3730 .3030 61.3750 7.0240 6.6650 75.2140 .2790 .2280 6.1370 .3200 .3400 .0092 % .0075 % 1.5136 % .1732 % .1644 % 1.8548 % .0069 % .0056 % .1513 % .0079 % .0084 % .0061 .0049 1.0000 .1144 .1086 1.2255 .0045 .0037 .1000 .0052 .0055 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -ANIMAL OBESE GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.5100 GRAMS BILE VOLUME IS 3.0000 ML LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL THYMUS (TH) : -ATROPHY,-MINIMAL SPINAL CORD (SC) : -PIGMENT, NEURONAL,-SLIGHT 003491 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 48 ANIMAL NUMBER: 105537 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 4055.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SB), BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU), HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM IIL) ,CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) I, 003492 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 49 ANIMAL NUMBER: 105541 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2510.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 9:47 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%| ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1 .4170 .3060 63.2760 4.9450 4.6880 47.6610 .1240 .1570 5.0750 .2130 .2300 .0166 % .0122 % 2.5210 % .1970 % .1868 % 1.8988 % .0049 % .0063 % .2022 % .0085 % .0092 % .0066 .0048 1.0000 .0781 .0741 .7532 .0020 .0025 .0802 .0034 .0036 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION(S! ; RIGHT AND LEFT CAUDAL LOBES AND LEFT INTERMEDIATE LOBE TO DIAPHRAGM: MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT -DARK FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK BROWN AREAS, PINPOINT AND UP TO 0.7 X 0.4 CM LIVER (LI) : -ADHESION (S) ; DIAPHRAGMATIC SURFACE OF RIGHT LATERAL LOBE TO SURROUNDING MESENTERY, ALONG MARGIN: MULTIPLE TAN, FIBROUS ADHESIONS (CAP 29) LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL THYMUS (TH) : -ATROPHY,-MODERATE SPINAL CORD (SC) : -PIGMENT, NEURONAL,-MODERATE 003493 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS.-T-6295 ) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 50 ANIMAL NUMBER: 105541 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2510.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 9:47 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:>GALLBLADDER WEIGHT IS 0.5260 GRAMS BILE VOLUME IS 1.0000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE|, MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), HEART (HT) , GALLBLADDER (GB) , SPLEEN |SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON ITB), LN, ANT MES/PANC (AP) APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT <PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 51 ANIMAL NUMBER: 105547 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2570.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TTO ) RT THYROID/PARA (TT1) . .3130 .2300 60.8690 5.4180 5.5840 49.9520 .1590 .2030 5.1480 .1550 .1410 .0122 % .0089 % 2.3684 % .2108 % .2173 % 1.9437 % .0062 % .0079 % .2003 % .0060 % .0055 % ,0051 .0038 1.0000 .0890 .0917 .8206 .0026 .0033 .0846 .0025 .0023 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION(S) ; LEFT CAUDAL LOBE TO DIAPHRAGM: MULTIPLE TAN, FIBROUS ADHESIONS; COLLECTED INTACT -DARK FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK BROWN AREAS, PINPOINT AND UP TO 0.5 X 0.3 CM GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL THYMUS (TH) : -CYST,-PRESENT -ATROPHY,-SLIGHT 003495 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT IPFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 52 ANIMAL NUMBER: 105547 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2570.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 9:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL INFORMATION (XX) : >NOTE :>GALLBLADDER WEIGHT IS 0.5380 GRAMS BILE VOLUME IS 1.2000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT), LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA ITR) , ESOPHAGUS (ES), THYROID <TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL), CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB|, UTERUS <UT), OVARY (OV),VAGINA (VA), CERVIX (CV) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: SPINAL CORD (SC) 003496 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-629S.7 PAGE: 53 ANIMAL NUMBER: 105550 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2820.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 6:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE 2IMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) .4230 .2680 56.9130 6.0900 6.1500 54.4840 .1270 .1270 7.2830 .1670 .2290 .0150 % .0095 % 2.0182 % .2160 % .2181 % 1.9321 % .0045 % .0045 % .2583 % .0059 % .0081 % .0074 .0047 1.0000 .1070 .1081 .9573 .0022 .0022 .1280 .0029 .0040 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION (S) ; ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC, CAUDAL LOBES TO DIAPHRAGM: MULTIPLE RED, TAN, FIBROUS ADHESIONS; COLLECTED INTACT GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -VACUOLATION, HEPATOCELLULAR,-SLIGHT, MULTI-FOCAL THYMUS <TH) : -ATROPHY,-MINIMAL SPINAL CORD (SC) : -PIGMENT, NEURONAL,-SLIGHT 003497 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 54 ANIMAL NUMBER: 105550 SEX: FEMALE DOSE GROUP: 2 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2820.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 6:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL INFORMATION (XX! : >NOTE:GALLBLADDER WEIGHT IS 0.6200 GRAMS BILE VOLUME IS 1.2000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE! , MARROW, FEMUR (FM) , MARROW, STERNUM (SB), BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE. SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) ,VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) 003498 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 55 ANIMAL NUMBER: 105532 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2550.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 6:47 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0 ) RT THYROID/PARA (TT1 ) .3230 .2160 60.2360 5.0310 4.9920 58.3190 .0630 .0870 4.5080 .1150 .1020 .0127 % .0085 % 2.3622 % .1973 % .1958 % 2.2870 % .0025 % .0034 % .1768 % .0045 % .0040 % .0054 .0036 1.0000 .0835 .0829 .9682 .0010 .0014 .0748 .0019 .0017 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY lu ng (LU) : -REP FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK RED PINPOINT FOCI GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:GALLBLADDER WEIGHT IS 0.4650 GRAMS BILE VOLUME IS 1.2000 ML LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL THYMUS (TH) : -ATROPHY, -SEVERE SPINAL CORD (SC) : -PIGMENT, NEURONAL,-MODERATE 003499 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295> IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 56 ANIMAL NUMBER: 105532 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2550.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 6:47 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE), MARROW, FEMUR <FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM! , SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL), CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (API THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER (LI) 003500 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295> IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 57 ANIMAL NUMBER: 105538 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3200.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 10:25 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OV0) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1 ) .3850 .2630 55.6900 5.8390 5.3480 59.5780 .2420 .1690 4.8070 .1350 .1480 .0120 % .0082 % 1.7403 % .1825 % .1671 % 1.8618 % .0076 % .0053 % .1502 % .0042 % .0046 % .0069 .0047 1.0000 .1048 .0960 1.0698 .0043 .0030 .0863 .0024 .0027 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -DARK FOCUS (I) /AREA (S) ; ALL LOBES, DIFFUSE: MULTIPLE BLACK PINPOINT FOCI SPLEEN (SP) : -LIGHT FOCUS(I)/AREA(S); DIFFUSE: MULTIPLE GRAY AREAS, UP TO 1.2 X 0.7 CM LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL SPLEEN (SP) : >N0T REQUIRED TO BE EXAMINED FOR ANIMAL THYMUS (TH) : -ATROPHY,-SLIGHT SPINAL CORD (SC) : -PIGMENT, NEURONAL,-MINIMAL CECUM (CE) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL 03501 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 58 ANIMAL NUMBER: 105538 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3200.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 10:25 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER NECROPSY OBSERVATIONS CECUM (CE) : -RED FOCUS(I)/AREA(S); SEROSAL SURFACE: MULTIPLE DARK RED FOCI, UP TO 0.5 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:GALLBLADDER WEIGHT IS 0.5060 GRAMS BILE VOLUME IS 1.6000 ML (CONTINUED) HISTOPATHOLOGY THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , LIVER (LI), GALLBLADDER (GB) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID <TY), PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) 003502 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covane 6329-223 3M T-6295.7 PAGE: 59 ANIMAL NUMBER: 105545 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2460.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TTO ) RT THYROID/PARA (TT1 ) .2640 .2060 55.6590 5.4870 5.2040 52.4930 .2040 .1400 4.1150 .2030 .1190 .0107 % .0084 % 2.2626 .2230 % .2115 % 2.1339 % .0083 % .0057 % .1673 % .0083 % .0048 % .0047 .0037 1.0000 .0986 .0935 .9431 .0037 .0025 .0739 .0036 .0021 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS -NO MACROSCOPIC LESIONS LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -DEGENERATION/NECROSIS, HEPATOCELLULAR,-MINIMAL, MULTI-FOCAL THYMUS (TH) : -CYST, -PRESENT -ATROPHY,-MINIMAL SPINAL CORD (SC) : -PIGMENT, NEURONAL,-MINIMAL 003503 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS.-T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 60 ANIMAL NUMBER: 105545 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2460.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 7:31 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE . PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL INFORMATION (XX) : >NOTE :GALLBLADDER WEIGHT IS 0.7210 GRAMS BILE VOLUME IS 1.4000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , LUNG (LU) , HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP), THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) ,CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY(OV) , VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) 003504 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 61 ANIMAL NUMBER: 105548 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2865.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0 ) RT THYROID/PARA (TT1 ) .3880 .2850 61.9790 6.0250 6.0670 57.7670 .2400 .1510 5.0690 .1640 .1640 .0135 % .0099 % 2.1633 % .2103 % .2118 % 2.0163 % .0084 % .0053 % .1769 % .0057 % .0057 % .0063 .0046 1.0000 .0972 .0979 .9320 .0039 .0024 .0818 .0026 .0026 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION (S) ; ADHERED TO PLEURA, DIAPHRAGM, PERICARDIUM, AND EACH OTHER: MULTIPLE GRAY, FIBROUS ADHESIONS; COLLECTED INTACT CECUM (CE) : -RED FOCUS(I)/AREA(S); DIFFUSE: MULTIPLE DARK RED FOCI, UP TO 0.5 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MODERATE, FOCAL THYMUS (TH) : -ATROPHY,-MODERATELY SEVERE SPINAL CORD (SC) : -PIGMENT, NEURONAL,-SLIGHT CECUM (CE) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL 003505 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS.-T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 62 ANIMAL NUMBER: 105548 SEX: FEMALE DOSE GROUP: 3 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2865.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 11:00 PROSECTOR: STEVE VAN ADESTINE ' RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE:GALLBLADDER WEIGHT IS 0.7810 GRAMS BILE VOLUME IS 2.6000 ML THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT) , LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP), THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SMI, SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DO), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) 003506 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 62 ANIMAL NUMBER: 105534 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL iSACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT : 2500.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 8:14 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S . HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .3290 .2270 54.3510 4.8280 4.9920 75.5500 .1600 .1480 4.4740 .1370 .1210 .5260 2.0000 mL .0132 % .0091 % 2.1740 % .1931 % .1997 % 3.0220 % .0064 % .0059 % .1790 % .0055 % .0048 % .0061 .0042 1.0000 .0888 .0918 1.3900 .0029 .0027 .0823 .0025 .0022 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -DARK FOCUS(I)/AREA(S); ALL LOBES: MULTIPLE DARK BROWN PINPOINT FOCI -LIGHT FOCUS (I)/AREA(S>j RIGHT AND LEFT CAUDAL LOBES: MULTIPLE TAN AREAS, UP TO 0.2 X 0.1 CM BONE, FEMUR (FE) : -GROWTH PLATE OPEN,-MODERATE KIDNEY (KD) : -MINERALIZATION, MEDULLA,-MINIMAL LUNG (LU) : -HYPERPLASIA, LYMPHOCYTIC, PERIBRONCHIOLAR/PERIVASCULAR,MINIMAL -INFILTRATE, MACROPHAGE, ALVEOLAR,-MINIMAL LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -HYPERTROPHY, HEPATOCELLULAR,-SLIGHT, DIFFUSE o CO Co/T <1 757 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 63 ANIMAL NUMBER: 105534 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2500.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 8:14 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN CECUM (CE) : -DARK FOCUS(I)/AREA(S); SEROSAL SURFACE AND LUMEN, DIFFUSE: MULTIPLE DARK BROWN, SLIGHTLY RAISED AREAS, UP TO 0.5 X 0.2 CM; COLLECTED ON ROUTINE SECTION COLON (CO) : -DARK FOCUS(I)/AREA(S); SEROSAL SURFACE AND LUMEN, DIFFUSE: MULTIPLE DARK BROWN, SLIGHTLY RAISED FOCI, UP TO 0.3 CM IN DIAMETER; COLLECTED ON ROUTINE SECTION ADIPOSE TISSUE (AT) : -RAISED FOCUS (I)/AREA(S) ; MESENTERY, DIFFUSE: MULTIPLE TAN FOCI, UP TO 0.3 CM IN DIAMETER (CAP 29) LIVER (LI) : -VACUOLATION, HEPATOCELLULAR,-SLIGHT, DIFFUSE THYMUS (TH) : -ATROPHY,-MODERATE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT ADRENAL, CORTEX (AC) : UNREMARKABLE DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-MODERATE JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT CECUM (CE) : -PARASITISM,-PRESENT COLON (CO) : -PARASITISM, INTRAMUSCULAR, -PRESENT URINARY BLADDER (UB) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL OVARY (OV) : -MINERALIZATION, -MINIMAL ADIPOSE TISSUE (AT) : -LYMPHOID TISSUE,-PRESENT O CO CA 00 758 APPENDIX 5 Individual Anatomie Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 64 ANIMAL NUMBER: 105534 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH:1: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2500.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 8:14 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW. FEMUR (FM) , MARROW, STERNUM <SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU) , PANCREAS (PA) , JEJUNUM (JE) , ILEUM (IL) , RECTUM (RE) , SKIN (SK) , MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES) , THYROID (TY) , PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), PANCREAS (PA), RECTUM (RE), SKIN (SK) , MAMMARY, FEMALE (MF) , UTERUS (UT) , VAGINA (VA) , CERVIX (CV) 003509 759 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 65 ANIMAL NUMBER: 105536 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3185.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:56 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADl) BRAIN (BR) LF KIDNEY (KD0) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TT0) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .3290 .2360 58.3990 6.9900 7.4110 93.8600 .1010 .1360 4.7900 .1910 .2400 .6650 2.6000 mL .0103 % .0074 % 1.8336 % .2195 % .2327 % 2.9469 % .0032 .0043 % .1504 .0060 % .0075 .0056 .0040 1.0000 .1197 .1269 1.6072 .0017 .0023 .0820 .0033 .0041 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -DARK FOCUS(I)/AREA(S); ALL LOBES, DIFFUSE: MULTIPLE PINPOINT BLACK FOCI LIVER (LI) : -MOTTLED; ALL LOBES: BROWN AND TAN MARROW, FEMUR (FM) : SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-MINIMAL LUNG (LU) : UNREMARKABLE LIVER (LI) : -HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR,-MODERATE -VACUOLATION, HEPATOCELLULAR, CENTRILOBULAR,-MODERATELY SEVERE oo CO C/l op 760 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 66 ANIMAL NUMBER: 105536 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3185.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:56 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY ADRENAL, CORTEX (AC) : -DIFFUSELY DARK; BILATERAL: BROWN GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL THYMUS (TH) -CYST,-PRESENT -ATROPHY,-MODERATELY SEVERE TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-SLIGHT THYROID (TY) : -CYST, ULTIMOBRANCHIAL,-PRESENT ADRENAL, CORTEX (AC) : -HYPERTROPHY, CORTICAL CELL,-MINIMAL -PIGMENT,-SLIGHT SAL1V GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL SPINAL CORD (SC) : -PIGMENT, NEURONAL,-MODERATE DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT ILEUM (IL) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT CECUM (CE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT UTERUS (UT) : -AMYLOID,-MODERATE OVARY (OV) : -AMYLOID, -MODERATE -ONE EXAMINED,-PRESENT 003511 776611 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 67 ANIMAL NUMBER: 105536 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/25/99 STUDY DAY OF DEATH: 184 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 3185.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/99 9:56 PROSECTOR: STEVE VAN ADESTINE RECORDER: TODD ACKER POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: TODD ACKER NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES) , THYROID (TY), PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: BONE, FEMUR (FE) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , KIDNEY (KD) , HEART (HT) , SPLEEN (SP) . LN, MESENTERIC (MS), ESOPHAGUS (ES) , PARATHYROID (PT) , ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), MUSCLE, SKELETAL (SM), NERVE, SCIATIC (SN), STOMACH, GL (ST), PANCREAS (PA), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), VAGINA (VA), CERVIX (CV) 003512 762 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 68 ANIMAL NUMBER: 105540 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2700..0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 10:20 PROSECTOR:: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OV0) RT OVARY (OVl) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .3440 .2550 56.3190 5.2090 4.8440 63.0760 .1400 .1410 4.4510 .2480 .2540 .5650 1.6000 mL .0127 % .0094 % 2.0859 % .1929 % .1794 % 2.3361 % .0052 % .0052 % .1649 % .0092 % .0094 % .0061 .0045 1.0000 .0925 .0860 1.1200 .0025 .0025 .0790 .0044 .0045 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -RED FOCUS (I) /AREA(S) ; RIGHT CAUDAL AND APICAL LOBES MULTIPLE DARK RED INDISTINCT AREAS MARROW, FEMUR (FM) : >SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFILTRATE, MACROPHAGES, PIGMENTED, PERIVASCULAR,-SLIGHT LUNG (LU) : -HEMORRHAGE,-MODERATE LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR,-SLIGHT THYMUS (TH) : -CYST,-PRESENT 003513 763 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 69 ANIMAL NUMBER: 105540 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2700.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 10:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY SKIN (SK) : -ALOPECIA-FOCAL; RIGHT DORSAL THORACIC REGION: 0.3 X 2.5 CM (CAP 29) GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS THYMUS (TH) : -ATROPHY,-SLIGHT TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL THYROID (TY) : -CYST, ULTIMOBRANCHIAL,-PRESENT AORTA (AO) : -PROLIFERATION, INTIMAL,-MODERATE MUSCLE, SKELETAL (SM) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL DUODENUM (DU) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT SKIN (SK) : -HAIR FOLLICLES, DECREASED,-MODERATE 003514 764 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 70 ANIMAL NUMBER: 105540 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2700.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 10:20 PROSECTOR: STEVE VAN ADESTINE RECORDER: JOHN S. HALFORD POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: JOHN S. HALFORD THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT), LIVER (LI), GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV), ADIPOSE TISSUE (AT), LN, TRACHEOBRON (TB), LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: BONE, FEMUR (FE) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , KIDNEY (KD) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP), LN, MESENTERIC (MS), ESOPHAGUS (ES) , PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , PITUITARY (PI), SALIV GL, MANDIB (SG) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB) , UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV) G 03515 765 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 71 ANIMAL NUMBER: 105551 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH:: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT : 2230..0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:43 PROSECTOR:: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST--FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA ORGAN NAME ABSOLUTE ORGAN WEIGHT (GRAMS) ORGAN WEIGHT RELATIVE TO BODY WEIGHT (%) ORGAN TO BRAIN WEIGHT RATIO ORGAN STATUS LEFT ADRENAL (ADO) RIGHT ADRENAL (ADI) BRAIN (BR) LF KIDNEY (KDO) RT KIDNEY (KD1) LIVER (LI) LF OVARY (OVO) RT OVARY (OV1) PANCREAS (PA) LF THYROID/PARA (TTO) RT THYROID/PARA (TT1) GALLBLADDER (GB) BILE(VOLUME) (BI) .3850 .2960 59.3140 6.0280 5.9040 68.7130 .2350 .1740 3.7750 .1730 .1630 .6040 1.8000 mL .0173 % .0133 % 2.6598 % .2703 .2648 % 3.0813 % .0105 % .0078 % .1693 .0078 % .0073 % .0065 .0050 1.0000 .1016 .0995 1.1585 .0040 .0029 .0636 .0029 .0027 WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN WEIGHT TAKEN NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -RED FOCUS (I)/AREA(S); ALL LOBES: MULTIPLE DARK RED FOCI, PINPOINT AND UP TO 1 MM IN DIAMETER MARROW, FEMUR (FM) : SECTION EXAMINED; TISSUE NOT PRESENT BRAIN (BR) : -INFLAMMATION, LYMPHOHISTIOCYTIC,-MINIMAL KIDNEY (KD) : -MINERALIZATION, MEDULLA, -MINIMAL LUNG (LU) : UNREMARKABLE LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL, MULTI-FOCAL -HYPERTROPHY, HEPATOCELLULAR, CENTRILOBULAR,-SLIGHT 003516 766 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 72 ANIMAL NUMBER: 105551 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2230.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA NECROPSY O B S E R V A T I O N S (CONTINUED) HISTOPATHOLOGY SKIN (SK) : -ALOPECIA-DIFFUSE; ALL FOUR LIMBS: HAIRCOAT THIN; COLLECTED GENERAL COMMENT (GC) : -BONE MARROW SMEAR TAKEN -EYES - DAVIDSONS GENERAL INFORMATION (XX) : >NOTE :>ANIMAL APPEARS TO BE IN ESTROUS GALLBLADDER (GB) : -INFILTRATE, LYMPHOHISTIOCYTIC, -MINIMAL TRACHEA (TR) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL THYROID (TY) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL SALIV GL, MANDIB (SG) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL MUSCLE, SKELETAL (SM) : -PARASITES, CYST,-PRESENT SPINAL CORD (SC) : -PIGMENT, NEURONAL,-MODERATE JEJUNUM (JE) : -INFILTRATE, MACROPHAGE, PIGMENTED,-SLIGHT SKIN (SK) : -HAIR FOLLICLES, DECREASED,-SLIGHT 003517 767 APPENDIX 5 Individual Anatomic Pathology Data Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 73 ANIMAL NUMBER: 105551 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, TERMINAL SACRIFICE DATE OF DEATH: 02/26/99 STUDY DAY OF DEATH: 185 STUDY WEEK OF DEATH: 27 TERMINAL BODY WEIGHT: 2230.0 GRAMS DATE AND TIME OF NECROPSY: 02/26/99 7:43 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: ROBERT LEEDLE WEIGHER: MICHELE ZIMA THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD) , HEART (HT), LIVER (LI), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL) , CECUM (CE) , COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF) , URINARY BLADDER (UB) , UTERUS (UT) , OVARY (OV) , VAGINA (VA) , CERVIX (CV) , ADIPOSE TISSUE (AT) , LN, TRACHEOBRON (TB) , LN, ANT MES/PANC (AP) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: BONE, FEMUR (FE) , MARROW, STERNUM (SE) , BONE, STERNUM (SB), EYE (EY) , HEART (HT) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS) , ESOPHAGUS (ES) , PARATHYROID (PT) . ADRENAL, CORTEX (AC) , ADRENAL, MEDULLA (MA) , AORTA (AO) , PITUITARY (PI), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV), VAGINA (VA), CERVIX (CV) 003518 768 APPENDIX 5 Individual Anatomic Pathology Data Recovery Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT !PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE : 1 ANIMAL NUMBER: 105511 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, FIRST POST-RECOV SAC DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 4240.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/00 7:56 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE 2IMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA *** ORGAN WEIGHTS WERE NOT RECORDED *** NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -NO MACROSCOPIC LESIONS LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC.-SLIGHT THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: LIVER (LI), BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD), LUNG (LU), HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, MALE (MM), URINARY BLADDER (UB), PROSTATE (PR), SEMINAL VESICLES (SV) , EPIDIDYMIDES (EP), TESTIS (TE), CAVITY, THORACIC (TA) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER, BIOPSY (LI0) 003519 APPENDIX 5 Individual Anatomic Pathology Data Recovery Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTAHE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOHOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 2 ANIMAL NUMBER: 105522 SEX: MALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, FIRST POST-RECOV SAC DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 4350.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/00 8:35 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA `** ORGAN WEIGHTS WERE NOT RECORDED *** NECROPSY OBSERVATIONS HISTOPATHOLOGY LUNG (LU) : -ADHESION( S ) ; ALL LOBES TO EACH OTHER, PLEURA, PERICARDIAL SAC AND CAUDAL LOBES TO DIAPHRAGM: MULTIPLE TAN FIBROUS ADHESIONS CAVITY, THORACIC (TA) : -NODULE(S); WITHIN ADHESIONS: MULTIPLE TAN AND FIRM NODULES, UP TO 0.3 CM IN DIAMETER LIVER, BIOPSY (LI0) : -PIGMENT, HEPATOCELLULAR,-SLIGHT LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCY'TIC,-MODERATE -PIGMENT, HEPATOCELLULAR,-SLIGHT -HYPERPLASIA, BILE DUCT,-MODERATE -INFLAMMATION, EOSINOPHILIC, PERI-BILE DUCT,-MODERATE LUNG (LU) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: LIVER (LI), BONE, FEMUR (FE), MARROW, FEMUR (FM), MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY), BRAIN (BR), KIDNEY (KD) , HEART (HT) , GALLBLADDER (GB) , SPLEEN (SP) , THYMUS (TH) , LN, MESENTERIC (MS), TRACHEA (TR) , ESOPHAGUS (ES) , THYROID (TY), PARATHYROID (PT) , ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA) , AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM), SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK) , MAMMARY, MALE (MM), URINARY BLADDER (UB) , PROSTATE (PR), SEMINAL VESICLES (SV), EPIDIDYMIDES (EP) , TESTIS (TE), GENERAL COMMENT (GC) APPENDIX 5 Individual Anatomic Pathology Data Recovery Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance 6329-223 3M T-6295.7 PAGE: 3 ANIMAL NUMBER: 105533 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, FIRST POST-RECOV SAC DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 2535.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/00 8:58 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA *** ORGAN WEIGHTS WERE NOT RECORDED *** NECROPSY OBSERVATIONS HISTOPATHOLOGY LIVER (LI) : -ADHESION(S) ; DIAPHRAGMATIC SURFACE OF RIGHT MEDIAN LOBE TO DIAPHRAGM: SINGLE TAN, FIBROUS LINEAR. AREA, 2.0 CM IN LENGTH GALLBLADDER (GB) : >NOTE :>NO BILE AVAILABLE FOR SPECIAL PROCEDURE LIVER (LI) : -FIBROSIS, CAPSULAR,-SLIGHT GALLBLADDER (GB) : >NOT REQUIRED TO BE EXAMINED FOR ANIMAL THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: BONE, FEMUR (FE) , MARROW, FEMUR (FM) , MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY) , BRAIN (BP.), KIDNEY (KD) , LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG), MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SN), STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE) , ILEUM (IL), CECUM (CE) , COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV),VAGINA (VA), CERVIX (CV), GENERAL COMMENT (GC), CAVITY, THORACIC (TA) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER, BIOPSY (LI0) 003521 APPENDIX 5 Individual Anatomic Pathology Data Recovery Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS Covance G329-223 3M T-6295.7 PAGE: 4 ANIMAL NUMBER: 105542 SEX: FEMALE DOSE GROUP: 4 SACRIFICE STATUS: SCHEDULED, FIRST POST-RECOV SAC DATE OF DEATH: 02/25/00 STUDY DAY OF DEATH: 549 STUDY WEEK OF DEATH: 79 TERMINAL BODY WEIGHT: 3705.0 GRAMS DATE AND TIME OF NECROPSY: 02/25/00 9:23 PROSECTOR: KEVIN BILLINGS RECORDER: MICHELE ZIMA POST-FIX WEIGHER: NOT AVAILABLE PATHOLOGIST: AS ASSIGNED WEIGHER: MICHELE ZIMA *** ORGAN WEIGHTS WERE NOT RECORDED *** NECROPSY OBSERVATIONS HISTOPATHOLOGY GENERAL COMMENT (GC) : -NO MACROSCOPIC LESIONS LIVER (LI) : -INFILTRATE, LYMPHOHISTIOCYTIC,-MINIMAL THE FOLLOWING ORGANS WERE UNREMARKABLE AT NECROPSY: LIVER (LI), BONE, FEMUR (FE) , MARROW. FEMUR IFM) , MARROW, STERNUM (SE), BONE, STERNUM (SB), EYE (EY) , BRAIN (BR) , KIDNEY (KD), LUNG (LU), HEART (HT), GALLBLADDER (GB), SPLEEN (SP), THYMUS (TH), LN, MESENTERIC (MS), TRACHEA (TR), ESOPHAGUS (ES), THYROID (TY), PARATHYROID (PT), ADRENAL, CORTEX (AC), ADRENAL, MEDULLA (MA), AORTA (AO), PITUITARY (PI), SALIV GL, MANDIB (SG) , MUSCLE, SKELETAL (SM) , SPINAL CORD (SC), NERVE, SCIATIC (SH) , STOMACH, GL (ST), DUODENUM (DU), PANCREAS (PA), JEJUNUM (JE), ILEUM (IL), CECUM (CE), COLON (CO), RECTUM (RE), SKIN (SK), MAMMARY, FEMALE (MF), URINARY BLADDER (UB), UTERUS (UT), OVARY (OV),VAGINA (VA), CERVIX (CV), CAVITY, THORACIC (TA) THE FOLLOWING TISSUES WERE UNREMARKABLE AT MICROSCOPIC EXAMINATION: LIVER, BIOPSY (LI0) 003522 APPENDIX 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Note: This appendix contains information supplied by Ani Lytics Inc. 003523 769 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day -50 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN ftg/dL Group : Male 1 Dose Level : 0 105508 105517 105519 105520 105526 105527 54.69 49.55 64.74 47.30 60.37 50.69 14.54 3.04 6.12 10.74 0.09 6.48 MEAN S.D. N 54.56 6.785 6 6.84 5.199 6 Group: Male 2 Dose Level: 0.03 105514 105515 105516 105521 71.04 38.63 58.36 58.05 1.18 9.81 0.34 14.26 MEAN S.D. N 56.52 13.374 4 6.40 6.767 4 Group: Male 3 Dose Level: 0.15 105505 105510 105518 105523 105524 105528 48.00 38.05 50.92 56.98 62.46 63.18 3.04 0.41 3.77 4.38 1.02 0.97 MEAN S.D. N 53.27 9.606 6 2.27 1.674 6 Dosage Unit: mg/kg/day 29.48 51.76 31.21 30.92 31.69 43.40 20.01 54.86 17.51 39.76 27.63 24.47 0.00 0.00 0.00 0.00 0.00 0.00 36.41 9.077 6 30.71 14.158 6 0.00 0.000 6 Dosage Unit: mg/kg/day 38.90 27.91 32.30 59.78 51.37 17.75 29.41 62.35 0.00 0.00 0.00 0.00 39.72 14.114 4 40.22 20.296 4 0.00 0.000 4 Dosage Unit: mg/kg/day 43.24 23.74 53.56 43.26 30.26 26.50 30.43 26.96 28.80 39.35 26.55 18.67 0.00 0.00 0.00 0.00 0.00 0.00 36.76 11.692 6 28.46 6.698 6 0.00 0.000 6 0.44 0.98 0.92 2.11 0.86 3.34 1.44 1.084 6 1.44 1.04 1.13 1.45 1.27 0.211 4 1.20 0.60 1.67 0.00 0.62 1,04 0.86 0.578 6 89.59 125.67 82.21 122.59 132.25 102.72 109.17 20.673 6 133.26 83.16 138.37 130.08 121.22 25.600 4 122.64 115.95 124.80 162.12 117.52 113.68 126.12 18.122 6 4.96 3.25 5.11 3.13 3.80 3.52 3.96 0.864 6 6.14 3.32 8.91 4.56 5.73 2.412 4 5.60 3.48 4.29 6.48 4.28 4.49 4.77 1.079 6 003524 770 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day -50 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING JAJ/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Male 4 Dose Level: 0.75 105506 105507 105509 105511 105512 105522 46.92 41.20 65.60 48.27 49.15 44.81 3.31 21.45 2.21 18.86 0.29 12.56 MEAN S.D. N 49.33 8.464 6 9.78 9.117 6 Group: Female 1 Dose Level: 0 105529 105530 105531 105535 105544 105549 68.63 64.90 55.89 51.86 55.61 52.20 0.49 0.03 0.36 0.38 0.38 0.04 MEAN S.D. N 58.18 6.956 6 0.28 0.195 6 Group : Female 2 Dose Level : 0.03 105537 105541 105547 105550 73.24 82.66 71.82 46.90 0.19 0.66 0.16 0.29 MEAN S.D. N 68.66 15.280 4 0.33 0.230 4 Dosage Unit: mg/kg/day 26.45 49.83 30.80 32.75 38.12 49.93 29.18 33.79 24.47 46.01 22.90 48.77 0.00 0.00 0.00 0.00 0.00 0.00 37.98 9.951 6 34.19 10.950 6 0.00 0.000 6 Dosage Unit: mg/kg/day 48.75 48.53 53.05 50.13 37.23 50.33 38.12 32.43 61.53 31.55 26.87 27.55 0.00 0.00 0.00 0.00 0.00 0.00 48.0 5.519 6 36.34 12.984 6 0.00 0.000 6 Dosage Unit: mg/kg/day 91.05 60.36 55.87 50.49 129.22 42.73 39.96 46.09 0.00 0.00 0.00 0.00 64.44 18.191 4 64.50 43.219 4 0.00 0.000 4 0.08 1.45 1.81 0.42 0.60 1.66 1.00 0.726 6 0.75 0.74 0.30 1.14 2.67 0.69 1.05 0.838 6 0.00 0.65 0.79 0.88 0.58 0.398 4 148.18 113.67 112.11 152.20 162.79 151.90 140.14 21.669 6 91.26 153.02 45.26 128.93 96.13 87.95 100.43 37.095 6 158.33 140.97 115.35 107.01 130.42 23.561 4 4.90 4.66 5.14 4.13 4.63 3.36 4.47 0.639 6 5.25 8.79 16.59 3.80 4.13 4.43 7.17 4.963 6 6.80 6.99 4.66 4.27 5.68 1.414 4 003525 771 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day -50 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING /AJ/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN /ig/dL Group : Female 3 Dose Level: 0.15 105532 105538 105539 105545 105548 105552 56.59 51.32 66.59 63.69 65.26 49.09 0.13 0.23 0.34 0.25 0.45 0.33 MEAN S.D. N 58.76 7.502 6 0.29 0.110 6 Group: Female 4 Dose Level: 0.75 105533 105534 105536 105540 105542 105551 58.99 59.49 51.68 46.17 87.39 67.04 0.35 0.05 0.29 0.15 0.63 0.38 MEAN S.D. N 61.79 14.438 6 0.31 0.201 6 Dosage Unit: mg/kg/day 51.67 52.69 129.12 176.45 63.53 23.32 35.53 35.81 82.62 132.50 47.80 15.96 0.00 0.00 0.00 0.00 0.00 0.00 82.80 57.794 6 58.37 42.484 6 0.00 0.000 6 Dosage Unit: mg/kg/day 96.99 42.90 47.76 54.58 39.07 86.86 64.39 34.98 46.31 88.38 31.81 107.99 0.00 0.00 0.00 0.00 0.00 0.00 61.36 24.447 6 62.31 30.672 6 0.00 0.000 6 4.46 0.00 1.48 0.67 0.00 1.52 1.36 1.663 6 2.10 0.98 0.17 1.51 0.32 0.21 0.88 0.795 6 64.50 137.04 117.92 135.57 104.23 71.94 105.20 31.182 6 101.63 97.38 124.27 126.16 109.29 95.16 108.98 13.480 6 5.49 3.21 5.68 5.05 4.24 6.35 5.00 1.123 6 4.25 4.94 5.78 5.23 6.44 5.78 5.40 0.766 6 003526 772 ANIMAL NUMBER CORTISOL pg/dL Appendix 6 Summary and Individual Blood Hormone Determination Day -40 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT <PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //u/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN /ig/dL Group: Male 1 Dose Level : 0 105508 105517 105519 105520 105526 105527 57.43 43.65 71.52 52.42 84.79 79.36 3.30 2.35 0.37 11.10 0.21 5.72 MEAN S.D. N 64.86 16.197 6 3.84 4.098 6 Group : Male 2 Dose Level: 0.03 105514 105515 105516 105521 79.55 67.38 87.16 62.83 1.10 5.86 0.19 9.82 MEAN S.D. N 74.23 11.141 4 4.24 4.473 4 Group: Male 3 Dose Level: 0.15 105505 105510 105518 105523 105524 105528 50.93 77.83 67.52 61.48 63.60 72.30 4.07 0.53 0.93 1.81 0.68 6.04 MEAN S.D. N 65.61 9.320 6 2.34 2.235 6 Dosage Unit: mg/kg/day 23.93 42.46 32.19 46.29 26.36 33.96 11.61 29.34 19.63 35.48 20.87 34.93 0.00 0.00 0.00 0.00 0.00 0.00 34.20 8.780 6 25.31 9.507 6 0.00 0.000 6 Dosage Unit: mg/kg/day 35.50 21.00 23.13 63.80 4.64 28.82 23.58 49.29 0.00 0.00 0.00 0.00 35.86 19.695 4 26.58 18.359 4 0.00 0.000 4 Dosage Unit: mg/kg/day 45.97 31.51 45.46 34.64 31.45 28.17 18.34 17.29 25.93 27.49 16.37 13.10 0.00 0.00 0.00 0.00 0.00 0.00 36.20 7.651 6 19.75 5.688 6 0.00 0.000 6 0.26 0.50 0.56 0.34 1.13 0.95 0.62 0.345 6 1.16 0.21 0.94 1.12 0.86 0.442 4 0.85 0.69 1.87 0.00 0.75 0.00 0.69 0.689 6 113.08 104.32 122.61 137.32 154.19 99.03 121.76 20.932 6 140.65 97.32 127.13 120.13 121.31 18.118 4 130.66 104.25 145.93 136.56 107.44 111.71 122.76 17.258 6 4.24 2.99 5.26 3.54 3.86 4.72 4.10 0.819 6 6.28 4.57 5.92 6.34 5.78 0.826 4 6.01 3.94 4.76 5.13 4.14 3.63 4.60 0.881 6 003527 773 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day -40 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING /AJ/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Male 4 Dose Level: 0.75 105506 105507 105509 105511 105512 105522 49.42 44.53 82.95 75.12 81.05 58.08 1.27 7.01 1.03 16.78 0.14 10.11 MEAN S.D. N 65.19 16.683 6 6.06 6.565 6 Group: Female 1 Dose Level: 0 105529 105530 105531 105535 105544 105549 81.80 70.50 85.44 85.08 89.58 66.75 0.41 0.01 0.25 0.37 0.44 0.15 MEAN S.D. N 79.86 9.123 6 0.27 0.168 6 Group: Female 2 Dose Level: 0.03 105537 105541 105547 105550 79.24 108.45 67.50 89.13 0.17 0.77 0.19 0.23 MEAN S.D. N 86.08 17.337 4 0.34 0.288 4 Dosage Unit: mg/kg/day 28.98 32.46 27.21 37.12 37.24 52.20 21.20 30.79 14.40 42.06 21.98 49.26 0.00 0.00 0.00 0.00 0.00 0.00 35.87 8.991 6 29.95 13.432 6 0.00 0.000 6 Dosage Unit: mg/kg/day 42.94 90.55 52.80 79.48 72.70 50.29 31.46 65.47 91.87 52.46 46.44 34.57 0.00 0.00 0.00 0.00 0.00 0.00 64.79 18.833 6 53.71 22.407 6 0.00 0.000 6 Dosage Unit: mg/kg/day 59.21 116.25 40.43 62.40 48.11 90.73 67.42 61.31 0.00 0.00 0.00 0.00 69.57 32.593 4 66.89 17.818 4 0.00 0.000 4 0.82 1.92 0.57 0.59 0.25 1.54 0.95 0.643 6 0.00 0.00 0.11 0.73 2.16 0.69 0.62 0.827 6 0.01 0.26 1.14 0.93 0.59 0.536 4 157.93 88.90 116.45 188.61 169.66 158.85 146.73 36.914 6 75.62 128.68 73.71 125.42 106.71 76.27 97.74 25.813 6 131.29 132.70 86.87 88.98 109.96 25.465 4 5.12 6.69 4.44 4.90 3.80 3.42 4.73 1.157 6 4.60 5.65 4.93 4.02 3.73 4.49 4.57 0.680 6 6.03 6.63 4.59 2.99 5.06 1.624 4 00352S 774 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day -40 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRI IODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Female 3 Dose Level: 0.15 105532 105538 105539 105545 105548 105552 63.15 70.84 68.60 64.50 67.75 53.55 0.06 0.08 0.35 0.13 0.66 0.40 MEAN S.D. N 64.73 6.148 6 0.28 0.234 6 Group: Female 4 Dose Level: 0.75 105533 105534 105536 105540 105542 105551 69.41 60.42 66.67 65.40 92.90 64.20 0.73 0.28 0.15 0.08 0.32 0.42 MEAN S.D. N 69.83 11.681 6 0.33 0.230 6 Dosage Unit: mg/kg/day 33.18 53.04 492.12 114.49 75.11 45.64 29.09 40.85 272.75 81.43 55.06 48.94 0.00 0.00 0.00 0.00 0.00 0.00 135.60 176.980 6 88.02 92.174 6 0.00 0.000 6 Dosage Unit: mg/kg/day 90.70 60.87 66.36 35.46 59.88 76.86 76.17 66.05 59.95 33.64 43.92 82.48 0.00 0.00 0.00 0.00 0.00 0.00 65.02 18.541 6 60.37 18.740 6 0.00 0.000 6 1.38 0.00 1.33 0.17 0.00 2.13 0.84 0.901 6 0.00 0.13 0.04 1.39 1.02 0.24 0.47 0.587 6 95.64 114.53 114.65 106.43 116.19 82.66 105.02 13.401 6 108.13 81.98 114.01 119.54 151.57 108.31 113.92 22.513 6 4.36 3.19 6.09 4.61 4.02 4.69 4.49 0.953 6 4.03 4.39 5.41 4.36 7.00 5.21 5.07 1.087 6 003529 775 ANIMAL NUMBER CORTISOL fig/6L Appendix 6 Summary and Individual Blood Hormone Determination Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING /IU/mL TOTAL TRI IODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN ftg/h Group: Male 1 Dose Level : 0 105508 105517 105519 105520 105526 105527 59.85 50.40 74.30 55.75 72.92 67.71 2.60 2.25 0.40 3.11 0.48 2.43 MEAN S.D. N 63.49 9.676 6 1.88 1.151 6 Group: Male 2 Dose Level : 0.03 105514 105515 105516 105521 81.35 77.44 50.15 61.80 1.41 1.40 0.31 3.03 MEAN S.D. N 67.69 14.422 4 1.54 1.121 4 Group: Male 3 Dose Level: 0.15 105505 105510 105518 105523 105524 105528 58.10 68.33 54.45 66.60 91.70 69.75 5.40 0.38 1.06 2.36 1.11 0.74 MEAN S.D. N 68.16 13.025 6 1.84 1.867 6 Dosage Unit : mg/kg/day 18.82 35.11 25.09 29.31 22.23 29.56 27.46 41.06 31.24 51.38 21.97 26.74 0.00 0.00 0.00 0.00 0.00 0.00 26.69 5.838 6 33.31 10.926 6 0.00 0.000 6 Dosage Unit: mg/kg/day 31.71 26.17 29.91 40.47 43.75 32.63 35.52 57.63 0.00 0.00 0.00 0.00 32.07 6.060 4 42.38 11.204 4 0.00 0.000 4 Dosage Unit: mg/kg/day 30.42 25.88 26.53 25.62 23.61 22.60 27.04 22.77 39.19 37.12 32.22 21.66 0.00 0.00 0.00 0.00 0.00 0.00 25.78 2.718 6 30.00 7.358 6 0.00 0.000 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000 6 0.00 0.00 0.00 0.00 0.00 0.000 4 0.00 0.00 0.32 0.00 0.00 0.00 0.05 0.131 6 101.15 112.05 112.26 115.75 127.37 92.95 110.26 11.939 6 120.88 126.21 97.87 105.02 112.50 13.269 4 117.98 114.00 149.51 140.05 86.43 100.82 118.13 23.608 6 3.82 3.11 4.39 2.89 2.83 3.90 3.49 0.637 6 5.30 2.51 5.85 4.16 4.46 1.475 4 5.76 3.90 4.50 6.33 3.74 3.55 4.63 1.155 6 003530 776 ANIMAL NUMBER CORTISOL /g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN /ig/dL Group : Male 4 Dose Level: 0.75 105506 105507 105509 105511 105512 105522 47.35 48.45 71.85 71.00 65.67 61.00 0.85 1.81 1.13 2.40 0.17 3.96 MEAN S.D. N 60.89 10.801 6 1.72 1.341 6 Group: Female 1 Dose Level : 0 105529 105530 105531 105535 105544 105549 72.55 76.75 48.35 68.60 52.84 55.44 0.28 0.07 0.50 0.35 0.42 0.07 MEAN S.D. N 62.42 11.701 6 0.28 0.179 6 Group: Female 2 Dose Level: 0.03 105537 105541 105547 105550 80.90 66.41 83.87 47.16 0.16 0.17 0.46 0.31 MEAN S.D. N 69.59 16.783 4 0.28 0.141 4 Dosage Unit: mg/kg/day 26.15 32.25 24.92 24.62 33.79 36.25 31.68 32.53 22.42 48.45 36.30 41.15 0.00 0.00 0.00 0.00 0.00 0.00 29.66 5.047 6 35.42 8.885 6 0.00 0.000 6 Dosage Unit: mg/kg/day 35.08 122.95 75.71 61.83 208.06 45.31 49.80 102.72 92.55 59.99 101.29 59.93 0.00 0.00 0.00 0.00 0.00 0.00 91.49 64.841 6 77.71 23.710 6 0.00 0.000 6 Dosage Unit: mg/kg/day 63.92 70.21 65.82 44.95 82.77 78.87 70.18 119.41 0.00 0.00 0.00 0.00 61.23 11.165 4 87.81 21.716 4 0.00 0.000 4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000 6 0.00 0.01 0.00 0.00 1.26 0.00 0.21 0.514 6 0.00 0.00 0.00 0.00 0.00 0.000 4 149.78 117.94 130.15 137.80 128.50 133.19 132.89 10.581 6 82.65 184.14 90.39 109.23 145.88 99.05 118.56 38.982 6 167.85 119.83 284.36 110.60 170.66 79.847 4 5.35 6.72 5.49 4.61 3.49 3.60 4.88 1.235 6 4.40 8.76 8.31 5.76 5.54 5.97 6.46 1.705 6 9.01 7.95 6.35 4.93 7.06 1.792 4 003531 777 ANIMAL NUMBER CORTISOL /g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day -27 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING /IU/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN /jg/dL Group: Female 3 Dose Level: 0.15 105532 105538 105539 105545 105548 105552 57.80 87.05 50.45 57.66 56.95 62.72 0.18 0.09 0.08 0.03 0.59 0.54 MEAN S.D. N 62.11 12.832 6 0.25 0.248 6 Group: Female 4 Dose Level: 0.75 105533 105534 105536 105540 105542 105551 80.05 71.00 48.50 68.05 82.95 63.39 0.55 0.19 0.16 0.05 0.37 0.18 MEAN S.D. N 68.99 12.436 6 0.25 0.179 6 Dosage Unit: mg/kg/day 73.31 34.86 45.40 97.36 80.60 35.64 64.68 46.45 87.24 92.73 76.53 71.52 0.00 0.00 0.00 0.00 0.00 0.00 61.20 26.181 6 73.19 16.617 6 0.00 0.000 6 Dosage Unit: mg/kg/day 197.69 75.81 51.69 27.69 53.10 133.61 243.31 98.79 75.52 27.51 54.14 259.85 0.00 0.00 0.00 0.00 0.00 0.00 89.93 63.894 6 126.52 99.828 6 0.00 0.000 6 1.98 0.00 0.00 0.00 0.00 0.08 0.34 0.802 6 0.04 0.00 0.00 0.00 0.00 0.00 0.01 0.016 6 221.66 133.62 122.82 126.61 125.43 99.82 138.33 42.411 6 298.47 161.23 130.92 94.60 124.93 119.61 154.96 73.494 6 8.42 6.15 8.69 7.04 5.95 6.53 7.13 1.168 6 7.38 6.76 6.89 4.96 8.88 7.73 7.10 1.295 6 003532 778 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRI IODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN /ig/dL Group: Male 1 Dose Level : 0 105508 105517 105519 105520 105526 105527 59.57 58.12 56.30 51.45 54.80 56.59 0.56 1.38 0.36 2.11 0.89 10.76 MEAN S.D. N 56.14 2.818 6 2.68 4.010 6 Group: Male 2 Dose Level: 0.03 105514 105515 105516 105521 ' 72.96 56.42 53.39 60.98 2.64 0.94 0.22 10.10 MEAN S.D. N 60.94 8.601 4 3.48 4.532 4 Group : Male 3 Dose Level: 0.15 105505 105510 105518 105523 105524 105528 61.35 66.10 52.23 61.98 64.07 73.61 0.76 0.60 0.83 2.11 0.68 1.04 MEAN S.D. N 63.22 6.968 6 1.00 0.563 6 Dosage Unit: mg/kg/day 14.21 30.66 19.61 31.75 17.02 31.22 21.01 42.28 34.97 65.45 32.02 47.15 0.00 0.00 0.00 0.00 0.00 0.00 24.08 8.004 6 40.48 15.181 6 0.00 0.000 6 Dosage Unit: mg/kg/day 32.81 23.69 14.32 37.38 84.41 39.25 48.23 98.72 0.00 0.00 0.00 0.00 27.05 10.218 4 67.65 28.460 4 0.00 0.000 4 Dosage Unit: mg/kg/day 23.37 24.13 26.75 27.07 15.77 10.40 36.78 29.76 38.59 44.88 33.62 23.33 0.00 0.00 0.00 0.00 0.00 0.00 21.25 6.703 6 34.49 7.452 6 0.00 0.000 6 0.02 0.86 0.00 0.00 0.47 0.70 0.34 0.387 6 0.70 0.43 0.13 0.14 0.35 0.272 4 0.07 0.68 0.92 0.00 0.32 0.01 0.33 0.387 6 252.81 298.92 279.29 241.26 316.62 250.74 273.27 30.081 6 306.12 283.59 272.54 229.90 273.04 31.973 4 265.64 255.41 272.85 284.01 221.20 228.32 254.57 25.007 6 3.21 4.67 4.18 4.63 3.30 4.37 4.06 0.649 6 6.21 3.96 4.83 5.43 5.11 0.951 4 4.21 4.29 3.46 5.45 3.41 3.17 4.00 0.844 6 003533 779 ANIMAL NUMBER CORTISOL pg/AL Appendix 6 Summary and Individual Blood Hormone Determination Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING /iU/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN flg/L Group: Male 4 Dose Level: 0.75 105506 105507 105509 105511 105512 105522 60.57 69.37 86.47 75.68 64.22 53.06 1.13 14.80 1.24 1.50 0.25 37.59 MEAN S.D. N 68.23 11.785 6 9.42 14.866 6 Group: Female 1 Dose Level: 0 105529 105530 105531 105535 105544 105549 58.61 77.09 60.99 61.72 62.18 56.68 0.31 0.08 0.20 0.25 0.46 0.18 MEAN S.D. N 62.88 7.266 6 0.25 0.130 6 Group: Female 2 Dose Level: 0.03 105537 105541 105547 105550 76.40 81.53 63.15 64.55 0.23 0.31 0.39 0.27 MEAN S.D. N 71.41 8.993 4 0.30 0.068 4 Dosage Unit: mg/kg/day 24.16 51.78 17.49 6.35 21.10 69.66 182.56 91.86 35.79 35.89 39.97 162.36 0.00 0.00 0.00 0.00 0.00 0.00 31.76 23.908 6 91.41 66.580 6 0.00 0.000 6 Dosage Unit: mg/kg/day 42.85 39.24 88.53 40.91 75.30 65.95 72.21 74.66 208.96 63.01 65.02 56.58 0.00 0.00 0.00 0.00 0.00 0.00 58.80 20.805 6 90.07 58.605 6 0.00 0.000 6 Dosage Unit: mg/kg/day 64.21 61.86 45.86 55.39 177.41 127.77 76.97 143.29 0.00 0.00 0.00 0.00 56.83 8.209 4 131.36 41.770 4 0.00 0.000 4 0.00 0.36 0.66 0.14 0.04 0.03 0.21 0.259 6 0.18 0.69 0.27 0.40 2.61 0.21 0.73 0.941 6 0.00 0.01 0.68 0.27 0.24 0.319 4 229.83 199.81 259.19 230.58 246.92 270.21 239.42 25.037 6 256.85 189.21 211.24 267.83 216.47 236.08 229.61 29.621 6 279.90 240.82 223.65 232.10 244.12 24.864 4 3.61 3.33 4.31 4.22 2.99 3.18 3.61 0.549 6 5.54 8.01 6.09 5.64 4.38 5.23 5.82 1.217 6 6.02 6.09 4.37 3.75 5.06 1.180 4 003534 780 ANIMAL NUMBER CORTISOL fig/Ah Appendix 6 Summary and Individual Blood Hormone Determination Day 37 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING flU/mL TOTAL TRI IODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN ftg/dL Group : Female 3 Dose Level: 0.15 105532 105538 105539 105545 105548 105552 66.39 54.30 50.23 46.45 46.73 56.82 0.20 0.07 0.08 0.09 0.30 0.48 MEAN S.D. N 53.49 7.537 6 0.20 0.162 6 Group: Female 4 Dose Level: 0.75 105533 105534 105536 105540 105542 105551 63.27 53.74 55.56 54.54 54.14 68.07 0.29 0.15 0.19 0.07 0.09 0.12 MEAN S.D. N 58.22 5.998 6 0.15 0.080 6 Dosage Unit: mg/kg/day 383.80 27.95 38.80 119.09 34.02 27.36 351.81 58.49 86.17 227.52 52.35 51.92 0.00 0.00 0.00 0.00 0.00 0.00 105.17 140.935 6 138.04 124.485 6 0.00 0.000 6 Dosage Unit: mg/kg/day 70.06 49.92 42.44 31.28 67.52 104.58 150.87 123.86 63.03 47.69 67.27 271.41 0.00 0.00 0.00 0.00 0.00 0.00 60.97 25.978 6 120.69 83.839 6 0.00 0.000 6 1.56 0.00 1.21 0.00 0.00 0.91 0.61 0.703 6 1.07 1.59 0.00 0.26 0.52 0.10 0.59 0.622 6 192.15 225.80 221.63 237.82 184.62 220.15 213.70 20.701 6 190.90 203.76 204.79 191.80 196.18 190.95 196.40 6.414 6 4.53 3.21 3.49 4.18 2.78 3.89 3.68 * 0.646 6 3.51 5.03 3.62 3.16 4.84 5.21 4.23 * 0.895 6 003535 781 ANIMAL NUMBER CORTISOL pg/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING flU/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN /ig/dL Group: Male 1 Dose Level : 0 105508 105517 105519 105520 105526 105527 64.62 57.71 60.20 50.13 63.25 43.13 0.50 1.30 0.39 2.28 0.65 1.40 MEAN S.D. N 56.51 8.318 6 1.09 0.719 6 Group: Male 2 Dose Level: 0.03 105514 105515 105516 105521 86.10 59.33 49.45 62.77 2.10 0.67 0.27 3.13 MEAN S.D. N 64.41 15.522 4 1.54 1.318 4 Group: Male 3 Dose Level: 0.15 105505 105510 105518 105523 105524 105528 70.82 58.68 60.80 76.60 62.76 63.38 1.07 0.51 0.77 2.83 0.94 0.77 MEAN S.D. N 65.51 6.813 6 1.15 0.845 6 Dosage Unit: mg/kg/day 17.70 35.89 27.43 27.41 15.13 38.03 28.21 51.07 24.22 69.97 34.66 42.05 0.00 0.00 0.00 0.00 0.00 0.00 26.93 9.256 6 41.70 16.877 6 0.00 0.000 6 Dosage Unit: mg/kg/day 29.19 27.02 17.22 44.97 71.76 53.19 77.85 95.20 0.00 0.00 0.00 0.00 29.60 11.494 4 74.50 * 17.333 4 0.00 0.000 4 Dosage Unit: mg/kg/day 34.40 25.73 31.30 35.79 21.61 14.54 36.91 26.22 30.11 62.53 31.79 33.29 0.00 0.00 0.00 0.00 0.00 0.00 27.23 8.199 6 36.81 13.086 6 0.00 0.000 6 0.25 1.72 0.00 0.00 0.00 1.42 0.57 0.790 6 0.54 0.11 0.47 0.57 0.42 0.213 4 1.22 1.53 2.85 0.00 0.00 0.29 0.98 1.118 6 119.34 163.61 145.97 164.61 139.41 135.30 144.71 17.407 6 147.03 143.03 118.77 148.62 139.36 13.928 4 131.32 117.68 167.15 166.99 135.36 131.96 141.74 20.528 6 2.89 2.79 2.77 3.81 1.73 2.55 2.76 0.667 6 4.36 3.15 4.47 3.64 3.91 * 0.624 4 3.22 2.56 2.73 4.44 2.60 2.90 3.08 0.711 6 003S36 782 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Male 4 Dose Level: 0.75 105506 105507 105509 105511 105512 105522 70.92 69.36 80.21 83.50 69.38 65.14 0.61 2.05 1.10 1.52 0.19 1.87 MEAN S.D. N 73.09 * 7.137 6 1.22 0.728 6 Group: Female 1 Dose Level: 0 105529 105530 105531 105535 105544 105549 73.17 80.23 63.57 77.78 72.02 67.18 0.25 0.03 0.23 0.29 0.24 0.11 MEAN S.D. N 72.33 6.264 6 0.19 0.100 6 Group : Female 2 Dose Level: 0.03 105537 105541 105547 105550 75.87 88.44 67.51 72.45 0.24 0.30 0.41 0.42 MEAN S.D. N 76.07 8.934 4 0.34 0.087 4 Dosage Unit: mg/kg/day 6.89 14.27 8.28 4.43 20.03 30.27 84.83 50.89 33.16 43.47 35.68 56.44 0.00 0.00 0.00 0.00 0.00 0.00 14.03 9.757 6 50.75 18.886 6 0.00 0.000 6 Dosage Unit: mg/kg/day 42.49 40.60 87.01 135.19 110.97 88.68 95.52 73.45 154.45 166.44 116.03 104.97 0.00 0.00 0.00 0.00 0.00 0.00 84.16 37.377 6 118.48 35.602 6 0.00 0.000 6 Dosage Unit: mg/kg/day 97.35 95.89 71.56 63.70 171.29 128.24 149.12 160.38 0.00 0.00 0.00 0.00 82.13 17.053 4 152.26 18.393 4 0.00 0.000 4 0.00 0.33 0.97 0.00 0.00 0.00 0.22 0.392 6 2.88 0.32 0.00 0.00 3.86 0.10 1.19 1.718 6 0.00 0.09 1.74 0.00 0.46 0.856 4 110.61 96.11 120.78 133.14 121.31 142.07 120.67 16.237 6 86.34 157.85 105.00 104.25 94.26 141.85 114.93 28.369 6 178.52 124.69 122.85 116.15 135.55 28.879 4 2.24 2.24 3.01 3.42 1.84 2.79 2.59 0.585 6 2.55 5.01 3.16 3.14 3.32 3.98 3.53 0.859 6 4.64 5.27 3.51 2.87 4.07 1.083 4 003537 783 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 62 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING fRJ/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Female 3 Dose Level: 0.15 105532 105538 105539 105545 105548 105552 63.46 62.14 65.91 60.86 48.14 61.25 0.05 0.06 0.00 0.05 0.36 0.44 MEAN S.D. N 60.29 6.228 6 0.16 0.189 6 Group: Female 4 Dose Level: 0.75 105533 105534 105536 105540 105542 105551 68.36 67.55 73.98 73.87 66.81 113.15 1.04 0.05 0.12 0.09 0.40 0.10 MEAN S.D. N 77.29 17.850 6 0.30 0.384 6 Dosage Unit: mg/kg/day 196.89 40.91 50.54 142.62 60.76 60.28 162.41 57.31 122.72 226.73 96.83 85.06 0.00 0.00 0.00 0.00 0.00 0.00 92.00 63.048 6 125.18 61.195 6 0.00 0.000 6 Dosage Unit: mg/kg/day 539.64 21.16 53.49 47.69 414.10 98.43 637.44 92.30 103.29 87.57 248.93 208.43 0.00 0.00 0.00 0.00 0.00 0.00 195.75 222.733 6 229.66 210.776 6 0.00 0.000 6 3.00 0.00 1.30 0.00 0.48 0.13 0.82 1.176 6 1.64 1.91 0.17 0.00 0.69 0.00 0.74 0.849 6 100.87 122.69 109.98 147.17 99.01 102.13 113.64 18.596 6 92.49 104.34 101.67 102.37 84.83 85.64 95.22 8.753 6 4.30 1.97 3.15 2.68 1.94 2.55 2.77 0.880 6 2.41 3.70 2.53 1.65 3.75 4.45 3.08 1.049 6 003538 784 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295> IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING ftU/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Male 1 Dose Level : 0 105508 105517 105519 105520 105526 105527 63.12 72.02 68.04 50.11 60.09 48.19 0.65 1.78 0.44 2.53 0.96 1.57 MEAN S.D. N 60.26 9.547 6 1.32 0.786 6 Group: Male 2 Dose Level: 0.03 105514 105515 105516 105521 70.30 48.85 58.29 64.30 1.86 0.96 0.34 10.76 MEAN S.D. N 60.44 9.148 4 3.48 4.893 4 Group: Male 3 Dose Level: 0.15 105505 105510 105518 105523 105524 105528 63.97 58.44 52.27 64.33 73.62 72.47 1.54 1.05 0.90 2.03 0.82 0.73 MEAN S.D. N 64.18 8.157 6 1.18 0.506 6 Dosage Unit: mg/kg/day 3.16 22.72 14.07 19.55 16.52 35.93 20.61 53.30 30.76 65.61 29.74 51.35 0.00 0.00 0.00 0.00 0.00 0.00 18.66 10.784 6 41.90 17.359 6 0.00 0.000 6 Dosage Unit: mg/kg/day 29.08 29.88 28.37 41.20 82.17 40.06 40.27 107.46 0.00 0.00 0.00 0.00 32.13 * 6.076 4 67.49 33.199 4 0.00 0.000 4 Dosage Unit: mg/kg/day 17.57 20.81 20.88 20.84 13.64 21.33 37.08 34.69 26.72 47.88 34.88 23.84 0.00 0.00 0.00 0.00 0.00 0.00 19.18 3.040 6 34.18 8.478 6 0.00 0.000 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000 6 0.00 0.00 0.00 0.00 0.00 0.000 4 0.00 0.00 0.17 0.00 0.00 0.00 0.03 0.069 6 141.51 162.07 144.10 148.94 161.62 162.45 153.45 9.720 6 166.24 148.07 151.67 146.06 153.01 9.120 4 143.76 141.60 156.52 174.10 119.61 143.77 146.56 18.023 6 3.96 4.25 3.67 4.53 2.93 4.02 3.89 0.553 6 5.41 4.38 5.22 6.17 5.30 * 0.735 4 4.56 4.37 4.49 6.03 3.93 3.45 4.47 0.870 6 003539 785 ANIMAL NUMBER CORTISOL fig/h Appendix 6 Summary and individual Blood Hormone Determination Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING /IU/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN fig/h Group: Male 4 Dose Level: 0.75 105506 105507 105509 105511 105512 105522 73.97 49.60 86.62 60.08 64.66 67.73 0.48 2.71 1.73 1.70 0.26 1.87 MEAN S.D. N 67.11 12.571 6 1.46 0.923 6 Group: Female 1 Dose Level : 0 105529 105530 105531 105535 105544 105549 74.49 69.78 50.36 62.89 70.71 65.26 0.55 0.06 0.30 0.29 1.05 0.32 MEAN S.D. N 65.58 8.513 6 0.43 0.342 6 Group: Female 2 Dose Level: 0.03 105537 105541 105547 105550 75.93 89.16 68.87 61.58 0.30 0.37 0.38 0.28 MEAN S.D. N 73.89 11.748 4 0.33 0.050 4 Dosage Unit: mg/kg/day 2.29 22.58 4.65 3.05 13.32 19.66 48.87 40.22 34.03 38.67 33.13 57.55 0.00 0.00 0.00 0.00 0.00 0.00 10.93 8.875 6 42.08 9.438 6 0.00 0.000 6 Dosage Unit: mg/kg/day 59.28 30.39 76.52 126.05 218.24 85.32 96.58 37.67 104.81 94.80 115.65 88.15 0.00 0.00 0.00 0.00 0.00 0.00 99.30 66.222 6 89.61 27.146 6 0.00 0.000 6 Dosage Unit: mg/kg/day 276.11 88.60 48.03 34.29 579.38 143.46 87.11 106.94 0.00 0.00 0.00 0.00 111.76 111.968 4 229.22 234.602 4 0.00 0.000 4 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000 6 0.00 0.00 0.00 0.00 0.00 0.000 4 107.40 89.57 127.61 144.57 102.29 136.40 117.97 * 21.468 6 95.65 200.64 117.41 144.43 160.65 139.16 142.99 36.187 6 161.68 144.58 121.55 160.17 147.00 18.641 4 4.98 4.45 4.61 5.46 3.78 4.38 4.61 0.570 6 3.94 6.12 4.52 4.54 4.46 5.01 4.77 0.746 6 5.86 6.55 5.03 6.54 6.00 0.720 4 003540 786 ANIMAL NUMBER CORTISOL (lq/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 91 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING faJ/mL TOTAL TRIIODOTHYRONINE ng/dL Covanee 6329-223 3M T-6295.7 TOTAL THYROXIN fig/dL Group : Female 3 Dose Level: 0.15 105532 105538 105539 105545 105548 105552 53.44 54.36 56.38 50.87 46.19 55.40 0.07 0.09 0.01 0.00 0.30 0.38 MEAN S.D. N 52.77 3.737 6 0.14 0.159 6 Group: Female 4 Dose Level : 0.75 105533 105534 105536 105540 105542 105551 63.67 57.80 71.04 85.09 58.02 91.43 0.51 0.04 0.14 0.26 0.23 0.42 MEAN S.D. N 71.18 14.228 6 0.27 0.174 6 Dosage Unit: mg/kg/day 208.42 55.31 48.35 64.59 29.92 74.01 161.28 71.47 96.47 142.80 64.58 74.24 0.00 0.00 0.00 0.00 0.00 0.00 80.10 64.629 6 101.81 40.773 6 0.00 0.000 6 Dosage Unit: mg/kg/day 162.24 34.90 29.06 42.06 95.90 394.36 186.20 67.09 60.95 65.39 72.08 503.53 0.00 0.00 0.00 0.00 0.00 0.00 126.42 140.697 6 159.21 175.397 6 0.00 0.000 6 0.09 0.00 0.00 0.00 0.00 0.00 0.02 0.037 6 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.000 6 120.33 113.79 114.24 113.45 109.64 92.26 110.62 * 9.628 6 95.87 81.56 92.51 90.84 81.86 83.67 87.72 * 6.128 6 4.88 3.27 3.49 4.38 3.13 3.47 3.77 0.697 6 4.18 5.45 4.94 3.81 5.99 5.15 4.92 0.807 6 003541 787 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Male 1 Dose Level: 0 105508 105517 105519 105520 105526 105527 49.36 44.88 54.72 37.96 60.22 39.62 0.80 0.89 0.41 3.20 0.91 2.05 MEAN S.D. N 47.79 8.681 6 1.38 1.049 6 Group : Male 2 Dose Level: 0.03 105514 105515 105516 105521 57.72 41.90 43.62 53.31 1.43 0.44 0.31 8.03 MEAN S.D. N 49.14 7.613 4 2.55 3.686 4 Group: Male 3 Dose Level: 0.15 105505 105510 105518 105523 105524 105528 42.54 39.10 46.25 57.87 51.67 52.89 0.25 2.63 0.70 2.06 0.73 0.42 MEAN S.D. N 48.39 7.014 6 1.13 0.973 6 Dosage Unit: mg/kg/day 11.03 26.64 21.40 19.07 15.79 43.81 16.55 34.19 24.00 35.67 22.56 46.79 0.00 0.00 0.00 0.00 0.00 0.00 22.96 11.485 6 29.96 10.990 6 0.00 0.000 6 Dosage Unit: mg/kg/day 29.26 9.14 16.57 41.46 65.16 29.60 29.96 70.45 0.00 0.00 0.00 0.00 24.11 14.242 4 48.79 22.060 4 0.00 0.000 4 Dosage Unit: mg/kg/day 28.98 25.43 28.63 26.43 20.26 9.63 21.56 19.76 25.41 39.59 20.89 13.61 0.00 0.00 0.00 0.00 0.00 0.00 23.23 7.363 6 23.47 8.774 6 0.00 0.000 6 0.01 1.43 0.48 0.35 0.30 0.02 0.43 0.524 6 0.76 0.32 0.11 0.15 0.34 0.298 4 1.10 0.51 2.09 0.18 0.09 0.46 0.74 0.751 6 153.39 155.85 152.78 168.82 162.99 164.16 159.67 6.579 6 148.24 133.97 77.19 117.72 119.28 * 30.705 4 134.08 110.87 136.26 144.20 114.48 107.88 124.63 * 15.365 6 4.94 4.14 4.19 4.97 3.38 4.68 4.38 0.608 6 5.02 3.70 5.04 5.13 4.72 0.683 4 4.41 3.40 4.42 4.67 3.94 3.12 3.99 0.621 6 003542 788 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Male 4 Dose Level: 0.75 105507 105511 105512 105522 59.90 43.70 70.20 59.49 2.10 0.69 0.04 1.80 MEAN S.D. N 58.32 10.935 4 1.16 0.961 4 Group : Female 1 Dose Level : 0 105529 105530 105531 105535 105544 105549 65.21 74.89 35.19 74.58 61.62 41.85 0.17 0.01 0.03 0.52 0.34 0.02 MEAN S.D. N 58.89 16.743 6 0.18 0.209 6 Group: Female 2 Dose Level: 0.03 105537 105541 105547 105550 76.03 61.45 39.39 59.31 0.29 0.13 0.26 0.14 MEAN S.D. N 59.05 15.063 4 0.21 0.082 4 Dosage Unit: mg/kg/day 0.00 1.01 0.00 2.00 33.59 27.68 22.69 36.89 0.00 0.00 0.00 0.00 0.75 * 0.958 4 30.21 6.298 4 0.00 0.000 4 Dosage Unit: mg/kg/day 232.49 47.22 51.65 318.47 162.44 78.63 351.64 68.58 77.36 239.29 153.92 61.78 0.00 0.00 0.00 0.00 0.00 0.00 148.48 110.143 6 158.76 116.512 6 0.00 0.000 6 Dosage Unit: mg/kg/day 254.69 47.66 41.73 156.72 492.79 101.86 164.10 364.55 0.00 0.00 0.00 0.00 125.20 101.227 4 280.83 180.363 4 0.00 0.000 4 1.59 0.34 0.59 1.18 0.93 0.566 4 1.33 0.00 0.00 0.06 2.75 0.22 0.73 1.115 6 0.00 0.08 0.85 1.77 0.68 0.824 4 58.09 97.68 34.06 75.57 66.35 * 26.941 4 95.65 183.66 115.47 139.41 152.04 125.36 135.27 30.659 6 148.10 131.20 98.77 102.12 120.05 23.703 4 5.27 7.00 3.25 5.85 5.34 1.569 4 4.83 7.22 5.01 5.84 5.08 5.95 5.66 0.894 6 5.29 5.85 3.35 2.84 4.33 1.462 4 003543 789 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 182 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING /IU/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3H T-6295.7 TOTAL THYROXIN /<g/dL Group : Female 3 Dose Level : 0.15 105532 105538 105539 105545 105548 105552 47.71 36.38 42.82 48.24 32.13 48.26 0.01 0.04 0.00 0.04 0.03 0.16 MEAN S.D. N 42.59 6.904 6 0.05 0.058 6 Group: Female 4 Dose Level: 0.75 105533 105534 105536 105540 105542 105551 63.42 66.38 51.73 60.27 56.03 96.30 0.17 0.05 0.09 0.15 0.19 0.07 MEAN S.D. N 65.69 15.876 6 0.12 0.058 6 Dosage Unit: mg/kg/day 197.86 45.10 52.30 52.62 39.61 36.02 141.98 64.69 100.79 74.46 51.74 60.51 0.00 0.00 0.00 0.00 0.00 0.65 70.59 62.705 6 82.36 33.716 6 0.11 0.265 6 Dosage Unit: mg/kg/day 36.11 9.45 0.00 47.41 93.61 52.80 55.31 37.27 53.37 60.05 115.82 99.85 0.00 0.00 0.00 0.00 0.00 0.00 39.90 33.589 6 70.28 30.505 6 0.00 0.000 6 4.33 0.25 0.89 0.62 0.98 0.57 1.27 1.520 6 2.31 1.10 0.62 0.21 0.55 0.22 0.84 0.793 6 90.44 100.45 106.11 86.22 103.15 93.10 96.58 * 7.824 6 83.76 81.38 76.41 71.65 92.22 104.92 85.06 * 11.963 6 4.36 2.83 3.63 4.00 4.03 4.59 3.91 * 0.622 6 5.31 6.31 5.96 3.74 5.83 6.49 5.61 1.002 6 003544 790 003545 ANIMAL NUMBER Appendix 6 Summary and Individual Blood Hormone Determination Additional Collection - Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TOTAL FREE TOTAL FREE TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN ng/dL pg/mL /lg/dL ng/dL Group: Male 1 Dose Level : 0 105508 105519 105527 126.89 110.98 107.16 5.18 3.61 3.83 MEAN S.D. N 115.01 10.464 3 4.21 0.850 3 Group: Male 2 Dose Level : 0.03 105514 105515 105516 105521 111.98 103.61 120.14 106.40 5.14 4.58 5.44 5.36 MEAN S.D. N 110.53 7.289 4 5.13 0.388 4 Group : Male 3 Dose Level : 0.15 105510 105518 105524 105528 95.90 93.03 86.79 100.26 4.19 4.41 3.88 4.85 MEAN S.D. N 94.00 * 5.649 4 4.33 0.408 4 Dosage Unit: mg/kg/day 3.46 2.73 3.56 1.02 0.86 1.15 3.25 0.453 3 1.01 0.145 3 Dosage Unit: mg/kg/day 3.97 3.01 4.11 4.31 1.07 1.10 1.16 1.50 3.85 0.577 4 1.21 0.199 4 Dosage Unit: mg/kg/day 2.88 2.49 2.38 3.07 1.02 0.93 0.79 1.01 2.71 0.324 4 0.94 0.106 4 791 Covance 6329-223 3M T-6295.7 003546 ANIMAL NUMBER Appendix 6 Summary and Individual Blood Hormone Determination Additional Collection - Terminal Sacrifice 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TOTAL FREE TOTAL FREE TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN ng/dL pg/mL fig/dL ng/dL Group: Male 4 Dose Level: 0.75 105506 105507 105512 59.28 55.46 13.96 2.74 3.07 1.55 MEAN S.D. N 42.90 * 25.135 3 2.45 * 0.800 3 Group: Female 1 Dose Level: 0 105530 105531 105535 105544 131.98 87.43 98.87 104.98 5.33 3.10 3.48 4.28 MEAN S.D. N 105.82 18.899 4 4.05 0.986 4 Group: Female 2 Dose Level: 0.03 105541 105547 105550 109.59 81.34 86.09 4.13 3.14 3.49 MEAN S.D. N 92.34 15.127 3 3.59 0.502 3 Dosage Unit: mg/kg/day 4.90 3.16 1.83 1.36 1.15 0.86 3.30 1.540 3 1.12 0.251 3 Dosage Unit: mg/kg/day 5.50 2.62 4.93 3.52 1.43 0.78 1.17 0.86 4.14 1.313 4 1.06 0.299 4 Dosage Unit: mg/kg/day 4.24 3.41 2.80 1.32 0.86 0.85 3.48 0.723 3 1.01 0.269 3 792 Covance 6329-223 3M T-6295.7 ANIMAL NUMBER Appendix 6 Summary and Individual Blood Hormone Determination Additional Collection - Terminal Sacrifice 26-WEEK c a p s u l e t o x i c i t y s t u d y w i t h p e r f l u o r o o c t a n e s u l f o n i c ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TOTAL FREE TOTAL FREE TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN ng/dL pg/mL //g/dL ng/dL Group: Female 3 Dose Level : 0.15 105532 105538 105545 105548 74.72 77.02 72.24 94.86 3.27 2.98 2.96 3.87 MEAN S.D. N 79.71 * 10.287 4 3.27 0.424 4 Group: Female 4 Dose Level : 0.75 105534 105536 105540 105551 51.14 59.03 60.77 64.05 2.88 2.43 3.13 2.83 MEAN S.D. N 58.75 * 5.482 4 2.82 0.290 4 Dosage Unit: mg/kg/day 3.03 1.89 2.71 3.88 1.04 0.59 0.90 1.06 2.88 0.823 4 0.90 0.217 4 Dosage Unit: mg/kg/day 4.52 3.87 2.04 3.30 1.49 1.00 0.79 1.03 3.43 1.054 4 1.08 0.295 4 Covance 6329-223 3M T-6295.7 003547 793 ANIMAL NUMBER CORTISOL /ig/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3H T-6295.7 TOTAL THYROXIN /ig/dL Group : Male 1 Dose Level : 0 105520 105526 38.18 44.16 2.66 2.51 MEAN S.D. N 41.17 4.228 2 2.59 0.106 2 Group: Male 3 Dose Level: 0.15 105505 105523 27.26 52.61 0.99 3.84 MEAN S.D. N 39.94 17.925 2 2.42 2.015 2 Group : Male 4 Dose Level: 0.75 105511 105522 51.54 44.31 4.72 5.36 MEAN S.D. N 47.93 5.112 2 5.04 0.453 2 Dosage Unit: mg/kg/day 17.90 10.98 64.49 25.43 0.00 0.00 14.44 4.893 2 44.96 27.620 2 0.00 0.000 2 Dosage Unit: mg/kg/day 17.56 21.73 32.66 59.98 0.00 0.00 19.65 2.949 2 46.32 19.318 2 0.00 0.000 2 Dosage Unit: mg/kg/day 0.00 27.09 37.83 70.81 0.00 0.00 13.55 19.156 2 54.32 23.320 2 0.00 0.000 2 1.61 2.12 1.87 0.361 2 1.21 0.97 1.09 0.170 2 1.67 1.05 1.36 0.438 2 159.60 183.22 171.41 16.702 2 154.43 164.81 159.62 7.340 2 165.18 129.72 147.45 25.074 2 3.75 2.87 3.31 0.622 2 3.28 4.20 3.74 0.651 2 4.74 2.51 3.625 1.577 2 003548 794 ANIMAL NUMBER CORTISOL fig/Ah Appendix 6 Summary and Individual Blood Hormone Determination Day 217 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING /JU/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN ftg/Ah Group : Female 1 Dose Level: 0 105529 105549 54.69 40.39 0.86 0.12 MEAN S.D. N 47.54 10.112 2 0.49 0.523 2 Group : Female 3 Dose Level: 0.15 105539 105552 57.55 59.07 0.10 0.82 MEAN S.D. N 58.31 1.075 2 0.46 0.509 2 Group : Female 4 Dose Level: 0.75 105533 105542 55.91 66.34 0.61 0.37 MEAN S.D. N 61.13 7.375 2 0.49 0.170 2 Dosage Unit: mg/kg/day 53.08 43.63 83.74 64.84 0.00 0.00 48.36 6.682 2 74.29 13.364 2 0.00 0.000 2 Dosage Unit: mg/kg/day 44.84 68.85 71.13 88.81 0.00 0.00 56.85 16.978 2 79.97 12.502 2 0.00 0.000 2 Dosage Unit: mg/kg/day 133.46 88.23 289.99 154.68 0.00 0.00 110.85 31.982 2 222.34 95.679 2 0.00 0.000 2 1.78 1.66 1.72 0.85 2 1.88 0.59 1.24 0.912 2 1.76 1.56 1.66 0.141 2 116.20 133.52 124.86 12.247 2 114.34 121.25 117.80 4.886 2 99.29 101.57 100.43 1.612 2 4.89 6.58 5.74 1.195 2 3.37 3.91 3.64 0.382 2 3.93 3.51 3.72 0.297 2 003549 795 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING nU/mL TOTAL TRI IODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //9/dL Group: Male 1 Dose Level : 0 105520 105526 52.17 44.90 2.83 1.40 MEAN S.D. N 48.54 5.141 2 2.12 1.011 2 Group: Male 3 Dose Level: 0.15 105505 105523 46.88 54.44 0.50 7.18 MEAN S.D. N 50.66 5.346 2 3.84 4.723 2 Group : Male 4 Dose Level: 0.75 105511 105522 37.08 25.17 1.55 2.99 MEAN S.D. N 31.13 8.422 2 2.27 1.018 2 Dosage Unit: mg/kg/day 40.85 16.61 79.85 31.48 0.00 0.00 28.73 17.140 2 55.67 34.203 2 0.00 0.000 2 Dosage Unit: mg/kg/day 23.84 25.40 43.65 59.41 0.00 0.00 24.62 1.103 2 51.53 11.144 2 0.00 0.000 2 Dosage Unit: mg/kg/day 17.87 26.57 53.06 77.43 0.00 0.00 22.22 6.152 2 65.25 17.232 2 0.00 0.000 2 0.25 0.00 0.13 0.177 2 0.10 0.00 0.05 0.071 2 0.67 0.33 0.50 0.240 2 171.00 133.39 152.20 26.594 2 154.84 151.74 153.29 2.192 2 170.42 137.27 153.85 23.441 2 4.18 1.74 2.96 1.725 2 3.79 3.37 3.58 0.297 2 4.18 2.45 3.32 1.223 2 003550 796 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 245 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //lJ/mL TOTAL TRI IODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Female 1 Dose Level : 0 105529 105549 56.47 43.54 0.12 0.07 MEAN S.D. N 50.01 9.143 2 0.10 0.035 2 Group: Female 3 Dose Level: 0.15 105539 105552 63.10 60.29 0.07 0.28 MEAN S.D. N 61.70 1.987 2 0.18 0.148 2 Group : Female 4 Dose Level: 0.75 105533 105542 62.75 81.69 0.66 0.06 MEAN S.D. N 72.22 13.393 2 0.36 0.424 2 Dosage Unit: mg/kg/day 38.61 112.14 95.66 115.58 0.00 0.00 75.38 51.994 2 105.62 14.086 2 0.00 0.000 2 Dosage Unit: mg/kg/day 61.24 88.08 137.78 94.05 0.00 0.00 74.66 18.979 2 115.92 30.922 2 0.00 0.000 2 Dosage Unit: mg/kg/day 257.61 114.63 255.84 120.11 0.00 0.00 186.12 101.102 2 187.98 95.976 2 0.00 0.000 2 0.68 0.98 0.83 0.212 2 0.81 0.00 0.41 0.573 2 1.04 0.82 0.93 0.156 2 130.32 136.09 133.21 4.080 2 127.17 142.77 134.97 11.031 2 118.99 121.98 120.49 2.114 2 4.93 5.81 5.37 0.622 2 3.56 3.76 3.66 0.141 2 3.84 3.38 3.61 0.325 2 TSSCO 797 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING flU/mL TOTAL TRIIODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN /ig/dL Group : Male 1 Dose Level : 0 105520 105526 34.89 45.23 1.76 1.40 MEAN S.D. N 40.06 7.311 2 1.58 0.255 2 Group: Male 3 Dose Level: 0.15 105505 105523 42.85 61.34 3.64 2.55 MEAN S.D. N 52.10 13.074 2 3.10 0.771 2 Group: Male 4 Dose Level: 0.75 105511 105522 59.62 26.17 2.36 4.12 MEAN S.D. N 42.90 23.653 2 3.24 1.245 2 Dosage Unit: mg/kg/day 17.17 14.11 62.84 34.27 0.00 0.00 15.64 2.164 2 48.56 20.202 2 0.00 0.000 2 Dosage Unit: mg/kg/day 25.06 25.26 39.86 63.44 0.00 0.00 25.16 0.141 2 51.65 16.674 2 0.00 0.000 2 Dosage Unit: mg/kg/day 6.94 30.46 51.42 83.94 0.00 0.00 18.70 16.631 2 67.68 22.995 2 0.00 0.000 2 0.00 0.02 0.01 0.014 2 0.25 0.00 0.13 0.177 2 0.24 0.09 0.17 0.106 2 134.97 167.54 151.26 23.030 2 146.70 161.73 154.22 10.628 2 163.13 163.73 163.43 0.424 2 5.56 2.40 3.98 2.234 2 2.43 3.31 2.87 0.622 2 4.19 2.36 3.28 1.294 2 003552 798 ANIMAL NUMBER CORTISOL //g/dL Appendix 6 Summary and Individual Blood Hormone Determination Day 274 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS TESTOSTERONE ng/mL ESTRADIOL pg/mL ESTRONE pg/mL ESTRIOL pg/mL THYROID STIMULATING //U/mL TOTAL TRI IODOTHYRONINE ng/dL Covance 6329-223 3M T-6295.7 TOTAL THYROXIN //g/dL Group: Female 1 Dose Level: 0 105529 105549 64.71 47.01 0.44 0.02 MEAN S.D. N 55.86 12.516 2 0.23 0.297 2 Group: Female 3 Dose Level: 0.15 105539 105552 45.77 44.48 0.04 0.18 MEAN S.D. N 45.13 0.912 2 0.11 0.099 2 Group: Female 4 Dose Level: 0.75 105533 105542 49.13 63.28 0.49 0.40 MEAN S.D. N 56.21 10.006 2 0.45 0.064 2 Dosage Unit: mg/kg/day 43.91 42.07 115.88 57.38 0.00 0.00 42.99 1.301 2 86.63 41.366 2 0.00 0.000 2 Dosage Unit: mg/kg/day 48.03 114.70 127.24 124.21 0.00 0.00 81.37 47.143 2 125.73 2.143 2 0.00 0.000 2 Dosage Unit: mg/kg/day 109.08 108.09 153.99 128.04 0.00 0.00 108.59 0.700 2 141.02 18.349 2 0.00 0.000 2 0.00 0.68 0.34 0.481 2 0.29 0.00 0.15 0.205 2 0.64 0.01 0.33 0.445 2 91.10 130.21 110.66 27.655 2 114.25 103.46 108.86 7.630 2 115.88 85.17 100.53 21.715 2 4.88 4.88 4.88 0.000 2 3.00 2.98 2.99 0.014 2 2.59 3.22 2.91 0.445 2 C O CCO/I c/l 0 799 ANIMAL NUMBER Appendix 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS THYROID TOTAL FREE TOTAL FREE CORTISOL TESTOSTERONE ESTRADIOL ESTRONE ESTRIOL STIMULATING TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN /g/dL ng/mL pg/mL pg/mL pg/mL /iU/mL ng/dL pg/mL /<g/dL ng/dL Group: Male 1 Dose Level: 0 Dosage Unit: mg/kg/day 105520 105526 48.93 54.85 1.68 1.47 22.29 12.73 66.72 34.79 0.00 0.00 0.00 0.08 MEAN S.D. N 51.89 4.186 2 1.58 0.148 2 17.51 6.760 2 50.76 22.578 2 0.00 0.000 2 0.04 0.057 2 Group : Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 105523 35.82 56.14 0.16 2.50 21.68 21.64 35.93 55.20 0.00 0.00 0.15 0.00 MEAN S.D. N 45.98 14.368 2 1.33 1.655 2 21.66 0.028 2 45.57 13.626 2 0.00 0.000 2 0.08 0.106 2 Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105511 105522 52.62 27.46 1.59 1.66 0.00 14.90 43.71 66.78 0.00 0.00 0.01 0.05 MEAN S.D. N 40.04 17.791 2 1.63 0.049 2 7.45 10.536 2 55.25 16.313 2 0.00 0.000 2 0.03 0.028 2 113.68 167.98 140.83 38.396 2 141.49 150.29 145.89 6.223 2 145.00 116.61 130.81 20.075 2 4.34 6.23 5.29 1.336 2 4.68 5.39 5.04 0.502 2 4.78 4.24 4.51 0.382 2 3.20 3.35 3.28 0.106 2 1.27 1.26 1.27 0.007 2 3.96 4.09 4.03 0.092 2 1.44 1.51 1.48 0.049 2 4.61 2.84 3.73 1.252 2 1.17 0.95 1.06 0.156 2 00355 800 ANIMAL NUMBER Appendix 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Day 322 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS THYROID TOTAL FREE TOTAL FREE CORTISOL TESTOSTERONE: ESTRADIOL ESTRONE ESTRIOL STIMULATING TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN /g/dL ng/mL pg/mL pg/mL pg/mL //U/mL ng/dL pg/mL /ig/dL ng/dL Group: Female 1 105529 105549 60.74 55.31 MEAN S.D. N 58.03 3.840 2 Group : Female 3 105539 105552 54.81 61.78 MEAN S.D. N 58.30 4.929 2 Group : Female 4 105533 105542 40.44 66.14 MEAN S.D. N 53.29 18.173 2 Dose Level : 0 Dosage Unit:: mg/kg/day 0.66 0.04 93.93 67.50 136.07 78.68 0.00 0.00 0.14 0.22 0.35 0.438 2 80.72 18.689 2 107 .38 40.581 2 0.00 0.000 2 0.18 0.057 2 Dose Level: 0.15 Dosage Unit: mg/kg/day 0.00 0.15 46.03 78.67 127.28 179.51 0.00 0.00 0.00 0.33 0.08 0.106 2 62.35 23.080 2 153.40 36.932 2 0.00 0.000 2 0.17 0.233 2 Dose Level : 0.75 Dosage Unit:: mg/kg/day 0.02 0.03 95.89 95.19 182.57 116.98 0.00 0.00 0.85 0.00 0.03 0.007 2 95.54 0.495 2 149.78 46.379 2 0.00 0.000 2 0.43 0.601 2 95.57 102.40 98.99 4.830 2 .102.53 86.79 94.66 11.130 2 127.50 94.51 111.01 23.327 2 3.84 3.31 3.58 0.375 2 2.30 2.66 2.48 0.255 2 4.40 2.64 3.52 1.245 2 3.87 4.09 3.98 0.156 2 1.16 1.37 1.27 0.148 2 3.24 3.34 3.29 0.071 2 0.99 1.04 1.02 0.035 2 4.41 4.04 4.23 0.262 2 1.38 1.08 1.23 0.212 2 003555 801 ANIMAL NUMBER Appendix 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS THYROID TOTAL FREE TOTAL FREE CORTISOL TESTOSTERONE ESTRADIOL ESTRONE ESTRIOL STIMULATING TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN flg/dL ng/mL pg/mL pg/mL pg/mL /JU/mh ng/dL pg/mL //g/dL ng/dL Group : Male 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 105526 56.87 50.92 2.87 2.98 31.48 22.18 71.33 39.48 0.00 0.00 0.00 0.01 MEAN S.D. N 53.90 4.207 2 2.93 0.078 2 26.83 6.576 2 55.41 22.521 2 0.00 0.000 2 0.01 0.007 2 Group: Male 3 Dose Level : 0.15 Dosage Unit: mg/kg/day 105505 105523 35.11 69.91 5.86 3.19 27.97 21.80 33.61 59.64 0.00 0.00 0.15 0.00 MEAN S.D. N 52.51 24.607 2 4.53 1.888 2 24.89 4.363 2 46.63 18.406 2 0.00 0.000 2 0.08 0.106 2 Group: Male 4 Dose Level : 0.75 Dosage Unit: mg/kg/day 105511 105522 53.56 42.27 2.07 1.98 12.59 22.13 50.72 61.86 0.00 0.00 0.00 0.00 MEAN S.D. N 47.92 7.983 2 2.03 0.064 2 17.36 6.746 2 56.29 7.877 2 0.00 0.000 2 0.00 0.000 2 142.33 173.51 157.92 22.048 2 141.33 136.42 138.88 3.472 2 189.73 142.92 166.33 33.100 2 4.92 5.87 5.40 0.672 2 4.17 4.73 4.45 0.396 2 6.84 6.13 6.49 0.502 2 3.54 3.31 3.43 0.163 2 1.36 1.43 1.40 0.049 2 3.71 3.76 3.74 0.035 2 1.35 1.21 1.28 0.099 2 3.92 3.06 3.49 0.608 2 1.07 1.07 1.07 0.000 2 003556 802 ANIMAL NUMBER Appendix 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Day 364 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS THYROID TOTAL FREE TOTAL FREE CORTISOL TESTOSTERONE: ESTRADIOL ESTRONE ESTRIOL STIMULATING TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN //g/dL ng/mL pg/mL pg/mL pg/mL //U/mL ng/dL pg/mL //g/dL ng/dL Group: Female 1 105529 105549 56.92 54.02 MEAN S.D. N 55.47 2.051 2 Group: Female 3 105539 105552 48.00 74.04 MEAN S.D. N 61.02 18.413 2 Group: Female 4 105533 105542 61.92 89.59 MEAN S.D. N 75.76 19.566 2 Dose Level: 0 Dosage Unit: mg/kg/day 0.36 0.01 46.66 72.28 106.07 120.53 0.00 0.00 0.38 0.00 0.19 0.247 2 59.47 18.116 2 113.30 10.225 2 0.00 0.000 2 0.19 0.269 2 Dose Level: 0.15 Dosage Unit: mg/kg/day 0.01 0.13 53.88 25.95 120.92 71.07 0.00 0.00 0.12 0.39 0.07 0.085 2 39.92 19.749 2 96.00 35.249 2 0.00 0.000 2 0.26 0.191 2 Dose Level : 0.75 Dosage Unit: mg/kg/day 0.13 0.07 166.75 164.57 352.52 175.61 0.00 0.00 0.28 0.00 0.10 0.042 2 165.66 1.541 2 264.07 125.094 2 0.00 0.000 2 0.14 0.198 2 114.22 94.96 104.59 13.619 2 113.58 89.22 101.40 17.225 2 108.62 105.87 107.25 1.945 2 3.48 2.75 3.12 0.516 2 2.73 3.99 3.36 0.891 2 3.84 3.34 3.59 0.354 2 3.48 3.89 3.69 0.290 2 1.17 1.40 1.29 0.163 2 3.40 3.06 3.23 0.240 2 1.10 1.03 1.07 0.049 2 3.20 3.31 3.26 0.078 2 1.15 1.07 1.11 0.057 2 003557 803 ANIMAL NUMBER Appendix 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS THYROID TOTAL FREE TOTAL FREE CORTISOL TESTOSTERONE ESTRADIOL ESTRONE ESTRIOL STIMULATING TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN /Rj/dL ng/mL pg/mL pg/mL pg/mL flU/mL ng/dL pg/mL fig/h ng/dL Group: Male 1 Dose Level : 0 Dosage Unit : mg/kg/day 105520 105526 45.28 42.55 3.12 2.03 24.62 20.60 33.29 17.89 0.00 0.00 4.00 3.18 MEAN S.D. N 43.92 1.930 2 2.58 0.771 2 22.61 2.843 2 25.59 10.889 2 0.00 0.000 2 3.59 0.580 2 Group: Male 3 Dose Level: 0.15 Dosage Unit: mg/kg/day 105505 105523 35.05 58.45 5.77 4.15 33.45 34.94 15.52 31.76 0.00 0.00 3.02 2.40 MEAN S.D. N 46.75 16.546 2 4.96 1.146 2 34.20 1.054 2 23.64 11.483 2 0.00 0.000 2 2.71 0.438 2 Group: Male 4 Dose Level: 0.75 Dosage Unit: mg/kg/day 105511 105522 34.37 18.72 2.19 5.27 15.15 32.89 34.29 47.87 0.00 0.00 2.70 2.67 MEAN S.D. N 26.55 11.066 2 3.73 2.178 2 24.02 12.544 2 41.08 9.603 2 0.00 0.000 2 2.69 0.021 2 160.85 158.81 159.83 1.442 2 156.75 189.99 173.37 23.504 2 200.22 142.75 171.49 40.637 2 7.90 7.34 7.62 0.396 2 5.12 8.58 6.85 2.447 2 8.55 6.89 7.72 1.174 2 5.07 3.03 4.05 1.442 2 2.53 1.83 2.18 0.495 2 4.10 4.63 4.37 0.375 2 1.85 2.07 1.96 0.156 2 3.56 4.05 3.81 0.346 2 1.51 1.83 1.67 0.226 2 003558 804 ANIMAL NUMBER Appendix 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Day 456 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS THYROID TOTAL FREE TOTAL FREE CORTISOL TESTOSTERONE ESTRADIOL ESTRONE ESTRIOL STIMULATING TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN /g/dL ng/mL pg/mL pg/mL pg/mL //U/mL ng/dL pg/mL dL ng/dL Group: Female 1 105529 105549 61.24 45.43 MEAN S.D. N 53.34 11.179 2 Group : Female 3 105539 105552 59.18 40.35 MEAN S.D. N 49.77 13.315 2 Group : Female 4 105533 105542 52.84 88.82 MEAN S.D. N 70.83 25.442 2 Dose Level: 0 Dosage Unit: mg/kg/day 0.75 0.16 60.82 58.64 62.11 17.39 0.00 0.00 3.41 2.27 0.46 0.417 2 59.73 1.541 2 39.75 31.622 2 0.00 0.000 2 2.84 0.806 2 Dose Level: 0.15 Dosage Unit: mg/kg/day 0.06 0.15 111.82 63.26 73.29 56.27 0.00 0.00 5.31 5.26 0.11 0.064 2 87.54 34.337 2 64.78 12.035 2 0.00 0.000 2 5.29 0.035 2 Dose Level : 0.75 Dosage Unit: mg/kg/day 0.73 0.30 101.24 180.10 86.37 115.95 0.00 0.00 5.20 4.19 0.52 0.304 2 140.67 55.762 2 101.16 20.916 2 0.00 0.000 2 4.70 0.714 2 131.39 127.08 129.24 3.048 2 127.44 104.90 116.17 15.938 2 140.68 147.41 144.05 4.759 2 6.12 5.03 5.58 0.771 2 4.32 5.02 4.67 0.495 2 4.86 4.23 4.55 0.445 2 4.81 4.72 4.77 0.064 2 2.15 2.27 2.21 0.085 2 3.48 3.31 3.40 0.120 2 1.46 1.10 1.28 0.255 2 3.55 3.15 3.35 0.283 2 1.56 1.11 1.34 0.318 2 003559 805 ANIMAL NUMBER Appendix 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS THYROID TOTAL FREE TOTAL FREE CORTISOL, TESTOSTERONE ESTRADIOL ESTRONE ESTRIOL STIMULATING TRI IODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN //g/dL ng/mL pg/mL pg/mL pg/mL //U/mL ng/dL pg/mL /ig/dL ng/dL Group : Male 1 Dose Level : 0 Dosage Unit: mg/kg/day 105520 105526 41.44 48.80 3.51 2.29 19.03 21.13 35.81 22.20 0.00 0.00 3.01 3.34 MEAN 45.12 2.90 20.08 29.01 0.00 S.D. 5.204 0.863 1.485 9.624 0.000 N 2 2 2 22 Group: Male 3 Dose Level : 0. 15 Dosage Unit: mg/kg/day 3.18 0.233 2 105505 105523 43.54 55.25 2.03 4.77 22.13 33.60 11.11 27.76 0.00 0.00 3.11 3.17 MEAN S.D. N 49.40 8.280 2 3.40 1.937 2 27.87 8.111 2 19.44 11.773 2 0.00 0.000 2 3.14 0.042 2 Group: Male 4 Dose Level : 0. 75 Dosage Unit: mg/kg/day 105511 105522 31.74 17.51 6.17 6.28 27.18 30.18 34.39 40.74 0.00 0.00 1.92 3.36 MEAN S.D. N 24.63 10.062 2 6.23 0.078 2 28.68 2.121 2 37.57 4.490 2 0.00 0.000 2 2.64 1.018 2 141.17 144.88 143.03 2.623 2 127.36 164.68 146.02 26.389 2 211.71 133.42 172.57 55.359 2 5.57 5.51 5.54 0.042 2 4.68 7.26 5.97 1.824 2 7.91 6.19 7.05 1.216 2 4.31 4.10 4.21 0.148 2 3.06 3.91 3.49 0.601 2 1.98 1.97 1.98 0.007 2 1.51 1.83 1.67 0.226 2 5.89 3.90 4.90 1.407 2 1.92 1.80 1.86 0.085 2 003560 806 ANIMAL NUMBER Appendix 6 Covance 6329-223 3M T-6295.7 Summary and Individual Blood Hormone Determination Day 546 26-WEEK CAPSULE TOXICITY STUDY WITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS;T-6295) IN CYNOMOLGUS MONKEYS THYROID TOTAL FREE TOTAL FREE CORTISOL TESTOSTERONE ESTRADIOL ESTRONE ESTRIOL STIMULATING TRIIODOTHYRONINE TRIIODOTHYRONINE THYROXIN THYROXIN pg/dL ng/mL pg/mL pg/mL pg/mL /iU/mL ng/dL pg/mL /Jg/dL ng/dL Group: Female 1 105529 105549 61.95 50.10 MEAN S.D. N 56.03 8.379 2 Group: Female 3 105539 105552 58.68 26.08 MEAN S.D. N 42.38 23.052 2 Group: Female 4 105533 105542 49.05 82.98 MEAN S.D. N 66.02 23.992 2 Dose Level : 0 Dosage Unit: mg/kg/day 0.32 0.15 88.86 55.18 60.95 29.70 0.00 0.00 2.28 2.86 0.24 0.120 2 72.02 23.815 2 45.33 22.097 2 0.00 0.000 2 2.57 0.410 2 Dose Level : 0.15 Dosage Unit: mg/kg/day 0.22 0.18 249.40 228.31 112.37 104.83 0.00 0.00 4.32 2.22 0.20 0.028 2 238.86 14.913 2 108.60 5.332 2 0.00 0.000 2 3.27 1.485 2 Dose Level : 0.75 Dosage Unit: mg/kg/day 0.73 0.40 89.07 94.97 85.47 46.34 0.00 0.00 3.89 4.50 0.57 0.233 2 92.02 4.172 2 65.91 27.669 2 0.00 0.000 2 4.20 0.431 2 113.93 122.28 118.11 5.904 2 133.88 194.67 164.28 42.985 2 122.53 131.85 127.19 6.590 2 4.61 4.59 4.60 0.014 2 QNS 7.69 7.69 1 4.63 4.36 4.50 0.191 2 4.23 4.96 4.60 0.516 2 1.65 1.91 1.78 0.184 2 3.65 6.48 5.07 2.001 2 1.63 1.81 1.72 0.127 2 3.41 3.46 3.44 0.035 2 1.41 1.31 1.36 0.071 2 003561 807 APPENDIX 7 Cell Proliferation Report Covance 6329-223 3M T-6295.7 Note: This appendix contains information supplied and audited by Pathology Associates International (PAI). 003562 808 Covance 6329-223 3M T-6295.7 r Pathology Associates International A Company of Science Applications International Corporation M&nploy*OmdCempv\r DRAFT CELL PROLIFERATION REPORT 26-W EEK CAPSULE TO XICITY STUDY W ITH PERFLUOROOCTANE SU LFO N IC ACID PO TASSIUM SALT (PFOS; T -6295) IN CYNOM OLGUS M O NK EYS COVANCE STUDY NUM BER 6329-223 PREPARED FOR: 3M TOXICOLOGY SERVICES BUILDING 220-2E -02,3M CENTER ST. PAUL, MN 55144-1000 PREPARED BY: PATHOLOGY ASSOCIATES INTERNATIONAL 15 W ORM AN'S M ILL COURT, SUITE I FREDERICK, MD 21701 FEBRUARY 25,2000 15 W orm an's Mill Court, Suite I * Frederick, M aryland 21701 * (301) 663-1644 * (301) 663-8994 FAX 003563 809 WUVCU4W& 3M T-6295.7 Draft Cell Proliferation Report Covance Study Number 6329-223 Page 2 TABLE OF CONTENTS L CELL PROLIFERATION REPORT IL TABLES m . SIGNATURE PAGE IV . QUALITY ASSURANCE STAYEMENT V . APPENDIX I 810 0 0 3 5 6 4 3M T-6295.7 Draft Cell Proliferation Report Covance Study Number 6329-223 Page 3 CELL PROLIFERATION REPORT 26-W EEK CAPSULE TO XICITY STUDY W ITH PERFLUOROOCTANE SU LFO N IC ACID PO TA SSIU M SALT (PFOS; T-6295) IN CYNOM OLGUS M O NK EYS COVANCE STUDY NUM BER 6329-223 PURPOSE The purpose o f title study was to assess the effect o f the test material on critical enzym e levels, hormones, and other selected biochem ical parameters when administered daily by capsule to cynomolgus m onkeys for at least 26 weeks. This report, submitted by Pathology Associates International (PAI) to the study Sponsor, 3M , represents the cell proliferation findings and interpretation for Covance Study Number 6329-223 entitled " 26-W eek Capsule Toxicity Study with Perfluorooctane Sulfonic Acid Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys" . A ll aspects o f the tasks associated w ith PA I's portion o f this study were conducted in compliance with the Environmental Protection A gency Good Laboratory Practice (GLP) Regulations as set forth in Title 40 o f the U S Code o f Federal Regulations, Part 792, issued November 29, 1983 (effective December 29, 1983), and w ith any applicable amendments. M ATERIALS AND M ETHODS T issue C ollection for C ell Proliferation Four animals per sex in groups 1 - 4 were sacrificed after at least 26 weeks on study. A representative sample o f the liver, testes (males only) and pancreas from each animal w as fixed in formalin, processed and embedded to paraffin block by Covance per protocol specifications. Tissue blocks were then shipped to PAI for sectioning and staining. From each block, a slide w as prepared for H&E evaluation and immunohistochemical detection o f proliferating cell nuclear antigen (PCNA), a marker o f cell proliferation. Im m unohistochem istry for C ell Proliferation Sections o f paraffin-embedded tissues were cut at approximately 5 pm and placed on positively charged slides (Superfrost Plus, Fisher Scientific, Pittsburgh, PA) to ensure adhesion during processing for PCNA. Standard immunohistochemical methods were used to stain tissues for PCNA (PAI's Standard Operating Procedure for Immunohistochemical Staining (SOP #707). Briefly, tissue sections were incubated with a monoclonal antibody to PCNA (DAKO, lot #107(101), PAI N o. A 2240) and reagents required for the avidin-biotin peroxidase (A BC Kit, lot #PK6102, PAI N o. K 444) method for the detection o f the antigen-antibody com plex. PCNA expression in cells was localized by the chromagen 3,3'-diaminobenzidine (D A B ; Sigma Chemical Co., lot #49H 8204 & 108H8210). Tissue sections were counterstained with hem atoxylin. 003565 811 ________________ 3M T-6295.7 Draft Cell Proliferation Report Covance Study Number 6329-223 Page 4 C ell Proliferation M easurem ents The percentage o f hepatocytes in S-phase (labeling index, LI) was determined by scoring at least 3000 hepatocytes in 10 fields o f liver. The LI in the testes (males only) w as determined by scoring the number o f PCNA-positive Leydig cells among at least 100 L eydig cells. The labeling index in file pancreas was scored subjectively with 4 being both acinar and islets stained heavily and 3 being predominant staining in the acinar region. A negative control slide was included in the staining run and consisted o f study tissue that was not incubated with the primary antibody. For cell proliferation evaluations, slides were first perused at low m agnification (100X ) to judge quality o f staining, processing and sectioning, potential patterns o f cellular proliferation, and histom orphologic changes. Cell proliferation was then quantified at higher m agnification (200X for liver and pancreas, and 400X for testes) as described above. H istom oiphology w as further assessed by evaluating the H&E slide prepared from the same tissue block for each animal evaluated for cell proliferation. Statistical A nalysis The Student's f-test (two-sided, unequal variance) was used to test for statistical significance in LI between control and treatment groups using M icrosoft Excel version 5 .0 . A P value o f 0.05 w as judged to be statistically significant. RESULTS C ell Proliferation Individual animal cell proliferation data are presented in Section II (Table 1). C ell proliferation in the liver, testes and pancreas o f control and test material-treated animals w as sim ilar. H istopathology Sections from the same tissue blocks used for preparation o f PCNA-stained slides were stained with hem atoxylin and eosin (H&E) for histopathologic evaluation to facilitate the interpretation o f the immunostained slides. Individual animal findings are presented in Appendix I. Single sections o f liver, pancreas, and testes from 16 adult male monkeys and single sections o f liver and pancreas from 16 adult fem ale monkeys representing control, low -dose (0.03 m g/kg/day), m id-dose (0.15 mg/kg/day) and high-dose (0.75 mg/kg/day) treatment groups were evaluated histologically. Each tissue section was stained with hem atoxylin and eosin. The purpose o f this evaluation was to determine whether or not morphologic changes were occurring in these tissues which may alter or confound the specificity o f the PCNA staining observed in these anim als. 003566 812 3M T-6295.7 Draft Cell Proliferation Report Covance Study Number 6329-223 PageS The results showed that no significant changes were observed in either the liver, pancreas, or testicular tissues from male monkeys or the liver and pancreas tissues from fem ale m onkeys, w hich would alter the interpretation o f the PCNA staining in this study. D IS C U SSIO N In the present study, cell proliferation was measured within the liver, testes and pancreas o f m ale m onkeys, and the liver and pancreas o f female monkeys from control (0 m g/kg/day), low dose (0.03 m g/kg/day), m id-dose (0.15 mg/kg/day) and high dose (0.75 m g/kg/day) groups after 26 w eeks on study to assess the effect o f the test material on critical enzyme levels, hormones, and other selected biological parameters, including cell proliferation. There did not appear to be a cell proliferative response to the test material in the liver, testes or pancreas, as determined by labeling indices, w hich were similar in all animals. SUM M ARY In the present study, cell proliferation, as determined by measuring the labeling index, w as not increased in the liver, testes or pancreas o f monkeys. 003567 813 covante 3M T-6295.7 Draft Cell Proliferation Report Covance Study Number 6329-223 n . TABLE Legend SEM = Standard Error o f the Mean 814 0 0 3 5 6 8 ______________3M T-6295.7 C O V A N C E S TU D Y N O . 6329-223 T A B L E 1-1. C E L L P R O L IF E R A T IO N IN M O N K E Y S A n im a l i L a b e lin g In d ex L a b e lin g In d e x L a b e lin g In d e x D os G roup S e x/G ro u p Num ber L iv e r P a n c re a s T estes 0 m g /kg /d ay (C ontrol) 0 m g /k g /d ay (C ontrol) F/1 0 5 5 3 0 F/1 105531 0 .0 0 0 % ' 0 .0 2 7 % ! 4 NP 3 NP 0 m g /kg /d ay (C ontrol) 1 F/1 1105535 0 .00 0% l 3 NP 0 m g /k g /d ay (C ontrol) i F/1 j I0 5 5 4 4 M ean 0 .1 9 9 % , 0.057% ! 4 3 .5 NP - 1 SEM 0 .048% i 0 .3 . 0 .0 3 m g /kg /d ay (Low dose) I F /2 I0 5 5 3 7 0 .11 3% 3 NP 0 .0 3 m g /kg /d ay (Low dose) i F /2 105541 0 .12 5% 4 NP 0 .0 3 m g /kg /d ay (Low dose) i F /2 105547 0 .000% 3 NP 0 .0 3 m g /kg /d ay (Low dose) ! F /2 I0 5 5 5 0 0 .212% 3 NP 1 M ean 0.11 2% ) 3 .3 - 1 SEM 0 .04 4% 0 .3 - 0 .1 5 m g /kg /d ay (M id dose) F /3 I0 5 5 3 2 0 .0 0 0 % l 3 NP 0 .1 5 m g /kg /d ay (M id dose) F /3 I0 5 5 3 8 0 .08 6% 3 NP 0 .1 5 m g /kg /d ay (M id dose) F /3 I0 5 5 4 5 0 .02 9% 3 NP 0 .1 5 m g /kg /d ay (M id dose) F /3 I0 5 5 4 8 0 .12 0% 4 NP M ean 0 .05 9% 3 .3 - SEM 0 .027% 0 .3 - 0 .7 5 m g /kg /d ay (H igh dose) F /4 I0 5 5 3 4 0 .00 0% 3 NP 0 .7 5 m g /kg /d ay (H igh dose) F /4 I0 5 5 3 6 0 .313% 3 NP 0 .7 5 m g /kg /d ay (H igh dose) F /4 1 05 5 4 0 0 .0 0 0 % 3 NP 0 .7 5 m g /kg /d ay (H ig h dose) F /4 105551 0 .0 0 0 % 3 NP M ean 0 .0 7 8 % 3 .0 - SEM 0 .07 8% 0 .0 - 0 m g /k g /d ay (C o n tro l) M /1 I0 5 5 0 8 0 .1 0 0 % 4 9 .5 2 % 0 m g /k g /d ay (C o n tro l) M /1 105517 i 0 .06 2% 3 9 .0 0 % 0 m g /k g /d ay (C ontrol) M /1 105519 T 0 .1 0 8 % 3 2 0 .7 5 % 0 m g /k g /d ay (C o n tro l) M /1 I0 5 5 2 7 0 .4 6 4 % i 4 1 9.2 3% M ean 0 .184% 3 .5 1 4.63% SEM 0 .09 4% 0 .3 3 .1 2 % 0 .0 3 m g /kg /d ay (L o w dose) M /2 105514 i 0 .0 9 5 % 3 1 6.3 6% 0 .0 3 m g /kg /d ay (L o w dose) M /2 105515 0 .0 0 0 % 3 1 8 .5 2 % 0 .0 3 m g /kg /d ay (Lo w dose) M /2 105516 ! 0 .0 0 0 % 3 2 2 .9 5 % 0 .0 3 m g /kg /d ay (L o w dose) M /2 105521 0 .0 0 0 % 4 1 2.3 8% M ean 0 .0 2 4 % 3 .3 1 7 .5 5 % SEM 0 .024% 0 .3 2 Ji0 % 0 .1 5 m g /kg /d ay (M id dose) M /3 105510 0 .0 5 3 % 3 9 .1 7 % 0 .1 5 m g /kg /d ay (M id dose) 0 .1 5 m g /kg /d ay (M id dose) M /3 105518 M /3 I0 5 5 2 4 0 .0 2 9 % J _ 0 .1 5 5 % ! 4 1 7.1 4% 3 1 4.42% 0 .1 5 m g /kg /d ay (M id dose) i 1 M /3 I0 5 5 2 8 M ean 0 .0 0 0 % ; 0 .05 9% I 4i 3 .5 1 0.71% 1 2.8 6% SEM 0 .0 3 4 % 0.3 ! 1 .8 0 % 0 .7 5 m g /kg /d ay (H igh dose) M /4 105506 0 .030% ! 3 7 .6 9 % 0 .7 5 m g /kg /d ay (H igh dose) M /4 105507 0 .0 2 7 % : 3 1 9.6 1% 0 .7 5 m g /kg /d ay (H igh dose) M /4 105509 NP' NP NP 0 .7 5 m g /kg /d ay (H igh dose) i M /4 j 105512 0 .0 0 0 % ! 3 ND M ean 0 .01 9% ! 3.0 1 3 .6 5 % ;S E M 0 .00 9% ! 0.0 5 .9 6 % N D , not d eterm in ed due to suboptim al staining j N P , slide not p resen t ! i L iv e r P e rc e n ta g e o f hep ato cytes in S -p h a s e i P an cre a s: S co red subjectively w ith 4= is lets and a cin a r stain ed h eavily (> 5 0 % la b e le d ); 3 = a c in a r> is le ts T e s te s : P e rc e n ta g e o f proliferating Leydig cells P ag e 1-1 815 003569 v-ovauu: 3M T-6295.7 Draft Cell Proliferation Report Covance Study Number 6329-223 HI. SIGNATURE PAGE 26-W eek C apsule T oxicity Study w ith Perfluorooctane Sulfonic A cid P otassium Salt (PFO S; T -6295) in Cynom olgus M onkeys (Covance Study N um ber 6329-223) Submitted by: PAI Project Manager: Sandra R. Eldridge, Ph.D. PAI Project Pathologist: Date Carolyn M oyer, D .V .M ., Diplomate, A .C.V.P. Date 816 003570 3M T-6295.7 Draft Cell Proliferation Report Covance Study Number 6329-223 IV. QUALITY ASSURANCE STATEM ENT 003571 817 Pathology Associates international A Com pany o f Science Applications International Corporation 3M T-6295.7 O tm tC en pu v Cell Proliferation Report 26-Week Capsule Toxicity Study with Perfluorooctane Sulfonic Addi Potassium Salt (PFOS; T-6295) in Cynomolgus Monkeys Covance Study Number: 6329-223 QUALITY ASSURANCE STATEMENT This cell proliferation project has been inspected and audited by the PAI Quality Assurance U nit (Q AU) as required by the Good Laboratory Practice (GLP) regulations promulgated by the U .S. Environmental Protection Agency (TSCA). The cell proliferation report is an accurate reflection o f the recorded data. The follow ing table is a record o f the inspections/audits performed and reported by the QAU. D ate of In sD ectio n 12/06/99 02/17/00 02/17/00 Phase InsDected D ate Findings R eported to PAI M anaeem ent/Proiect M anaeer Primary Antibody Dilution Study Data and Supporting Documentation Draft Cell Proliferation Report 12/06/99 02/17/00 02/17/00 Karen E. Butler Quality Assurance Officer 003572 818 1 5 W o rm a n 's M ill C o u rt, S u ite I F re d e ric k , M a ry la n d 2 1 7 0 1 (3 0 1 ) 6 6 3 -1 6 4 4 (3 0 1 ) 6 6 3 -8 9 9 4 F A X Covance 6329-223 ________________ 3M T-6295.7 Draft Cell Proliferation Report Covance Study Number 6329-223 APPENDIX I 003573 819 Individual Animal Findings 3M T-6295.7 3MP #6329-223 26-WEEK CAPSULE TO XICITY STUDY W ITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T6295) IN CYNOMOLGUS MONKEYS A N IM A L NUMBER SEX DOSE GROUP HISTO LOG IC FINDINGS _______________________________________________________ 105530 105531 105535 105544 105537 105541 105547 105550 105532 105538 105545 105548 105534 105536 105540 105551 F F F F F F F F F F F F F F F F 105517 105519 105527 105514 105515 105516 105521 105510 M M M M M M M M 1 Liver-NSF Pancreas - NSF 1 Liver-NSF Pancreas - NSF 1 Liver - chronic inflammation, minimal Pancras - NSF 1 Liver-NSF Pancreas - NSF 2 Liver-NSF Pancreas - NSF 2 Liver - chronic inflammation, minimal Pancras - NSF 2 Liver-NSF Pancreas - NSF 2 Liver-NSF Pancreas - NSF 3 Liver - NSF Pancreas - NSF 3 Liver - chronic inflammation, minimal Pancreas - NSF 3 Liver - chronic inflammation, minimal Pancreas - NSF 3 Liver - chronic inflammation, minimal Pancras - NSF 4 Liver-NSF Pancreas - NSF 4 Liver - fat infiltration, centrilobular, moderate Pancreas - NSF 4 Liver - NSF Pancreas - NSF 4 Liver-NSF Pancreas - NSF Liver - chronic inflammation, minir Pancreas - chronic inflammation, minimal Testes - NSF 1 Liver - NSF Pancreas - NSF Testes - crush artifact, focal 1 Liver - NSF Pancreas - NSF Testes - NSF 1 Liver-NSF Pancreas - NSF Testes - NSF 2 Liver - chronic inflammation, minimal Pancreas - chronic inflammation, minimal Testes - NSF 2 Liver - chronic inflammation, minimal Pancreas - NSF Testes - NSF 2 Liver-NSF Pancreas - NSF Testes - NSF 2 Liver-NSF Pancreas - NSF Testes - NSF 3 Liver - chronic inflammation, minimal Pancreas - NSF Testes - NSF Legend: NSF = no significant findings 820 003574 Individual Animal Findings v^ovance 3M T-6295.7 3MP #6329-223 26-WEEK CAPSULE TOXICITY STUDY W ITH PERFLUOROOCTANE SULFONIC ACID POTASSIUM SALT (PFOS; T629S) IN CYNOMOLGUS MONKEYS A N IM A L NUMBER SEX DOSE GROUP HISTOLOGIC FINDINGS 105518 105524 105528 105507 105512 105506 105509 M M M M M M M 3 Liver-NSF Pancreas - NSF Testes - NSF 3 Liver-NSF Pancreas - NSF Testes - NSF 3 Liver-NSF Pancreas - NSF Testes - NSF 4 Liver - fat infiltration, centrilobular, moderate Pancreas - NSF T estes-N S F 4 Liver-NSF Pancreas - NSF Testes - NSF 4 Liver-NSF Pancreas - NSF Testes - NSF 4 No microscopic slides available. (Inventory shows blocks submitted; STPR does not show blocks sectioned.) Legend: NSF = no significant findings 821 003575